Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells

ABSTRACT

Disclosed are methods for delivering a therapeutic or diagnostic agent to the cytosol of a cell in a subject. The disclosed methods generally include administering to the subject an effective amount of a lipid nanoparticle comprising the therapeutic or diagnostic agent and an effective amount of a membrane-destabilizing polymer. Also disclosed are related compositions and delivery systems.

REFERENCE TO SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted in ASCII format via EFS-Web and is hereby incorporated byreference in its entirety. Said ASCII Copy, created on Jan. 13, 2016, isnamed “3900_PCT1_Seq_Listing_ST25” and is 66,448 bytes in size.

BACKGROUND OF THE INVENTION

Lipid nanoparticles (LNPs) are effective drug delivery systems forbiologically active compounds such as therapeutic nucleic acids,proteins, and peptides, which are otherwise cell impermeable. Liposomalformulations have also been developed for small molecule drugs,generally with the aim to enrich the drug in certain tissues as well asto mitigate toxicity.

Drugs based on nucleic acids, which include large nucleic acid moleculessuch as, e.g., in vitro transcribed messenger RNA (mRNA) as well assmaller polynucleotides that interact with a messenger RNA or a gene,have to be delivered to the proper cellular compartment in order to beeffective. For example, double-stranded nucleic acids such asdouble-stranded RNA molecules (dsRNA), including, e.g., siRNAs, sufferfrom their physico-chemical properties that render them impermeable tocells. Upon delivery into the proper compartment, siRNAs block geneexpression through a highly conserved regulatory mechanism known as RNAinterference (RNAi). Typically, siRNAs are large in size with amolecular weight ranging from 12-17 kDa, and are highly anionic due totheir phosphate backbone with up to 50 negative charges. In addition,the two complementary RNA strands result in a rigid helix. Thesefeatures contribute to the siRNA's poor “drug-like” properties. Whenadministered intravenously, the siRNA is rapidly excreted from the bodywith a typical half-life in the range of only 10 minutes. Additionally,siRNAs are rapidly degraded by nucleases present in blood and otherfluids or in tissues, and have been shown to stimulate strong immuneresponses in vitro and in vivo. See, e.g., Robbins et al.,Oligonucleotides 19:89-102, 2009. mRNA molecules suffer from similarissues of impermeability, fragility, and immunogenicity.

By introduction of appropriate chemical modifications, stability towardsnucleases can be increased and at the same time immune stimulation canbe suppressed. Conjugation of lipophilic small molecules to the siRNAsimproves the pharmacokinetic characteristics of the double-stranded RNAmolecule. It has been demonstrated that these small molecule siRNAconjugates are efficacious in a specific down regulation of a geneexpressed in hepatocytes of rodents. However, in order to elicit thedesired biologic effect, a large dose was needed. See Soutschek et al.,Nature 432:173-178, 2004.

Lipid nanoparticle formulations have improved nucleic acid delivery invivo. For example, such formulations have significantly reduced siRNAdoses necessary to achieve target knockdown in vivo. See Zimmermann etal., Nature 441:111-114, 2006. Typically, such lipid nanoparticle drugdelivery systems are multi-component formulations comprising cationiclipids, helper lipids, and lipids containing polyethylene glycol. Thepositively charged cationic lipids bind to the anionic nucleic acid,while the other components support a stable self-assembly of the lipidnanoparticles.

Efforts have been directed toward improving delivery efficacy of lipidnanoparticle formulations. Many such efforts have been aimed towarddeveloping more appropriate cationic lipids. See, e.g., Akinc et al.,Nature Biotechnology 26:561-569, 2008; Love et al., Proc. Natl. Acad.Sci. USA 107:1864-1869, 2010; Baigude et al., Journal of ControlledRelease 107:276-287, 2005; Semple et al., Nature Biotechnology28:172-176, 2010. Despites these efforts, improvements in terms ofincreased efficacy and/or decreased toxicity are still needed,especially for lipid nanoparticle based drug delivery systems intendedfor therapeutic uses.

SUMMARY OF THE INVENTION

In one aspect, the present invention provides a method for delivering atherapeutic or diagnostic agent to the cytosol of a target cell within asubject. The method generally includes administering to the subject (a)an effective amount of a lipid nanoparticle comprising the therapeuticor diagnostic agent and (b) an effective amount of amembrane-destabilizing polymer, where the therapeutic or diagnosticagent is delivered to the cytosol of the target cell. The lipidnanoparticle and membrane-destabilizing polymer can be administeredseparately (e.g., the membrane-destabilizing polymer administered afteradministration of the lipid nanoparticle) or, alternatively, togetherwithin a single composition. Typically, the lipid nanoparticle is lessthan about 200 nm in size. In certain variations, the lipid nanoparticleand the membrane-destabilizing polymer are administered in a repeatdosage regime (e.g., a weekly or bi-weekly repeated administrationprotocol).

In some embodiments, the lipid nanoparticle comprises a cationic lipid.Particularly suitable cationic lipids includeN-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA);N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTAP);1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC);1,2-dilauroyl-sn-glycero-3-ethylphosphocholine (DLEPC);1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine (DMEPC);1,2-dimyristoleoyl-sn-glycero-3-ethylphosphocholine (14:1),N1-[2-((1S)-1-[(3-aminopropyl)amino]-4-[di(3-amino-propyl)amino]butylcarboxamido)ethyl]-3,4-di[oleyloxy]-benzamide(MVL5); Dioctadecylamido-glycylspermine (DOGS);3b-[N—(N′,N′-dimethylaminoethyl)carbamoyl]cholesterol (DC-Chol);Dioctadecyldimethylammonium Bromide (DDAB); a Saint lipid (e.g.,SAINT-2, N-methyl-4-(dioleyl)methylpyridinium);1,2-dimyristyloxypropyl-3-dimethylhydroxyethylammonium bromide (DMRIE);1,2-dioleoyl-3-dimethyl-hydroxyethyl ammonium bromide (DORIE);1,2-dioleoyloxypropyl-3-dimethylhydroxyethyl ammonium chloride (DORI);Di-alkylated Amino Acid (DILA²) (e.g., C18:1-norArg-C16);Dioleyldimethylammonium chloride (DODAC);1-palmitoyl-2-oleoyl-sn-glycero-3-ethylphosphocholine (POEPC); and1,2-dimyristoleoyl-sn-glycero-3-ethylphosphocholine (MOEPC). In somevariations, the cationic lipid is an ionizable cationic lipid such as,e.g., Dioctadecyldimethylammonium bromide (DDAB),1,2-dilinolcyloxy-3-dimethylaminopropane (DLinDMA),2,2-dilinoleyl-4-(2dimethylaminoethyl)-[1,3]-dioxolane (DLin-KC2-DMA),heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate(DLin-MC3-DMA), 1,2-Dioleoyloxy-3-dimethylaminopropane (DODAP),1,2-Diolcyloxy-3-dimethylaminopropane (DODMA), Morpholinocholesterol(Mo-CHOL), (R)-5-(dimethylamino)pentane-1,2-diyl dioleate hydrochloride(DODAPen-Cl), (R)-5-guanidinopentane-1,2-diyl dioleate hydrochloride(DOPen-G), (R)-N,N,N-trimethyl-4,5-bis(oleoyloxy)pentan-1-aminiumchloride (DOTAPen). In certain embodiments, a lipid nanoparticleincludes a combination or two or more cationic lipids (e.g., two or morecationic lipids as above).

In some embodiments of a method as above, the lipid nanoparticleincludes an ionizable anionic lipid such as, e.g., cholesterylhemisuccinate (CHEMS), phosphatidylserine, palmitoylhomoserine, orα-tocopherol hemisuccinate. In certain variations, a lipid nanoparticleincludes a combination or two or more ionizable anionic lipids (e.g.,two or more ionizable anionic lipids as above).

In some variations of a method as above, the lipid nanoparticle includesa helper lipid. Particularly suitable helper lipids includes cholesterol(CHOL); 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC);1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC);1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC);1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE);1,2-dilauroyl-sn-glycero-3-phosphoethanolamine (DLPE);1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE); and1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (DPHyPE). In certainembodiments, a lipid nanoparticle includes a combination or two or morehelper lipids (e.g., two or more helper lipids as above).

In certain embodiments of a method as above, the lipid nanoparticleincludes a polyethylenegycol-lipid conjugate (PEG-lipid) such as, e.g.,N-(Carbonyl-methoxypolyethyleneglycol_(n))-1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine(DMPE-PEG_(n) where n is 350, 500, 750, 1000 or 2000),N-(Carbonyl-methoxypolyethyleneglycol_(n))-1,2-distearoyl-sn-glycero-3-phosphoethanolamine(DSPE-PEG_(n) where n is 350, 500, 750, 1000 or 2000),DSPE-polyglycelin-cyclohexyl-carboxylic acid,DSPE-polyglycelin-2-methylglutar-carboxylic acid, polyethyleneglycol-dimyristolglycerol (PEG-DMG), polyethylene glycol-distearoylglycerol (PEG-DSG), orN-octanoyl-sphingosine-1-{succinyl[methoxy(polyethylene glycol)2000]}(C8 PEG2000 Ceramide). In some variations of DMPE-PEG_(n) where n is350, 500, 750, 1000 or 2000, the PEG-lipid isN-(Carbonyl-methoxypolyethyleneglycol2000)-1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE-PEG 2,000).In some variations of DSPE-PEG_(n) where n is 350, 500, 750, 1000 or2000, the PEG-lipid is N-(Carbonyl-methoxypolyethyleneglycol2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE-PEG 2,000).In certain embodiments, a lipid nanoparticle includes a combination ortwo or more PEG-lipids (e.g., two or more PEG-lipids as above).

In some embodiments of a method as above, at least one of the lipidnanoparticle and membrane-destabilizing polymer includes a firsttargeting ligand that specifically binds to a molecule on the surface ofthe target cell. The membrane-destabilizing polymer, the lipidnanoparticle, or both the membrane-destabilizing polymer and lipidnanoparticle may include the first targeting ligand. In someembodiments, one of the lipid nanoparticle and membrane-destabilizingpolymer includes the first targeting ligand, and the other of the lipidnanoparticle and membrane-destabilizing polymer includes a secondtargeting ligand that is different from the first targeting ligand andeither (i) specifically binds to the same cell surface moleculerecognized by the first targeting ligand or (ii) specifically binds to adifferent cell surface molecule on the surface of the target cell. Inparticular variations, either the first targeting ligand, the secondtargeting ligand, or both the first and second targeting ligandsspecifically bind(s) to a cell surface molecule selected fromtransferrin receptor type 1, transferrin receptor type 2, the EGFreceptor, HER2/Neu, a VEGF receptor, a PDGF receptor, an integrin, anNGF receptor, CD2, CD3, CD4, CD8, CD19, CD20, CD22, CD33, CD43, CD38,CD56, CD69, the asialoglycoprotein receptor (ASGPR), prostate-specificmembrane antigen (PSMA), a folate receptor, and a sigma receptor.

In certain embodiments of a method as above in which at least one of thelipid nanoparticle and membrane-destabilizing polymer includes a firsttargeting ligand (and the other of the lipid nanoparticle andmembrane-destabilizing polymer optionally includes a second targetingligand), the first and/or second targeting ligand includes a smallmolecule targeting moiety. In specific variations, the small moleculetargeting moiety is a sugar (e.g., lactose, galactose, N-acetylgalactosamine (NAG, also referred to as GalNAc), mannose, andmannose-6-phosphate (M6P)), a vitamin (e g , folate), a bisphosphonate,or an analogue thereof. In other embodiments, the first and/or secondtargeting ligand is a protein such as, e.g., an antibody, a peptideaptamer, or a protein derived from a natural ligand of the cell surfacemolecule. In yet other embodiments, the first and/or second targetingligand is a peptide such as, e.g., an integrin-binding peptide, aLOX-1-binding peptide, and epidermal growth factor (EGF) peptide, aneurotensin peptide, an NL4 peptide, or a YIGSR laminin peptide.

In certain embodiments of a method as above, target cell is selectedfrom a secretory cell, a chondrocyte, an epithelial cell, a nerve cell,a muscle cell, a blood cell, an endothelial cell, a pericyte, afibroblast, a glial cell, and a dendritic cell. Other suitable targetcells include cancer cells, immune cells, bacterially-infected cells,virally-infected cells, or cells having an abnormal metabolic activity.

In a particular variation where the target cell is a secretory cell, thetarget secretory cell is a hepatocyte. In some such embodiments, atleast one of the lipid nanoparticle and membrane-destabilizing polymerincludes a first targeting ligand that specifically binds to a moleculeon the surface of the hepatocyte. In certain embodiments, the firsttargeting ligand specifically binds to the asialoglycoprotein receptor(ASGPR); for example, in particular variations, the first targetingligand includes an N-acetylgalactosamine (NAG) residue. In someembodiments as above comprising a first targeting ligand that binds to amolecule on the surface of hepatocytes, both the lipid nanoparticle andthe membrane-destabilizing polymer include the first targeting ligand.In other embodiments one of the lipid nanoparticle andmembrane-destabilizing polymer includes the first targeting ligand, andthe other of the lipid nanoparticle and membrane destabilizing polymerincludes a second targeting ligand that is different from the firsttargeting ligand and either (i) specifically binds to theasialoglycoprotein receptor (ASGPR) or (ii) specifically binds to adifferent cell surface molecule on the surface of the hepatocyte; insome such embodiments, the second targeting ligand includes anN-acetylgalactosamine (NAG) residue.

In some embodiments of a method as above, the membrane-destabilizingpolymer is a copolymer, a synthetic peptide, a membrane-destabilizingtoxin or derivative thereof, or a viral fusogenic peptide or derivativethereof. In a particular variation, the membrane-destabilizing polymeris a pH-sensitive polymer such as, e.g., a pH-sensitive copolymer. Thecopolymer may be a block copolymer such as, for example, a diblockcopolymer. In some variations, the block copolymer includes ahydrophobic, membrane-destabilizing block and a hydrophilic block. Insome such embodiments, the hydrophilic block is polymerized from bothhydrophilic monomers and hydrophobic monomers such that there are morehydrophilic monomeric residues than hydrophobic monomeric residues inthe hydrophilic block. The hydrophilic block may be cleavably linked tothe hydrophobic block, such as through a disulfide bond or apH-sensitive bond. In some embodiments, the hydrophilic block includesmonomeric residues linked to a pendant shielding moiety such as, e.g., apolyethylene glycol (PEG) moiety. The shielding moiety may be cleavablylinked to the hydrophilic block, such as through a disulfide bond or apH-sensitive bond. Particularly suitable pH-sensitive bonds (for linkageof the hydrophilic and hydrophobic blocks or linkage of the shieldingmoiety to the hydrophilic block) include hydrazone, acetal, ketal,imine, orthoester, carbonate, and maleamic acid linkages.

The pH-sensitive polymer may include monomeric residues having acarboxylic acid functional group, monomeric residues having an aminefunctional group, and/or monomeric residues having a hydrophobicfunctional group. In some variations, the pH-sensitive polymer includesmonomeric residues derived from polymerization of a (C₂-C₈) alkylacrylicacid (e.g., propylacrylic acid); monomeric residues derived frompolymerization of a (C₂-C₈) alkyl-ethacrylate, a (C₂-C₈)alkyl-methacrylate, or a (C₂-C₈) alkyl-acrylate; and/or monomericresidues derived from polymerization of(N,N-di(C₁-C₆)alkyl-amino(C₁-C₆)alkyl-ethacrylate,(N,N-di(C₁-C₆)alkyl-amino (C₁-C₆) alkyl-methacrylate, or(N,N-di(C₁-C₆)alkyl-amino(C₁-C₆)alkyl-acrylate. In a specific variation,the pH-sensitive polymer includes a random copolymer chain havingmonomeric residues derived from polymerization of propyl acrylic acid,N,N-dimethylaminoethylmethacrylate, and butyl methacrylate; in some suchembodiments, the pH-sensitive polymer is a block copolymer comprisingthe random copolymer chain as a membrane disrupting polymer block, andfurther including one or more additional blocks.

In certain embodiments, the pH-sensitive membrane-destabilizing polymeris a diblock copolymer having a hydrophilic random copolymer block and ahydrophobic random copolymer block, where (i) the hydrophilic block isan amphiphilic block comprising both hydrophilic monomeric residues andhydrophobic monomeric residues, where the number of hydrophilicmonomeric residues in the hydrophilic block is greater than the numberof hydrophobic monomeric residues, (ii) the hydrophobic block is anamphiphilic, membrane-destabilizing block comprising both hydrophobicmonomeric residues and hydrophilic monomeric residues and having anoverall hydrophobic character at a pH of about 7.4; and (iii) each ofthe hydrophilic monomeric residues of the hydrophilic and hydrophobicblocks is independently selected from the group consisting of monomericresidues that are ionic at a pH of about 7.4, monomeric residues thatare neutral at a pH of about 7.4, and monomeric residues that arezwitterionic at a pH of about 7.4.

In yet other variations, the pH-sensitive polymer is covalently linkedto a membrane-destabilizing peptide. In some such embodiments, thepH-sensitive polymer includes a plurality of pendant linking groups, anda plurality of membrane-destabilizing peptides are linked to thepH-sensitive polymer via the plurality of pendant linking groups.

In some embodiments, the pH-sensitive polymer includes a random blockcopolymer of formula I:

where

A₀, A₁, A₂, A₃, A₄ and A₅ are each independently selected from the groupconsisting of —C—C—, —C(O)(C)_(a)C(O)O—, —O(C)_(a)C(O)—, —O(C)_(b)—, and—CR₈—CR₉; where tetravalent carbon atoms of A₀-A₅ that are not fullysubstituted with R₁-R₆ and Y₀-Y₅ are completed with an appropriatenumber of hydrogen atoms; wherein a and b are each independently 1-4;and where R₈ and R₉ are each independently selected from the groupconsisting of —C(O)OH, —C(O)Oalkyl, and —C(O)NR₁₀, where R₈ and R₉ areoptionally covalently linked together to form a ring structure (e.g., acyclic anhydride or cyclic imide);

Y₅ is hydrogen or is selected from the group consisting of-(1C-10C)alkyl, -(3C-6C)cycloalkyl, —O-(1C-10C)alkyl,—C(O)O(1C-10C)alkyl, —C(O)NR₁₁(1C-10C)alkyl, and -(6C-10C)aryl, any ofwhich is optionally substituted with one or more fluorine atoms;

Y₀, Y₃, and Y₄ are each independently selected from the group consistingof a covalent bond, -(1C-10C)alkyl-, —C(O)O(2C-10C)alkyl-,—OC(O)(1C-10C)alkyl-, —O(2C-10C)alkyl-, —S(2C-10C)alkyl-, and—C(O)NR₁₂(2C-10C)alkyl-;

Y₁ and Y₂ are each independently selected from the group consisting of acovalent bond, -(1C-18C)alkyl-, -(3C-18C)branched alkyl,—C(O)O(2C-18C)alkyl-, —C(O)O(2C-18C)branched alkyl,—OC(O)(1C-18C)alkyl-, —OC(O)(1C-18C)branched alkyl-, —O(2C-18C)alkyl-,—O(2C-18C)branched alkyl-, —S(2C-18C)alkyl-, —S(2C-18C)branched alkyl-,—C(O)NR₁₂(2C-18C)alkyl-, and —C(O)NR₁₂(2C-18C)branched alkyl-, where anyalkyl or branched alkyl group of Y₁ or Y₂ is optionally substituted withone or more fluorine atoms;

R₁, R₂, R₃, R₄, R₅, R₆, R₈, R₉, R₁₀, R₁₁, and R₁₂ are each independentlyhydrogen, —CN, or selected from the group consisting of alkyl, alkynyl,heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, any ofwhich is optionally substituted with one or more fluorine atoms;

Q₀ is a residue selected from the group consisting of residues which arehydrophilic at physiologic pH; O—[(C)₂₋₃—O]_(x)—R₇; andO—[(C)₂₋₃—O]_(x)—C(O)—NR₁₃R₁₄; where x is 1-48; R₇ is —CH₃ or —CO₂H; andR₁₃ and R₁₄ are each independently hydrogen, —CN, or selected from thegroup consisting of alkyl, alkynyl, heteroalkyl, cycloalkyl,heterocycloalkyl, aryl and heteroaryl, any of which is optionallysubstituted with one or more fluorine atoms;

Q₁ and Q₂ are each independently absent or selected from a residue whichis hydrophilic at normal physiological pH; a conjugatable orfunctionalizable residue; a residue which is hydrophobic at normalphysiological pH; an alkyl group optionally substituted with one or morefluorine atoms; and a branched alkyl group optionally substituted withone or more fluorine atoms;

Q₃ is a residue which is positively charged at normal physiological pH;

Q₄ is a residue which is negatively charged at normal physiological pH,but undergoes protonation at lower pH;

m is a mole fraction of greater than 0 to 1.0;

n is a mole fraction of 0 to less than 1.0;

p is a mole fraction of 0 to less than 1.0; wherein m+n+p=1;

q is a mole fraction of 0.1 to 0.9;

r is a mole fraction of 0.05 to 0.9;

s is present up to a mole fraction of 0.85; wherein q+r+s=1;

v is from 1 to 25 kDa; and

w is from 1 to 50 kDa.

In some embodiments comprising a pH-sensitive polymer of formula I asabove, m is greater than n+p. In some such variations, p is 0.

In some embodiments comprising a pH-sensitive polymer of formula I asabove, n is greater than 0. In some such variations, at least one of Y₁and Q₁ contains the alkyl or branched alkyl group substituted with theone or more fluorine atoms. In more particular variations, p is 0 and/orm is greater than n.

In certain embodiments comprising a pH-sensitive polymer of formula I,the pH-sensitive polymer is a polymer of formula II:

T1-L-[PEGMA_(m)-PDSMA_(n)-BPAM_(p)]_(v)-[DMAEMA_(q)-PAA_(r)-BMA_(s)]_(w)  II

where

PEGMA is polyethyleneglycol methacrylate residue with 2-20 ethyleneglycol units;

PDSMA is pyridyl disulfide methacrylate residue;

BPAM is 2-[2-Boc amino ethoxy] ethyl methacrylate residue;

BMA is butyl methacrylate residue;

PAA is propyl acrylic acid residue;

DMAEMA is dimethylaminoethyl methacrylate residue;

m is a mole fraction of 0.6 to 1;

n is a mole fraction of 0 to 0.4 (e.g., 0 to 0.2);

p is a mole fraction of 0 to 0.4 (e.g., 0 to 0.2);

m+n+p=1;

q is a mole fraction of 0.2 to 0.75;

r is a mole fraction of 0.05 to 0.6;

s is a mole fraction of 0.2 to 0.75;

q+r+s=1;

v is 1 to 25 kDa;

w is 1 to 25 kDa;

T1 is absent or is the first targeting ligand; and

L is absent or is a linking moiety.

In other embodiments comprising a pH-sensitive polymer of formula I, thepH-sensitive polymer is a polymer of formula V:

T1-L-[PEGMA_(m)-M2_(n)]_(v)-[DMAEMA_(q)-PAA_(r)-BMA_(s)]_(w)   V

where

PEGMA is polyethyleneglycol methacrylate residue with 2-20 ethyleneglycol units;

M2 is a methacrylate residue selected from the group consisting of

-   -   a (C4-C18)alkyl-methacrylate residue;    -   a (C4-C18)branched alkyl-methacrylate residue;    -   a cholesteryl methacrylate residue;    -   a (C4-C18)alkyl-methacrylate residue substituted with one or        more fluorine atoms; and    -   a (C4-C18)branched alkyl-methacrylate residue substituted with        one or more fluorine atoms;

BMA is butyl methacrylate residue;

PAA is propyl acrylic acid residue;

DMAEMA is dimethylaminoethyl methacrylate residue;

m and n are each a mole fraction greater than 0, wherein m is greaterthan n and m+n=1;

q is a mole fraction of 0.2 to 0.75;

r is a mole fraction of 0.05 to 0.6;

s is a mole fraction of 0.2 to 0.75;

q+r+s=1;

v is 1 to 25 kDa;

w is 1 to 25 kDa;

T1 is absent or is the first targeting ligand; and

L is absent or is a linking moiety.

In some specific embodiments of a polymer of formula V, M2 is selectedfrom 2,2,3,3,4,4,4-heptafluorobutyl methacrylate residue;3,3,4,4,5,6,6,6-octafluoro-5(trifluoromethyl)hexyl methacrylate residue;2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctyl 2-methylacrylateresidue; 3,3,4,4,5,5,6,6,6-nonafluorohexyl methacrylate residue (alsoreferred to as 2-propenoic acid, 2-methyl-,3,3,4,4,5,5,6,6,6-nonafluorohexyl ester residue);3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl methacrylate residue;1,1,1-trifluoro-2-(trifluoromethyl)-2-hydroxy-4-methyl-5-pentylmethacrylate residue;2-[(1′,1′,1′-trifluoro-2′-(trifluoromethyl)-2′-hydroxy)propyl]-3-norbornylmethacrylate residue; 2-ethylhexyl methacrylate residue; butylmethacrylate residue; hexyl methacrylate residue; octyl methacrylateresidue; n-decyl methacrylate residue; lauryl methacrylate residue;myristyl methacrylate residue; stearyl methacrylate residue; cholesterylmethacrylate residue; ethylene glycol phenyl ether methacrylate residue;2-propenoic acid, 2-methyl-, 2-phenylethyl ester residue; 2-propenoicacid, 2-methyl-, 2-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl esterresidue; 2-propenoic acid, 2-methyl-, 2-(1H-imidazol-1-yl)ethyl esterresidue; 2-propenoic acid, 2-methyl-, cyclohexyl ester residue;2-propenoic acid, 2-methyl-, 2-[bis(1-methylethyl)amino]ethyl esterresidue; 2-propenoic acid, 2-methyl-, 3-methylbutyl ester residue;neopentyl methacrylate residue; tert-butyl methacrylate residue;3,3,5-trimethyl cyclohexyl methacrylate residue; 2-hydroxypropylmethacrylate residue; 5-nonyl meth acrylate residue; 2-butyl-1-octylmethacrylate residue; 2-hexyl-1-decyl methacrylate residue; and2-(tert-butyl amino)ethyl methacrylate residue.

In particular variations of a method as above comprising a pH-sensitivepolymer of formula II or formula V, PEGMA has 4-5 ethylene glycol unitsor 7-8 ethylene glycol units; T1 and L are present and T1 includes anN-acetylgalactosamine (NAG) residue; and/or L includes a polyethyleneglycol (PEG) moiety having 2-20 ethylene glycol units.

In certain embodiments, the lipid nanoparticle includes the therapeuticagent. The therapeutic agent may be an anti-cancer agent, an anti-viralagent, an immunomodulatory agent, an anti-inflammatory agent, or anagent that modulates a cellular metabolic activity. Suitable therapeuticagents may be selected from polynucleotides, proteins, peptides, andsmall molecules.

In some embodiments, the therapeutic agent is a polynucleotide. In somesuch variations, the lipid nanoparticle has an N:P (nitrogen tophosphate) ratio of about 1 to about 30. In certain embodiments, thepolynucleotide is an mRNA, such as, for example, an mRNA encoding afunctional protein associated with a protein deficiency disease. Inparticular variations, the target cell is a hepatocyte and the mRNAencodes a protein selected from the group consisting ofalpha-1-antitrypsin (A1AT), carbamoyl phosphate synthetase I (CPS1),fumarylacetoacetase (FAH) enzyme, alanine:glyoxylate-aminotransferase(AGT), methylmalonyl CoA mutase (MUT), propionyl CoA carboxylase alphasubunit (PCCA), propionyl CoA carboxylase beta subunit (PCCB), a subunitof branched-chain ketoacid dehydrogenase (BCKDH), ornithinetranscarbamylase (OTC), copper-transporting ATPase Atp7B, bilirubinuridinediphosphate glucuronyltransferase (BGT) enzyme, hepcidin,glucose-6-phosphatase (G6Pase), glucose 6-phosphate translocase,lysosomal glucocerebrosidase (GB), Niemann-Pick C1 protein (NPC1),Niemann-Pick C2 protein (NPC2), acid sphingomyelinase (ASM), Factor IX,galactose-1-phosphate uridylyltransferase, galactokinase, UDP-galactose4-epimerase, transthyretin, a complement regulatory protein,phenylalanine hydroxylase (PAH), homogentisate 1,2-dioxygenase,porphobilinogen deaminase, hypoxanthine-guaninephosphoribosyltransferase (HGPRT), argininosuccinate lyase (ASL),argininosuccinate synthetase (ASS1), P-type ATPase protein FIC-1,alpha-galactosidase A, acid ceramidase, acid α-L-fucosidase, acidβ-galactosidase, iduronate-2-sulfatase, alpha-L-iduronidase,galactocerebrosidase, acid α-mannosidase, β-mannosidase, arylsulfataseB, arylsulfatase A, N-acetylgalactosamine-6-sulfate sulfatase, acidβ-galactosidase, acid α-glucosidase, β-hexosaminidase B,heparan-N-sulfatase, alpha-N-acetylglucosaminidase,acetyl-CoA:α-glucosaminide N-acetyltransferase,N-acetylglucosamine-6-sulfate sulfatase,alpha-N-acetylgalactosaminidase, sialidase, β-glucuronidase,β-hexosaminidase A. In some embodiments, the polynucleotide is a DNA,such as, for example, a DNA encoding a functional protein associatedwith a protein deficiency disease (e.g., a protein selected from theproteins listed above).

In certain embodiments, the therapeutic agent is an mRNA encoding asecreted protein. Suitable secreted proteins include hormones,cytokines, growth factors, clotting factors, anti-protease proteins,angiogenic proteins, antiangiogenic proteins, chemokines, andantibodies. In particular variations, the secreted protein is selectedfrom erythropoietin (EPO), thrombopoietin (TPO), granulocyte-colonystimulating factor (G-CSF), granulocyte macrophage-colony stimulatingfactor, (GM-CSF), leptin, a platelet-derived growth factor (e.g.,platelet-derived growth factor B (PDGF-B)), keratinocyte growth factor(KGF), bone morphogenic protein 2 (BMP-2), bone morphogenic protein 7(BMP-7), insulin, glucagon-like peptide-1 (GLP-1), human growth hormone(HGF), Factor VII, Factor VIII, Factor IX, a relaxin (e.g., relaxin-2),an interferon (e.g., interferon-α (IFN-α), interferon-β (IFN-β),interferon-γ (IFN-γ)), interleukin-2 (IL-2), interleukin-4 (IL-4),interleukin-10 (IL-10), interleukin-11 (IL-11), interleukin-12 (IL-12),interleukin-18 (IL-18), interleukin-21 (IL-21), a CC subfamilychemokine, a CXC subfamily chemokine, a C subfamily chemokine, and aCX3C subfamily chemokine. In some embodiments where the secreted proteinis an antibody, the antibody is a genetically engineered antibodyselected from a chimeric antibody, a humanized antibody, a single-chainantibody (e.g., a single-chain Fv (scFv)), and a bispecific antibody.

In other embodiments where the therapeutic agent is a polynucleotide,the polynucleotide is an oligonucleotide. Suitable oligonucleotidetherapeutic agents include siRNAs, antisense oligonucleotides, anti-miRs(also known as antagomiRs), locked nucleic acid (LNA)-basedoligonucleotides, dicer substrates, miRNAs, aiRNAs, shRNAs, ribozymes,and nucleic acid aptamers.

In certain embodiments, the therapeutic agent is a protein, such as,e.g., an antibody or a peptide aptamer. Particular variations ofantibody therapeutic agents include single chain antibodies and abispecific antibodies.

In some embodiments, the therapeutic agent is a peptide. Exemplarypeptide therapeutic agents include peptide vaccines comprising one ormore short or long amino acid sequences from disease-associated antigens(e.g., tumor antigens).

In other embodiments, the therapeutic agent is a small molecule. Inspecific variations, the small molecule is selected from an anti-tubulinagent, a DNA minor groove binding agent, and a DNA replicationinhibitor. In other variations, the small molecule is selected from ananthracycline, an auristatin, a camptothecin, a duocarmycin, anetoposide, a maytansinoid, a vinca alkaloid, and a platinum (II)compound.

In other embodiments, the therapeutic agent is a component of a geneediting system that disrupts or corrects a gene associated with adisease. In some embodiments, the component of the gene editing systemis a polynucleotide (e.g., an mRNA) encoding a nuclease. Particularlysuitable nucleases include zinc finger nucleases (ZFNs), transcriptionactivator-like effector nucleases (TALENs), CRISPR-associated protein 9(Cas9), and engineered meganucleases. In particular variations in whichthe nuclease is Cas9, the lipid nanoparticle further includes a guideRNA that targets the nuclease to a specific site in the target cellgenome. In some variations directed to gene editing as above, the lipidnanoparticle further includes a polynucleotide containing a DNA donorsequence for correcting a disease-associated gene by homologousrecombination. In other variations, the method further includesadministering to the subject an effective amount of a second lipidnanoparticle that includes a polynucleotide containing a DNA donorsequence for correcting a disease-associated gene by homologousrecombination.

In some embodiments, the therapeutic agent is an immunogen. Suitableimmunogens include peptides, proteins, mRNAs, short RNAs, DNAs, andsimple or complex carbohydrates. In certain variations, the immunogen isderived from an infectious agent (e.g., a virus or bacteria) or a cancercell. In some such embodiments, the membrane destabilizing polymer isalso associated with an immunogen, which may be the same or differentthan the immunogen of the lipid nanoparticle.

In certain embodiments of a method as above where the therapeutic agentis a polynucleotide, the lipid nanoparticle includes a mixture of lipidcomponents comprising (i) a cationic lipid that is permanently chargedat physiological pH, where the cationic lipid is present in the mixturefrom about 35 mole % to about 55 mole %; (ii) an ionizable anioniclipid, where the anionic lipid is optionally absent and, if present, ispresent in the mixture from about 25 mole % to about 40 mole %; (iii) ahelper lipid, where if the ionizable anionic lipid is absent, then thehelper lipid is present in the mixture from about 40 mole % to about 50mole %, and if the ionizable anionic lipid is present, then the helperlipid is present in the mixture from about 5 mole % to about 20 mole %;and (iv) a PEG-lipid, where the PEG-lipid is present in the mixture fromabout 2 mole % to about 15 mole %. In some such embodiments, thecationic lipid is DOTAP, the ionizable anionic lipid is CHEMS, thehelper lipid is CHOL, and/or the PEG-lipid is DSPE-PEG2 k or DMPE-PEG2k. In some variations of a method comprising a lipid nanoparticle asabove, the ionizable anionic lipid is absent, the cationic lipid ispresent from about 35 mole % to about 45 mole %, and the PEG-lipid ispresent from about 5% mole % to about 15 mole %. In other variations,the ionizable anionic lipid is present, and the cationic lipid ispresent from about 40 mole % to about 55 mole %; in some suchvariations, the PEG-lipid is present from about 5 mole % to about 15mole %. In more specific embodiments, (a) the cationic lipid is DOTAP,the ionizable anionic lipid is absent, the helper lipid is CHOL, thePEG-lipid is DSPE-PEG2 k, and the molar ratio of DOTAP:CHOL:DSPE-PEG2 kis about 40:50:10; (b) the cationic lipid is DOTAP, the ionizableanionic lipid is CHEMS, the helper lipid is CHOL, the PEG-lipid isDMPE-PEG2 k, and the molar ratio of DOTAP:CHEMS:CHOL:DMPE-PEG2 k isabout 50:32:16:2; (c) the cationic lipid is DOTAP, the ionizable anioniclipid is CHEMS, the helper lipid is CHOL, the PEG-lipid is DSPE-PEG2 k,and the molar ratio of DOTAP:CHEMS:CHOL:DSPE-PEG2 k is about 50:32:8:10;or (d) the cationic lipid is DOTAP, the ionizable anionic lipid isCHEMS, the helper lipid is CHOL, the PEG-lipid is DMPE-PEG2 k, and themolar ratio of DOTAP:CHEMS:CHOL:DMPE-PEG2 k is about 50:32:8:10.

In another aspect, the present invention provides a composition fordelivering a therapeutic or diagnostic agent to the cytosol of a targetcell within a subject. The composition generally includes (a) a lipidnanoparticle comprising the therapeutic or diagnostic agent and (b) amembrane-destabilizing polymer. In some embodiments, at least one of thelipid nanoparticle and membrane-destabilizing polymer includes a firsttargeting ligand that specifically binds to a molecule on the surface ofthe target cell. The lipid nanoparticle, membrane-destabilizing polymer,therapeutic agent, and/or targeting ligand(s) of the composition includethe various embodiments described above with respect to a method fordelivering a therapeutic or diagnostic agent to a cell.

In yet another aspect, the present invention provides a delivery systemfor delivering a therapeutic or diagnostic agent to the cytosol of atarget cell within a subject. The system generally includes (a) acarrier composition comprising a lipid nanoparticle, wherein the lipidnanoparticle comprises the therapeutic or diagnostic agent, and (b) anenhancer composition comprising a membrane-destabilizing polymer. Insome embodiments, at least one of the lipid nanoparticle andmembrane-destabilizing polymer includes a first targeting ligand thatspecifically binds to a molecule on the surface of the target cell. Thelipid nanoparticle, membrane-destabilizing polymer, therapeutic agent,and/or targeting ligand(s) of the composition include the variousembodiments described above with respect to a method for delivering atherapeutic or diagnostic agent to a cell.

In still another aspect, the present invention provides a method fortreating a disease characterized by a genetic defect that results in adeficiency of a functional protein. The method generally includesadministering to a subject having the disease (a) an effective amount ofa lipid nanoparticle comprising an mRNA that encodes the functionalprotein or a protein having the same biological activity as thefunctional protein and (b) an effective amount of amembrane-destabilizing polymer, where the mRNA is delivered to thecytosol of target cells of a target tissue associated with the disease,and where the mRNA is translated during protein synthesis so as toproduce the encoded protein within the target tissue, thereby treatingthe disease. In some embodiments, at least one of the lipid nanoparticleand membrane-destabilizing polymer comprises a first targeting ligandthat specifically binds to a molecule on the surface of the target cellsof the target tissue. The lipid nanoparticle and membrane-destabilizingpolymer can be administered separately (e.g., the membrane-destabilizingpolymer administered after administration of the lipid nanoparticle) or,alternatively, together within a single composition. The lipidnanoparticle and membrane-destabilizing polymer include the variousembodiments described above with respect to a method for delivering atherapeutic or diagnostic agent to a cell, provided that the therapeuticagent is the mRNA, the lipid nanoparticle includes a cationic lipid(e.g., an ionizable cationic lipid), and the targeting ligand, ifpresent, is selected to bind to the target cells of the target tissueexhibiting the protein deficiency. In certain variations, the lipidnanoparticle and the membrane-destabilizing polymer are administered ina repeat dosage regime (e.g., a weekly or bi-weekly repeatedadministration protocol).

In certain embodiments, the disease is a protein deficiency disease ofthe liver. In some such embodiments, the mRNA encodes a functionalprotein selected from alpha-1-antitrypsin (A1AT), carbamoyl phosphatesynthetase I (CPS1), fumarylacetoacetase (FAH) enzyme, alanine:glyoxylate-aminotransferase (AGT), methylmalonyl CoA mutase (MUT),propionyl CoA carboxylase alpha subunit (PCCA), propionyl CoAcarboxylase beta subunit (PCCB), a subunit of branched-chain ketoaciddehydrogenase (BCKDH), ornithine transcarbamylase (OTC),copper-transporting ATPase Atp7B, bilirubin uridinediphosphateglucuronyltransferase (BGT) enzyme, hepcidin, glucose-6-phosphatase(G6Pase), glucose 6-phosphate translocase, lysosomal glucocerebrosidase(GB), Niemann-Pick C1 protein (NPC1), Niemann-Pick C2 protein (NPC2),acid sphingomyelinase (ASM), Factor IX, galactose-1-phosphateuridylyltransferase, galactokinase, UDP-galactose 4-epimerase,transthyretin, a complement regulatory protein, phenylalaninehydroxylase (PAH), homogentisate 1,2-dioxygenase, porphobilinogendeaminase, hypoxanthine-guanine phosphoribosyltransferase (HGPRT),argininosuccinate lyase (ASL), argininosuccinate synthetase (ASS1),P-type ATPase protein FIC-1, alpha-galactosidase A, acid ceramidase,acid α-L-fucosidase, acid β-galactosidase, iduronate-2-sulfatase,alpha-L-iduronidase, galactocerebrosidase, acid α-mannosidase,β-mannosidase, arylsulfatase B, arylsulfatase A,N-acetylgalactosamine-6-sulfate sulfatase, acid β-galactosidase, acidα-glucosidase, β-hexosaminidase B, heparan-N-sulfatase,alpha-N-acetylglucosaminidase, acetyl-CoA:α-glucosaminideN-acetyltransferase, N-acetylglucosamine-6-sulfate sulfatase,alpha-N-acetylgalactosaminidase, sialidase, β-glucuronidase, andβ-hexosaminidase A.

In other embodiments in which the disease is a protein deficiencydisease of the liver, the disease is a urea cycle disorder. In some suchembodiments, the urea cycle disorder is selected from ornithinetranscarbamylase (OTC) deficiency, carbamoyl phosphate synthetase I(CPS1) deficiency, argininosuccinic aciduria (argininosuccinate lyase(ASL) deficiency), and citrullinemia (argininosuccinate synthetase(ASS1) deficiency). In certain variations where the urea cycle disorderis ornithine transcarbamylase (OTC) deficiency, the mRNA encodes afunctional OTC protein comprising an amino acid sequence having at least90% or at least 95% sequence identity with residues 35-354 of SEQ IDNO:1. In certain variations where the urea cycle disorder isargininosuccinic aciduria (argininosuccinate lyase (ASL) deficiency),the mRNA encodes a functional ASL protein comprising an amino acidsequence having at least 90% or at least 95% sequence identity with SEQID NO:48. In certain variations where the urea cycle disorder iscitrullinemia (argininosuccinate synthetase (ASS1) deficiency), the mRNAencodes a functional ASS1 protein comprising an amino acid sequencehaving at least 90% or at least 95% sequence identity with SEQ ID NO:50.

In certain embodiments for treating a protein deficiency disease of theliver as above, at least one of the membrane-destabilizing polymer andthe lipid nanoparticle comprises a targeting ligand that specificallybinds to the asialoglycoprotein receptor (ASGPR). Particularly suitableASGPR-specific targeting ligands comprise an N-acetylgalactosamine (NAG)residue.

In another aspect, the present invention provides a pH-sensitive,membrane-destabilizing polymer. In some embodiments, the pH-sensitive,membrane-destabilizing polymer comprises a random block copolymer offormula Ia:

wherein

A₀, A₁, A₂, A₃, A₄ and A₅ are each independently selected from the groupconsisting of —C—C—, —C(O)(C)_(a)C(O)O—, —O(C)_(a)C(O)—, —O(C)_(b)—, and—CR₈—CR₉—; where tetravalent carbon atoms of A₀-A₅ that are not fullysubstituted with R₁-R₆ and Y₀-Y₅ are completed with an appropriatenumber of hydrogen atoms; wherein a and b are each independently 1-4;and where R₈ and R₉ are each independently selected from the groupconsisting of —C(O)OH, —C(O)Oalkyl, and —C(O)NR₁₀, where R₈ and R₉ areoptionally covalently linked together to form a ring structure;

Y₅ is hydrogen or is selected from the group consisting of-(1C-10C)alkyl, -(3C-6C)cycloalkyl, —O-(1C-10C)alkyl,—C(O)O(1C-10C)alkyl, —C(O)NR₁₁(1C-10C)alkyl, and -(6C-10C)aryl, any ofwhich is optionally substituted with one or more fluorine atoms;

Y₀, Y₃, and Y₄ are each independently selected from the group consistingof a covalent bond, -(1C-10C)alkyl-, —C(O)O(2C-10C)alkyl-,—OC(O)(1C-10C)alkyl-, —O(2C-10C)alkyl-, —S(2C-10C)alkyl-, and—C(O)NR₁₂(2C-10C) alkyl-;

Y₁ and Y₂ are each independently selected from the group consisting of acovalent bond, -(1C-18C)alkyl-, -(3C-18C)branched alkyl,—C(O)O(2C-18C)alkyl-, —C(O)O(2C-18C)branched alkyl,—OC(O)(1C-18C)alkyl-, —OC(O)(1C-18C)branched alkyl-, —O(2C-18C)alkyl-,—O(2C-18C)branched alkyl-, —S(2C-18C)alkyl-, —S(2C-18C)branched alkyl-,—C(O)NR₁₂(2C-18C)alkyl-, and —C(O)NR₁₂(2C-18C)branched alkyl-, where anyalkyl or branched alkyl group of Y₁ or Y₂ is optionally substituted withone or more fluorine atoms;

R₁, R₂, R₃, R₄, R₅, R₆, R₈, R₉, R₁₀, R₁₁, and R₁₂ are each independentlyhydrogen, —CN, or selected from the group consisting of alkyl, alkynyl,heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, any ofwhich is optionally substituted with one or more fluorine atoms;

Q₀ is a residue selected from the group consisting of residues which arehydrophilic at physiologic pH; O—[(C)₂₋₃—O]_(x)—R₇; andO—[(C)₂₋₃—O]_(x)—C(O)—NR₁₃R₁₄; where x is 1-48; R₇ is —CH₃ or —CO₂H; andR₁₃ and R₁₄ are each independently hydrogen, —CN, or selected from thegroup consisting of alkyl, alkynyl, heteroalkyl, cycloalkyl,heterocycloalkyl, aryl and heteroaryl, any of which is optionallysubstituted with one or more fluorine atoms;

Q₁ and Q₂ are each independently absent or selected from a residue whichis hydrophilic at normal physiological pH; a conjugatable orfunctionalizable residue; a residue which is hydrophobic at normalphysiological pH; an alkyl group optionally substituted with one or morefluorine atoms; and a branched alkyl group optionally substituted withone or more fluorine atoms;

Q₃ is a residue which is positively charged at normal physiological pH;

Q₄ is a residue which is negatively charged at normal physiological pH,but undergoes protonation at lower pH;

m is a mole fraction of greater than 0.5 to less than 1.0;

n is a mole fraction of greater than 0 to less than 0.5;

p is a mole fraction of 0 to less than 0.5; wherein m+n+p=1;

q is a mole fraction of 0.1 to 0.9;

r is a mole fraction of 0.05 to 0.9;

s is present up to a mole fraction of 0.85; wherein q+r+s=1;

v is from 1 to 25 kDa;

w is from 1 to 50 kDa; and

at least one of Y₁ and Q₁ contains the alkyl or branched alkyl groupsubstituted with the one or more fluorine atoms.

In some embodiments of a pH-sensitive polymer comprising a copolymer offormula Ia as above, p is 0.

In some embodiments of a pH-sensitive polymer comprising a copolymer offormula Ia as above, R₂-A₁-Y₁-Q₁ taken together is a methacrylateresidue selected from the group consisting of2,2,3,3,4,4,4-heptafluorobutyl methacrylate residue;3,3,4,4,5,6,6,6-octafluoro-5(trifluoromethyl)hexyl methacrylate residue;2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctyl 2-methylacrylateresidue; 3,3,4,4,5,5,6,6,6-nonafluorohexyl methacrylate residue (alsoreferred to as 2-propenoic acid, 2-methyl-,3,3,4,4,5,5,6,6,6-nonafluorohexyl ester residue);3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl methacrylate residue;1,1,1-trifluoro-2-(trifluoromethyl)-2-hydroxy-4-methyl-5-pentyl methacrylate residue; and 2-[(1′,1′,1′-trifluoro-2′-(trifluoromethyl)-2′-hydroxy)propyl]-3-norbornylmethacrylate residue.

In some embodiments of a pH-sensitive polymer comprising a copolymer offormula Ia as above,

-   -   (a) Y₃ is —C(O)OCH₂CH₂, Q₃ is dimethylamino, and/or R₄ is —CH₃;    -   (b) Y₄ is a covalent bond, Q₄ is a carboxyl residue, and/or R₅        is —CH₂CH₂CH₃;    -   (c) Y₅ is —C(O)O(CH₂)₃CH₃ and/or R₆ is —CH₃; and/or    -   (d) Y₀ is —C(O)O(2C-10C)alkyl-, Q₀ is O—[(C)₂₋₃—O]_(x)—R₇ (where        x is 1-48 and R₇ is —CH₃), and/or R₁ is —CH₃.

In certain embodiments of a pH-sensitive polymer comprising a copolymerof formula Ia as above, the pH-sensitive polymer is a polymer of formulaVa:

T1-L-[PEGMA_(m)-M2_(n)]_(v)-[DMAEMA_(q)-PAA_(r)-BMA_(s)]_(w)   Va

where

PEGMA is polyethyleneglycol methacrylate residue with 2-20 ethyleneglycol units;

M2 is a methacrylate residue selected from the group consisting of

-   -   a (C4-C18)alkyl-methacrylate residue substituted with one or        more fluorine atoms, and    -   a (C4-C18)branched alkyl-methacrylate residue substituted with        one or more fluorine atoms,

BMA is butyl methacrylate residue;

PAA is propyl acrylic acid residue;

DMAEMA is dimethylaminoethyl methacrylate residue;

m and n are each a mole fraction greater than 0, where m is greater thann and m+n=1;

q is a mole fraction of 0.2 to 0.75;

r is a mole fraction of 0.05 to 0.6;

s is a mole fraction of 0.2 to 0.75;

q+r+s=1;

v is 1 to 25 kDa;

w is 1 to 25 kDa;

T1 is absent or is the first targeting ligand; and

L is absent or is a linking moiety.

In certain variations of a pH-sensitive polymer of formula Va as above,M2 is a methacrylate residue selected from the group consisting of2,2,3,3,4,4,4-heptafluorobutyl methacrylate residue;3,3,4,4,5,6,6,6-octafluoro-5(trifluoromethyl)hexyl methacrylate residue;2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctyl 2-methylacrylateresidue; 3,3,4,4,5,5,6,6,6-nonafluorohexyl methacrylate residue; and3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl methacrylate residue;1,1,1-trifluoro-2-(trifluoromethyl)-2-hydroxy-4-methyl-5-pentylmethacrylate residue; and2-[(1′,1′-trifluoro-2′-(trifluoromethyl)-2′-hydroxy)propyl]-3-norbornylmethacrylate residue.

In other embodiments, a pH-sensitive, membrane-destabilizing polymer isa polymer of formula V:

T1-L-[PEGMA_(m)-M2_(n)]_(v)-[DMAEMA_(q)-PAA_(r)-BMA_(s)]_(w)   V

where

PEGMA is polyethyleneglycol methacrylate residue with 2-20 ethyleneglycol units;

M2 is a methacrylate residue selected from the group consisting of

-   -   a (C4-C18)alkyl-methacrylate residue;    -   a (C4-C18)branched alkyl-methacrylate residue;    -   a cholesteryl methacrylate residue;    -   a (C4-C18)alkyl-methacrylate residue substituted with one or        more fluorine atoms; and    -   a (C4-C18)branched alkyl-methacrylate residue substituted with        one or more fluorine atoms;

BMA is butyl methacrylate residue;

PAA is propyl acrylic acid residue;

DMAEMA is dimethylaminoethyl methacrylate residue;

m and n are each a mole fraction greater than 0, wherein m is greaterthan n and m+n=1;

q is a mole fraction of 0.2 to 0.75;

r is a mole fraction of 0.05 to 0.6;

s is a mole fraction of 0.2 to 0.75;

q+r+s=1;

v is 1 to 25 kDa;

w is 1 to 25 kDa;

T1 is absent or is the first targeting ligand; and

L is absent or is a linking moiety.

In certain variations of a pH-sensitive polymer of formula V as above,M2 is a methacrylate residue selected from the group consisting of2,2,3,3,4,4,4-heptafluorobutyl methacrylate residue;3,3,4,4,5,6,6,6-octafluoro-5(trifluoromethyl)hexyl methacrylate residue;2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctyl 2-methylacrylateresidue; 3,3,4,4,5,5,6,6,6-nonafluorohexyl methacrylate residue;3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl methacrylate residue;1,1,1-trifluoro-2-(trifluoromethyl)-2-hydroxy-4-methyl-5-pentylmethacrylate residue;2-[(1′,1′,1′-trifluoro-2′-(trifluoromethyl)-2′-hydroxy)propyl]-3-norbornylmethacrylate residue; 2-ethylhexyl methacrylate residue; butylmethacrylate residue; hexyl methacrylate residue; octyl methacrylateresidue, n-decyl methacrylate residue; lauryl methacrylate residue;myristyl methacrylate residue; stearyl methacrylate residue; cholesterylmethacrylate residue; ethylene glycol phenyl ether methacrylate residue;2-propenoic acid, 2-methyl-, 2-phenylethyl ester residue; 2-propenoicacid, 2-methyl-, 2-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl esterresidue; 2-propenoic acid, 2-methyl-, 2-(1H-imidazol-1-yl)ethyl esterresidue; 2-propenoic acid, 2-methyl-, cyclohexyl ester residue;2-propenoic acid, 2-methyl-, 2-[bis(1-methylethyl)amino]ethyl esterresidue; 2-propenoic acid, 2-methyl-, 3-methylbutyl ester residue;neopentyl methacrylate residue; tert-butyl methacrylate residue;3,3,5-trimethyl cyclohexyl methacrylate residue; 2-hydroxypropylmethacrylate residue; 5-nonyl methacrylate residue; 2-butyl-1-octylmethacrylate residue; 2-hexyl-1-decyl methacrylate residue; and2-(tert-butyl amino)ethyl methacrylate residue.

In yet another aspect, the present invention provides a lipidnanoparticle. In some embodiments, the lipid nanoparticle comprises (a)a polynucleotide, and (b) a mixture of lipid components comprising (i) acationic lipid that is permanently charged at physiological pH, wherethe cationic lipid is present in the mixture from about 35 mole % toabout 55 mole %; (ii) an ionizable anionic lipid, where the anioniclipid is optionally absent and, if present, is present in the mixturefrom about 25 mole % to about 40 mole %; (iii) a helper lipid, where ifthe ionizable anionic lipid is absent, then the helper lipid is presentin the mixture from about 40 mole % to about 50 mole %, and if theionizable anionic lipid is present, then the helper lipid is present inthe mixture from about 5 mole % to about 20 mole %; and (iv) aPEG-lipid, where the PEG-lipid is present in the mixture from about 5mole % to about 15 mole %. In some such embodiments, the cationic lipidis DOTAP, the ionizable anionic lipid is CHEMS, the helper lipid isCHOL, and/or the PEG-lipid is DSPE-PEG2 k or DMPE-PEG2 k. In somevariations of a lipid nanoparticle as above, the ionizable anionic lipidis absent and the cationic lipid is present from about 35 mole % toabout 45 mole %. In other variations, the ionizable anionic lipid ispresent, and the cationic lipid is present from about 40 mole % to about55 mole %. In more specific embodiments, (a) the cationic lipid isDOTAP, the ionizable anionic lipid is absent, the helper lipid is CHOL,the PEG-lipid is DSPE-PEG2 k, and the molar ratio ofDOTAP:CHOL:DSPE-PEG2 k is about 40:50:10; (b) the cationic lipid isDOTAP, the ionizable anionic lipid is CHEMS, the helper lipid is CHOL,the PEG-lipid is DSPE-PEG2 k, and the molar ratio ofDOTAP:CHEMS:CHOL:DSPE-PEG2 k is about 50:32:8:10; or (c) the cationiclipid is DOTAP, the ionizable anionic lipid is CHEMS, the helper lipidis CHOL, the PEG-lipid is DMPE-PEG2 k, and the molar ratio ofDOTAP:CHEMS:CHOL:DMPE-PEG2 k is about 50:32:8:10. In certain embodimentsof a lipid nanoparticle as above, the polynucleotide is an mRNA.

These and other aspects of the invention will become evident uponreference to the following detailed description of the invention.

Definitions

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art pertinent to the methods and compositions described. As usedherein, the following terms and phrases have the meanings ascribed tothem unless specified otherwise.

The terms “a,” “an,” and “the” include plural referents, unless thecontext clearly indicates otherwise.

As used herein, the term “lipid nanoparticle” or “LNP” refers to aparticle of less than about 1,000 nm, typically less than about 200 nm,that is formulated with at least one lipid molecular species. Lipidnanoparticles include (but are not limited to) liposomes, irrespectiveof their lamellarity, shape, or structure. As used herein, a “liposome”is a structure having lipid-containing membranes enclosing an aqueousinterior. Liposomes may have one or more lipid membranes. Single-layeredliposomes are referred to as “unilamellar,” and multi-layered liposomesare referred to as “multilamellar.” Lipid nanoparticles may furtherinclude one or more additional lipids and/or other components, which maybe included in the liposome compositions for a variety of purposes, suchas to stabilize a lipid membrane, to prevent lipid oxidation, or toattach ligands on the liposome surface. Any number of lipids may bepresent, including amphipathic, neutral, cationic, and anionic lipids.Lipid nanoparticles can be complexed with therapeutic or diagnosticagents, including polynucleotides, proteins, peptides, or smallmolecules, and are useful as in vivo delivery vehicles.

The term “cationic lipid” refers to any of a number of lipid specieswhich carry a net positive charge at physiological pH. Such lipidsinclude, but are not limited to, DODAC, DOTMA, DOTAP, DC-Chol, DMRIE,DOEPC, DLEPC, DMEPC, 14:1, MVL5, DOGS, DORIE, DORI, and DILA².

The term “neutral lipid” refers to any of a number of lipid species thatexist either in an uncharged or neutral zwitterionic form atphysiological pH. Such lipids include, for example cholesterol, DOPE,DLPE, DLPC, phosphatidylcholines, phosphatidylethanolamines,phosphatidylserines, ceramide, sphingomyelin, cephalin, andcerebrosides.

The term “non-cationic lipid” refers to any neutral lipid as describedabove as well as anionic lipids (i.e., lipid species that carry a netnegative charge at physiological pH). Examples of anionic lipidsinclude, but are not limited to, cardiolipin, phosphatidylserine andphosphatidic acid.

An “ionizable anionic lipid” means an anionic lipid that undergoesprotonation as the pH is reduced toward the pK_(a) of the lipid. At thepK_(a) of the ionizable anionic lipid, half of the lipid is in theanionic form and half of the lipid is in the protonated form. In thecontext of lipid nanoparticles, at pH values above the pK_(a) of theionizable anionic lipid, more of the lipid is negatively charged, andthe negatively charged form of the lipid can stabilize other lipids in abilayer organization, allowing the formation of bilayer vesicles. Thesevesicles then fuse as the pH is reduced toward the pK_(a) of theionizable anionic lipid, such as in the endosomal environment, and moreof the ionizable anionic lipid becomes protonated. Examples of ionizableanionic lipids include cholesteryl hemisuccinate (CHEMS),phosphatidylserine, palmitoylhomoserine, and α-tocopherol hemisuccinate.

An “ionizable cationic lipid” means a cationic lipid that undergoesprotonation as the pH is reduced toward the pK_(a) of the lipid. At thepK_(a) of the ionizable cationic lipid, half of the lipid in in theprotonated form and half of the lipid is in the neutral form. In thecontext of lipid nanoparticles, at pH values below the pK_(a) of theionizable cationic lipid, the positively charged form of the lipid caninteract with negatively charged oligonucleotides, allowing forencapsulation of the oligonucleotides inside of vesicles andnanoparticles. At pH values above the pK_(a), more of the cationic lipidis neutral and this lack of charge can affect the surface potential oflipid nanoparticles as well as affect release of oligonucleotides fromthese lipids. Additionally, appropriately designed cationic lipids withunsaturated tails can mediate fusion events with other membranes byundergoing lamellar to inverse hexagonal phase transitions. Such fusionevents can result in endosomolysis which can enable delivery of materialinto the cytosol. Examples of ionizable anionic lipids include DDAB,DlinDMA, DLin-KC2-DMA, MC3 lipid (DLin-MC3-DMA), DODAP, DODMA, andMo-CHOL.

An “exchangeable PEG-lipid” means a PEG-lipid that is not stable in alipid nanoparticle (LNP) membrane at physiologic temperature, such thatPEG-lipid molecules in the LNP leave the LNP membrane over time.Exchangeable PEG-lipids leaving the LNP membrane typically move into abiological membrane (e.g., blood cell membranes) or may form micelles bythemselves. The rate of release of a PEG-lipid from an LNP is mainly afunction of the length of the alkyl chain and the level of unsaturationin the alkyl chain (i.e., the number of carbon-to-carbon double bonds).Typically, a PEG-lipid having a saturated chain of 14 carbons or lesswill be exchangeable. A C18 chain with one or more double bonds (e.g.,18:1, 18:2) will also be exchangeable. Generally, a PEG-lipid having analkyl chain of greater than 18 carbons will not be exchangeable orexchanges at a much lower rate than a PEG-lipid having an alkyl chain of14 carbons or less. Other factors that can increase the rate of releaseof a PEG-lipid include asymmetry in the alkyl chain (e.g., PEG-Ceramideswith different alkyl chain lengths (e.g., cerC8)) as well as the size ofthe PEG moiety, with larger molecular weight PEG moieties contributingto exchangeability of the lipid.

As used herein, “amphipathic” or “amphiphilic” compounds have bothhydrophilic (water-soluble) and hydrophobic (water-insoluble) parts.

As used herein, the term “therapeutic agent” refers to any molecularspecies (e.g., polynucleotide, protein, peptide, or small molecule) thatmay have a therapeutic effect upon delivery into a cell. In the case ofa polynucleotide, this effect can be mediated by the nucleic acid itself(e.g., anti-sense polynucleotide), following transcription (e.g.,anti-sense RNA, ribozymes, interfering dsRNA, mRNA), or followingexpression into a protein. A “therapeutic” effect of an expressedprotein in attenuating or preventing the disease state can beaccomplished by the protein either staying within the cell, remainingattached to the cell in the membrane, or being secreted and dissociatedfrom the cell where it can enter the general circulation and blood.Secreted proteins that can be therapeutic include hormones, cytokines,growth factors, clotting factors, anti-protease proteins (e.g.,alpha1-antitrypsin), angiogenic proteins (e.g., vascular endothelialgrowth factor, fibroblast growth factors), antiangiogenic proteins(e.g., endostatin, angiostatin), and other proteins that are present inthe blood. Proteins on the membrane can have a therapeutic effect byproviding a receptor for the cell to take up a protein or lipoprotein.Therapeutic proteins that stay within the cell (intracellular proteins)can be enzymes that clear a circulating toxic metabolite as inphenylketonuria. They can also cause a cancer cell to be lessproliferative or cancerous (e.g., less metastatic), or interfere withthe replication of a virus. Intracellular proteins can be part of thecytoskeleton (e.g., actin, dystrophin, myosins, sarcoglycans, anddystroglycans) and thus have a therapeutic effect in cardiomyopathiesand musculoskeletal diseases (e.g., Duchenne muscular dystrophy,limb-girdle disease). Protein agents may also be delivered directly intoa cell (i.e., in protein form, rather than as an encoding polynucleotideto be expressed). Other therapeutic proteins of particular interest totreating heart disease include polypeptides affecting cardiaccontractility (e.g., calcium and sodium channels), inhibitors ofrestenosis (e.g., nitric oxide synthetase), angiogenic factors, andanti-angiogenic factors. Protein agents may also include antibodies(e.g., small single-chain antibodies or bispecific antibodies) directedat intracellular targets. Other exemplary “therapeutic agents” includesmall molecules, such as, for example, small molecule inhibitors oragonists of intracellular target molecules (e.g., kinase inhibitors,inhibitors of DNA synthesis pathways) or small molecules having acytotoxic or cytostatic effect on a cell (such as chemotherapeuticagents for cancer treatment); anti-infective agents (e.g., anti-viralagents or anti-bacterial agents); or vaccines (which may includeproteins, peptides, DNA, or RNA). In some embodiments, a “therapeuticagent” is a component of a gene editing system that disrupts or correctsgenes that cause disease (e.g., a polynucleotide encoding a nuclease; aguide RNA that may be formulated with a polynucleotide encoding anuclease; or a donor DNA sequence for correcting a gene by homologousrecombination).

As used herein, the term “diagnostic agent” refers to a component thatcan be detected in a subject or test sample from a subject. Exemplarydiagnostic agents include radioactive agents, fluorescent agents,contrast agents (e.g., an MRI or X-ray contrast agent), and otherimaging reagents. Diagnostic reagents also include, for example,immunodiagnostic reagents (e.g., antibodies directed to intracellulartargets) as well as other specific binding agents. A diagnostic agentmay consist of, for example, a diagnostically detectable label that iscomplexed with a lipid nanoparticle, or may comprise a diagnosticallydetectable label conjugated to another molecule (e.g., a specificbinding molecule, such as, e.g., a peptide, protein, or polynucleotide).Many different labels exist in the art and methods of labeling arewell-known by the skilled artisan. General classes of labels that can beused in the present invention include, but are not limited to,radioactive isotopes, paramagnetic isotopes, compounds that can beimaged by positron emission tomography (PET), fluorescent or coloredcompounds, compounds which can be imaged by magnetic resonance,chemiluminescent compounds, bioluminescent compounds, and the like.Particularly suitable detectable labels include, but are not limited to,radioactive, fluorescent, fluorogenic, or chromogenic labels. Usefulradiolabels (radionuclides), which are detected simply by y counter,scintillation counter or autoradiography include, but are not limitedto, ³H, ¹²⁵I, ¹³¹I, ³⁵S and ¹⁴C.

As used herein, the term “membrane-destabilizing polymer” refers to apolymer that is capable of inducing one or more of the following effectsupon a biological membrane: an alteration or disruption that allowssmall molecule permeability, pore formation in the membrane, a fusionand/or fission of membranes, an alteration or disruption that allowslarge molecule permeability, a dissolving of the membrane, or causingmembrane perturbation that opens tight junctions and enablesparacellular transport. This alteration can be functionally defined bythe compound's activity in at least one the following assays: red bloodcell lysis (homolysis), liposome leakage, liposome fusion, cell fusion,cell lysis, and release of endosomal contents. Typically, amembrane-destabilizing polymer allows for the transport of moleculeswith a molecular weight greater than 50 atomic mass units to cross amembrane. This transport may be accomplished by either the loss ofmembrane structure or the formation of holes or pores in the membrane.In particular variations, a membrane- destabilizing polymer is acopolymer (e.g., an amphipathic copolymer), a synthetic amphipathicpeptide, a membrane active toxin (e.g., pardaxin, melittin, cecropin,magainin, PGLa, indolicidin, dermaseptin, or a derivative thereof), or aviral fusogenic peptide (e.g., the influenza virus hemagglutinin subunitHA-2 peptide).

As used herein, a “block copolymer” refers to a structure comprising oneor more sub-combination of constitutional or monomeric units. In someembodiments, the block copolymer is a diblock copolymer, a tri-blockcopolymer or a higher-ordered block copolymer. For example, a diblockcopolymer can comprise two blocks; a schematic generalization of such apolymer is represented by the following: [A_(a)-B_(b)-C_(c)- . . .]_(m)—[X_(x)—Y_(y)—Z_(z)- . . . ]_(n) or [A_(a)-B_(b)-C_(c)- . . .]_(m)-b-[X_(x)—Y_(y)—Z_(z)- . . . ]_(n), wherein each letter stands fora constitutional or monomeric unit, and wherein each subscript to aconstitutional unit represents the mole fraction of that unit in theparticular block, the three dots indicate that there may be more (theremay also be fewer) constitutional units in each block, and m and nindicate the molecular weight (or weight fraction) of each block in thediblock copolymer. As suggested by such schematic representation, insome instances, the number and the nature of each constitutional unit isseparately controlled for each block. The schematic is not meant to, andshould not be construed to, infer any relationship whatsoever betweenthe number of constitutional units or between the number of differenttypes of constitutional units in each of the blocks. Nor is theschematic meant to describe any particular number or arrangement of theconstitutional units within a particular block. In each block theconstitutional units may be disposed in a purely random, an alternatingrandom, a regular alternating, a regular block or a random blockconfiguration unless expressly stated to be otherwise. A purely randomconfiguration, for example, may have the form: x-x-y-z-x-y-y-z-y-z-z-z .. . . An exemplary alternating random configuration may have the form:x-y-x-z-y-x-y-z-y-x-z . . . , and an exemplary regular alternatingconfiguration may have the form: x-y-z-x-y-z-x-y-z . . . . An exemplaryregular block configuration may have the following generalconfiguration: . . . x-x-x-y-y-y-z-z-z-x-x-x . . . , while an exemplaryrandom block configuration may have the general configuration: . . .x-x-x-z-z-x-x-y-y-y-y-z-z-z-x-x-z-z-z- . . . . In a gradient polymer,the content of one or more monomeric units increases or decreases in agradient manner from the a end of the polymer to the ω end. In none ofthe preceding generic examples is the particular juxtaposition ofindividual constitutional units or blocks or the number ofconstitutional units in a block or the number of blocks meant nor shouldthey be construed as in any manner bearing on or limiting the actualstructure of block copolymers forming the polymeric carrier of thisinvention.

As used herein, the brackets enclosing the constitutional units are notmeant and are not to be construed to mean that the constitutional unitsthemselves form blocks. That is, the constitutional units within thesquare brackets may combine in any manner with the other constitutionalunits within the block, i.e., purely random, alternating random, regularalternating, regular block or random block configurations. The blockcopolymers described herein are, optionally, alternate, gradient orrandom block copolymers.

As used herein, the term “molecular weight” for a polymer or polymerblock is the number average molecular weight. It is understood in theart that a population of polymer molecules will have a distribution ofdifferent molecular weights. This distribution of molecular weights canbe described by the term dispersity index or polydispersity index (PI orPDI), which is the weight average molecular weight/number averagemolecular weight.

As used herein the term “polynucleotide” refers to a polymer comprisingtwo or more nucleotide monomeric units (“nucleotides”). Typicalpolynucleotides in accordance with certain embodiments of the presentinvention include those comprising 7-20,000 nucleotide monomeric units,7-15,000 nucleotide monomeric units, 7-10,000 nucleotide monomericunits, 7-5,000 nucleotide monomeric units and 7-1000 nucleotidemonomeric units. Polynucleotides of less than 200 nucleotides aregenerally referred to as “oligonucleotides.” Polynucleotides includedeoxyribonucleic acid (DNA) and ribonucleic acid (RNA), or theirderivatives, and combinations of DNA, RNA. DNA may be in form of cDNA,in vitro polymerized DNA, plasmid DNA, parts of a plasmid DNA, geneticmaterial derived from a virus, linear DNA, vectors (Pl, PAC, BAC, YAC,and artificial chromosomes), expression vectors, expression cassettes,chimeric sequences, recombinant DNA, chromosomal DNA, anti-sense DNA, orderivatives of these groups. RNA may be in the form of messenger RNA(mRNA), in vitro polymerized RNA, recombinant RNA, transfer RNA (tRNA),small nuclear RNA (snRNA), ribosomal RNA (rRNA), chimeric sequences,dicer substrate and the precursors thereof, locked nucleic acids,anti-sense RNA, interfering RNA (RNAi), asymmetric interfering RNA(aiRNA), small interfering RNA (siRNA), microRNA (miRNA), ribozymes,external guide sequences, small non-messenger RNAs (snmRNA),untranslatedRNA (utRNA), snoRNAs (24-mers, modified snmRNA that act byan anti-sense mechanism), tiny non-coding RNAs (tncRNAs), small hairpinRNA (shRNA), or their derivatives. In addition, DNA and RNA may besingle, double, triple, or quadruple stranded. Double stranded RNA(dsRNA) and siRNA are of interest particularly in connection with thephenomenon of RNA interference. Examples of oligonucleotides as usedherein include, but are not limited to, siRNA, an antisenseoligonucleotide, a dicer substrate, a miRNA, an aiRNA or an shRNA.Further examples of oligonucleotides as used herein include, but arc notlimited to dsRNA having a length of from 17 to 29 nucleotides, or from19 to 25 nucleotides, and being at least 90 percent, or 95 percent or100 percent (of the nucleotides of a dsRNA) complementary to a coding ora non-coding section of the nucleic acid sequence of a therapeuticallyrelevant protein or antigen. Ninety percent complementary means that a20 nucleotide length of a dsRNA contains not more than 2 nucleotideswithout a corresponding complementarily with the corresponding sectionof the mRNA. Yet further examples of polynucleotides as used hereininclude, but are not limited to single stranded mRNA which can bemodified or unmodified. Modified mRNA includes at least one modificationand a translatable region. Modification(s) may be located on thebackbone, a nucleoside of the nucleic acid molecule, and/or a 5′ capstructure. For example, a modification may be located on a nucleoside(e.g., substitution of uridine residues with pseudouridine), ormodifications may be located on both a nucleoside and a backbonelinkage. Typically, mRNAs in accordance with certain compositions andmethods of the present invention include those comprising 300-20,000nucleotide monomeric units, 300-15,000 nucleotide monomeric units,300-10,000 nucleotide monomeric units, 300-5,000 nucleotide monomericunits, 300-2000 nucleotide monomeric units, 300-1,500 nucleotidemonomeric units, and 300-1000 nucleotide monomeric units. In somevariations, an mRNA in accordance with compositions and methods of thepresent disclosure is at least 500, at least 1,000, at least 1,200, orat least 1,500 nucleotide monomeric units.

Polynucleotides may include nucleotides that have been modified relativeto naturally occurring nucleotides. Modified nucleotides can havealterations in sugar moieties and/or in pyrimidine or purine basemoieties. Sugar modifications include, for example, replacement of oneor more hydroxyl groups with halogens, alkyl groups, amines, and azidogroups, or sugars can be functionalized as ethers or esters. Moreover,the entire sugar moiety can be replaced with sterically andelectronically similar structures, such as aza-sugars and carbocyclicsugar analogs. Examples of modifications in a base moiety includealkylated purines and pyrimidines, acylated purines or pyrimidines, orother well-known heterocyclic substitutes. Nucleotide monomeric unitscan be linked by phosphodiester bonds or analogs of such linkages.Analogs of phosphodiester linkages include phosphorothioate,phosphorodithioate, phosphoroselenoate, phosphorodiselenoate,phosphoroanilothioate, phosphoranilidate, phosphoramidate, and the like.The term “polynucleotide” also includes so-called “peptide nucleicacids,” which comprise naturally-occurring or modified nucleic acidbases attached to a polyamide backbone.

A “polypeptide” is a polymer of amino acid residues joined by peptidebonds, whether produced naturally or synthetically. Polypeptides of lessthan about 50 amino acid residues are commonly referred to as“peptides.”

A “protein” is a macromolecule comprising one or more polypeptidechains. A protein may also comprise non-peptidic components, such ascarbohydrate groups. Carbohydrates and other non-peptidic substituentsmay be added to a protein by the cell in which the protein is produced,and will vary with the type of cell. Proteins are defined herein interms of their amino acid backbone structures; substituents such ascarbohydrate groups are generally not specified, but may be presentnonetheless.

With regard to proteins as described herein, reference to amino acidresidues corresponding to those specified by SEQ ID NO includespost-translational modifications of such residues.

As used herein, the term “antibody” refers to any immunoglobulin proteinthat specifically binds to an antigen, as well as antigen-bindingfragments thereof and engineered variants thereof. Hence, the term“antibody” includes, for example, polyclonal antibodies, monoclonalantibodies, and antigen-binding antibody fragments that contain theparatope of an intact antibody, such as Fab, Fab′, F(ab′)₂ and F(v)fragments. Genetically engineered intact antibodies and fragments, suchas chimeric antibodies, humanized antibodies, single-chain Fv fragments,single-chain antibodies, diabodies, minibodies, linear antibodies,multivalent or multispecific hybrid antibodies, and the like are alsoincluded. Thus, the term “antibody” is used expansively to include anyprotein that comprises an antigen binding site of an antibody and iscapable of binding to its antigen. In some embodiments, an antibody hasaffinity to a cell surface molecule.

The term “genetically engineered antibodies” means antibodies whereinthe amino acid sequence has been varied from that of a native antibody.Because of the relevance of recombinant DNA techniques in the generationof antibodies, one need not be confined to the sequences of amino acidsfound in natural antibodies; antibodies can be redesigned to obtaindesired characteristics. The possible variations are many and range fromthe changing of just one or a few amino acids to the complete redesignof, for example, the variable or constant region. Changes in theconstant region will, in general, be made in order to improve or altercharacteristics, such as complement fixation, interaction with cells andother effector functions. Typically, changes in the variable region willbe made in order to improve the antigen binding characteristics, improvevariable region stability, or reduce the risk of immunogenicity.

An “antigen-binding site of an antibody” is that portion of an antibodythat is sufficient to bind to its antigen. The minimum such region istypically a variable domain or a genetically engineered variant thereof.Single-domain binding sites can be generated from camelid antibodies(see Muyldermans and Lauwereys, J. Mol. Recog. 12:131-140, 1999; Nguyenet al., EMBO J. 19:921-930, 2000) or from V_(H) domains of other speciesto produce single-domain antibodies (“dAbs”; see Ward et al., Nature341:544-546, 1989; U.S. Pat. No. 6,248,516 to Winter et al.). In certainvariations, an antigen-binding site is a polypeptide region having only2 complementarity determining regions (CDRs) of a naturally ornon-naturally (e.g., mutagenized) occurring heavy chain variable domainor light chain variable domain, or combination thereof (see, e.g., Pessiet al., Nature 362:367-369, 1993; Qiu et al., Nature Biotechnol.25:921-929, 2007). More commonly, an antigen-binding site of an antibodycomprises both a heavy chain variable domain and a light chain variabledomain that bind to a common epitope. Examples of molecules comprisingan antigen-binding site of an antibody are known in the art and include,for example, Fv fragments, single-chain Fv fragments (scFv), Fabfragments, diabodies, minibodies, Fab-scFv fusions, bispecific(scFv)₄-IgG, and bispecific (scFv)₂-Fab. (See, e.g., Hu et al., CancerRes. 56:3055-3061, 1996; Atwell et al., Molecular Immunology33:1301-1312, 1996; Carter and Merchant, Curr. Opin. Biotechnol.8:449-454, 1997; Zuo et al., Protein Engineering 13:361-367, 2000; andLu et al., J. Immunol. Methods 267:213-226, 2002.)

As used herein, the terms “single-chain Fv” and “single-chain antibody”refer to antibody fragments that comprise, within a single polypeptidechain, the variable regions from both heavy and light chains, but lackconstant regions. In general, a single-chain antibody further comprisesa polypeptide linker between the V_(H) and V_(L) domains, which enablesit to form the desired structure that allows for antigen binding.Single-chain antibodies are discussed in detail by, for example,Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113(Rosenburg and Moore eds., Springer-Verlag, New York, 1994), pp.269-315. (See also WIPO Publication WO 88/01649; U.S. Pat. Nos.4,946,778 and 5,260,203; Bird et al., Science 242:423-426, 1988.)Single-chain antibodies can also be bi-specific and/or humanized.

A “bispecific antibody” is a hybrid antibody having two differentheavy/light chain pairs and two different binding sites. Bispecificantibodies are well-established in the art as a standard technique tocreate a single protein that binds to two different determinants. See,e.g., Kufer et al., Trends Biotechnol. 22:238-244, 2004. Bispecificantibodies may be made in many different formats, including but notlimited to quadroma, F(ab′)2, tetravalent, heterodimeric scFv,bispecific scFv, tandem scFv, diabody and minibody formats, or scFvsappended to or recombinantly fused with whole antibodies. See e.g.,Kufer et al., 2004; Holliger and Hudson Nature Biotechnology23:1126-1136, 2005; Morrison and Coloma, WO 95/09917.

As used herein, an “immunogen” is an entity (e.g., a peptide, protein, anucleic acid, or a carbohydrate) that induces an immune response, whichmay include an innate or an adaptive immune response (e.g., thatprotects a subject from an infection or cancer). An adaptive immuneresponse can be a humoral and/or cell-mediated immune response. Incertain embodiments, an immunogen in the context of the presentdisclosure is used as a vaccine.

As used herein the term “sugar” refers to saccharides such asmonosaccharides, disaccharides, oligosaccharides, and polysaccharidesfor example. Typically, sugars as used herein target or delivercopolymers to target cells or tissues, or specific cells types andenhance the association of molecules with the target cells. For example,liver hepatocytes contain asialoglycoprotein (ASGP) receptors.Therefore, galactose-containing targeting groups may be used to targethepatocytes. Examples of galactose containing targeting groups include,but are not limited to, galactose or galactose derivatives such as itsprotected analogs, N-acetylgalactosamine (NAG, also referred to asGalNAc) or N-acetylgalactosamine derivatives such as its protectedanalogs, oligosaccharides, and saccharide clusters such asTyr-Glu-Glu-(aminohexyl GalNAc)3, lysine-based galactose clusters, andcholane-based galactose clusters. Other examples of sugars include, butare not limited to, mannose and mannose derivatives such as itsprotected analogs. In some variations, a sugar is a multivalentstructure comprising two or more sugar moieties (e.g., three or fourmoieties). In some such multivalent sugar embodiments, each moiety isconnected to a common branching point via a linker. An exemplarymultivalent sugar is a tri-N-acetylgalactosamine (tri-NAG) structurehaving three NAG moieties. Tri-NAG structures are generally known in theart and are described, for example, in Lee et al., Carbohydrates andChemistry and Biology (B. Ernst, G.W. Hart, & P. Sinay, Eds., Wiley-WCH:Weinheim, 2000), Vol. 4, p 459 (and references cited therein); Biessenet al. J. Med. Chem. 38:1538, 1995; Sliedregt et al., J. Med. Chem.42:609, 1999; Rensen et al., J. Med. Chem. 47:5798, 2004; Khorev et al.,Bioorg. Med. Chem. 16:5216, 2008. Another exemplary multivalent sugar isa bis-mannose-6-phosphate (bis-M6P) structure having twomannose-6-phosphate moieties (see, e.g., U.S. Pat. No. 8,399,657 to Zhuet al.).

As used herein the term “vitamin” refers any of various fat-soluble orwater-soluble organic substances that are essential in minute amountsfor normal growth and activity of living organisms. Exemplary vitaminsinclude Vitamin A (Retinol), Vitamin B1 (Thiamine), Vitamin C (Ascorbicacid), Vitamin D (Calciferol), Vitamin B2 (Riboflavin), Vitamin E(Tocopherol), Vitamin B12 (Cobalamins), Vitamin K1 (Phylloquinone),Vitamin B5 (Pantothenic acid), Vitamin B7 (Biotin), Vitamin B6(Pyridoxine), Vitamin B3 (Niacin), Vitamin B9 (Folic acid) and theirderivatives. Typically, vitamins as used herein target or deliver lipidnanoparticles and/or membrane-destabilizing polymers to target cells ortissues, or specific cells types and enhance the association ofmolecules with the target cells. An example of a vitamin as used hereinincludes Vitamin B₉, including folic acid, folate and their derivatives.

As used herein, a “targeting ligand” refers to a moiety that is capableof specifically binding to a molecule on the surface of a target cell,such as a cell within a target tissue of a subject. A molecule (e.g.,cell surface molecule) that specifically binds to a targeting moiety isalso referred to herein as a “binding partner.”

As used herein, “alkyl” refers to a straight or branched chain fullysaturated (no double or triple bonds) hydrocarbon (carbon and hydrogenonly) group, optionally having a cycloalkyl group as part of thehydrocarbon chain (either at a terminal position or non-terminalposition in the chain). An alkyl group herein contains from one to tencarbon atoms in the principal chain and up to 20 carbon atoms, and maybe linear or branched. Examples of alkyl groups include, but are notlimited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl,sec-butyl, tertiary butyl, pentyl and hexyl. As used herein, “alkyl”includes “alkylene” groups, which refer to straight or branched fullysaturated hydrocarbon groups having two rather than one open valencesfor bonding to other groups. Examples of alkylene groups include, butare not limited to methylene (—CH₂—), ethylene (—CH₂CH₂—), propylene(—CH₂CH₂CH₂—), n-butylene (—CH₂CH₂CH₂CH₂—), sec-butylene(—CH₂CH₂CH(CH₃)—), and the like. An alkyl group of this disclosure mayoptionally be substituted with one or more fluorine groups.

As used herein, “mC to nC,” “Cm to Cn,” or “C_(m) to C_(n),” wherein mand n are integers, refers to the number of possible carbon atoms in theindicated group. That is, the group can contain from “m” to “n”,inclusive, carbon atoms. An alkyl group of this disclosure may comprisefrom 1 to 18 carbon atoms, that is, m is 1 and n is 18. Of course, aparticular alkyl group may be more limited. For instance withoutlimitation, an alkyl group of this disclosure may consist of 3 to 8carbon atoms, in which case it would be designated as a (3C-8C)alkylgroup. The numbers are inclusive and incorporate all straight orbranched chain structures having the indicated number of carbon atoms.For example without limitation, a “1C to 4C alkyl” or “(1C-4C)alkyl”group refers to all alkyl groups having from 1 to 4 carbons, that is,CH₃—, CH₃CH₂—, CH₃CH₂CH₂—, CH₃CH(CH₃)—, CH₃CH₂CH₂CH₂—, CH₃CH₂CH(CH₃)—,(CH₃)₂CHCH₂— and (CH₃)₃CH—.

As used herein, the term “aryl” or “aryl group” refers to optionallysubstituted monocyclic, bicyclic, and tricyclic ring systems having atotal of five to fourteen ring members, wherein at least one ring in thesystem is aromatic and wherein each ring in the system contains three toseven ring members. The terms “aryl” or “ar” as used herein alone or aspart of another group denote optionally substituted homocyclic aromaticgroups, preferably monocyclic or bicyclic groups containing from 6 to 12carbons in the ring portion, such as phenyl, biphenyl, naphthyl,substituted phenyl, substituted biphenyl or substituted naphthyl. Phenyland substituted phenyl are the more preferred aryl.

As used herein, the term “heteroalkyl” means an alkyl group wherein atleast one of the backbone carbon atoms is replaced with a heteroatom.

As used herein, the term “heteroaryl” means an aryl group wherein atleast one of the ring members is a heteroatom, and preferably 5 or 6atoms in each ring. The heteroaromatic group preferably has 1 or 2oxygen atoms, 1 or 2 sulfur atoms, and/or 1 to 4 nitrogen atoms in thering, and may be bonded to the remainder of the molecule through acarbon or heteroatom. Exemplary heteroaromatics include furyl, thienyl,pyridyl, oxazolyl, pyrrolyl, indolyl, quinolinyl, or isoquinolinyl andthe like. Exemplary substituents include one or more of the followinggroups: hydrocarbonyl, substituted hydrocarbonyl, keto (i.e., ═O),hydroxy, protected hydroxy, acyl, acyloxy, alkoxy, alkenoxy, alkynoxy,aryloxy, halogen, amido, amino, nitro, cyano, thiol, ketals, acetals,esters and ethers.

As use herein, “cycloalkyl” refers to an alkyl group in which the endcarbon atoms of the alkyl chain are covalently bonded to one another.The numbers “m” and “n” refer to the number of carbon atoms in the ringformed. Thus for instance, a (3C-8C) cycloalkyl group refers to a three,four, five, six, seven or eight member ring, that is, cyclopropane,cyclobutane, cyclopentane, cyclohexane, cycloheptane and cyclooctane. Acycloalkyl group of this invention may optionally be substituted withone or more fluorine groups and/or one or more alkyl groups.

As used herein, the term “heterocycloalkyl” means a cycloalkyl groupwherein at least one of the backbone carbon atoms is replaced with aheteroatom.

As used herein, the term “alkynyl” refers to an unsaturated, straightchain hydrocarbon group having from two to ten carbon atoms therein andin which at least two carbon atoms are bonded together by a triple bond.

As used herein, the term “alkenyl” refers to an unsaturated, straightchain hydrocarbon group having from two to ten carbon atoms therein andin which at least two carbon atoms are bonded together by a double bond.

When a functional group, such as an amine, is termed “protected,” thismeans that the group is in modified form to preclude undesired sidereactions at the protected site. Suitable protecting groups for thecopolymers of the present disclosure will be recognized from the presentapplication taking into account the level of skill in the art, and withreference to standard textbooks, such as Greene, T. W. et al.,Protective Groups in Organic Synthesis Wiley, New York (1991). Carboxygroups can be protected as esters thereof, for example methyl, ethyl,tert-butyl, benzyl, and 4-nitrobenzyl esters. Hydroxy groups can beprotected as ethers or esters thereof, for example methoxymethyl ethers,tetrahydropyranyl ethers, benzyl ethers, acetates or benzoates. Mercaptogroups can be protected as thioethers or thioesters, for example pyridylthioethers, maleimide thioethers, tert-butyl thioethers, thioacetates orthiobenzoates. Amino groups can be protected as carbamates, such astert-butoxycarbonyl derivatives, or as amides, such as acetamides andbenzamides.

As is well-known in the art, nomenclature of PEG molecular weight canuse the overall molecular weight (including the PEG end groups) or thenumber of repeat units. For example PEG₁₂ is also known as PEG_(0.6 kDa)or PEG_(0.6 k). PEG₃₆ is also known as PEG_(1.6 kDa) or PEG_(1.6 k).PEG₄₈ is also known as PEG_(2.2 kDa) or PEG_(2.2 k). A particular formof PEG₄₈ is also known as PEG₂₄-amido-PEG₂₄, but has also been generallydescribed as PEG_(2.2 kDa) or PEG_(2.2 k).

PEGMA₄₋₅ (Poly(ethylene glycol) methyl ether methacrylate, averageMn=300) is also known as PEGMA_(0.3 kDA) or PEGMA_(0.3 k) or PEGMA₃₀₀,which is the average molecular weight of a mixture of PEGMA₄ and PEGMA₅.Similarly, PEGMA₇₋₉ (Poly(ethylene glycol) methyl ether methacrylate,average Mn=500) is also known as PEGMA_(0.5 kDA) or PEGMA_(0.5 k) orPEGMA₅₀₀, which is the average molecular weight of a mixture of PEG₇ andPEG₉. Similarly, PEGMA₁₇₋₁₉ (Poly(ethylene glycol) methyl ethermethacrylate, average Mn=1000) is also known as PEGMA_(1 kDA) orPEGMA_(1 k) or PEGMA₁₀₀₀, which is the average molecular weight of amixture of PEGMA₁₇ and PEGMA₁₉.

As used herein, a “labile bond” is a covalent bond that is capable ofbeing selectively broken. That is, the labile bond may be broken in thepresence of other covalent bonds without the breakage of the othercovalent bonds. For example, a disulfide bond is capable of being brokenin the presence of thiols without cleavage of other bonds, such ascarbon-carbon, carbon-oxygen, carbon-sulfur, carbon-nitrogen bonds,which may also be present in the molecule. Labile also means“cleavable.”

As used herein, a “labile linkage” is a chemical compound that containsa labile bond and provides a link or spacer between two other groups.The groups that are linked may be chosen from compounds such asbiologically active compounds, membrane active compounds, compounds thatinhibit membrane activity, functional reactive groups, monomers, andcell targeting signals. The spacer group may contain chemical moietieschosen from a group that includes alkanes, alkenes, esters, ethers,glycerol, amide, saccharides, polysaccharides, and heteroatoms such asoxygen, sulfur, or nitrogen. The spacer may be electronically neutral,may bear a positive or negative charge, or may bear both positive andnegative charges with an overall charge of neutral, positive ornegative.

As used herein, “pH-labile” or “pH-sensitive” refers to the selectivebreakage of a covalent bond under acidic conditions (pH<7), or that thecovalent bond is broken more rapidly under acidic conditions (pH<7) thanunder neutral conditions. That is, the pH-labile bond may be brokenunder acidic conditions in the presence of other covalent bonds that arenot broken.

As used herein, a “micelle” includes a particle comprising a core and ahydrophilic shell, wherein the core is held together at least partially,predominantly or substantially through hydrophobic interactions. Incertain instances, as used herein, a “micelle” is a multi-component,nanoparticle comprising at least two domains, the inner domain or core,and the outer domain or shell. The core is at least partially,predominantly or substantially held together by hydrophobicinteractions, and is present in the center of the micelle. As usedherein, the “shell of a micelle” is defined as non-core portion of themicelle.

As used herein, a particle or assembly is “micelle-like” if itsubstantially behaves like a micelle: (1) it is formed by spontaneousself association of block copolymers to form organized assemblies (e.g.,micelles) upon dilution from a water-miscible solvent (such as but notlimited to ethanol) to aqueous solvents (for example phosphate-bufferedsaline, pH 7.4); (2) it is stable to dilution (e.g., down to a polymerconcentration of 100 μg/ml, 50 μg/ml, 10 μg/ml, 5 μg/ml or 1 μg/ml,which constitutes the critical stability concentration or the criticalmicelle concentration (CMC)); and/or (3) it has an increasinginstability as the concentration of organic solvent increases, suchorganic solvents including, but not limited to dimethylformamide (DMF),dimethylsulfoxide (DMS), and dioxane.

The term “effective amount,” in the context of methods as describedherein for delivering a therapeutic or diagnostic agent intracellularlyby administering to a subject a lipid nanoparticle and amembrane-destabilizing polymer, refers to an amount the lipidnanoparticle and an amount of the membrane-destabilizing polymer thattogether is sufficient to achieve detectable delivery of the therapeuticor diagnostic agent to the cytosol of a target cell or target tissue.Reference herein to delivery of a therapeutic or diagnostic agent to the“cytosol” includes delivery of such a therapeutic or diagnostic agentthat may ultimately be targeted to the nucleus of a cell subsequent toits delivery to the cytosol.

The term “effective amount” or “therapeutically effective amount,” inthe context of treatment of a disease by administering to a subject alipid nanoparticle and membrane-destabilizing polymer as describedherein, refers to an amount the lipid nanoparticle (comprising thetherapeutic agent) and an amount of the membrane-destabilizing polymerthat together is sufficient to inhibit the occurrence or ameliorate oneor more symptoms of the disease in the subject. An effective amount ofan agent-containing lipid nanoparticle and membrane-destabilizingpolymer is administered according to the present methods in an“effective regime.” The term “effective regime” refers to a combinationof agent-containing lipid nanoparticle being administered,membrane-destabilizing polymer being administered, and dosage frequencyadequate to accomplish treatment or prevention of the disease.

The term “patient” or “subject,” in the context of therapeutic ordiagnostic agent delivery in vivo as described herein, includes humanand other mammalian subjects.

Percent sequence identity is determined by conventional methods. See,e.g., Altschul et al., Bull. Math. Bio. 48:603, 1986, and Henikoff andHenikoff, Proc. Natl. Acad. Sci. USA 89:10915, 1992. For example, twoamino acid sequences can be aligned to optimize the alignment scoresusing a gap opening penalty of 10, a gap extension penalty of 1, and the“BLOSUM62” scoring matrix of Henikoff and Henikoff, supra. The percentidentity is then calculated as: ([Total number of identicalmatches]/[length of the longer sequence plus the number of gapsintroduced into the longer sequence in order to align the twosequences])(100). Those skilled in the art appreciate that there aremany established algorithms available to align two amino acid sequences.The “FASTA” similarity search algorithm of Pearson and Lipman (Proc.Nat'l Acad. Sci. USA 85:2444, 1988, and by Pearson, Meth. Enzymol.183:63, 1990) is a suitable protein alignment method for examining thelevel of identity shared by an amino acid sequence disclosed herein anda second amino acid sequence.

When such a value is expressed as “about” X or “approximately” X, thestated value of X will be understood to be accurate to ±10%.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A and 1B show reduction in orotic acid (OA) and plasma ammonialevels in hyperammonemic OTC-spf^(ash) mice treated with mRNA encodingornithine transcarbamylase (OTC). Hyperammonemia was induced inOTC-spf^(ash) mice by treatment with AAV2/8 vector/OTC shRNA, and fourdays after AAV dosing, mice were treated twice per week with 1 mg/kg ofOTC mRNA formulated in DOTAP:CHEMS:CHOL:DMPE-PEG_(2 k) (50:32:16:2) atN:P 7+co-injection of 50 mg/kg P67. See Example 21. Urine collected atday 6 and day 13 (post-AAV treatment) was analyzed for OA levels thatwere normalized to creatine levels, and plasma collected at day 13 wasanalyzed for ammonia levels. Orotic acid levels are shown in FIG. 1A(black fill=day 6; crosshatch fill=day 13). Plasma ammonia levels areshown in FIG. 1B.

FIGS. 2A and 2B show reduction in orotic acid (OA) and plasma ammonialevels in hyperammonemic OTC-spf^(ash) mice treated with mRNA encodingornithine transcarbamylase (OTC). Hyperammonemia was induced inOTC-spf^(ash) mice by treatment with AAV2/8 vector/OTC shRNA, and fourdays after AAV dosing, mice were treated twice per week with 1 mg/kg ofOTC mRNA formulated in DOTAP:CHEMS:CHOL:DSPE-PEG_(2 k) (50:32:8:10) atN:P 7+co-injection of 35 mg/kg P82. See Example 21. Urine collected atday 6 and day 13 (post-AAV treatment) was analyzed for OA levels thatwere normalized to creatine levels, and plasma collected at day 13 wasanalyzed for ammonia levels. Orotic acid levels are shown in FIG. 2A(black fill=day 6; crosshatch fill=day 13). Plasma ammonia levels areshown in FIG. 2B.

FIG. 3 schematically depicts a proposed mechanism of action for deliveryof an mRNA to the cytosol of a target cell using amembrane-destabilizing polymer and an LNP carrier in accordance with anembodiment of the present disclosure. (A) Two separate nanoparticlesolutions are prepared: one nanoparticle containing themembrane-destabilizing polymer and a second nanoparticle that is the LNPcomprising the mRNA. (B) The two nanoparticle solutions are then mixedimmediately prior to in vivo administration. (C) While not intending tobe bound by theory, it is believed that the polymer and mRNA/LNPnanoparticles co-localize within the same intracellular vesicle (e.g.,endosome) of the target cell, where (D) the membrane-destabilizingpolymer triggers release of the mRNA into the cytosol for translationinto protein.

DESCRIPTION OF THE INVENTION

The present invention is directed to methods, compositions, and deliverysystems for in vivo delivery of a therapeutic or diagnostic agent to thecytosol of a target cell (e.g., in vivo cytosolic delivery of the agentto a plurality of target cells within a target tissue). The methods,compositions, and delivery systems may be used for intracellulardelivery of a wide variety of molecular agents, includingpolynucleotides, peptide, proteins, and small molecules, and thus have avariety of diagnostic and therapeutic applications, including, e.g., thetreatment of cancer, infectious disease, and diseases characterized byprotein deficiencies.

The present invention relates, inter alia, to formulations used fordelivery of the therapeutic or diagnostic agent. Generally, thetherapeutic or diagnostic agent is formulated in a lipid nanoparticle(“LNP”; e.g., a liposome) and either a membrane-destabilizing polymer isadded to the formulation (a co-formulation for co-injection of LNP andpolymer) or the LNP “carrier” formulation and the membrane-destabilizingpolymer are used separately via separate (e.g., sequential) injectionsinto a subject. Either one or both of the LNP and membrane-destabilizingpolymer may include a targeting ligand that binds to a molecule on thesurface of the desired cell target. In certain other embodiments,neither the LNP nor the membrane-destabilizing polymer have a targetingligand. The function of the lipid nanoparticle is to encapsulate thetherapeutic or diagnostic agent, preventing its interaction with variouscomponents of the systemic circulation and facilitating delivery to anduptake into the desired tissues and cells. The lipid nanoparticle mayalso participate in lysis of endosomes. While not intending to be boundby theory, it is believed that the membrane-destabilizing polymerfunctions as an agent to elicit or enhance the delivery of thetherapeutic or diagnostic agent into the cytosol of target cells,possibly by improving endosomal escape of the LNP from the endosome. Forexample, the lipid nanoparticle and the membrane-destabilizing polymermay co-localize to an intracellular vesicle within the target cell,where the membrane-destabilizing polymer may facilitate release of thetherapeutic or diagnostic agent by disrupting the vesicle membrane. Asshown in the working examples herein, the combination of LNP andmembrane-destabilizing polymer demonstrated enhanced activity of thedelivered agent (either using co-injection or sequential injections) ascompared to the use of LNPs alone. See Examples 1, 2, 18, and 20, infra.Again without intending to be bound by theory, this result is believedto be due to enhanced delivery of the agent into the target cells whenpolymer is used in combination with an LNP carrier.

Accordingly, in one aspect, the present invention provides a method fordelivering a therapeutic or diagnostic agent to the cytosol of a targetcell. The method generally includes administering to the subject (a) aneffective amount of a lipid nanoparticle comprising the therapeutic ordiagnostic agent and (b) an effective amount of a membrane-destabilizingpolymer, where the therapeutic or diagnostic agent is delivered to thecytosol of the target cell. In some embodiments of the method, at leastone of the lipid nanoparticle and membrane-destabilizing polymerincludes a first targeting ligand that specifically binds to a moleculeon the surface of the target cell.

In another aspect, the present invention provides a composition fordelivering a therapeutic or diagnostic agent to the cytosol of a targetcell. The composition generally includes (a) a lipid nanoparticlecomprising the therapeutic or diagnostic agent and (b) amembrane-destabilizing polymer. In some embodiments of the composition,at least one of the lipid nanoparticle and membrane-destabilizingpolymer includes a first targeting ligand that specifically binds to amolecule on the surface of the target cell. Such compositions may beused in certain embodiments of the delivery methods described herein,particularly embodiments comprising co-injection of amembrane-destabilizing polymer and a lipid nanoparticle comprising thetherapeutic or diagnostic agent.

In another aspect, the present invention provides a delivery system fordelivering a therapeutic or diagnostic agent to the cytosol of a targetcell. The delivery system generally includes (a) a carrier compositioncomprising a lipid nanoparticle, where the lipid nanoparticle comprisesthe therapeutic or diagnostic agent and (b) an enhancer compositioncomprising a membrane-destabilizing polymer. In some embodiments of thedelivery system, at least one of the lipid nanoparticle andmembrane-destabilizing polymer includes a first targeting ligand thatspecifically binds to a molecule on the surface of the target cell. Suchdelivery systems may be used in certain embodiments of the deliverymethods described herein, particularly embodiments comprising separate(e.g., sequential) injection of a membrane-destabilizing polymer and alipid nanoparticle comprising the therapeutic or diagnostic agent.

In another aspect, the present invention provides amembrane-destabilizing polymer as described herein.

In another aspect, the present invention provides a lipid nanoparticleas described herein.

Typically, where a membrane-destabilizing polymer is added to a lipidnanoparticle formulation in accordance with the present disclosure(e.g., for making a composition comprising (a) a lipid nanoparticlecomprising a therapeutic or diagnostic agent and (b) amembrane-destabilizing polymer), the polymer is not contained within thelipid nanoparticle. In certain embodiments of the various aspectsdisclosed herein, the membrane-destabilizing polymer forms ananoparticle that is compositionally distinct from the lipidnanoparticle. For example, where the membrane-destabilizing polymer is apolymer comprising hydrophilic and hydrophobic segments, the polymer mayform a micelle or micelle-like particle in aqueous solution.

A wide variety of therapeutic and diagnostic agents are generally knownand may be used in accordance with the present methods, compositions,and delivery systems. The therapeutic or diagnostic agent to bedelivered can be, for example, a polynucleotide, a protein, a peptide,or a small molecule. Suitable classes of therapeutic agents include, forexample, anti-cancer agents, anti-infective agents (e.g., anti-viral oranti-bacterial agents), immunomodulatory agents (e.g., immunosuppressiveor immunostimulatory agents), anti-inflammatory agents, or agents thatmodulate a cellular metabolic activity. Suitable diagnostic agentsinclude, e.g., a variety of detectable agents, which may be used aloneor as a conjugate (label) to another molecule (e.g., a polynucleotide, aprotein, a peptide, or a small molecule) having a desired propertyuseful in a diagnostic method (e.g., a binding specificity for a desiredintracellular target). General classes of labels that can be used in thepresent invention include, but are not limited to, radioactive isotopes,paramagnetic isotopes, compounds that can be imaged by positron emissiontomography (PET), fluorescent or colored compounds, compounds which canbe imaged by magnetic resonance, chemiluminescent compounds,bioluminescent compounds, and other imaging reagents.

Methods for formulating lipid nanoparticles for drug delivery aregenerally known in the art and may be adapted for use in the context ofthe present invention. For example, lipid nanoparticle formulations fordelivery of small RNAs are discussed in, e.g., Hong and Nam,Theranostics 4:1211-1232, 2014; Asai and Oku, Biol. Pharm. Bull.37:201-205, 2014; and Tam et al., Pharmaceutics 5:498-507, 2013. Lipidparticle formulations and lipid design for drug delivery are alsodiscussed in, e.g., Samad et al., Current Drug Delivery 4:297-305, 2007;Martin et al., Current Pharmaceutical Design 11:375-394, 2005; Hafez etal., Biophysical Journal 79:1438-1446, 2000; Jayaraman et al., Angew.Chem. Int. Ed. 51:8529-8533, 2012; Li and Schick, Biophysical Journal80:1703-1711, 2001; Adami et al., Molecular Therapy 19:1141-1151, 2011);Dabkowska et al., J. R. Soc. Interface 9:548-561, 2012; Gubernator,Expert Opinion on Drug Delivery 8:565-80, 2011; Whitehead et al., Nat.Commun. 5:4277, 2014; and Dong et al., Proc. Natl. Acad. Sci. USA111:3955-60, 2014.

For LNP formulations comprising a polynucleotide agent, a lipidnanoparticle includes one or more cationic lipids, which are useful,inter alia, in complexing with the polynucleotide via electrostaticinteractions. The lipid nanoparticle may further include additionallipids, which may serve various purposes such as aiding manufacturingand storage stability as well as modulation of the biodistribution.Biodistribution may also be modulated by incorporation of targetingligands conjugated to the lipids part of the lipid nanoparticle. Lipidnanoparticles comprising polynucleotides are typically formulated with aN:P ratio ranging from about 1 to about 30. In more specific variations,the N:P ratio is from about 1 to about 14, from 1 to about 7, or fromabout 3 to about 7 (e.g., an N:P ratio of about 3, about 3.5, or about7).

In certain embodiments, a cationic lipid for forming the lipidnanoparticle comprises a quaternary amine and is consequentlypermanently positively charged. Particularly suitable, permanentlycharged cationic lipids that may be used in polynucleotide LNPformulations include, for example,N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA),N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTAP),1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC),1,2-dilauroyl-sn-glycero-3-ethylphosphocholine (DLEPC),1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine (DMEPC),1,2-dimyristoleoyl-sn-glycero-3-ethylphosphocholine (14:1),N1-[2-((1S)-1-[(3-aminopropyl)amino]-4-[di(3-amino-propyl)amino]butylcarboxamido)ethyl]-3,4-di[oleyloxy]-benzamide(MVL5), Dioctadecylamido-glycylspermine (DOGS),3b-[N-(N′,N′-dimethylaminoethyl)carbamoyl]cholesterol (DC-Chol),Dioctadecyldimethylammonium Bromide (DDAB), Saint lipids such asSAINT-2, N-methyl-4-(dioleyl)methylpyridinium,1,2-dimyristyloxypropyl-3-dimethylhydroxyethylammonium bromide (DMRIE),1,2-dioleoyl-3-dimethyl-hydroxyethyl ammonium bromide (DORIE),1,2-dioleoyloxypropyl-3-dimethylhydroxyethyl ammonium chloride (DORI),Di-alkylated Amino Acid (DILA) (e.g., C18:1-norArg-C16),Dioleyldimethylammonium chloride (DODAC),1-palmitoyl-2-oleoyl-sn-glycero-3-ethylphosphocholine (POEPC),1,2-dimyristoleoyl-sn-glycero-3-ethylphosphocholine (MOEPC), and(R)-N,N,N-trimethyl-4,5-bis(oleoyloxy)pentan-1-aminium chloride(DOTAPen). Also suitable are cationic lipids with headgroups that arecharged at physiological pH, such as primary amines (e.g., DODAGN′,N′-dioctadecyl-N-4,8-diaza-10-aminodecanoylglycine amide) andguanidinium head groups (e.g., bis-guanidinium-spermidine-cholesterol(BGSC), bis-guanidiniumtren-cholesterol (BGTC), PONA, and(R)-5-guanidinopentane-1,2-diyl dioleate hydrochloride (DOPen-G)). Yetanother suitable cationic lipid is (R)-5-(dimethylamino)pentane-1,2-diyldioleate hydrochloride (DODAPen-Cl). In certain embodiments, thecationic lipid is a particular enantiomer or the racemic form, andincludes the various salt forms of a cationic lipid as above (e.g.,chloride or sulfate). For example, in some embodiments, the cationiclipid is N-[1-(2,3-diolcoyloxy)propyl]-N,N,N-trimethylammonium chloride(DOTAP-Cl) or N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammoniumsulfate (DOTAP-Sulfate).

In certain variations, a cationic lipid for forming the lipidnanoparticle utilizes side chains of amino acids as the head groups,where the α-amino and α-carboxyl groups serve as attachment sites forthe hydrophobic tails (also referred to as a “DiLA²” architecture; seeAdami et al., Molecular Therapy 19:1141-1151, 2011). A particularvariant of a cationic lipid having a DiLA² structure isC18:1-norArg-C16. See Adami et al., supra.

Typically, a lipid nanoparticle comprising a cationic lipid as aboveincludes one or more additional lipids. Additional lipids suitable to beincorporated into the lipid nanoparticles may include one or more of ananionic lipid, a neutral helper lipid, and a PEG-conjugated lipid (alsoreferred to herein as a “PEG-lipid”). Hence in certain embodiments,lipid nanoparticles are provided that comprise a cationic lipid as aboveand one or more additional lipids selected from the group of an anioniclipid, a helper lipid and a PEG-lipid.

Anionic lipids for use in cationic lipid-containing LNP formulations aretypically ionizable anionic lipids. While negatively charged at pHvalues above the pK_(a) of the anionic lipid, an ionizable anionic lipidwill generally stabilize other lipids in the LNP and allow the formationof bilayer vesicles, but will facilitate fusion of these vesicles as thepH is reduced toward the pK_(a), such as in the acidic endosomalenvironment of a cell. Suitable ionizable anionic lipids includecholesteryl hemisuccinate (CHEMS), phosphatidylserine,palmitoylhomoserine, and α-tocopherol hemisuccinate.

Helper lipids are neutral lipids that help make a stable liposomedispersion and may also enhance the effectiveness of cationiclipid-based delivery formulations. Cholesterol (CHOL) is oneparticularly suitable helper lipid for used in lipid nanoparticleformulations. Suitable helper lipids also include neutral zwitterioniclipids such as, for example, 1,2-distearoyl-sn-glycero-3-phosphocholine(DSPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC),1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), or any relatedphosphatidylcholine such as natural sphingomyelin (SM) and syntheticderivatives thereof such as1-oleoyl-2-cholesteryl-hemisuccinoyl-sn-glycero-3-phosphocholine(OChemsPC). Other suitable helper lipids include1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE),1,2-dilauroyl-sn-glycero-3-phosphoethanolamine (DLPE),1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE), and1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (DPHyPE).

In some embodiments, LNPs contain uncharged lipids modified withhydrophilic polymers such as, e.g., polyethylene glycol (also referredto herein as “PEG-lipids”). Such PEG-lipids generally serve to help withassembly of the nanoparticle during its manufacture, stabilize the lipidnanoparticle, avoid its aggregation, and prevent its interaction withserum proteins, opsonins, and RBCs. The polyethylene glycol (PEG) sizecan vary from approximately 1 to 5 approximately kDa. Depending on therelative amounts of these molecules in the formulation and the length ofthe hydrocarbon chain, the PEG-lipid can influence the pharmacokineticcharacteristics, biodistribution, and efficacy of a formulation.PEG-lipids having relatively short lipid hydrocarbon chains of about 14carbons dissociate from the LNP in vivo in plasma with a half-life ofless than 1 h. In contrast, a PEG-lipid with a relatively long lipidhydrocarbon chain length of about 18 carbons circulates fully associatedwith the formulation for several days. Hence, in typical embodiments,the PEG-lipid comprises a lipid hydrocarbon chain of 12 to 20 carbonatoms, 14 to 18 carbon atoms, or of 14 carbon atoms. Typically, theconcentration of the PEG-lipid is about 0.5 to 10 mol %. Examples ofsuitable PEG modified lipids include PEGylated ceramide conjugates andPEGylated distcaroylphosphatidyl-ethanolamine (PEG-DSPE). Othercompounds that can be used to stabilize lipid nanoparticles includegangliosides (GM_(t), GM3, and the like). Preferred PEG-lipids have aPEG size ranging from about 1 to about 5 kDa, with a preferred sizerange of about 2 to about 5 kDa. Specific examples aremethoxy-polyethyleneglycol-carbamoyl-dimyristyloxy-propylamine(PEG2000-c-DMA),α-(3′-(1,2-dimyristoyl-3-propanoxy)-carboxamide-propyl]-ω-me-thoxy-polyoxyethylene(PEG2000-c-DOMG), N-(Carbonyl-methoxypolyethyleneglycol2000)-1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE-PEG 2,000),polyethylene gycol-dimyristolglycerol (PEG-DMG), andN-octanoyl-sphingosine-1-{succinyl[methoxy(polyethylene glycol)2000]}(C8 PEG2000 Ceramide). In some variations of DMPE-PEG_(n) where n is350, 500, 750, 1000 or 2000, the PEG-lipid isN-(Carbonyl-methoxypolyethyleneglycol2000)-1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE-PEG 2,000).In some variations of DSPE-PEG_(n) where n is 350, 500, 750, 1000 or2000, the PEG-lipid is N-(Carbonyl-methoxypolyethyleneglycol2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE-PEG 2,000).In some embodiments, a PEG-lipid is conjugated to a targeting ligandthat specifically binds to molecule on the surface of a target cell(e.g., an N-acetylgalactosamine (NAG) sugar residue); such PEG-lipidsare particularly useful for formulating lipid nanoparticles that includea targeting ligand as further described herein. An exemplary PEG-lipidcomprising a NAG moiety is DSPE-PEG2 k-NAG (see, e.g., Examples 19 and22, infra).

In certain embodiments, a lipid nanoparticle as above comprises anionizable cationic lipid, typically in lieu of any permanently chargedcationic lipid. The ionizable cationic lipid will have at least oneprotonatable or deprotonatable group, typically such that the lipid ispositively charged at a pH at or below physiological pH (e.g., pH 7.4),and neutral at a second pH, preferably at or above physiological pH. Itwill be understood that the addition or removal of protons as a functionof pH is an equilibrium process, and that the reference to a charged ora neutral lipid refers to the nature of the predominant species and docsnot require that all of the lipid be present in the charged or neutralform. In certain embodiments, ionizable cationic lipids have a pK_(a) ofthe protonatable group in the range of about 4 to about 11. Mostpreferred is a pK_(a) of about 4 to about 7, because these lipids willbe cationic at a lower pH formulation stage, while particles will belargely (though not completely) surface neutralized at physiological pHaround pH 7.4. One of the benefits of this pK_(a) is that at least somenucleic acid associated with the outside surface of the particle willlose its electrostatic interaction at physiological pH and be removed bysimple dialysis; thus greatly reducing the particle's susceptibility toclearance. Suitable ionizable cationic lipids for use in accordance withthe present invention include, for example, Dioctadecyldimethylammoniumbromide (DDAB), 1,2-dilinoleyloxy-3-dimethylaminopropane (DLinDMA),2,2-dilinoleyl-4-(2dimethylaminoethyl)-[1,3]-dioxolane (DLin-KC2-DMA),heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate(DLin-MC3-DMA), 1,2-Dioleoyloxy-3-dimethylaminopropane (DODAP),1,2-Dioleyloxy-3-dimethylaminopropane (DODMA), Morpholinocholesterol(Mo-CHOL), lipidoids such as C12-200 (see Love et al., Proc. Natl. Acad.Sci. USA 107:1864-9, 2010), lipopeptide type compounds such as cKK-E12(Dong et al., Proc. Natl. Acad. Sci. USA 111:3955-60, 2014), and lipidssuch as AIC-0217 and AIC-0218 (Acuitas Therapeutics, Vancouver, BC).Other suitable ionizable cationic lipids may, for example, be derivedfrom cationic lipid structures previously described herein.

In some embodiments, a lipid nanoparticle composition contains one ormore cationic lipids that are from about 0.5% to about 70% (mol %) ofthe total amount of lipid and delivery-enhancing components, includingany polymeric (e.g., PEG) component, but not including thepolynucleotide (e.g., RNA) component. In more particular variations, alipid nanoparticle composition contains one or more cationic lipids fromabout 10% to about 55%, one or more cationic lipids from about 15% toabout 35%, or one or more cationic lipids from about 35% to about 55%.

In certain embodiments, a lipid nanoparticle composition contains one ormore non-cationic lipids, where the non-cationic lipids are from about2% to about 95% (mol %) of the total amount of lipid anddelivery-enhancing components, including any polymeric (e.g., PEG)component, but not including the polynucleotide (e.g., RNA) component.In some embodiments, a lipid nanoparticle composition contains one ormore non-cationic lipids from about 20% to about 75%, or from about 45%to about 75%, or from about 45% to about 55%. In other variations, alipid nanoparticle composition contains one or more non-cationic lipidsfrom about 10% to about 50%.

In some embodiments, a lipid nanoparticle composition contains one ormore polymeric lipids (e.g., PEG-lipid), where the polymeric lipids arefrom about 0.2% to about 20% (mol %) of the total amount of lipid anddelivery-enhancing components, including any polymeric (e.g., PEG)component, but not including the polynucleotide (e.g., RNA) component.In some embodiments, a lipid nanoparticle composition contains one ormore polymeric lipids from about 0.5% to about 10%, or one or morepolymeric lipids from about 1% to about 5% of the composition.

Lipid nanoparticle formulations comprising small molecule agents arealso known. See, e.g., Gubernator, Expert Opinion on Drug Delivery8:565-80, 2011. For example, small molecules can be encapsulated in,e.g., a DSPC:CHOL:DSPE-PEG (50:45:5 mol %) liposome using a passive oran active loading method. Basically, for a passive loading method, thelipids are solubilized in organic solvent, then the solvent isevaporated to form a thin lipid film which is hydrated with an aqueoussolution containing a hydrophilic or hydrophobic drug to beencapsulated. The liposome mixture is then typically homogenized byvortex and extruded through polycarbonate membrane in order to reducethe particle size (e.g., to ˜100 nm). Non-encapsulated drug can beremoved using dialysis or column filtration.

Ionizable small molecules can be actively trapped into liposomes (remoteloading method). Typically, in this particular case, the drug isprotonated or precipitated inside the preformed liposomes thus remainingentrapped in the liposome core. Typically, a pH gradient (acetate,citrate or ammonium sulfate) where there is a 1 to 3 pH unit differencebetween the liposome inner and outer compartment is used to encapsulatethe ionizable small molecules. A metal gradient (Cu²⁺, Mn²⁺ or Mg²⁺gradient) can also be used to actively load a drug into liposomes.Ionophores such as A23187 can also be used generate a pH gradient in theliposome using K⁺, Mn²⁺ or Mg²⁺. An EDTA gradient method can also beused to actively trap small molecules inside a liposome. In the remoteloading method, the liposomes typically are formed by a simplelipid-film hydration technique (e.g., as described above for the passiveentrapment method with the exception that the hydration buffer containthe solute required to generate the gradient across the lipid bilayer).The non-encapsulated solute is typically removed by dialysis or columnfiltration. Following the liposome formation and establishment of agradient across the liposomal bilayers, an unprotonated drug is added inthe loading buffer outside the liposome and can cross the lipid bilayerand becomes protonated inside the liposome, and then become stabilizedby the anions present in the internal aqueous compartment of theliposome. The suspension may need to be incubated above the phasetransition temperature of the liposomal lipids to accelerate the drugloading. The non-encapsulated free drug can be removed, by dialysis orby ion exchange chromatography.

Lipid nanoparticle formulations for protein or peptide therapeutics arealso generally known. In some embodiments, proteinaceous agents areincorporated into liposomes by a lipid film hydration method. Forexample, a protein may be incorporated into PEGylated liposomes composedof, e.g., egg phosphatidylcholine (EPC), cholesterol, sodiumcholesterol-3-sulfate and distearolyphosphatidyl ethanolamine-N-PEG 2000(DSPE-PEG [2000]). Such a formulation method was shown to increasepharmacokinetics substantially for tPA incorporated into a liposome. SeeKim et al., Biomaterials 30:5751-5756, 2009.

In some embodiments, a lipid nanoparticle composition includes acationic lipid, an anionic lipid, a helper lipid, and a PEG-lipid. Sucha mixture of LNP lipid components can be represented by the formula[cationic lipid]_(w):[anionic lipid]_(x):[helperlipid]_(y):[PEG-lipid]_(z), where the subscripts w, x, y, and zrepresent the mole % of each lipid component within the mixture (notincluding the therapeutic or diagnostic agent component (e.g.,polynucleotide) of the LNP). This formula can be alternatively expressedas [cationic lipid]:[anionic lipid]:[helper lipid]:[PEG-lipid](w:x:y:z), where w, x, y, and z represent the mole % of the cationiclipid, anionic lipid, helper lipid, and PEG-lipid, respectively. Invarious embodiments, each of the cationic lipid, anionic lipid, helperlipid, and PEG-lipid are selected from the exemplary lipids disclosedherein. In some embodiments, w is from about 10 to about 70, from about30 to about 60, or from about 35 to about 55; x is from 0 to about 60,from 0 to about 50, from about 10 to about 50, or from about 20 to about45; y is from about 5 to about 40, from about 5 to about 30, or fromabout 5 to about 20; and z is from about 1 to about 20, from about 2 toabout 20, or from about 5 to about 15. For example, a lipid mixturehaving the cationic lipid DOTAP present at about 50 mole %, the anioniclipid CHEMS present at about 32 mole %, the helper lipid CHOL present atabout 8 mole %, and the PEG-lipid DMPE-PEG2 k present at about 10 mole %can be expressed as DOTAP₅₀:CHEMS₃₂:CHOL₈:DMPE-PEG2 k₁₀ or asDOTAP:CHEMS:CHOL:DMPE-PEG2 k (50:32:8:10).

In particular embodiments, a lipid nanoparticle for use in accordancewith the present invention includes a mixture of lipid componentscomprising (i) a cationic lipid from about 30 mole % to about 60 mole %;(ii) an anionic lipid from 0 mole % to about 50 mole %; (iii) a helperlipid from about 1 mole % to about 50 mole %; and (iv) a PEG-lipid fromabout 1 mole % to about 20 mole %. Typically, the cationic lipid is acationic lipid that is permanently charged at physiological pH (e.g.,DOTAP). If present, the anionic lipid is typically an ionizable anioniclipid such as, for example, CHEMS. A particularly suitable helper lipidfor use such embodiments is cholesterol (CHOL), and particularlysuitable PEG-lipids include DSPE-PEG2 k and DMPE-PEG2 k. An excess ofcationic lipid to anionic lipid, if present, is preferred. In somevariations, (i) the cationic lipid (e.g., DOTAP) is present in the lipidmixture from about 35 mole % to about 55 mole %, from about 40 mole % toabout 55 mole %, from about 45 mole % to about 55 mole %, or from about40 mole % to about 50 mole %; (ii) the anionic lipid (e.g., CHEMS) ispresent in the lipid mixture from 0 mole % to about 45 mole %, fromabout 10 mole % to about 45 mole %, from about 20 mole % to about 45mole %, from about 30 mole % to about 45 mole %, or from about 30 mole %to about 40 mole %; (iii) the helper lipid (e.g., CHOL) is present inthe lipid mixture from about 5 mole % to about 50 mole %, from about 5mole % to about 40 mole %, from about 5 mole % to about 30 mole %, fromabout 5 mole % to about 20 mole %, or from about 5 mole % to about 10mole %; and (iv), the PEG-lipid (e.g., DSPE-PEG2 k or DMPE-PEG2 k) ispresent in the lipid mixture from about 1 mole % to about 5 mole %, fromabout 2 mole % to about 20 mole %, from about 2% mole % to about 15 mole%, from about 2 mole % to about 10 mole %, from about 5 mole % to about20 mole %, from about 5 mole % to about 15 mole %, or from about 5 mole% to about 10 mole %. In some preferred embodiments, the PEG-lipid ispresent in the lipid mixture at a mole % greater than 5 (e.g., from amole % greater than 5 to about 20 mole %, to about 15 mole %, or toabout 10 mole %); in some such embodiments, the PEG-lipid is present atmole % of at least about 6, at least about 7, at least about 8, at leastabout 9, or least about 10. In some embodiments of an LNP composition asabove wherein an anionic lipid is absent, the cationic lipid (e.g.,DOTAP) is present in the lipid mixture from about 35 mole % to about 45mole %; the helper lipid (e.g., CHOL) is present in the lipid mixturefrom about 40 mole % to about 50 mole %; and the PEG-lipid (e.g.,DSPE-PEG2 k or DMPE-PEG2 k) is present in the lipid mixture from about 5mole % to about 15 mole %; in some such embodiments, the molar ratio of[cationic lipid]:[helper lipid]:[PEG-lipid] is about 40:50:10. In otherembodiments of an LNP composition as above wherein an anionic lipid ispresent, the cationic lipid (e.g., DOTAP) is present in the lipidmixture from about 40 mole % to about 55 mole %; the anionic lipid(e.g., CHEMS) is present in the lipid mixture from about 25 mole % toabout 40 mole %; the helper lipid (e.g., CHOL) is present in the lipidmixture from about 5 mole % to about 20 mole %; and the PEG-lipid (e.g.,DSPE-PEG2 k or DMPE-PEG2 k) is present in the lipid mixture from about 2mole % to about 15 mole %, from about 2 mole % to about 10 mole %, orfrom about 5 mole % to about 15 mole %; in some such embodiments, themolar ratio of [cationic lipid]:[anionic lipid]:[helperlipid]:[PEG-lipid] is about 50:32:16:2 or about 50:32:8:10. In morespecific variations, the LNP composition includes a mixture of lipidcomponents (with the molar ratio of components specified in parentheses)selected from (a) DOTAP:CHEMS:CHOL:DMPE-PEG2 k (50:32:16:2); (b)DOTAP:CHEMS:CHOL:DSPE-PEG2 k (50:32:8:10); (c)DOTAP:CHEMS:CHOL:DMPE-PEG2 k (50:32:8:10); and (d) DOTAP:CHOL:DSPE-PEG2k (40:50:10). Mixtures of lipid components as described above areparticularly suitable for lipid nanoparticle compositions comprising apolynucleotide such as, for example, an mRNA. LNPs comprising a highPEG-lipid content (for example, a mole % of greater than 5, such as,e.g., about 10%) represent some preferred embodiments for polynucleotide(e.g., mRNA) delivery, and as shown by studies described herein, higherPEG-lipid content was particularly efficacious in methods for deliveryof polynucleotides to cells in vivo. See, e.g., Example 20.

In some embodiments, a lipid nanoparticle is less than about 200 nm insize. For example, the lipid nanoparticle may be from about 30 nm toabout 150 nm in size. In certain variations, the size of the lipidnanoparticle (e.g., between about 30 nm and about 150 nm) facilitatesdelivery to the liver by an enhanced permeation and retention effect.The lipid nanoparticle may further include a targeting ligand to targetthe particle to a desired tissue. The lipid nanoparticle may have apositive or negative zeta potential; in some variations, the zetapotential of the lipid nanoparticle is substantially neutral.

In accordance with the present invention, a membrane-destabilizingpolymer is either co-formulated with the lipid nanoparticle containingthe therapeutic or diagnostic agent, for co-injection into a subject, oris separately formulated for separate injection (e.g., sequentialinjection) of the LNP and membrane-destabilizing polymer. Typically, forco-injection variations, the lipid nanoparticle andmembrane-destabilizing polymer are initially formulated as separatecompositions and then mixed together into a single composition prior toadministration (typically within one hour prior to administration, moretypically within 30 minutes prior to administration, and preferablywithin 15 minutes or within five minutes prior to administration). Themembrane-destabilizing polymer elicits a permeability change in acellular membrane structure (e.g., an endosomal membrane) so as topermit macromolecules or biomolecules, or small molecules, to enter acell or to exit a cellular vesicle (e.g., an endosome or lysosome). Avariety of membrane-destabilizing polymers are generally known in theart and may be used in accordance with the present methods describedherein. Known types of membrane-destabilizing polymers include, forexample, copolymers such as amphipathic copolymers, polycationic oramphipathic peptides, membrane active toxins, and viral fusogenicpeptides. Certain types of particularly suitable membrane-destabilizingpolymers are described, e.g., in International PCT ApplicationPublication Nos. WO 2009/140427 and WO 2009/140429, each incorporated byreference herein in its entirety.

In some embodiments, a membrane-destabilizing polymer is or comprises amembrane-destabilizing peptide. In particular variations, amembrane-destabilizing peptide is selected from

GALA (e.g., WEAALAEALAEALAEHLAEALAEALEALAA (SEQ ID NO: 15));truncated GALA (e.g., CAEALAEALAEALAEALA (SEQ ID NO: 16)); melittin(e.g., GIGAVLKVLTTGLPALISWIKRKRQQ (SEQ ID NO: 17) orCGIGAVLKVLTTGLPALISWIKRKRQQ (SEQ ID NO: 18));HPH-1 (e.g., FIIDHAFLLMGGFIVYVKNL (SEQ ID NO: 19) orCAAFIIDIIAFLLMGGFIVYVKNL (SEQ ID NO :20));sHGP (e.g., CARGWEVLKYWWNLLQY (SEQ ID NO: 21));bPrPp (e.g., MVKSKIGSWILVLFVAMWSDVGLCKKRPKP (SEQ ID NO: 22));MAP (e.g., KLALKLALKALKAALKLA (SEQ ID NO: 23)); PTD4 (e.g., YARAAARQARA(SEQ ID NO: 24)); Maurocalcine (e.g., GDCLPHLKLCKENKDCCSKKCKRRGTNIE(SEQ ID NO: 25)); SynB3 (e.g., RRLSYSRRRF (SEQ ID NO: 26));SynB1 (e.g., RGGRLSYSRRRFSTSTGR (SEQ ID NO: 27));YTA4 (e.g., IAWVKAFIRKLRKGPLG (SEQ ID NO: 28));YTA2 (e.g., YTAIAWVKAFIRKLRK (SEQ ID NO: 29));CADY (e.g., GLWRALWRLLRSLWRLLWRA (SEQ ID NO: 30));Pep-3 (e.g., KWFETWFTEWPKKRK (SEQ ID NO: 31));Pep-1 (e.g., KETWVVETWVVTEWSQPKKKRKV (SEQ ID NO: 32));PepFect (e.g., AGYLLGK(eNHa)INLKALAALAKKIL (SEQ ID NO: 33));PepFect-3 (e.g., AGYLLGKINLKALAALAKKIL (SEQ ID NO: 34));Penetratin (e.g., RQIKIVVFQNRRMKWKK (SEQ ID NO: 35));KALA (e.g., WEAKLAKALAKALAKHLAKALAKALKACEA (SEQ ID NO: 36));pVEC (e.g., LLIILRRRIRKQAHAHSK (SEQ ID NO: 37));RVG (e.g., YTIVVMPENPRPGTPCDIFTNSRGKRASNG (SEQ ID NO: 38));MPS (e.g., AAVALLPAVLLALLAK (SEQ ID NO: 39));Transportan (e.g., GWTLNSAGYLLGKINLKALAALAKKIL (SEQ ID NO: 40));TAT (e.g., GRKKRRQRRPPQ (SEQ ID NO: 41));BMV Gag-(7-25) (e.g., KMTRAQRRAAARRNRRWTAR (SEQ ID NO: 42));hCT(18-32)-k7 (e.g., KKRKAPKKKRKFA-KFHTFPQTAIGVGAP (SEQ ID NO :43));M1073 (e.g., MVTVLFRRLRIRRASGPPRVRV (SEQ ID NO: 44));EB1 (e.g., LIRLWSHLIHIVVFQNRRLKWKKK (SEQ ID NO: 45)); andMPG-β (e.g., GALFLGFLGAAGSTMGAWSQPKKKRKV (SEQ ID NO: 46) orGALFLAFLAAALSLMGLWSQPKKKRKV (SEQ ID NO: 47)).

The membrane-destabilizing polymer can be a pH sensitive polymer havingmembrane-destabilizing activity at a desired pH. In some embodiments,membrane-destabilizing polymers (e.g., copolymers such as blockcopolymers) provided herein are membrane destabilizing (e.g., in anaqueous medium) at an endosomal pH. In some embodiments, themembrane-destabilizing polymers are membrane destabilizing (e.g., in anaqueous medium) at a pH of about 6.5 or lower, preferably at a pHranging from about 5.0 to about 6.5, or at a pH of about 6.2 or lower,preferably at a pH ranging from about 5.0 to about 6.2, or at a pH ofabout 6.0 or lower, preferably at a pH ranging from about 5.0 to about6.0.

Typically, in each case, the membrane-destabilizing polymer can havemembrane destabilizing activity at a desired quantity (e.g.,concentration) of polymer. A membrane-destabilizing characteristic of apolymer can be determined by suitable assays known in the art. Forexample, membrane-destabilizing activity of a polymer can be determinedin an in vitro cell assay such as the red blood cell hemolysis assay ora liposomal leakage assay. An endosomolytic polymer activity can bedetermined in an in vitro cell assay.

In general, the membrane-destabilizing polymer is composed of monomericresidues with particular properties. For example, the polymer may haveamines that are primary, secondary, tertiary, or quaternary and whichdrive interactions of the polymer with membranes. These amines may bepermanently charged or have pK_(a)s ranging from 4 to 14. In particular,these pK_(a)s may be between 4.5 and 7.5 such that they can undergoacid-base reactions in endosome. The polymers may also have hydrophobicgroups to further enhance interaction with membranes. The polymer mayalso have carboxylic functional groups with pK_(a)s in the range of 4.0to 7.5.

In certain embodiments, a membrane-destabilizing polymer includes one ormore monomeric species selected from anionic, cationic, hydrophobic, andhydrophilic monomeric residues. Anionic monomeric residues comprise aspecies charged or chargeable to an anion, including a protonatableanionic species. Anionic monomeric residues can be anionic at anapproximately neutral pH of 7.2-7.4. Cationic monomeric residuescomprise a species charged or chargeable to a cation, including adeprotonatable cationic species. Cationic monomeric residues can becationic at an approximately neutral pH of 7.2-7.4. Hydrophobicmonomeric residues comprise a hydrophobic species. Hydrophilic monomericresidues comprise a hydrophilic species.

In some variations, a membrane-destabilizing polymer is or comprises atleast one polymer chain that is hydrophobic. In some such embodiments,the polymer is or comprises at least one polymer chain that includes aplurality of anionic monomeric residues. In this regard, for example,the polymer may be or comprise at least one polymer chain that includes(i) a plurality of hydrophobic monomeric residues having a hydrophobicspecies, and (ii) a plurality of anionic monomeric residues that arepreferably anionic at approximately neutral pH, and substantiallyneutral or non-charged at an endosomal pH or weakly acidic pH.

In such aforementioned embodiments, the polymer can further include aplurality of cationic species. Accordingly, for example, the polymer canbe or comprise at least one polymer chain that includes a plurality ofanionic monomeric residues (e.g., having species that are anionic atabout neutral pH), and a plurality of hydrophobic monomeric residues(e.g., having hydrophobic species), and optionally a plurality ofcationic monomeric residues (e.g., having species that are cationic atabout neutral pH). In such embodiments, and as discussed further below,the polymer can be or comprise at least one polymer chain that is chargemodulated, and preferably charge balanced—being substantially overallneutral in charge.

In some embodiments, membrane-destabilizing polymer is a block copolymercomprising a membrane-destabilizing segment (e.g., as a block or regionof the polymer). The membrane-destabilizing segment can comprise aplurality of anionic monomeric residues (e.g., having species that areanionic at about neutral pH), and a plurality of hydrophobic monomericresidues (e.g., having hydrophobic species), and optionally a pluralityof cationic monomeric residues (e.g., having species that are cationicat about neutral pH). In such embodiments, the segment (e.g., block orregion) can be hydrophobic considered in the aggregate. In suchembodiments, the block copolymer may further comprise a hydrophilicsegment.

In some embodiments of a block copolymer comprising amembrane-destabilizing block, the block copolymer includes a firstpolymer chain defining a first block A of the copolymer and a second,membrane-destabilizing polymer chain defining a second block B of thecopolymer. For example, the block copolymer can comprise a first polymerchain defining a first block A of the copolymer, which is hydrophilic,and a second polymer chain defining a second block B of the copolymerthat includes (i) a plurality of hydrophobic monomeric residues and (ii)a plurality of anionic monomeric residues being anionic at serumphysiological pH and substantially neutral or non-charged at anendosomal pH.

In some embodiments, the membrane-destabilizing polymer is or comprisesat least one polymer chain that includes a plurality of anionicmonomeric residues, a plurality of hydrophobic monomeric residues, andoptionally a plurality of cationic monomeric residues in ratios adaptedto enhance membrane destabilizing or membrane destabilizing activity ofthe polymer chain. For example and without limitation, in suchembodiments at pH 7.4, the ratio of hydrophobic: (anionic+cationic)species ranges from about 1:2 to about 3:1, and the ratio ofanionic:cationic species ranges from about 1:0 to about 1:5. In othersuch embodiments, at pH 7.4, the ratio of hydrophobic:(anionic+cationic) species ranges from about 1:1 to about 2:1, and theratio of anionic:cationic species ranges from about 4:1 to about 1:5.

In some embodiments, the membrane-destabilizing polymer is or comprisesat least one polymer chain that includes a plurality of cationicmonomeric residues, a plurality of hydrophobic monomeric residues, andoptionally a plurality of anionic monomeric residues in ratios adaptedto enhance membrane destabilizing or membrane destabilizing activity ofthe polymer chain. For example and without limitation, in suchembodiments at pH 7.4, the ratio of hydrophobic: (cationic+anionic)species ranges from about 1:2 to about 3:1, and the ratio ofcationic:anionic species ranges from about 1:0 to about 1:20. In othersuch embodiments, at pH 7.4, the ratio of hydrophobic:(cationic+anionic) species ranges from about 1:1 to about 2:1, and theratio of cationic:anionic species ranges from about 1:0 to about 1:5.

In some embodiments, the membrane-destabilizing polymer is or comprisesat least one polymer chain that includes a plurality of cationicmonomeric residues, and optionally a plurality of hydrophobic monomericresidues in ratios adapted to enhance membrane destabilizing or membranedestabilizing activity of the polymer chain. For example and withoutlimitation, in such embodiments at pH 7.4, the ratio of hydrophobic:cationic species ranges from about 0:1 to about 5:1. In other suchembodiments, at pH 7.4, the ratio of hydrophobic: cationic speciesranges from about 0:1 to about 2:1.

Generally, the membrane-destabilizing polymer can be or comprise atleast one polymer chain that is charge modulated, for example includinghydrophobic monomeric residues together with both anionic monomericresidues and cationic monomeric residues. The relative ratio of anionicmonomeric residues and cationic monomeric residues can be controlled toachieve a desired overall charge characteristic. In typical embodiments,for example, such polymer or polymer chain can be charge balanced—havinga substantially neutral overall charge in an aqueous medium atphysiological pH (e.g., pH 7.2 to 7.4).

Embodiments comprising a block copolymer, in which at least one block isor comprises a membrane-destabilizing polymer, such as a hydrophobicmembrane-destabilizing polymer, can comprise one or more further polymerchains as additional blocks of the block copolymer. Generally, suchfurther polymer blocks are not narrowly critical, and can be or comprisea polymer chain which is hydrophilic, hydrophobic, amphiphilic, and ineach case, which is neutral, anionic or cationic in overall chargecharacteristics.

In some embodiments, the membrane-destabilizing polymer is or comprisesa polymer chain that is adapted to facilitate one or more additionalconstituent components and/or functional features. For example, suchpolymer chain can comprise an end functional group (e.g., on the alphaend or omega end of the polymer chain) adapted for covalently linking,directly or indirectly, to a targeting ligand (affinity reagent) or ashielding agent. Additionally or alternatively, such polymer chain cancomprise one or more monomeric residues having a pendant functionalgroup adapted for conjugating to an agent. Such conjugatable monomericresidues can be effected for covalently linking, directly or indirectly,to an affinity reagent, a shielding agent, or other biomolecular agent.Additionally or alternatively, such polymer chain can comprise one ormore monomeric residues having a shielding species. For example,shielding monomeric residues can be derived directly from apolymerization reaction which includes polymerizable monomers comprisinga shielding moiety. Shielding agents include poly ethylene glycolmonomers and/or polymers. Additionally or alternatively, such polymerchain can comprise one or more monomeric residues having a two or morependant functional groups suitable for cross-linking between polymerchains. Such cross-linking monomeric residues can be a constituentmoiety of a cross-linked polymer or polymer chain, as derived directlyfrom a polymerization reaction that includes one or more polymerizablemonomers comprising a multi-functional (e.g., bis-functional)cross-linking monomer.

Generally, one or more blocks of a block copolymer can be a randomcopolymer block which comprises two or more compositionally distinctmonomeric residues.

Generally, a single monomeric residue can include multiple moietieshaving different functionality—e.g., can comprise hydrophobic species aswell as anionic species, can comprise hydrophobic species as well ascationic species, or can comprise anionic species as well as cationicspecies. Hence, in any embodiment, the polymer can be or can comprise apolymer comprising a monomeric residue such as an anionic hydrophobicmonomeric residue—which includes hydrophobic species and anionic species(e.g., species that are anionic at about neutral pH).

In typical variations, anionic monomeric residues comprise aprotonatable anionic species. Considered in the aggregate, asincorporated into a polymer chain, such anionic monomeric residues canbe substantially anionic at a pH of or greater than 7.0 andsubstantially neutral (non-charged) at pH of or less than 6.0.Preferably, such anionic monomeric residues have a pK_(a) ranging fromabout 4 to about 6.8, (e.g., from about 4 to about 6, from about 4 toabout 5, from about 5 to about 6, from about 5 to about 6.8, or fromabout 5.5 to about 6.8). Anionic monomeric residues can independentlycomprise a plurality of monomeric residues having a protonatable anionicspecies selected from carboxylic acid, sulfonamide, boronic acid,sulfonic acid, sulfinic acid, sulfuric acid, phosphoric acid, phosphinicacid, and phosphorous acid groups, and combinations thereof.Particularly suitable anionic monomeric residues may be derived frompolymerization of a (C₂-C₈) alkylacrylic acid.

Hydrophobic monomeric residues can be charged or noncharged, generally.Some embodiments include neutral (non-charged) hydrophobic monomericresidues. In some embodiments, polymer chains can independently comprisea plurality of monomeric residues having a hydrophobic species selectedfrom (C₁-C₁₈) alkyl (e.g., (C₂-C₈) alkyl), (C₁-C₁₈) alkenyl (e.g.,(C₂-C₈) alkenyl), (C₁-C₁₈) alkynyl (e.g., (C₂-C₈) alkynyl), aryl,heteroaryl, and cholesterol (each of which may be optionallysubstituted). In certain embodiments, the plurality of monomericresidues can be derived from polymerization of (C₁-C₁₈)alkyl-ethacrylate (e.g., (C₂-C₈) alkyl-ethacrylate), a (C₁-C₁₈)alkyl-methacrylate (e.g., (C₂-C₈) alkyl-methacrylate), or a (C₁-C₁₈)alkyl-acrylate (e.g., (C₂-C₈) alkyl-acrylate) (each of which may beoptionally substituted).

Cationic monomeric residues can preferably comprise a deprotonatablecationic species. Considered in the aggregate, as incorporated into apolymer chain, such cationic monomeric residues can be substantiallycationic at a pH of or greater than 7.0. Preferably, such cationicmonomeric residues have a pK_(a) ranging from about 5.5 to about 9.0(e.g., from about 6.5 to about 9.0). Cationic monomeric residues canindependently comprise a plurality of monomeric residues having adeprotonatable cationic species selected from the group consisting ofacyclic amine, acyclic imine, cyclic amine, cyclic imine, andnitrogen-containing heteroaryl. Preferred cationic monomeric residuescan be derived from polymerization of, in each case optionallysubstituted, (N,N-di(C₁-C₆)alkyl-amino(C₁-C₆)alkyl-ethacrylate,N,N-di(C₁-C₆)alkyl-amino(C₁-C₆)alkyl-methacrylate, orN,N-di(C₁-C₆)alkyl-amino(C₁-C₆)alkyl-acrylate.

In some embodiments, a pH-sensitive membrane-destabilizing polymerincludes a random copolymer chain, such as, e.g., a random copolymerchain comprising two or more monomeric residue species as describedabove. For example, in particular variations, the random copolymer chainhas monomeric residues derived from polymerization of propyl acrylicacid, N,N-dimethylaminoethylmethacrylate, and butyl methacrylate. Inparticular embodiments, the pH-sensitive polymer is a block copolymercomprising the random copolymer chain as a membrane-destabilizingpolymer block, and further comprising one or more additional blocks(e.g., a hydrophilic block). For example, in some embodiments, thepolymer is a diblock copolymer comprising a membrane-destabilizingrandom copolymer block and a second block, which can be represented bythe schematic [A]_(v)-[B]_(w), where [B] represents themembrane-destabilizing block, [A] represents the second block (e.g., ahydrophilic block or an amphiphilic block), and the letters v and wrepresent the molecular weight (number average) of the respective blocksin the copolymer. In certain variations of a block copolymer comprisinga membrane-destabilizing polymer block and a hydrophilic block, thehydrophilic block is polymerized from both hydrophilic monomers andhydrophobic monomers such that there are more hydrophilic monomericresidues than hydrophobic monomeric residues in the hydrophilic block.

In some variations, a pH-sensitive membrane-destabilizing polymer is adiblock copolymer having a hydrophilic random copolymer block and ahydrophobic random copolymer block, where (i) the hydrophilic block isan amphiphilic block comprising both hydrophilic monomeric residues andhydrophobic monomeric residues, where the number of hydrophilicmonomeric residues in the hydrophilic block is greater than the numberof hydrophobic monomeric residues, (ii) the hydrophobic block is anamphiphilic, membrane-destabilizing block comprising both hydrophobicmonomeric residues and hydrophilic monomeric residues and having anoverall hydrophobic character at a pH of about 7.4, and (iii) each ofthe hydrophilic monomeric residues of the hydrophilic and hydrophobicblocks is independently selected from monomeric residues that are ionicat a pH of about 7.4, monomeric residues that are neutral at a pH ofabout 7.4, and monomeric residues that are zwitterionic at a pH of about7.4. In some such embodiments, the monomers used to prepare the diblockcopolymer comprise acrylate(s), methacrylate(s), acrylamide(s), and/ormethacrylamide(s). In particular variations, the hydrophilic blockcomprises hydrophilic monomeric residues that are neutral at a pH ofabout 7.4, and/or the hydrophobic block comprises both hydrophilicmonomeric residues that are cationic at a pH of about 7.4 andhydrophilic monomeric residues that are anionic at a pH of about 7.4.Suitable hydrophilic and hydrophobic monomeric residues for use in adiblock copolymer as above are further described herein. In someembodiments, a diblock copolymer as above is a random block copolymer offormula I as set forth herein.

In some variations, a pH-sensitive membrane-destabilizing polymer is adiblock copolymer having a hydrophilic random copolymer block and ahydrophobic random copolymer block, where (i) the hydrophilic block isan amphiphilic block comprising both hydrophilic monomeric residues andhydrophobic monomeric residues and having an overall hydrophiliccharacter at a pH of about 7.4, (ii) the hydrophobic block is anamphiphilic, membrane-destabilizing block comprising both hydrophobicmonomeric residues and hydrophilic monomeric residues and having anoverall hydrophobic character at a pH of about 7.4, and (iii) each ofthe hydrophilic monomeric residues of the hydrophilic and hydrophobicblocks is independently selected from monomeric residues that are ionicat a pH of about 7.4, monomeric residues that are neutral at a pH ofabout 7.4, and monomeric residues that are zwitterionic at a pH of about7.4. In some such embodiments, the monomers used to prepare the diblockcopolymer comprise acrylate(s), methacrylate(s), acrylamide(s), and/ormethacrylamide(s).

In certain embodiments, a pH-sensitive polymer is covalently linked to amembrane-destabilizing peptide. For example, the pH-sensitive polymermay include a plurality of pendant linking groups, and a plurality ofmembrane-destabilizing peptides may be linked to the pH-sensitivepolymer via the plurality of pendant linking groups. In some variations,a peptide comprising a cysteine residue at either the amino or carboxylterminus is conjugated to a monomer containing a disulfide moietythrough the cysteine thiol to form a disulfide bridge. Exemplarymembrane-destabilizing peptides that may be linked to a polymer include,for example,

GALA (e.g., WEAALAEALAEALAEHLAEALAEALEALAA (SEQ ID NO: 15));truncated GALA (e.g., CAEALAEALAEALAEALA (SEQ ID NO: 16));melittin (e.g., GIGAVLKVLTTGLPALISWIKRKRQQ (SEQ ID NO: 17) orCGIGAVLKVLTTGLPALISWIKRKRQQ (SEQ ID NO: 18));HPH-1 (e.g., FIIDIIAFLLMGGFIVYVKNL (SEQ ID NO: 19) orCAAFTIDITAFLLMCiCiFTVYVKNL (SEQ ID NO: 20));sHGP (e.g., CARGWEVLKYWVVNLLQY (SEQ ID NO: 21));bPrPp (e.g., MVKSKIGSWILVLFVAMWSDVGLCKKRPKP (SEQ ID NO: 22));MAP (e.g., KLALKLALKALKAALKLA (SEQ ID NO: 23)); PTD4 (e.g., YARAAARQARA(SEQ ID NO: 24)); Maurocalcine (e.g., GDCLPHLKLCKENKDCCSKKCKRRGTNIE(SEQ ID NO: 25)); SynB3 (e.g., RRLSYSRRRF (SEQ ID NO: 26));SynB1 (e.g., RGGRLSYSRRRFSTSTGR (SEQ ID NO: 27));YTA4 (e.g., IAWVKAFIRKLRKGPLG (SEQ ID NO: 28));YTA2 (e.g., YTAIAWVKAFIRKLRK (SEQ ID NO: 29));CADY (e.g., GLWRALWRLLRSLWRLLWRA (SEQ ID NO: 30));Pep-3 (e.g., KWFETWFTEWPKKRK (SEQ ID NO: 31));Pep-1 (e.g., KETWVVETWWTEWSQPKKKRKV (SEQ ID NO: 32));PepFect (e.g., AGYLLGK(eNHa)INLKALAALAKKIL (SEQ ID NO: 33));PepFect-3 (e.g., AGYLLGKINLKALAALAKKIL (SEQ ID NO: 34));Penetratin (e.g., RQIKIVVFQNRRMKWKK (SEQ ID NO: 35));KALA (e.g., WEAKLAKALAKALAKHLAKALAKALKACEA (SEQ ID NO: 36));pVEC (e.g., LLIILRRRIRKQAHAHSK (SEQ ID NO: 37));RVG (e.g., YTIVVMPENPRPGTPCDIFTNSRGKRASNG (SEQ ID NO: 38));MPS (e.g., AAVALLPAVLLALLAK (SEQ ID NO: 39));Transportan (e.g., GWTLNSAGYLLGKINLKALAALAKKIL (SEQ ID NO: 40));TAT (e.g., GRKKRRQRRPPQ (SEQ ID NO: 41));BMV Gag-(7-25) (e.g., KMTRAQRRAAARRNRRWTAR (SEQ ID NO: 42));hCT(18-32)-k7 (e.g., KKRKAPKKKRKFA-KFHTFPQTAIGVGAP (SEQ ID NO :43));M1073 (e.g., MVTVLI-RRLRIRRASGPPRVRV (SEQ ID NO: 44));EB1 (e.g., LIRLWSHLIHIVVFQNRRLKWKKK (SEQ ID NO: 45));MPG-β (e.g., GALFLGFLGAAGSTMGAWSQPKKKRKV (SEQ ID NO: 46) orGALFLAFLAAALSLMGLWSQPKKKRKV (SEQ ID NO: 47)).

In some embodiments, a pH-sensitive polymer includes a random blockcopolymer of formula I:

where

A₀, A₁, A₂, A_(3,) A₄ and A₅ are each independently selected from thegroup consisting of —C—C—, —C(O)(C)_(a)C(O)O—, —O(C)_(a)C(O)—,—O(C)_(b)—, and —CR₈—CR₉; where tetravalent carbon atoms of A₀-A₅ thatare not fully substituted with R₁-R₆ and Y₀-Y₅ are completed with anappropriate number of hydrogen atoms; wherein a and b are eachindependently 1-4; and where R₈ and R₉ are each independently selectedfrom the group consisting of —C(O)OH, —C(O)Oalkyl, and —C(O)NR₁₀, whereR₈ and R₉ are optionally covalently linked together to form a ringstructure (e.g., a cyclic anhydride or cyclic imide);

Y₅ is hydrogen or is selected from the group consisting of-(1C-10C)alkyl, -(3C-6C)cycloalkyl, —O-(1C-10C)alkyl,—C(O)O(1C-10C)alkyl, —C(O)NR₁₁(1C-10C)alkyl, and -(6C-10C)aryl, any ofwhich is optionally substituted with one or more fluorine atoms;

Y₀, Y₃, and Y₄ are each independently selected from the group consistingof a covalent bond, -(1C-10C)alkyl-, —C(O)O(2C-10C)alkyl-,—OC(O)(1C-10C)alkyl-, —O(2C-10C)alkyl-, —S(2C-10C)alkyl-, and—C(O)NR₁₂(2C-10C)alkyl-;

Y₁ and Y₂ are each independently selected from the group consisting of acovalent bond, -(1C-18C)alkyl-, -(3C-18C)branched alkyl,—C(O)O(2C-18C)alkyl-, —C(O)O(2C-18C)branched alkyl,—OC(O)(1C-18C)alkyl-, —OC(O)(1C-18C)branched alkyl-, —O(2C-18C)alkyl-,—O(2C-18C)branched alkyl-, —S(2C-18C)alkyl-, —S(2C-18C)branched alkyl-,—C(O)NR₁₂(2C-18C)alkyl-, and —C(O)NR₁₂(2C-18C)branched alkyl-, where anyalkyl or branched alkyl group of Y₁ or Y₂ is optionally substituted withone or more fluorine atoms;

R₁, R₂, R₃, R₄, R₅, R₆, R₈, R₉, R₁₀, R₁₁, and R₁₂ are each independentlyhydrogen, —CN, or selected from the group consisting of alkyl, alkynyl,heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, any ofwhich is optionally substituted with one or more fluorine atoms;

Q₀ is a residue selected from the group consisting of residues which arehydrophilic at physiologic pH; O—[(C)₂₋₃—O]_(x)—R₇; andO—[(C)₂₋₃—O]_(x)—C(O)—NR₁₃R₁₄; where x is 1-48; R₇ is —CH₃ or —CO₂H; andR₁₃ and R₁₄ are each independently hydrogen, —CN, or selected from thegroup consisting of alkyl, alkynyl, heteroalkyl, cycloalkyl,heterocycloalkyl, aryl and heteroaryl, any of which is optionallysubstituted with one or more fluorine atoms;

Q₁ and Q₂ are each independently absent or selected from a residue whichis hydrophilic at normal physiological pH; a conjugatable orfunctionalizable residue; a residue which is hydrophobic at normalphysiological pH; an alkyl group optionally substituted with one or morefluorine atoms; and a branched alkyl group optionally substituted withone or more fluorine atoms;

Q₃ is a residue which is positively charged at normal physiological pH;

Q₄ is a residue which is negatively charged at normal physiological pH,but undergoes protonation at lower pH;

m is a mole fraction of greater than 0 to 1.0;

n is a mole fraction of 0 to less than 1.0;

p is a mole fraction of 0 to less than 1.0; wherein m+n+p=1;

q is a mole fraction of 0.1 to 0.9;

r is a mole fraction of 0.05 to 0.9;

s is present up to a mole fraction of 0.85; wherein q+r+s=1;

v is from 1 to 25 kDa; and

w is from 1 to 50 kDa.

In certain embodiments of a polymer of formula I as above, m is greaterthan n+p. In some such variations, p is 0.

In certain embodiments of a polymer of formula I as above, n is greaterthan 0. Particularly suitable polymers of formula I where n is greaterthan 0 include polymers where R₂-A₁-Y₁-Q₁ taken together is a monomericresidue having an overall hydrophobic character. In some suchvariations, the hydrophobic monomer contains an alkyl or branched alkylgroup substituted with one or more fluorine atoms (e.g., at least one ofY₁ and Q₁ contains the alkyl or branched alkyl group as specified informula I for Y₁ and Q₁, and where the alkyl or branched alkyl group issubstituted with the one or more fluorine atoms).

In some variations of a polymer of formula I where n is greater than 0,p is 0. In some such embodiments, m is greater than n. For example, m istypically greater than n where R₂-A₁-Y₁-Q₁ taken together is a monomericresidue having an overall hydrophobic character.

In some specific embodiments of a polymer of formula I, the ratio of w:vranges from about 1:1 to about 5:1, or from about 1:1 to about 2:1.

Exemplary but non-limiting membrane-destabilizing polymers can be orcomprise a polymer chain which is a random copolymer represented asformula 1, optionally with one or more counterions.

In certain embodiments, the constitutional units of the second block offormula 1 are derived from the polymerizable monomersN,N-dimethylaminoethylmethacrylate (DMAEMA), propylacrylic acid (PAA)and butyl methacrylate (BMA).

In certain embodiments comprising a pH-sensitive polymer of formula I,the pH-sensitive polymer is a polymer of formula II:

T1-L-[PEGMA_(m)-PDSMA_(n)-BPAM_(p)]_(v)-[DMAEMA_(q)-PAA_(r)-BMA_(s)]_(w)  II

where

PEGMA is polyethyleneglycol methacrylate residue with 2-20 ethyleneglycol units;

PDSMA is pyridyl disulfide methacrylate residue;

BPAM is 2-[2-Boc amino ethoxy] ethyl methacrylate residue;

BMA is butyl methacrylate residue;

PAA is propyl acrylic acid residue;

DMAEMA is dimethylaminoethyl methacrylate residue;

m is a mole fraction of 0.6 to 1;

n is a mole fraction of 0 to 0.4 (e.g., 0 to 0.2);

p is a mole fraction of 0 to 0.4 (e.g., 0 to 0.2);

m+n+p=1;

q is a mole fraction of 0.2 to 0.75;

r is a mole fraction of 0.05 to 0.6;

s is a mole fraction of 0.2 to 0.75;

q+r+s=1;

v is 1 to 25 kDa;

w is 1 to 25 kDa;

T1 is absent or is the first targeting ligand; and

L is absent or is a linking moiety.

In other embodiments comprising a pH-sensitive polymer of formula I, thepH-sensitive polymer is a polymer of formula V:

T1-L-[PEGMA_(m)-M2_(n)]_(v)-[DMAEMA_(q)-PAA_(r)-BMA_(s)]_(w)   V

where

PEGMA is polyethyleneglycol methacrylate residue with 2-20 ethyleneglycol units;

M2 is a meth acrylate residue selected from the group consisting of

-   -   a (C4-C18)alkyl-methacrylate residue;    -   a (C4-C18)branched alkyl-methacrylate residue;    -   a cholesteryl methacrylate residue;    -   a (C4-C18)alkyl-methacrylate residue substituted with one or        more fluorine atoms; and    -   a (C4-C18)branched alkyl-methacrylate residue substituted with        one or more fluorine atoms;

BMA is butyl methacrylate residue;

PAA is propyl acrylic acid residue;

DMAEMA is dimethylaminoethyl methacrylate residue;

m and n are each a mole fraction greater than 0, wherein m is greaterthan n and m+n=1;

q is a mole fraction of 0.2 to 0.75;

r is a mole fraction of 0.05 to 0.6;

s is a mole fraction of 0.2 to 0.75;

q+r+s=1;

v is 1 to 25 kDa;

w is 1 to 25 kDa;

T1 is absent or is the first targeting ligand; and

L is absent or is a linking moiety.

Particularly suitable M2 methacrylate residues for use in a polymer offormula V include 2,2,3,3,4,4,4-heptafluorobutyl methacrylate residue;3,3,4,4,5,6,6,6-octafluoro-5(trifluoromethyl)hexyl methacrylate residue;2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctyl 2-methylacrylateresidue; 3,3,4,4,5,5,6,6,6-nonafluorohexyl methacrylate residue (alsoreferred to as 2-propenoic acid, 2-methyl-,3,3,4,4,5,5,6,6,6-nonafluorohexyl ester residue);3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl methacrylate residue;1,1,1-trifluoro-2-(trifluoromethyl)-2-hydroxy-4-methyl-5-pentylmethacrylate residue;2-[(1′,1′,1′-trifluoro-2′-(trifluoromethyl)-2′-hydroxy)propyl]-3-norbornylmethacrylate residue; 2-ethylhexyl methacrylate residue; butylmethacrylate residue; hexyl methacrylate residue; octyl methacrylateresidue; n-decyl methacrylate residue; lauryl methacrylate residue;myristyl methacrylate residue; stearyl methacrylate residue; cholesterylmethacrylate residue; ethylene glycol phenyl ether methacrylate residue;2-propenoic acid, 2-methyl-, 2-phenylethyl ester residue; 2-propenoicacid, 2-methyl-, 2-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl esterresidue; 2-propenoic acid, 2-methyl-, 2-(1H-imidazol-1-yl)ethyl esterresidue; 2-propenoic acid, 2-methyl-, cyclohexyl ester residue;2-propenoic acid, 2-methyl-, 2-[bis(1-methylethyl)amino]ethyl esterresidue; 2-propenoic acid, 2-methyl-, 3-methylbutyl ester residue;neopentyl methacrylate residue; tert-butyl methacrylate residue;3,3,5-trimethyl cyclohexyl methacrylate residue; 2-hydroxypropylmethacrylate residue; 5-nonyl meth acrylate residue; 2-butyl-1-octylmethacrylate residue; 2-hexyl-1-decyl methacrylate residue; and2-(tert-butyl amino)ethyl methacrylate residue.

In particular variations of a pH-sensitive polymer of formula II orformula V, PEGMA has 4-5 ethylene glycol units or 7-8 ethylene glycolunits. In some embodiments, T1 and L are present. T1 may include, forexample, an N-acetylgalactosamine (NAG) residue, such as, e.g., atri-NAG moiety as described further herein. L may be a hydrophilicmoiety such as, for example, a moiety comprising one or more PEG chains.In some embodiments, L is a hydrophilic moiety comprising from 2 to 240ethylene glycol units (e.g., a polyethylene glycol (PEG) moiety having2-20 ethylene glycol units).

In specific embodiments, a pH-sensitive polymer of formula II isselected from the group consisting of

NAG-PEG₁₂-[PEGMA300_(m)-PDSMA_(n)]_(v)-[D_(q)P_(r)B_(s)]_(w)   IIa

NAG-PEG₁₂-[PEGMA300_(m)-PDSMA_(n)-BPAM_(p)]_(v)-[D_(q)-P_(r)-B_(s)]_(w)  IIb

where “D” is DMAEMA as defined above for formula II, “P” is PAA asdefined above for formula II, “B” is BMA as defined above for formulaII, “NAG” is an N-acetylgalactosamine residue, “PEG₁₂” is polyethyleneglycol having 12 ethylene glycol units and functionalized at each endfor attachment to the NAG residue and chain transfer agent, “PEGMA,”“PDSMA,” and “BPAM” are as defined above for formula II, and the valuesfor m, n, p, q, r, s, v, and w are as defined above for formula II. Inparticular variations of a polymer of formula IIa, m is from 0.85 to0.9, n is from 0.1 to 0.15, q is from 0.33 to 0.37, r is from 0.07 to0.15, s is from 0.52 to 0.57, v is from 3 kDa to 4.5 kDa, and/or w isfrom 5.5 kDa to 7 kDa. In particular variations of a polymer of formulaIIb, m is from 0.75 to 0.8, n is from 0.1 to 0.13, p is from 0.1 to0.12, q is from 0.25 to 0.37, r is from 0.07 to 0.25, s is from 0.5 to0.57, v is from 3 kDa to 4.5 kDa, and w is from 5.5 kDa to 7 kDa. Insome specific embodiments, the ratio of w:v ranges from about 1:1 toabout 5:1, or from about 1:1 to about 2:1.

In specific embodiments, a pH-sensitive polymer of formula V is selectedfrom the group consisting of

NAG-PEG₁₂-[PEGMA300_(m)-(F1-BMA)_(n)]_(v)-[D_(q)-P_(r)-B_(s)]_(w)   Vb

NAG-PEG₁₂-[PEGMA300_(m)-(OF1-5TFM-HMA)_(n)]_(v)-[D_(q)-P_(r)-B_(s)]_(w)  Vc

NAG-PEG₁₂-[PEGMA300_(m)-(F115-OMA)_(n)]_(v)-[D_(q)-P_(r)-B_(s)]_(w)   Vd

NAG-PEG₁₂-[PEGMA300_(m)-(B-F1-HMA)_(n)]_(v)-[D_(q)-P_(r)-B_(s)]_(w)   Ve

NAG-PEG₁₂-[PEGMA300_(m)-(B-F1-OMA)_(n)]_(v)-[D_(q)-P_(r)-B_(s)]_(w)   Vf

NAG-PEG₁₂-[PEGMA300_(m)-EHMA_(n)]_(v)-[D_(q)-P_(r)-B_(s)]_(w)   Vg

NAG-PEG₁₂-[PEGMA300_(m)-B_(n)]_(v)-[D_(q)-P_(r)-B_(s)]_(w)   Vh

NAG-PEG₁₂-[PEGMA300_(m)-HMA_(n)]_(v)-[D_(q)-P_(r)-B_(s)]_(w)   Vi

NAG-PEG₁₂-[PEGMA300_(m)-C8MA_(n)]_(v)-[D_(q)-P_(r)-B_(s)]_(w)   Vj

NAG-PEG₁₂-[PEGMA300_(m)-C12MA_(n)]_(v)-[D_(q)-P_(r)B_(s)]_(w)   Vk

NAG-PEG₁₂-[PEGMA300_(m)-Bu1-OMA_(n)]_(v)-[D_(q)-P_(r)-B_(s)]_(w)   Vl

NAG-PEG₁₂-[PEGMA300_(m)-NMA_(n)]_(v)-[D_(q)-P_(r)-B_(s)]_(w)   Vm

where “D” is DMAEMA as defined above for formula V, “P” is PAA asdefined above for formula V, “B” is BMA as defined above for formula V,“NAG” is an N-acetylgalactosamine residue, “PEG₁₂” is polyethyleneglycol having 12 ethylene glycol units and functionalized at each endfor attachment to the NAG residue and chain transfer agent, “PEGMA” isas defined above for formula V, “F1-BMA” is2,2,3,3,4,4,4-heptafluorobutyl methacrylate residue, “OF1-5TFM-HMA” is3,3,4,4,5,6,6,6-octafluoro-5(trifluoromethyl)hexyl methacrylate residue,“F115-OMA” is 2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctyl2-methylacrylate residue, “B-F1-HMA” is3,3,4,4,5,5,6,6,6-nonafluorohexyl methacrylate residue, “B-F1-OMA” is3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl methacrylate residue,“EHMA” is 2-ethylhexyl methacrylate residue, “HMA” is hexyl methacrylateresidue, “C8MA” is octyl methacrylate residue, “C12MA” is laurylmethacrylate residue, “2-Bu1-OMA” is 2-butyl-1-octyl methacrylateresidue, “5-NMA” is 5-nonyl methacrylate residue, and the values for m,n, q, r, s, v, and w are as defined above for formula V.

In some embodiments, the pH-sensitive, membrane-destabilizing polymercomprises a random block copolymer of formula Ia:

where

A₀, A₁, A₂, A₃, A₄ and A₅ are each independently selected from the groupconsisting of —C—C—, —C(O)(C)_(a)C(O)O—, —O(C)_(a)C(O)—, —O(C)_(b)—, and—CR₈—CR₉—; where tetravalent carbon atoms of A₀-A₅ that are not fullysubstituted with R₁-R₆ and Y₀-Y₅ are completed with an appropriatenumber of hydrogen atoms; wherein a and b are each independently 1-4;and where R₈ and R₉ are each independently selected from the groupconsisting of —C(O)OH, —C(O)Oalkyl, and —C(O)NR₁₀, where R₈ and R₉ areoptionally covalently linked together to form a ring structure;

Y₅ is hydrogen or is selected from the group consisting of-(1C-10C)alkyl, -(3C-6C)cycloalkyl, —O—(1C-10C)alkyl,—C(O)O(1C-10C)alkyl, —C(O)NR₁₁(1C-10C)alkyl, and -(6C-10C)aryl, any ofwhich is optionally substituted with one or more fluorine atoms;

Y₀, Y₃, and Y₄ are each independently selected from the group consistingof a covalent bond, -(1C -10C)alkyl-, —C(O)O(2C-10C)alkyl-,—OC(O)(1C-10C)alkyl-, —O(2C-10C)alkyl-, —S(2C-10C)alkyl-, and—C(O)NR₁₂(2C-10C) alkyl-;

Y₁ and Y₂ are each independently selected from the group consisting of acovalent bond, -(1C-18C)alkyl-, -(3C-18C)branched alkyl,—C(O)O(2C-18C)alkyl-, —C(O)O(2C-18C)branched alkyl,—OC(O)(1C-18C)alkyl-, —OC(O)(1C-18C)branched alkyl-, —O(2C-18C)alkyl-,—O(2C-18C)branched alkyl-, —S(2C-18C)alkyl-, —S(2C-18C)branched alkyl-,—C(O)NR₁₂(2C-18C)alkyl-, and —C(O)NR₁₂(2C-18C)branched alkyl-, where anyalkyl or branched alkyl group of Y₁ or Y₂ is optionally substituted withone or more fluorine atoms;

R₁, R₂, R₃, R₄, R₅, R₆, R₈, R₉, R₁₀, R₁₁, and R₁₂ are each independentlyhydrogen, —CN, or selected from the group consisting of alkyl, alkynyl,heteroalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, any ofwhich is optionally substituted with one or more fluorine atoms;

Q₀ is a residue selected from the group consisting of residues which arehydrophilic at physiologic pH; O—[(C)₂₋₃—O]_(x)—R₇; andO—[(C)₂₋₃—O]_(x)—C(O)—NR₁₃R₁₄; where x is 1-48; R₇ is —CH₃ or —CO₂H; andR₁₃ and R₁₄ are each independently hydrogen, —CN, or selected from thegroup consisting of alkyl, alkynyl, heteroalkyl, cycloalkyl,heterocycloalkyl, aryl and heteroaryl, any of which is optionallysubstituted with one or more fluorine atoms;

Q₁ and Q₂ are each independently absent or selected from a residue whichis hydrophilic at normal physiological pH; a conjugatable orfunctionalizable residue; a residue which is hydrophobic at normalphysiological pH; an alkyl group optionally substituted with one or morefluorine atoms; and a branched alkyl group optionally substituted withone or more fluorine atoms;

Q₃ is a residue which is positively charged at normal physiological pH;

Q₄ is a residue which is negatively charged at normal physiological pH,but undergoes protonation at lower pH;

m is a mole fraction of greater than 0.5 to less than 1.0;

n is a mole fraction of greater than 0 to less than 0.5;

p is a mole fraction of 0 to less than 0.5; wherein m+n+p=1;

q is a mole fraction of 0.1 to 0.9;

r is a mole fraction of 0.05 to 0.9;

s is present up to a mole fraction of 0.85; wherein q+r+s=1;

v is from 1 to 25 kDa;

w is from 1 to 50 kDa; and

at least one of Y₁ and Q₁ contains the alkyl or branched alkyl groupsubstituted with the one or more fluorine atoms.

In some embodiments of a pH-sensitive polymer comprising a copolymer offormula Ia as above, p is 0.

Suitable polymers of formula Ia include polymers where R₂-A₁-Y₁-Q₁ takentogether is a methacrylate residue selected from the group consisting of2,2,3,3,4,4,4-heptafluorobutyl methacrylate residue;3,3,4,4,5,6,6,6-octafluoro-5(trifluoromethyl)hexyl methacrylate residue;2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctyl 2-methylacrylateresidue; 3,3,4,4,5,5,6,6,6-nonafluorohexyl methacrylate residue;3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl methacrylate residue;1,1,1-trifluoro-2-(trifluoromethyl)-2-hydroxy-4-methyl-5-pentylmethacrylate residue; and2-[(1′,1′-trifluoro-2′-(trifluoromethyl)-2′-hydroxy)propyl]-3-norbornylmethacrylate residue.

In various embodiments of a pH-sensitive polymer comprising a copolymerof formula Ia as above, (a) Y₃ is —C(O)OCH₂CH₂, Q₃ is dimethylamino,and/or R₄ is —CH₃; (b) Y₄ is a covalent bond, Q₄ is a carboxyl residue,and/or R₅ is —CH₂CH₂CH₃; (c) Y₅ is —C(O)O(CH₂)₃CH₃ and/or R₆ is —CH₃;and/or (d) Y₀ is —C(O)O(2C-10C)alkyl-, Q₀ is O—[(C)₂₋₃—O]_(x)—R₇ (wherex is 1-48 and R₇ is —CH₃), and/or R₁ is —CH₃. For example, in morespecific variations, R₄-A₃-Y₃-Q₃ taken together is a dimethylaminoethylmethacrylate residue (DMAEMA); R₅-A₄-Y₄-Q₄ taken together is a propylacrylic acid residue (PAA); R₆-A₅-Y₅ taken together is a butylmethacrylate residue (BMA); and/or R₁-A₀-Y₀-Q₀ taken together is apolyethyleneglycol methacrylate residue with 2-20 ethylene glycol units(PEGMA).

In some embodiments of a polymer comprising a copolymer of formula Ia asabove, the pH-sensitive polymer is a polymer of formula Va:

T1-L-[PEGMA_(m)-M2_(n)]_(v)-[DMAEMA₁-PAA_(r)-BMA_(s)]_(w)   Va

where

PEGMA is polyethyleneglycol methacrylate residue with 2-20 ethyleneglycol units;

M2 is a methacrylate residue selected from the group consisting of

-   -   a (C4-C18)alkyl-methacrylate residue substituted with one or        more fluorine atoms, and    -   a (C4-C18)branched alkyl-methacrylate residue substituted with        one or more fluorine atoms,

BMA is butyl methacrylate residue;

PAA is propyl acrylic acid residue;

DMAEMA is dimethylaminoethyl methacrylate residue;

m and n are each a mole fraction greater than 0, where m is greater thann and m+n=1;

q is a mole fraction of 0.2 to 0.75;

r is a mole fraction of 0.05 to 0.6;

s is a mole fraction of 0.2 to 0.75;

q+r+s=1;

v is 1 to 25 kDa;

w is 1 to 25 kDa;

T1 is absent or is the first targeting ligand; and

L is absent or is a linking moiety.

Particularly suitable M2 methacrylate residues for use in a polymer offormula Va include 2,2,3,3,4,4,4-heptafluorobutyl methacrylate residue;3,3,4,4,5,6,6,6-octafluoro-5(trifluoromethyl)hexyl methacrylate residue;2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctyl 2-methylacrylateresidue3,3,4,4,5,5,6,6,6-nonafluorohexyl methacrylate residue;3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl methacrylate residue;1,1,1-trifluoro-2-(trifluoromethyl)-2-hydroxy-4-methyl-5-pentylmethacrylate residue; and2-[(1′,1′,1′-trifluoro-2′-(trifluoromethyl)-2′-hydroxy)propyl]-3-norbornylmethacrylate residue.

In particular variations of a polymer of formula V, formula Va, or anyof formulae Vb-Vm, m is from 0.55 to 0.9 (e.g., from 0.65 to 0.9 or from0.7 to 0.85), n is from 0.1 to 0.45 (e.g., from 0.1 to 0.35 or from 0.15to 0.3), q is from 0.25 to 0.4 (e.g., 0.28 to 0.37), r is from 0.07 to0.15 (e.g., 0.9 to 0.15), s is from 0.5 to 0.65 (e.g., 0.5 to 0.6), v isfrom 2.5 kDa to 10 kDa (e.g., from 2.5 kDa to 7 kDa, from 2.5 kDa to 5kDa, from 2.5 kDa to 4.5 kDa, or from 0.29 to 4 kDa), and/or w is from 4kDa to 9 kDa (e.g., from 4 kDa to 7 kDa, from 4 kDa to 6 kDa, or from 5kDa to 7 kDa). In some specific embodiments, the ratio of w:v rangesfrom about 1:0.8 to about 5:1, or from about 1:1 to about 2:1.

Generally, a membrane-destabilizing polymer (or polymer chains includedas constituent moieties such as blocks of a block copolymer) can includea shielding agent or solubilizing agent. The shielding agent can beeffective for improving solubility of the polymer chain. The shieldingagent can also be effective for reducing toxicity of the certaincompositions. In some embodiments, the shielding agent can be a polymercomprising a plurality of neutral hydrophilic monomeric residues. Theshielding polymer can be covalently coupled to a membrane destabilizingpolymer, directly or indirectly, through an end group of the polymer orthrough a pendant functional group of one or more monomeric residues ofthe polymer. In some embodiments, a plurality of monomeric residues ofthe polymer chain can have a shielding species; preferably, suchshielding species is a pendant moiety from a polymerizable monomer (fromwhich the shielding monomeric residues are derived). For example, thepolymer can comprise a plurality of monomeric residues having a pendantgroup comprising a shielding oligomer. A shielding/solubilizing speciesmay be conjugated to a polymer via a labile linkage such as, forexample, a pH-sensitive bond or linker. Particularly suitablepH-sensitive bonds and linkers include hydrazone, acetal, ketal, imine,orthoester, carbonate, and maleamic acid linkages. Labile linkages maybe utilized, e.g., for linkage via a plurality of monomeric residueshaving pendant linking groups or for linkage of a polymer blockcomprising the shielding species to another polymer block (e.g., linkageof a shielding block to a membrane-destabilizing block).

A preferred shielding/solubilizing polymer can be a polyethylene glycol(PEG) oligomer (e.g., having 20 or less repeat units) or polymer (e.g.,having more than 20 repeat units). PEG can be described as apolyethylene glycol or as a polyethylene oxide, and is understood to bea oligomer or polymer from —CH2-CH2-O— repeat units (which repeat unitsare also referred to herein as “ethylene glycol units” or “ethyleneoxide units”). In certain embodiments, one block of a block copolymercan be or comprises a polyethylene glycol (PEG) oligomer or polymer—forexample, covalently coupled to the alpha end or the omega end of themembrane destabilizing block of the copolymer. In another embodiment, apolyethylene glycol (PEG) oligomer or polymer can be covalently coupledto the polymer through a conjugating monomeric residue having a specieswhich includes a functional group suitable for linking, directly orindirectly, to the polyethylene glycol oligomer or polymer. In anotherembodiment, the monomeric residue can be derived from a polymerizablemonomer which includes a polyethylene glycol oligomer pendant to themonomer (e.g., PEGMA as described above).

In one general approach, PEG chains or blocks are covalently coupled toa membrane-destabilizing polymer chain. For such embodiments, forexample, PEG chains or blocks can have molecular weights rangingapproximately from 1,000 to approximately 30,000. In some embodiments,the PEG is effective as (i.e., is incorporated into) a second block of ablock copolymer. For example, PEG can be a second block coupledcovalently to a block comprising a membrane destabilizing polymer. Insome embodiments, PEG is conjugated to block copolymer ends groups, orto one or more pendant modifiable group present in polymeric compound,such as conjugated to modifiable groups within a hydrophilic segment orblock (e.g., a second block) of a polymer (e.g., block copolymer). As anexample, a block of a copolymer can be or can be conjugated to ashielding polymer having a repeat unit of formula III

where R¹ and R² are each independently selected from the groupconsisting of hydrogen, halogen, hydroxyl, and optionally substitutedC₁-C₃ alkyl, and having a molecular weight ranging from about 1,500 toabout 15,000.

In another general approach, a monomeric residue is derived from apolymerizable monomer comprising a PEG oligomer; for example, suchmonomeric residues can be incorporated into the polymer or into one ormore blocks of a block copolymer during polymerization. In preferredembodiments, monomeric residues can be derived from a polymerizablemonomer having a pendant group comprising an oligomer of formula IV

where R¹ and R² are each independently selected from the groupconsisting of hydrogen, halogen, hydroxyl, and optionally substitutedC₁-C₃ alkyl, and n is an integer ranging from 2 to 20.

Generally, a membrane-destabilizing polymer (or polymer chains includedas constituent moieties such as blocks of a block copolymer) can beprepared in any suitable manner. Suitable synthetic methods used toproduce, for example, a membrane-destabilizing copolymer include, by wayof non-limiting example, well-known “living polymerization” methods suchas, e.g., cationic, anionic and free radical polymerization.

Using living polymerization, polymers of very low polydispersity ordifferences in chain length can be obtained. Polydispersity is usuallymeasured by dividing the weight average molecular weight of the polymerchains by their number average molecular weight. The number averagemolecule weight is sum of individual chain molecular weights divided bythe number of chains. The weight average molecular weight isproportional to the square of the molecular weight divided by the numberof molecules of that molecular weight. Since the weight averagemolecular weight is always greater than the number average molecularweight, polydispersity is always greater than or equal to one. As thenumbers come closer and closer to being the same, i.e., as thepolydispersity approaches a value of one, the polymer becomes closer tobeing monodisperse in which every chain has exactly the same number ofconstitutional units. Polydispersity values approaching one areachievable using radical living polymerization. Methods of determiningpolydispersity such as, without limitation, size exclusionchromatography, dynamic light scattering, matrix-assisted laserdesorption/ionization mass spectrometry, and electrospray massspectrometry are well-known in the art.

Reversible addition-fragmentation chain transfer or RAFT is an exemplaryliving polymerization technique for use in synthesizing ethylenicbackbone polymers. RAFT is well-known to those skilled in the art. RAFTcomprises a free radical degenerative chain transfer process. Most RAFTprocedures employ thiocarbonylthio compounds such as, withoutlimitation, dithioesters, dithiocarbamates, trithiocarbonates andxanthates to mediate polymerization by a reversible chain transfermechanism. Reaction of a polymeric radical with the C═S group of any ofthe preceding compounds leads to the formation of stabilized radicalintermediates. These stabilized radical intermediates do not undergo thetermination reactions typical of standard radical polymerization but,rather, reintroduce a radical capable of re-initiation or propagationwith monomer, reforming the C═S bond in the process. This cycle ofaddition to the C═S bond followed by fragmentation of the ensuingradical continues until all monomer has been consumed or the reaction isquenched. The low concentration of active radicals at any particulartime limits normal termination reactions. In other embodiments, polymersare synthesized by Macromolecular design via reversibleaddition-fragmentation chain transfer of Xanthates (MADIX) (DirectSynthesis of Double Hydrophilic Statistical Di- and Triblock CopolymersComprised of Acrylamide and Acrylic Acid Units via the MADIX Process”,Daniel Taton et al., Macromolecular Rapid Communications, 22:1497-1503,2001.)

In certain embodiments of the present invention, the lipid nanoparticleand/or the membrane destabilizing polymer includes at least onetargeting ligand that specifically binds to a molecule on the surface ofthe target cell. In some embodiments, the membrane-destabilizing polymercomprises the targeting ligand. In some embodiments, the lipidnanoparticle comprises the targeting ligand. In some embodiments, boththe membrane-destabilizing polymer and the lipid nanoparticle comprise atarget ligand, which may be the same or different (e.g., differenttargeting ligand species that bind to the same target cell).

A targeting ligand specifically recognizes a molecule on the surface ofthe target cell, such as, e.g., a cell surface receptor. Particularlysuitable targeting moieties include antibodies, antibody-like molecules,polypeptides, proteins (e.g., insulin-like growth factor II (IGF-II)),peptides (e.g., an integrin-binding peptide such as an RGD-containingpeptide), and small molecules such as, for example, sugars (e.g.,lactose, galactose, N-acetyl galactosamine (NAG), mannose,mannose-6-phosphate (M6P)) or vitamins (e.g., folate). In somevariations, a targeting moiety is a protein derived from a naturalligand of a cell-surface molecule (e.g., derived from a cytokine or fromthe extracellular domain of a cell-surface receptor that binds to a cellsurface counter-receptor). Examples of cell surface molecules that maybe targeted by a targeting moiety of a copolymer provided hereininclude, but are not limited to, the transferrin receptor type 1 and 2,the EGF receptor, HER2/Neu, VEGF receptors, integrins, NGF, CD2, CD3,CD4, CD8, CD19, CD20, CD22, CD33, CD43, CD38, CD56, CD69, theasialoglycoprotein receptor, mannose receptor, the cation-independentmannose-6-phosphate/IGF-II receptor, prostate-specific membrane antigen(PSMA), a folate receptor, and a sigma receptor.

In particular variations, a targeting ligand includes anN-acetylgalactosamine (NAG) sugar residue, which specifically binds tothe asialoglycoprotein receptor (ASGPR) on hepatocytes. In some suchembodiments, the targeting ligand has the formula

In other embodiments comprising a NAG sugar residue, the targetingligand comprises multiple NAG sugar residues (e.g., three NAG residues,also referred to herein as a “tri-NAG” structure), which may increaseavidity for the asialoglycoprotein receptor relative to a monovalent NAGmoiety. In some such embodiments, a tri-NAG structure has the formula

where

designates a point of attachment.

In various embodiments, a targeting ligand is attached to either end ofa membrane-destabilizing polymer (e.g., block copolymer), attached to aside chain of a monomeric unit, incorporated into a polymer block, orattached to a lipid or polymeric component of a lipid nanoparticle.Attachment of a targeting ligand to the membrane-destabilizing polymeror LNP is achieved in any suitable manner, e.g., by any one of a numberof conjugation chemistry approaches including, but not limited to,amine-carboxyl linkers, amine-sulfhydryl linkers, amine-carbohydratelinkers, amine-hydroxyl linkers, amine-amine linkers,carboxyl-sulfhydryl linkers, carboxyl-carbohydrate linkers,carboxyl-hydroxyl linkers, carboxyl-carboxyl linkers,sulfhydryl-carbohydrate linkers, sulfhydryl-hydroxyl linkers,sulfhydryl-sulfhydryl linkers, carbohydrate-hydroxyl linkers,carbohydrate-carbohydrate linkers, and hydroxyl-hydroxyl linkers. Inspecific embodiments, “click” chemistry is used to attach the targetingligand to a polymer (for example of “click” reactions, see Wu and Fokin,“Catalytic Azide-Alkyne Cycloaddition: Reactivity and Applications,”Aldrichim. Acta 40:7-17, 2007). A large variety of conjugationchemistries are optionally utilized (see, e.g., Bioconjugation, Aslamand Dent, Eds, Macmillan, 1998 and chapters therein). In someembodiments, targeting ligands are attached to a monomer and theresulting compound is then used in the polymerization synthesis of apolymer (e.g., block copolymer). In some embodiments, targeting moietiesare attached to a block of a first block copolymer, or to a block of asecond block copolymer in a mixed polymer micellic assembly.

Targeting of lipid particles using a variety of targeting ligands hasbeen previously described. See, e.g., U.S. Pat. Nos. 4,957,773 and4,603,044. Targeting mechanisms generally require that the targetingligand be positioned on the surface of the lipid particle in such amanner that the targeting moiety is available for interaction with thetarget, for example, a cell surface receptor. A variety of differenttargeting ligands and methods are known and available in the art,including those described above as well as, e.g., in Sapra and Allen,Prog. Lipid Res. 42:439-62, 2003, and Abra et al., J. Liposome Res.12:1-3, 2002. Various targeting counter-receptors can be bound to thesurface of the liposome, such as antibodies, antibody fragments,carbohydrates, vitamins, and transport proteins. For example, fortargeting to the liver, liposomes can be modified with branched typegalactosyllipid derivatives to target asialoglycoprotein receptors. SeeKato and Sugiyama, Crit. Rev. Ther. Drug Carrier Syst. 14:287, 1997;Murahashi et al., Biol. Pharm. Bull. 20:259, 1997. In a more generalapproach to tissue targeting, target cells are prelabeled withbiotinylated antibodies specific for a molecule expressed by the targetcell. See Harasym et al., Adv. Drug Deliv. Rev. 32:99, 1998. Afterplasma elimination of free antibody, streptavidin-conjugated liposomesare administered. In another approach, targeting antibodies are directlyattached to liposomes. See Harasym et al., supra.

In specific variations, a targeting ligand is attached to a polymerusing a linker having a formula selected from

where m is 1-100 or 10-250 and each of w, x, y, and z is independently1-48. In certain variations of a linker comprising m as above, m is1-15, 10-20, 20-30, 20-25, 11 or 12. In other variations of a linkercomprising m as above, m is 20-60, 25-60, 25-55, 25-50, 25-48, 30-60,30-55, 30-50, 30-48, 34-60, 34-55, 34-50, 34-48, 36-60, 36-55, 36-50,36-48, 36, or 48. In yet other embodiments of a linker comprising m asabove, m is 60-250, 100-250, 150-250, or 200-250. In certain variationsof L1 comprising x and y, x, y and z, or w, x, y and z as above, each ofw, x, y, and z is independently 20-30, 20-25, or 23. In other variationsof Ll comprising x and y, x, y and z, or w, x, y and z as above, each ofw, x, y, and z is independently 1-12, 1-24, 1-36, 8-16, 10-14, 20-28,22-26, 32-40, 34-38, 8-48, 10-48, 20-48, 22-48, 32-48, 34-48, or 44-48.

Particular embodiments of the present invention are directed at in vivodelivery of therapeutic agents. In some embodiments, the therapeuticagent is a polynucleotide. Suitable polynucleotide therapeutic agentsinclude DNA agents, which may be in the form of cDNA, in vitropolymerized DNA, plasmid DNA, genetic material derived from a virus,linear DNA, vectors, expression vectors, expression cassettes, chimericsequences, recombinant DNA, anti-sense DNA, or derivatives of thesegroups. Other suitable polynucleotide therapeutic agents include RNA,which may be in the form of messenger RNA (mRNA), in vitro polymerizedRNA, recombinant RNA, transfer RNA (tRNA), small nuclear RNA (snRNA),ribosomal RNA (rRNA), chimeric sequences, dicer substrate and theprecursors thereof, locked nucleic acids, anti-sense RNA, interferingRNA (RNAi), asymmetric interfering RNA (aiRNA), small interfering RNA(siRNA), microRNA (miRNA), ribozymes, external guide sequences, smallnon-messenger RNAs (snmRNA), untranslatedRNA (utRNA), snoRNAs (24-mers,modified snmRNA that act by an anti-sense mechanism), tiny non-codingRNAs (tncRNAs), small hairpin RNA (shRNA), or their derivatives. Doublestranded RNA (dsRNA) and siRNA are of interest particularly inconnection with the phenomenon of RNA interference. Examples oftherapeutic oligonucleotides as used herein include, but are not limitedto, siRNA, an antisense oligonucleotide, a dicer substrate, a miRNA, anaiRNA or an shRNA. An example of a large therapeutic polynucleotide asused herein includes, but is not limited to, messenger RNAs (mRNAs)encoding functional proteins for gene replacement therapy.Polynucleotide therapeutic agents may also be nucleic acid aptamers,which are nucleic acid oligomers that specifically bind othermacromolecules; such aptamers that bind specifically to othermacromolecules can be readily isolated from libraries of such oligomersby known technologies such as SELEX. See, e.g., Stoltenburg et al.,Biomol. Eng., 24:381, 2007.

In other embodiments, the therapeutic agent is a protein or a peptide.For example, in certain variations, the agent is an antibody that bindsto and either antagonizes or agonizes an intracellular target.Antibodies for use in the present invention may be raised through anyknown method, such as through injection of immunogen into mice andsubsequent fusions of lymphocytes to create hybridomas. Such hybridomasmay then be used either (a) to produce antibody directly, or (b) toclone cDNAs encoding antibody fragments for subsequent geneticmanipulation. To illustrate one method employing the latter strategy,mRNA is isolated from the hybridoma cells, reverse-transcribed into cDNAusing antisense oligo-dT or immunoglobulin gene-specific primers, andcloned into a plasmid vector. Clones are sequenced and characterized.They may then be engineered according to standard protocols to combinethe heavy and light chains of the antibody into a bacterial or mammalianexpression vector to generate, e.g., a single-chain scFv. A similarapproach may be used to generate recombinant bispecific antibodies bycombining the heavy and light chains of each of two differentantibodies, separated by a short peptide linker, into a bacterial ormammalian expression vector. Recombinant antibodies are then expressedand purified according to well-established protocols in bacteria ormammalian cells. See, e.g., Kufer et al., 2004, supra; AntibodyEngineering: A Practical Approach, McCafferty, Hoogenboom and ChiswellEds, IRL Press 1996. Antibodies or other proteinaceous therapeuticmolecules such as peptides, may also be created through displaytechnologies that allow selection of interacting affinity reagentsthrough the screening of very large libraries of, for example,immunoglobulin domains or peptides expressed by bacteriophage (AntibodyEngineering: A Practical Approach, McCafferty, Hoogenboom and ChiswellEds, IRL Press 1996). Antibodies may also be humanized through graftingof human immunoglobulin domains, or made from transgenic mice orbacteriophage libraries that have human immunoglobulin genes/cDNAs. Insome embodiments of the invention, a specific binding proteintherapeutic may include structures other than antibodies that are ableto bind to targets specifically, including but not limited to avimers(see Silverman et al., Nature Biotechnology 23:1556-1561, 2005), ankyrinrepeats (see Zahnd et al., J. Mol. Biol. 369:1015-1028, 2007) andadnectins (see U.S. Pat. No. 7,115,396), and other such proteins withdomains that can be evolved to generate specific affinity for antigens,collectively referred to as “antibody-like molecules”. Modifications ofprotein therapeutics through the incorporation of unnatural amino acidsduring synthesis may be used to improve their properties (see Datta etal., J. Am. Chem. Soc. 124:5652-5653, 2002; and Liu et al., Nat. Methods4:239-244, 2007). Such modifications may have several benefits,including the addition of chemical groups that facilitate subsequentconjugation reactions.

In some embodiments, the therapeutic agent is a peptide. In certainvariations, the peptide is a bispecific peptide. Peptides can readily bemade and screened to create affinity reagents that recognize and bind tomacromolecules such as, e.g., proteins. See, e.g., Johnsson and Ge,Current Topics in Microbiology and Immunology, 243:87-105, 1999.

In other embodiments, a protein therapeutic is a peptide aptamer. Apeptide aptamer comprises a peptide molecule that specifically binds toa target protein and interferes with the functional ability of thattarget protein. See, e.g., Kolonin et al., Proc. Natl. Acad. Sci. USA95:14266, 1998. Peptide aptamers consist of a variable peptide loopattached at both ends of a protein scaffold. Such peptide aptamers canoften have a binding affinity comparable to that of an antibody(nanomolar range). Due to the highly selective nature of peptideaptamers, they can be used not only to target a specific protein, butalso to target specific functions of a given protein (e.g., a signalingfunction). Further, peptide aptamers can be expressed in a controlledfashion by use of promoters that regulate expression in a temporal,spatial or inducible manner. Peptide aptamers act dominantly, therefore,they can be used to analyze proteins for which loss-of-function mutantsare not available. Peptide aptamers are usually prepared by selectingthe aptamer for its binding affinity with the specific target from arandom pool or library of peptides. Peptide aptamers can be isolatedfrom random peptide libraries by yeast two-hybrid screens. See, e.g., Xuet al., Proc. Natl. Acad. Sci. USA 94:12473, 1997. They can also beisolated from phage libraries (see, e.g., Hoogenboom et al.,Immunotechnology 4:1, 1998) or from chemically generatedpeptides/libraries.

In yet other embodiments, the therapeutic agent is a small moleculetherapeutic. Small molecule therapeutics are generally well-known in theart and may be used in accordance with the present invention. Suchmolecules include anti-infective (e.g., anti-viral) small molecules,immunomodulatory small molecules, and anti-cancer small molecules, toname a few broad categories. In some variations, the small moleculetherapeutic is a hydrophobic small molecule. Small molecule anti-cancertherapeutics include, e.g., a variety of chemotherapeutic drugs such as,for example, tyrosine kinase inhibitors (TKIs), small molecules thatinfluence either DNA or RNA, or small molecules that inhibit cellmitosis by preventing polymerization or depolymerization ofmicrotubules. Particular examples of small molecule chemotherapeuticagents include anti-metabolites (such as Azathioprine, Cytarabine,Fludarabine phosphate, Fludarabine, Gemcitabine, cytarabine, Cladribine,capecitabine 6-mercaptopurine, 6-thioguanine, methotrexate,5-fluoroouracil and hyroxyurea); alkylating agents (such as Melphalan,Busulfan, Cis-platin, Carboplatin, Cyclophosphamide, Ifosphamide,Dacarabazine, Procarbazine, Chlorambucil, Thiotepa, Lomustine,Temozolamide); anti-mitotic agents (such as Vinorelbine, Vincristine,Vinblastine, Docetaxel, Paclitaxel); topoisomerase inhibitors (such asDoxorubincin, Amsacrine, Irinotecan, Daunorubicin, Epirubicin,Mitomycin, Mitoxantrone, Idarubicin, Teniposide, Etoposide, Topotecan);antibiotics (such as Actinomycin and Bleomycin); Asparaginase;anthracyclines; and taxanes. In certain variations, the small moleculechemotherapeutic is selected from an anti-tubulin agent, a DNA minorgroove binding agent, a DNA replication inhibitor, and a tyrosine kinaseinhibitor. In other specific variations, the small moleculechemotherapeutic is an anthracycline, an auristatin, a camptothecin, aduocarmycin, an etoposide, a maytansinoid, a vinca alkaloid, or aplatinum (II) compound.

In still other embodiments, the therapeutic agent is a component of agene editing system that disrupts or corrects genes that cause disease.These include, for example, zinc finger nucleases (ZFNs) (see, e.g.,Smith et al., Nucleic Acids Res. 28:3361-3369, 2000), transcriptionactivator-like effector nucleases (TALENs) (see, e.g., Li et al.,Nucleic Acids Res. 39:359-372, 2011), the CRISPR/Cas system (see, e.g.,Richter et al., Int. J. Mol. Sci. 14:14518-14531, 2013), and engineeredmeganucleases (see, e.g., Silva et al., Curr. Gene Ther. 11:11-27,2011). In such embodiments, the nuclease(s) are encoded by one or morenucleic acids such as mRNA or DNA that are formulated in the lipidnanoparticle. In some variations, multiple mRNAs are formulated in theLNP carrier to deliver two nucleases to the same cell for gene editingto occur (e.g., for a ZFNs or TALENs gene editing system, whichtypically requires two nucleases to recognize the specific target sitewithin the genome to cause a modification at that site). In the contextof the present disclosure, the membrane destabilizing polymerfacilitates delivery of the nucleic acid(s) to the cytoplasm, wheretranslation or subsequent nuclear delivery occur. In some variations,one or more additional components of a gene editing system are deliveredto a target cell together with the one or more nucleic acids encodingthe nuclease(s). For example, in the CRISPR/Cas system, in addition to anucleic acid encoding the Cas9 protein, a short guide RNA to target theenzyme to a specific site in the genome is typically formulated withinthe LNP carrier. In certain embodiments, to correct a gene by homologousrecombination, a donor DNA sequence may also be delivered and formulatedeither in the same or a different LNP than with the nucleic acid(s) thatencode the nuclease(s). In certain embodiments where the gene editingsystem corrects a gene associated with a disease, the disease ischaracterized by deficiency of a functional protein as disclosed herein(see, e.g., discussion of protein deficiency diseases, infra.)

In some embodiments, the therapeutic agent is an immunogen. Usingmethods as disclosed herein, an immunogen can be effectively deliveredto a variety of immune cells to elicit an immune response. In somevariations, only the LNP comprises an immunogen. In other embodiments,the membrane destabilizing polymer is also associated with (e.g.,covalently coupled to) an immunogen. Suitable immunogens includepeptides, proteins, mRNAs, short RNAs, DNAs, simple or complexcarbohydrates as well as substances derived from viruses, bacteria,cancer cells, and the like. In some variations, a hapten or adjuvantcomponent is attached (conjugated) or self-associated with the membranedestabilizing polymer or the LNP. In certain embodiments in which boththe membrane destabilizing polymer and LNP are associated with animmunogen, the immunogen associated with the polymer is different thanthat for the LNP; alternatively, both the polymer and LNP have the sameimmunogenic cargo. For example, in some variations, a immunogenicpeptide that is a promiscuous T-cell epitope is attached to the membranedestabilizing polymer or the LNP to enable a more robust immuneresponse. This hapten can be derived from, e.g., the protein sequenceencoded by an mRNA component of the LNP or can be from another proteinor a combination of more than one T-cell epitope. As another example,the immunogen may be a component of a bacterial cell wall that isattached to the polymer or LNP to enhance the immune response by actingas an adjuvant. In yet other variations, an immmunostimulatingoligonucleotide or long nucleic acid is attached or self-associated withthe polymer or LNP to activate the innate immune response. Utilizing thedual nature of the delivery system described herein (using both amembrane destabilizing polymer component and an LNP component), onecomponent may be used to initiate a T-cell response while the othercomponent is utilized to initiate a B-cell response. The polymer and LNPcomponents of the hybrid delivery system may be used to elicit an innateimmune response, a T-cell response, a B-cell response, or a combinationthereof through the attachment or self-association of immunogenicsubstances. In some embodiments, a first polymer is used to attach andcarry an immunogen while a second, membrane destabilizing polymer isused to enable uptake into antigen presenting cells. In certainembodiments for delivering an immunogen to a cell as disclosed herein,at least one of the polymer and the LNP has a targeting ligand to directthe polymer and/or LNP to an immune cell of interest.

For delivery of a therapeutic or diagnostic agent to the cytosol of atarget cell (e.g., for delivery to a target tissue comprising the targetcells), a membrane-destabilizing polymer and a lipid nanoparticlecomprising the therapeutic or diagnostic agent are each administered toa subject in amounts effective to achieve intracellular delivery of theagent. The lipid nanoparticle and membrane-destabilizing polymer may beco-formulated as a single composition for co-injection into a subject.Alternatively, the lipid nanoparticle and membrane-destabilizing polymermay be formulated separately for separate administration. Typically, forseparate administration, the lipid nanoparticle andmembrane-destabilizing polymer are administered sequentially. Forexample, in particular embodiments, the membrane-destabilizing polymeris administered after administration of the lipid nanoparticle. Inspecific variations, the timing between administration of LNP andpolymer is about two hours or less, typically about one hour or less,and more typically about 30 minutes or less, about 10 minutes or less,about five minutes or less, or about one minute or less. In someembodiments, the timing between administration of LNP and polymer isabout 30 minutes, about 15 minutes, about 10 minutes, about fiveminutes, or about one minute. Typically, in variations comprisingco-injection of the lipid nanoparticle and membrane-destabilizingpolymer, the LNP and polymer are initially formulated as separatecompositions and then mixed together into a single composition prior toadministration.

Any cell type or corresponding tissue may be targeted for agent deliveryusing the present methods. Suitable target cells include, e.g.,chondrocytes, epithelial cells, nerve cells, muscle cells, blood cells(e.g., lymphocytes or myeloid leukocytes), endothelial cells, pericytes,fibroblasts, glial cells, and dendritic cells. Other suitable targetcells include cancer cells, immune cells, bacterially-infected cells,virally-infected cells, or cells having an abnormal metabolic activity.In a particular variation where the target cell is a secretory cell, thetarget secretory cell is a hepatocyte. In some such embodiments, eitheror both of the LNP and membrane-destabilizing polymer includes atargeting ligand that specifically binds to the asialoglycoproteinreceptor (ASGPR); for example, in particular variations, a targetingligand includes an N-acetylgalactosamine (NAG) residue (e.g., amonovalent NAG moiety or a tri-NAG structure). Target cells furtherinclude those where the cell is in a mammalian animal, including, forexample, a human, rodent, murine, bovine, canine, feline, sheep, equine,and simian mammal.

In particular embodiments comprising delivery of a polynucleotide, thepolynucleotide is an mRNA molecule encoding a functional protein, suchas a functional protein associated with a protein deficiency disease,and the method increases the amount of the functional protein within thetarget cell. For example, in specific variations, the mRNA encodes aprotein selected from erythropoietin, thrombopoietin, Factor VII, FactorVIII, LDL receptor, alpha-1-antitrypsin (A1AT), carbamoyl phosphatesynthetase I (CPS1), fumarylacetoacetase (FAH) enzyme, alanine:glyoxylate-aminotransferase (AGT), methylmalonyl CoA mutase (MUT),propionyl CoA carboxylase alpha subunit (PCCA), propionyl CoAcarboxylase beta subunit (PCCB), a subunit of branched-chain ketoaciddehydrogenase (BCKDH), ornithine transcarbamylase (OTC),copper-transporting ATPase Atp7B, bilirubin uridinediphosphateglucuronyltransferase (BGT) enzyme, hepcidin, glucose-6-phosphatase(G6Pase), glucose 6-phosphate translocase, lysosomal glucocerebrosidase(GB), Niemann-Pick C1 protein (NPC1), Niemann-Pick C2 protein (NPC2),acid sphingomyelinase (ASM), Factor IX, galactose-1-phosphateuridylyltransferase, galactokinase, UDP-galactose 4-epimerase,transthyretin, a complement regulatory protein, phenylalaninehydroxylase (PAH), homogentisate 1,2-dioxygenase, porphobilinogendeaminase, hypoxanthine-guanine phosphoribosyltransferase (HGPRT),argininosuccinate lyase (ASL), argininosuccinate synthetase (ASS1),P-type ATPase protein FIC-1, alpha-galactosidase A, acid ceramidase,acid α-L-fucosidase, acid β-galactosidase, iduronate-2-sulfatase,alpha-L-iduronidase, galactocerebrosidase, acid α-mannosidase,β-mannosidase, arylsulfatase B, arylsulfatase A,N-acetylgalactosamine-6-sulfate sulfatase, acid β-galactosidase, acidα-glucosidase, β-hexosaminidase B, heparan-N-sulfatase,alpha-N-acetylglucosaminidase, acetyl-CoA:α-glucosaminideN-acetyltransferase, N-acetylglucosamine-6-sulfate sulfatase,alpha-N-acetylgalactosaminidase, sialidase, β-glucuronidase, andβ-hexosaminidase A.

In certain embodiments comprising delivery of an mRNA molecule encodinga functional protein, the mRNA encodes a secreted protein. Exemplarysecreted proteins include erythropoietin, thrombopoietin,granulocyte-colony stimulating factor, granulocyte macrophage-colonystimulating factor, leptin, platelet-derived growth factors (e.g.,platelet-derived growth factor B), keratinocyte growth factor, bonemorphogenic protein 2, bone morphogenic protein 7, insulin,glucagon-like peptide-1, human growth hormone, clotting factors (e.g.,Factor VII, Factor VIII, Factor IX), relaxins (e.g., relaxin-2),interferons (e.g., interferon-α, interferon-β, interferon-γ),interleukins (e.g., interleukin-2, interleukin-4, interleukin-10,interleukin-11, interleukin-12, interleukin-18, interleukin-21), andchemokines (e.g., CC subfamily chemokines, CXC subfamily chemokines, Csubfamily chemokines, CX3C subfamily chemokines). Secreted proteins alsoinclude antibodies, which may be selected from various antibodyembodiments described herein. Particularly suitable antibodies includegenetically engineered antibodies such as, for example, chimericantibodies, humanized antibodies, single-chain antibodies (e.g., asingle-chain Fv (scFv)), and bispecific antibodies. In some variations,the mRNA encodes an antibody that specifically binds and antagonizes aprotein selected from vascular endothelial growth factor A (VEGF-A),tumor necrosis factor α (TNFα), interleukin-6 (IL-6), interleukin-17A(IL-17A), interleukin-17F (IL-17F), interleukin-21 (IL-21),interleukin-23 (IL-23), cytotoxic T-lymphocyte-associated protein 4(CTLA-4), and programmed cell death protein 1 (PD-1).

In certain embodiments comprising increasing the amount of a protein ina cell, the protein is ornithine transcarbamylase (OTC). In suchembodiments, an mRNA encoding an OTC protein is formulated into a lipidnanoparticle composition and is administered to a subject withco-injection or separate injection of a membrane-destabilizing polymeras described herein. In particular variations, the mRNA molecule encodesan OTC protein comprising an amino acid sequence having at least 90% orat least 95% sequence identity with residues 35-354 of SEQ ID NO:1(e.g., at least 96%, at least 97%, at least 98%, at least 99%, at least99.5%, or 100% sequence identity with residues 35-354 of SEQ ID NO:1).To direct an encoded OTC protein to the mitochondria of the cell, anmRNA molecule encoding the OTC protein includes a sequence encoding amitochondrial targeting signal peptide (also referred to herein as a“mitochondrial leader sequence”). The mitochondrial leader sequence maybe that of a native OTC protein (e.g., residues 1-34 of SEQ ID NO:1 (anative human mitochondrial leader sequence) or residues 1-34 of SEQ IDNO:2 (a native mouse mitochondrial leader sequence)), or may be derivedfrom another protein comprising a mitochondrial targeting signalpeptide, or synthesized de novo. An engineered cleavage site may beincluded at the junction between the mitochondrial leader sequence andthe remainder of the polypeptide to optimize proteolytic processing inthe cell. The mitochondrial leader sequence is operably linked to themRNA sequence encoding the mature OTC protein, i.e., the two sequencesare joined in the correct reading frame and positioned to direct thenewly synthesized polypeptide to the mitochondria of a cell.Mitochondrial leader sequences are commonly positioned at the aminoterminus of the protein. In specific variations, the encoded OTC proteinwith a mitochondrial leader sequence has an amino acid sequence as setforth in SEQ ID NO:1 or SEQ ID NO:2. Suitable mRNA sequences encoding anOTC protein of SEQ ID NO:1, and which may be formulated into a lipidnanoparticle composition, may comprise sequences as shown in SEQ ID NO:6or SEQ ID NO:8 (coding sequence (CDS) for each corresponding to residues48-1112). Suitable mRNA sequences encoding an OTC protein of SEQ IDNO:2, and which may be formulated into a lipid nanoparticle composition,may comprise a sequence as shown in SEQ ID NO:7 (coding sequence (CDS)corresponding to residues 48-1112). An OTC-encoding mRNA for formulationwith a lipid nanoparticle typically further includes a poly(A) at its 3′end (e.g., a polyA tail of from about 50 to about 500 adenine residues),which may be added to a construct using well-known genetic engineeringtechniques (e.g., via PCR). Exemplary DNA sequences that may be used forinsertion into an appropriate DNA vector for production and preparationof mRNA constructs of SEQ ID NOs. 6-8 are shown in SEQ ID NOs. 3-5,respectively.

In other embodiments comprising increasing the amount of a protein in acell, the protein is methylmalonyl CoA mutase (MUT), propionyl CoAcarboxylase subunit A (PCCA), propionyl CoA carboxylase subunit B(PCCB), or a subunit of branched-chain ketoacid dehydrogenase (BCKDH).In such embodiments, an mRNA encoding a MUT, PCCA, PCCB, or BCKDHsubunit protein is formulated into a lipid nanoparticle composition andis administered to a subject with co-injection or separate injection ofa membrane-destabilizing polymer as described herein. In particularvariations, the mRNA molecule encodes a MUT protein comprising an aminoacid sequence having at least 90% or at least 95% sequence identity withresidues 33-750 of SEQ ID NO:9 (e.g., at least 96%, at least 97%, atleast 98%, at least 99%, at least 99.5%, or 100% sequence identity withresidues 33-750 of SEQ ID NO:9). In other variations, the mRNA moleculeencodes a PCCA protein comprising an amino acid sequence having at least90% or at least 95% sequence identity with residues 53-728 of SEQ IDNO:11 (e.g., at least 96%, at least 97%, at least 98%, at least 99%, atleast 99.5%, or 100% sequence identity with residues 53-728 of SEQ IDNO:11). In other variations, the mRNA molecule encodes a PCCB proteincomprising an amino acid sequence having at least 90% or at least 95%sequence identity with residues 29-539 of SEQ ID NO:13 (e.g., at least96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or 100%sequence identity with residues 29-539 of SEQ ID NO:13). To direct anencoded MUT, PCCA, PCCB, or BCKDH subunit protein to the mitochondria ofthe cell, an mRNA molecule encoding the protein includes a sequenceencoding a mitochondrial leader sequence. The mitochondrial leadersequence may be that of a native protein (e.g., residues 1-32 of SEQ IDNO:9 (a native human MUT mitochondrial leader sequence), residues 1-52of SEQ ID NO:11 (a native human PCCA mitochondrial leader sequence), orresidues 1-28 of SEQ ID NO:13 (a native human PCCB mitochondrial leadersequence)), or may be derived from another protein comprising amitochondrial targeting signal peptide, or synthesized de novo. Anengineered cleavage site may be included at the junction between themitochondrial leader sequence and the remainder of the polypeptide tooptimize proteolytic processing in the cell. The mitochondrial leadersequence is operably linked to the mRNA sequence encoding the matureMUT, PCCA, PCCB, or BCKDH subunit protein, i.e., the two sequences arejoined in the correct reading frame and positioned to direct the newlysynthesized polypeptide to the mitochondria of a cell. In specificvariations, the encoded MUT protein with a mitochondrial leader sequencehas an amino acid sequence as set forth in SEQ ID NO:9, the encoded PCCAprotein with a mitochondrial leader sequence has an amino acid sequenceas set forth in SEQ ID NO:11, or the encoded PCCB protein with amitochondrial leader sequence has an amino acid sequence as set forth inSEQ ID NO:13. A suitable mRNA sequence encoding a MUT protein of SEQ IDNO:9, and which may be formulated into a composition comprising a lipidnanoparticle in accordance with the present disclosure, may comprise thesequence shown in SEQ ID NO:10 (coding sequence corresponding toresidues 48-2297). A suitable mRNA sequence encoding a PCCA protein ofSEQ ID NO:11, and which may be formulated into a composition comprisinga lipid nanoparticle in accordance with the present disclosure, maycomprise the sequence shown in SEQ ID NO:12 (coding sequencecorresponding to residues 48-2231). A suitable mRNA sequence encoding aPCCB protein of SEQ ID NO:13, and which may be formulated into acomposition comprising a lipid nanoparticle in accordance with thepresent disclosure, may comprise the sequence shown in SEQ ID NO:14(coding sequence corresponding to residues 48-1664). A MUT-, PCCA-,PCCB-, or BCKDH-subunit-encoding mRNA for formulation with a lipidnanoparticle typically includes a poly(A) at its 3′ end (e.g., a polyAtail of from about 50 to about 500 adenine residues).

In yet other embodiments comprising increasing the amount of a proteinin a cell the protein is argininosuccinate lyase (ASL) orargininosuccinate synthetase (ASS1). In such embodiments, an mRNAencoding an ASL or ASS1 protein is formulated into a lipid nanoparticlecomposition and is administered to a subject with co-injection orseparate injection of a membrane-destabilizing polymer as describedherein. In particular variations, the mRNA molecule encodes an ASLprotein comprising an amino acid sequence having at least 90% or atleast 95% sequence identity with SEQ ID NO:48 (e.g., at least 96%, atleast 97%, at least 98%, at least 99%, at least 99.5%, or 100% sequenceidentity with SEQ ID NO:48). In other variations, the mRNA moleculeencodes an ASS1 protein comprising an amino acid sequence having atleast 90% or at least 95% sequence identity with SEQ ID NO:50 (e.g., atleast 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or100% sequence identity with SEQ ID NO:50). A suitable mRNA sequenceencoding an ASL protein of SEQ ID NO:48, and which may be formulatedinto a composition comprising a lipid nanoparticle in accordance withthe present disclosure, may comprise the sequence shown in SEQ ID NO:49(coding sequence corresponding to residues 48-1439). A suitable mRNAsequence encoding an ASS1 protein of SEQ ID NO:50, and which may beformulated into a composition comprising a lipid nanoparticle inaccordance with the present disclosure, may comprise the sequence shownin SEQ ID NO:51 (coding sequence corresponding to residues 48-1283). AnASL- or ASS1-encoding mRNA for formulation with a lipid nanoparticletypically includes a poly(A) at its 3′ end (e.g., a polyA tail of fromabout 50 to about 500 adenine residues).

Thus, in certain embodiments of the present invention, an mRNA isformulated into a lipid nanoparticle as the mRNA carrier. In somevariations, a sequential injection of a membrane-destabilizing polymernanoparticle is given approximately 1 to 15 minutes following themRNA/LNP that enhances delivery of the mRNA to the cytoplasm in thetarget cell. In some embodiments of the present disclosure, the LNPcomprises a cationic lipid, a PEG-lipid, cholesterol, and an anioniclipid. The lipids are typically solubilized, e.g., in 100% ethanol,typically from 20 mg/mL to 200 mg/mL individually and then mixedtogether to obtain, for example, the following lipid ratio ranges: 20-60mol % cationic lipid, 0-50 mol % anionic lipid, 0-40 mol % cholesterol,and 0-15 mol % PEG-lipid. A lipid mixture in ethanol is typicallyprepared in a range from 1 mg/mL to 40 mg/mL. The mRNA may be preparedusing a standard in vitro transcription reaction according to well-knownprocedures. The mRNA solution is typically diluted in anaqueous/isotonic buffer at about normal physiological pH (e.g., pH 7.4)at a concentration from 0.01 mg/mL to 1 mg/mL. The lipid mixture inethanol and mRNA aqueous solution may then be mixed together at a 1:3ratio of lipid:mRNA using a microfluidic device. Lipid concentrations,mRNA concentrations, and mixing ratio can be adjusted to preparelipid:mRNA formulations at N:P ratios (nitrogen to phosphorous ratiobetween the cationic lipid and the mRNA) from 0.5 to 40. After anincubation time, the mRNA/LNP is typically dialyzed overnight in anaqueous/isotonic buffer. The polymer may be solubilized in anaqueous/isotonic buffer at about normal physiological pH (e.g., pH 7.4).Particularly suitable concentrations of solubilized polymer range from 1mg/mL to 50 mg/mL. The formulations may be used for delivery of the mRNAinto target cells (e.g., the formulations may be contacted with cells invitro or administered to a subject, such as mice, in vivo).

In further variations where an mRNA is formulated into a lipidnanoparticle and delivered in accordance with the present disclosure,the mRNA/LNP is formulated so as to reduce or eliminate an undesiredimmune response in a subject. For example, RNA transcribed in vitrotypically contains multiple contaminants, including short RNAs producedby abortive initiation events, and double-stranded (ds)RNAs generated byself-complementary 3′ extension, RNA-primed transcription from RNAtemplates and RNA-dependent RNA polymerase activity. See Karikó et al.,Nucleic Acids Research, 2011, 1-10, doi:10.1093/nar/gkr695. These dsRNAcontaminants can be immunostimulatory through binding and activating anumber of innate immune receptors, including toll-like receptors TLR3,TLR7, TLR8, retinoic acid-inducible gene I (RIG-I), and RNA-dependentprotein kinase (PKR). Further, the presence of immunostimulatory nucleicacid encapsulated in lipid nanoparticles containing surface-associatedPEG can stimulate an immune response against the carrier. See Semple etal., J. Pharmacol. Exp. Ther. 312:1020-1026, 2005. Semple et al. showedthis immune response to depend on the presence of non-exchangeablePEG-lipids (DSPE-PEG2000 or PEG ceramide C₂₀) in the LNP and to lead torapid plasma elimination of subsequent repeat administrations ofliposome-encapsulated oligodeoxynucleotide (ODN); in contrast, nucleicacid encapsulated in a LNP containing an exchangeable PEG-lipid with ashorter acyl chain (PEG ceramide C₁₄) showed no change in circulationlevels following repeat administrations. See Semple et al., supra.

To reduce or eliminate a potential immune response against mRNAencapsulated in an LNP, as well as to reduce or eliminate a potentialrapid plasma clearance following repeat administrations of the mRNA/LNP,certain variations of the mRNA or mRNA/LNP formulation may be used. Forexample, the mRNA may be purified (e.g., using HPLC purification) toremove immunostimulatory dsRNA contaminants. HPLC-purified mRNA has beenshown to avoid stimulating type I interferon cytokines (IFN-α, IFN-β andTNF-α). See Karikó et al., supra. In some variations, one or moreuridines in the mRNA sequence are substituted with pseudouridine orN1-methyl-pseudouridine, which has been shown to avoid activating innateimmune receptors (see id.). In other embodiments, the mRNA sequence maybe codon optimized to remove or reduce the number of uridines, which canactivate the innate immune response. In yet other embodiments, anexchangeable PEG-lipid (e.g., DMPE-PEG2000) in the LNP is used tomaintain activity following repeat administration. Any one or more ofthese variations may be used for in vivo delivery of mRNA and relatedmethods of treatment in accordance with the present disclosure.

Methods for purifying mRNA are generally known in the art and may beused to prepare mRNA for formulation with a lipid nanoparticle inaccordance with the present disclosure. For example, after isolation ofin vitro-transcribed (IVT) mRNA constructs from transcription mixtures,further purification of the material may be performed usingion-pair/reversed-phase HPLC or anion-exchange HPLC. These techniquesmay remove length-based sequence variants and other nucleic acidimpurities when performed under denaturing conditions. Ion-pair/reversedphase HPLC utilizes a traditional C8 or C18 stationary phase(alternatively, polymeric-based media may be used) and a mobile phasesystem containing a suitable ion-pairing agent such as triethylammoniumacetate. The material is traditionally eluted using an acetonitrilegradient. The purification occurs under denaturing conditions (typicallyat temperatures>55° C.). Strong or weak anion-exchange HPLC may also beutilized. For example, a strong anion exchange column (utilizing aquaternary ammonium in the stationary phase) may be used with a mobilephase system buffered at neutral to basic pH (e.g., 20 mM sodiumphosphate at pH 8.0), with elution modulated by gradient addition of astronger salt solution (e.g., 1M sodium bromide) to displace interactionof the nucleic acid backbone with the column stationary phase. Becausethe strong ionic environment increases the stability of the mRNAconformation (and therefore confers a higher Tm relative to theIon-pair/reversed phase separations), the purification may require ahigher temperature and/or pH environment to fully melt out secondary ordouble-stranded structures.

In certain embodiments of the present invention, a therapeutic agent isdelivered intracellularly to cells of a target tissue for treatment of adisease amenable to treatment with the therapeutic agent. In suchembodiments, the therapeutic agent is delivered to the target tissue viacombined administration of a membrane-destabilizing polymer and lipidnanoparticle comprising the therapeutic agent as described herein,typically in a manner otherwise consistent with conventionalmethodologies associated with management of the disease or disorder forwhich treatment is sought. In accordance with the disclosure herein, atherapeutically effective amount of the agent is administered to asubject in need of such treatment for a time and under conditionssufficient to prevent or treat the disease.

Subjects for administration of a therapeutic agent as described hereininclude patients at high risk for developing a particular disease aswell as patients presenting with an existing disease. In certainembodiments, the subject has been diagnosed as having the disease forwhich treatment is sought. Further, subjects can be monitored during thecourse of treatment for any change in the disease (e.g., for an increaseor decrease in clinical symptoms of the disease).

In prophylactic applications, pharmaceutical compositions areadministered to a patient susceptible to, or otherwise at risk of, aparticular disease in an amount sufficient to eliminate or reduce therisk or delay the onset of the disease. In therapeutic applications,compositions are administered to a patient suspected of, or alreadysuffering from, such a disease in an amount sufficient to cure, or atleast partially arrest, the symptoms of the disease and itscomplications. An amount adequate to accomplish this is referred to as atherapeutically- or pharmaceutically-effective dose or amount. In bothprophylactic and therapeutic regimes, agents are usually administered inseveral dosages until a sufficient response has been achieved.Typically, the response is monitored and repeated dosages are given ifthe desired response starts to fade.

To identify subject patients for treatment according to the methods ofthe invention, accepted screening methods may be employed to determinerisk factors associated with specific diseases or to determine thestatus of an existing disease identified in a subject. Such methods caninclude, for example, determining whether an individual has relativeswho have been diagnosed with a particular disease. Screening methods canalso include, for example, blood tests to assay for buildups ofmetabolites caused by missing or mutated proteins in the liver (forcertain liver diseases) or conventional work-ups to determine familialstatus for a particular disease known to have a heritable component (forexample, various cancers and protein deficiency diseases are known tohave certain inheritable components). Inheritable components of cancersinclude, for example, mutations in multiple genes that are transforming(e.g., Ras, Raf, EGFR, cMet and others), the presence or absence ofcertain HLA and killer inhibitory receptor (KIR) molecules, ormechanisms by which cancer cells are able to modulate immune suppressionof cells like NK cells and T cells, either directly or indirectly (see,e.g., Ljunggren and Malmberg, Nature Rev. Immunol. 7:329-339, 2007;Boyton and Altmann, Clin. Exp. Immunol. 149:1-8, 2007). Toward this end,nucleotide probes can be routinely employed to identify individualscarrying genetic markers associated with a particular disease ofinterest. In addition, a wide variety of immunological methods are knownin the art that are useful to identify markers for specific diseases.For example, various ELISA immunoassay methods are available andwell-known in the art that employ monoclonal antibody probes to detectantigens associated with specific tumors. Screening may be implementedas indicated by known patient symptomology, age factors, related riskfactors, etc. These methods allow the clinician to routinely selectpatients in need of the methods described herein for treatment.

For administration, a lipid nanoparticle and membrane-destabilizingpolymer are formulated as a single pharmaceutical composition (forco-injection embodiments; typically mixed together just prior toadministration) or as separate pharmaceutical compositions (for separateadministration embodiments). A pharmaceutical composition comprising anLNP and/or membrane-destabilizing polymer can be formulated according toknown methods to prepare pharmaceutically useful compositions, wherebythe LNP and/or polymer component(s) are combined in a mixture with apharmaceutically acceptable carrier. A composition is said to be a“pharmaceutically acceptable carrier” if its administration can betolerated by a recipient patient. Sterile phosphate-buffered saline isone example of a pharmaceutically acceptable carrier. Other suitablecarriers are well-known to those in the art. (See, e.g., Gennaro (ed.),Remington's Pharmaceutical Sciences (Mack Publishing Company, 19th ed.1995).) Formulations may further include one or more excipients,preservatives, solubilizers, buffering agents, etc.

For disease treatment, a pharmaceutical composition is administered to asubject in a therapeutically effective amount. According to the methodsof the present invention, the lipid nanoparticle andmembrane-destabilizing polymer may be administered to subjects by avariety of administration modes, including, for example, byintramuscular, subcutaneous, intravenous, intra-atrial, intra-articular,parenteral, intranasal, intrapulmonary, transdermal, intrapleural,intrathecal, and oral routes of administration. For prevention andtreatment purposes, the compositions may be administered to a subject ina single bolus delivery, via continuous delivery (e.g., continuoustransdermal delivery) over an extended time period, or in a repeatedadministration protocol (e.g., on an hourly, daily, weekly, or bi-weeklybasis).

Determination of the proper dosage for a particular situation is withinthe skill in the art. Determination of effective dosages in this contextis typically based on animal model studies followed up by human clinicaltrials and is guided by determining effective dosages and administrationprotocols that significantly reduce the occurrence or severity of thesubject disease in model subjects. Effective doses of the compositionsof the present invention vary depending upon many different factors,including means of administration, target site, physiological state ofthe patient, whether the patient is human or an animal, othermedications administered, whether treatment is prophylactic ortherapeutic, as well as the specific activity of the composition itselfand its ability to elicit the desired response in the individual.Usually, the patient is a human, but in some diseases, the patient canbe a nonhuman mammal. Typically, dosage regimens are adjusted to providean optimum therapeutic response, i.e., to optimize safety and efficacy.Accordingly, a therapeutically or prophylactically effective amount isalso one in which any undesired collateral effects are outweighed bybeneficial effects. For administration of a therapeutic agent, a dosagetypically ranges from about 0.1 μg to about 100 mg/kg or about 1 μg/kgto about 50 mg/kg, and more usually about 1 μg/kg to about 10 mg/kg orabout 10 μg to about 5 mg/kg of the subject's body weight, exclusive ofother LNP components. In more specific embodiments, an effective amountof the agent is between about 1 μg/kg and about 20 mg/kg, between about10 μg/kg and about 10 mg/kg, or between about 0.1 mg/kg and about 5mg/kg, exclusive of other LNP component. The quantity of amembrane-destabilizing polymer may be varied or adjusted, for example,from about 10 μg to about 200 mg/kg, about 10 μg to about 100 mg/kg,about 0.1 mg/kg to about 100 mg/kg, about 0.1 mg/kg to about 50 mg/kg,or about 0.5 mg/kg to about 50 mg/kg. Dosages within this range can beachieved by single or multiple administrations, including, e.g.,multiple administrations per day or daily, weekly, bi-weekly, or monthlyadministrations. For example, in certain variations, a regimen consistsof an initial administration followed by multiple, subsequentadministrations at weekly or bi-weekly intervals. Another regimenconsists of an initial administration followed by multiple, subsequentadministrations at monthly or bi-monthly intervals. Alternatively,administrations can be on an irregular basis as indicated by monitoringof physiological correlates of the disease and/or clinical symptoms ofthe disease.

Lipid nanoparticles can adsorb to virtually any type of cell and thenslowly release the encapsulated agent. Alternatively, an absorbed lipidnanoparticle may be endocytosed by cells (e.g., cells that arephagocytic). Endocytosis is typically followed by intralysosomaldegradation of LNP lipids and release of the encapsulated agents (seeScherphof et al., Ann. N.Y. Acad. Sci. 446:368, 1985). After intravenousadministration, lipid nanoparticles (e.g., liposomes of about 0.1 to 1.0μm) are typically taken up by cells of the reticuloendothelial system,located principally in the liver and spleen. This preferential uptake ofsmaller liposomes by the cells of the reticuloendothelial system hasbeen used to deliver chemotherapeutic agents to macrophages and totumors of the liver. As described herein, it is believed the combiningadministration of a lipid nanoparticle together with administration of amembrane-destabilizing polymer enhances efficiency of delivery of theLNP-associated therapeutic agent to the cytosol of a cell.

The reticuloendothelial system can be circumvented by several methodsincluding saturation with large doses of lipid nanoparticles, orselective macrophage inactivation by pharmacological means (see Claassenet al., Biochim. Biophys. Acta 802:428, 1984). In addition,incorporation of glycolipid- or polyethelene glycol-derivatizedphospholipids into liposome membranes has been shown to result in asignificantly reduced uptake by the reticuloendothelial system (seeAllen et al., Biochim. Biophys. Acta 1068:133, 1991; Allen et al.,Biochim. Biophys. Acta 1150:9, 1993).

Lipid nanoparticles can also be prepared to target particular cells ortissues by varying phospholipid composition of the lipid nanoparticles.For example, liposomes prepared with a high content of a nonionicsurfactant have been used to target the liver. (See, e.g., JapanesePatent 04-244,018 to Hayakawa et al.; Kato et al., Biol. Pharm. Bull.16:960, 1993.) These formulations were prepared by mixing soybeanphospatidylcholine, α-tocopherol, and ethoxylated hydrogenated castoroil (HCO-60) in methanol, concentrating the mixture under vacuum, andthen reconstituting the mixture with water. A liposomal formulation ofdipalmitoylphosphatidylcholine (DPPC) with a soybean-derivedsterylglucoside mixture (SG) and cholesterol (Ch) has also been shown totarget the liver. (See Shimizu et al., Biol. Pharm. Bull. 20:881, 1997.)

Lipid nanoparticles and/or membrane-destabilizing polymers can also beprepared to target particular cells or tissues by using a targetingligand as discussed herein.

In some embodiments, a lipid nanoparticle and membrane-destabilizingpolymer as described herein are used in a method for treating a diseaseassociated with defective gene expression and/or activity in a subject.Such methods of treatment include administering to a subject having thedisease associated with defective gene expression and/or activity (a) aneffective amount of a lipid nanoparticle comprising a polynucleotidethat is homologous to and can silence, for example by cleavage, a geneor that specifies the amino acid sequence of a protein and is translatedduring protein synthesis, and (b) an effective amount of amembrane-destabilizing polymer, where the polynucleotide is deliveredinto the cytosol of target cells of a target tissue associated with thedisease, thereby treating the disease. In some embodiments, at least oneof the lipid nanoparticle and membrane-destabilizing polymer includes atargeting ligand that specifically binds to a molecule on the surface ofthe target cells of the target tissue within the subject. Examples of adisease associated with defective gene expression and/or activity in asubject treatable by the methods disclosed herein include liver cancer(e.g., hepatocellular carcinoma), hepatitis, hypercholesterolemia, liverfibrosis, and haemochromatosis. In other variations, a disease orcondition associated with defective gene expression and/or activity in asubject treatable by the methods disclosed herein is a cancer of thebreast, ovaries, pancreas, endometrium, lungs, kidneys, colon, brain(e.g., glioblastoma), or myeloid cells of hematopoietic origin.

In certain embodiments, the disease associated with defective geneexpression is a disease characterized by a deficiency in a functionalpolypeptide (also referred to herein as a “disease associated with aprotein deficiency” or a “protein deficiency disease”). Such methods oftreatment include administering to a subject having the proteindeficiency disease (a) an effective amount of a lipid nanoparticlecomprising an mRNA that encodes the functional protein or a proteinhaving the same biological activity as the functional protein and (b) aneffective amount of a membrane-destabilizing polymer, where the mRNA isdelivered into the cytosol of target cells of a target tissue associatedwith the protein deficiency, and where the mRNA is translated duringprotein synthesis so as to produce the encoded protein within the targettissue in an amount sufficient to treat the disease. In someembodiments, at least one of the lipid nanoparticle andmembrane-destabilizing polymer comprises a targeting ligand thatspecifically binds to a molecule on the surface of the target cells ofthe target tissue. In specific variations, the mRNA encodes a functionalerythropoietin, alpha-galactosidase A, LDL receptor, Factor VII, FactorVIII, Factor IX, alpha-L-iduronidase, iduronate-2-sulfatase,heparan-N-sulfatase, alpha-N-acetylglucosaminidase, galactose6-sulfatase, acid β-galactosidase, lysosomal acid lipase, ornithinetranscarbamylase (OTC), alpha-1-antitrypsin, arylsulfatase A,arylsulfatase B, acid ceramidase, acid α-L-fucosidsase, acidβ-glucosidase (also known as glucocerebrosidase), galactocerebrosidase,acid α-mannosidase, acid β-mannosidase, N-acetylgalactosamine-6-sulfatesulfatase, acid sphingomyelinase, acid α-glucosidase, β-hexosaminidaseB, acetyl-CoA:α-glucosaminide N-acetyltransferase,N-acetylglucosamine-6-sulfate sulfatase,alpha-N-acetylgalactosaminidase, sialidase, β-glucuronidase, orβ-hexosaminidase A. In other embodiments, the mRNA encodes a functionalRetinoblastoma protein (pRb), p53 tumor-suppressor protein, Phosphataseand tensin homolog (PTEN), Von Hippel-Lindau tumor suppressor (pVHL),Adenomatous polyposis coli (APC), FAS receptor (FasR), Suppression oftumorigenicity 5 (ST5), YPEL3, Suppressor of tumorigenicity protein 7(ST7), or Suppressor of tumorigenicity 14 protein (ST14). In yet otherembodiments, the mRNA encodes a functional Galactose-1-phosphateuridylyltransferase, Galactokinase, UDP-galactose 4-epimerase,Transthyretin, complement regulatory protein (e.g., factor H, factor I,or membrane cofactor protein), phenylalanine hydroxylase (PAH),homogentis ate 1,2-dioxygenase, Porphobilinogen deaminase,hypoxanthine-guanine phosphoribosyltransferase (HGPRT),argininosuccinate lyase (ASL), argininosuccinate synthetase (ASS1), orP-type ATPase protein, FIC-1.

Further examples of a disease or condition associated with defectivegene expression and/or activity in a subject treatable by the methodsdisclosed herein include protein deficiency diseases associated withsingle-gene metabolic defects in the liver. Exemplary protein deficiencydiseases of the liver include diseases associated with urea cycledefects (e.g., ornithine transcarbamylase (OTC) deficiency, carbamoylphosphate synthetase I (CPS1) deficiency, argininosuccinic aciduria(argininosuccinate lyase (ASL) deficiency), and citrullinemia(argininosuccinate synthetase (ASS1) deficiency)); tyrosinemia type 1(fumarylacetoacetase (FAH) enzyme deficiency); primary hyper-oxaluriatype 1 (alanine:glyoxylate-aminotransferase (AGT) deficiency); organicacidemia (e.g., methylmalonic acidemia (MMA; deficiency in, for example,methylmalonyl CoA mutase), propionic acidemia (PA; propionyl CoAcarboxylase (PCC) deficiency), and maple syrup urine disease (MSUD;branched-chain ketoacid dehydrogenase (BCKDH) deficiency)); Wilson'sDisease (deficiency in copper-transporting ATPase, Atp7B);Crigler-Najjar Syndrome Type 1 (bilirubin uridinediphosphateglucuronyltransferase (BGT) enzyme deficiency); hemochromatosis(hepcidin deficiency); glycogen storage disease (GSD) type 1a(glucose-6-phosphatase (G6Pase) deficiency); glycogen storage disease(GSD) type 1b (glucose 6-phosphate translocase deficiency); lysosomalstorage diseases (LSDs; deficiencies in lysosomal enzymes) such as,e.g., Gaucher's Disease types 1 , 2, and 3 (lysosomal glucocerebrosidase(GB) deficiency), Niemann-Pick Disease Type C (mutation in either theNPC1 or NPC2 gene), and Niemann-Pick Disease Types A and B (acidsphingomyelinase (ASM) deficiency); alpha-1 antitrypsin (A1AT)deficiency; hemophilia B (Factor IX deficiency); galactosemia types 1,2, and 3 (galactose-1-phosphate uridylyltransferase, galactokinase, andUDP-galactose 4-epimerase deficiencies, respectively);transthyretin-related hereditary amyloidosis (TTR-familial amyloidpolyneuropathy; transthyretin deficiency); atypical haemolytic uremicsyndrome-1 (deficiencies in complement regulatory proteins, e.g., factorH, factor I, or membrane cofactor protein); phenylketonuria(phenylalanine hydroxylase (PAH) deficiency); alcaptonuria(homogentisate 1,2-dioxygenase deficiency); acute intermittent porphyria(porphobilinogen deaminase deficiency); Lesch-Nyhan syndrome(hypoxanthine-guanine phosphoribosyltransferase (HGPRT) deficiency; andprogressive familial intrahepatic cholestasis (PFIC) (P-type ATPaseprotein, FIC-1 deficiency). Additional examples of protein deficiencydiseases that are lysosomal storage diseases (LSDs) include Fabrydisease (alpha-galactosidase A deficiency); Farber disease (acidceramidase deficiency); fucosidosis (acid α-L-fucosidsase deficiency);GM1 gangliosidosis (acid β-galactosidase deficiency); Hunter syndrome(mucopolysaccharidosis type II (MPS IT); iduronate-2-sulfatasedeficiency); Hurler-Scheie, Hurler, and Scheie syndromes(mucopolysaccharidosis type I (MPS I); alpha-L-iduronidase deficiency);Krabbe disease (galactocerebrosidase deficiency); α-mannosidosis (acidα-mannosidase deficiency); β-mannosidosis (acid β-mannosidasedeficiency); Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI (MPSVI); arylsulfatase B deficiency); metachromatic leukodystrophy(arylsulfatase A deficiency); Morquio syndrome type A(mucopolysaccharidosis type IVA (MPS IVA);N-acetylgalactosamine-6-sulfate sulfatase deficiency); Morquio syndrometype B (mucopolysaccharidosis type IVB (MPS IVB); acid β-galactosidasedeficiency); Pompe disease (acid α-glucosidase deficiency); Sandhoffdisease (β-hexosaminidase B deficiency); Sanfilippo syndrome type A(mucopolysaccharidosis type IIIA (MPS IIIA); heparan-N-sulfatasedeficiency); Sanfilippo syndrome type B (mucopolysaccharidosis type IIIB(MPS IIIB); alpha-N-acetylglucosaminidase deficiency); Sanfilipposyndrome type C (mucopolysaccharidosis type IIIC (MPS IIIC);acetyl-CoA:α-glucosaminide N-acetyltransferase deficiency); Sanfilipposyndrome type D (mucopolysaccharidosis type IIID (MPS IIID);N-acetylglucosamine-6-sulfate sulfatase deficiency); Schindler/Kanzakidisease (alpha-N-acetylgalactosaminidase deficiency); sialidosis(sialidase deficiency); Sly syndrome (mucopolysaccharidosis type VII(MPS VII); β-glucuronidase deficiency); and Tay-Sachs disease(β-hexosaminidase A deficiency).

In particular variations, an mRNA encoding an ornithine transcarbamylase(OTC) protein is delivered in accordance with the present methods totreat ornithine transcarbamylase deficiency (OTCD). OTCD is a urea cycledisorder that can trigger hyperammonemia, a life-threatening illnessthat leads to brain damage, coma or even death. This is due todeficiency in the activity of OTC, a key enzyme in the urea cycle, whichprimarily takes place in the liver and is responsible for removal ofexcess nitrogen in the body. Ammonium nitrogen is produced from proteinintake as well as protein breakdown in the body. In the liver, thisammonium nitrogen is converted into urea by enzymes in the urea cycle.Urea is non-toxic and cleared easily through the kidneys in urine,normally. However, when the OTC enzyme is deficient, ammonia levels risein blood and cause severe brain damage. Patients with severe OTCdeficiency are most often identified 2-3 days after birth where thepatient has significantly elevated blood ammonia levels and ends up in acoma. Patients with milder OTC deficiency can have crises during timesof stress resulting in elevated ammonia levels that can also lead tocoma. Current therapies include ammonia scavenger drugs (Buphenyl,Ravicti) for use in patients with hyperammonemia.

The OTC gene is X-linked. The disease is present in males with onemutant allele and in females either homozygous or heterozygous withmutant alleles. Male patients are typically those with the severest OTCdeficiency found right after birth. In addition to elevation in bloodammonia levels, urinary orotic acid levels are also elevated. Inpatients with severe OTC deficiency, OTC enzyme activity is <20% ofnormal levels. In patients with milder OTC deficiency, OTC enzymeactivity is up to 30% of normal levels.

A method for treating OTCD with a lipid nanoparticle comprising anOTC-encoding mRNA and a membrane-destabilizing polymer generallyincludes administering to a subject having OTCD an effective amount ofthe lipid nanoparticle and an effective amount of themembrane-destabilizing polymer, where at least one of the lipidnanoparticle and membrane-destabilizing polymer includes a targetingligand that specifically binds to a molecule on the surface of livercells within the subject, and whereby the OTC-encoding mRNA is deliveredto liver cells and translated during protein synthesis to produce theOTC protein. The OTC-encoding mRNA may be an mRNA as set forth abovewith respect to a method for increasing OTC protein in a cell.

The efficacy of a composition or method for treating a disease can beevaluated in vivo in animal models of disease. Particularly suitableanimal models for evaluating efficacy of a [lipidnanoparticle]/[membrane-destabilizing polymer] composition (orcombination of LNP composition and polymer composition) for treatment ofOTCD includes known mouse models having deficiencies of the OTC enzymein the liver. One such mouse model, OTC-spf^(ash) (sparse fur andabnormal skin and hair) mice, contain an R129H mutation resulting inreduced levels of OTC protein and have only 5-10% of the normal level ofenzyme activity in liver (see Hodges et al., Proc. Natl. Acad. Sci. USA86:4142-4146, 1989). Another model, OTC-spf mice, contain an H117Nmutation which results in reduced levels of enzyme activity to 5-10% ofnormal levels (see Rosenberg et al., Science 222:426-428, 1983). Both ofthese mouse models have elevated urine orotic acid levels compared totheir wild-type littermate mice. A third model for OTC deficiency isinducing hyperammonemia in OTC-spf or OTC-spf^(ash) mice (Cunningham etal., Mol Ther 19: 854-859, 2011). These mice are treated with OTC siRNAor AAV2/8 vector/OTC shRNA to knockdown residual endogenous OTCexpression and activity. Plasma ammonia levels are elevated and mice diewithin approximately 7-28 days.

In additional variations, an mRNA encoding an enzyme deficient in anorganic acidemia is delivered in accordance with the present methods totreat the organic acidemia. Organic acidemia (also known as aciduria)(OA) is a group of disorders characterized by the excretion of non-aminoorganic acids in the urine. Most organic acidemias result fromdysfunction of a specific step in amino acid catabolism, usually theresult of deficient enzyme activity. The majority of organic aciddisorders are caused by abnormal amino acid catabolism of branched-chainamino acids or lysine. They include propionic acidemia (PA),methylmalonic acidemia (MMA), maple syrup urine disease (MSUD), andothers. These organic acidemias are inherited in an autosomal recessivemanner. A neonate affected with an OA is usually well at birth and forthe first few days of life. The usual clinical presentation is that oftoxic encephalopathy and includes vomiting, poor feeding, neurologicsymptoms such as seizures and abnormal tone, and lethargy progressing tocoma. Outcome can be improved by diagnosis and treatment in the firstten days of life. In the older child or adolescent, variant forms of theOAs can present as loss of intellectual function, ataxia or other focalneurologic signs, Reye syndrome, recurrent ketoacidosis, or psychiatricsymptoms.

Clinical laboratory findings indicate that organic acidemias includeacidosis, ketosis, hyperammonemia, abnormal liver function,hypoglycemia, and neutropenia. First-line diagnosis in the organicacidemias is urine organic acid analysis using gas chromatography withmass spectrometry (GC/MS). The urinary organic acid profile is nearlyalways abnormal in the face of acute illness. Confirmatory testinginvolves assay of the activity of the deficient enzyme in lymphocytes orcultured fibroblasts and/or molecular genetic testing. Characteristicsof the three primary disorders are summarized in Table 1.

TABLE 1 Metabolic Findings in Organic Acidemias Caused by Abnormal AminoAcid Catabolism Diagnostic Analytes by GC/MS and Amino Acid QuantitativeAmino Disorder Pathway(s) Affected Enzyme Acid Analysis Propionicacidemia Isoleucine, valine, Propionyl CoA Propionic acid, 3-OH (PA)methionine, threonine carboxylase (PCC) propionic acid, methyl (composedof three citric acid, propionyl PCCA subunits and glycine in urine threePCCB subunits) Propionyl carnitine, increased glycine in bloodMethylmalonic Isoleucine, valine, Methylmalonyl CoA Methylmalonic acidin acidemia (MMA) methionine, threonine mutase (MUT) blood and urinePropionic acid, 3-OH propionic acid, methyl citrate in urine Acylcarnitines, increased glycine in blood Maple syrup urine Leucine,isoleucine, Branched-chain Branched-chain disease (MSUD) valine ketoacidketoacids and dehydrogenase hydroxyacids in urine (BCKDH) Alloisoleucinein (composed of four plasma different subunits)

Once the detection of specific analytes narrows the diagnosticpossibilities, the activity of the deficient enzyme is assayed inlymphocytes or cultured fibroblasts as a confirmatory test. For manypathways, no single enzyme assay can establish the diagnosis. Forothers, tests such as complementation studies need to be done.

The goal of therapy is to restore biochemical and physiologichomeostasis. Neonates require emergency diagnosis and treatmentdepending on the specific biochemical lesion, the position of themetabolic block, and the effects of the toxic compounds. Treatmentstrategies include: (1) dietary restriction of the precursor amino acidsand (2) use of adjunctive compounds to (a) dispose of toxic metabolitesor (b) increase activity of deficient enzymes. Liver transplantation hasbeen successful in a small number of affected individuals. Even withcurrent clinical management approaches, individuals with organicacidemias have a greater risk of infection and a higher incidence ofpancreatitis, which can be fatal.

Enzyme replacement therapy via specific mRNA delivery to the liveroffers the most effective treatment of the organic acidemias. In certainembodiments of a method for treating an organic acidemia, an mRNAencoding a methylmalonyl CoA mutase (MUT) is delivered to a subject inaccordance with the present methods to treat methylmalonic acidemia MMA.In other embodiments, an mRNA encoding a PCC subunit (PCCA or PCCB) isdelivered to a subject in accordance with the present methods to treatpropionic acidemia (PA). In yet other embodiments, an mRNA encoding aBCKDH subunit is delivered to a subject in accordance with the presentmethods to treat maple syrup urine disease (MSUD). A method for treatingMMA, PA, or MSUD with a lipid nanoparticle comprising an Mut, Pcca/b, orBCKDH subunit mRNA and a membrane-destabilizing polymer generallyincludes administering to a subject having an organic acidemia of thespecified type an effective amount of the lipid nanoparticle and aneffective amount of the membrane-destabilizing polymer, where at leastone of the lipid nanoparticle and membrane-destabilizing polymerincludes a targeting ligand that specifically binds to a molecule on thesurface of liver cells within the subject, and whereby the Mut, Pcca/b,or BCKDH subunit mRNA is delivered to liver cells and translated duringprotein synthesis to produce the respective protein. A Mut or Pcca/bmRNA may be an mRNA as set forth above with respect to a method forincreasing the respective protein in a cell.

The efficacy of a composition or method for treating an organic acidemiadisease can be evaluated in vivo in animal models of disease. Forexample, particularly suitable animal models for evaluating efficacy ofa mRNA/LNP and polymer composition (or combination of mRNA/LNPcomposition and polymer composition) for treatment of MMA and PA are asfollows. Mut^(−/−) neonatal mice with a severe form of MMA, whichnormally die within the first 21 days of life, have been successfullytreated with hepatocyte-directed delivery of the methylmalonyl-CoAmutase (Mut) gene. Following an intrahepatic injection ofadeno-associated virus expressing the murine Mut gene, Mut^(−/−) micewere rescued and lived beyond 1 year of age (Carrillo-Carrasco et al.,Hum. Gene Ther. 21:1147-1154, 2010). Another MMA disease model wheremice survive into adulthood is Mut^(−/−) mice with Mut cDNA expressedunder the control of an insulated, muscle-specific promoter(Mut^(−/−);Tg^(INS-MCK-Mut)) (Manoli et al., 2011, SIMD Abstract). Thesemice have elevated plasma methylmalonic acid levels and decreasedoxidative capacity as measured by a ¹³C propionate oxidation/breatheassay. A mouse model of PA (Pcca^(−/−) mice) succumbs to death 24-36 hafter birth and is associated with fatal ketoacidosis (Miyazaki et al.,J. Biol. Chem. 276:35995-35999, 2001). Pcca gene transfer that providesa postnatal PCC activity of 10-20% in the liver of a transgenic mousestrain attenuates the fatal ketoacidosis in newborn mice (Miyazaki etal., 2001, supra). Recently, an intrahepatic adeno-associated virusmediated gene transfer for human Pcca was tested in neonatal Pcca^(−/−)mice (Chandler et al., Hum. Gene Ther. 22:477-481, 2010). The authorsfound a sustained therapeutic effect as demonstrated in a survival rateof approximately 64% and reduction of disease-related metabolites(Chandler et al., 2010, supra). Another mouse disease model of PA is ahypomorphic model where Pcca^(−/−) mice express a transgene bearing anA138T mutant of the PCCA protein. These mice have 2% of wild-type PCCactivity, survive to adulthood and have elevations in disease-relatedmetabolites (Guenzel et al., Mol. Ther. 21:1316-1323, 2013). Treatmentof these mice with adeno-virus or AAV vector expressing human PCCA cDNAresulted in increased PCC enzyme activity and correction of diseasemarker levels (Guenzel et al., 2013, supra). Taken together, in murinemodels of MMA and PA gene transfer approaches rescue neonatal mice orrestore enzyme activity and correct disease metabolite levels in adultdisease models thereby permitting evaluation of mRNA delivery forrestoration of the defective enzymes.

In additional variations, an mRNA encoding arginosuccinate lyase (ASL)or argininosuccinate synthetase (ASS1) is delivered in accordance withthe present methods to treat argininosuccinate aciduria (ASA) orcitrullinemia type I (CTLN I), respectively. Suitable animal models forevaluating efficacy of a mRNA/LNP and polymer for treatment of ASA andCTLN I are as follows. ASL hypomorphic mice have a neomycin geneinserted into intron 9 which leads to deficiency in the ASL enzyme (˜10%of wild type levels of mRNA and protein) and elevations inargininosuccinate and citrulline plasma levels (Erez et al., Nat Med.17:1619-1626, 2011) which is the signature of ASA. These mice if leftuntreated will die on their own starting around 3 weeks of age.Treatment of these mice with helper dependent adenoviral vectorexpressing mouse ASL at 4 weeks of age led to improved survival,normalized ASL protein expression, and reduction in argininosuccinateand citrulline plasma levels (Nagamani et al., Am J Hum Genet.90:836-846, 2012). ASS1 hypomorphic mice result from a spontaneousrecessive mutation (T389I substitution) known as follicular dystrophy(fold). This mutation leads to unstable ASS1 protein structure and˜5-10% of normal enzyme activity. Homozygous fold/fold mice haveelevated plasma citrulline and ammonia levels. These mice will also dieon their own if untreated (Perez et al., Am J Pathol. 177:1958-1968,2010). Treatment of these mice with AAV8 vector expressing human ASS1led to improved survival and decreased plasma citrulline and ammonialevels (Chandler et al., Gene Ther. 20:1188-1191, 2013). Thus, in murinemodels of ASA and CTLN I hepatic gene transfer methods restore enzymeactivity and correct the disease thereby permitting evaluation of mRNAdelivery for restoration of the defective enzymes.

In certain other embodiments of a method of treating a diseaseassociated with defective gene expression and/or activity, the gene isselected from a growth factor gene, a growth factor receptor gene, agene encoding an enzyme (for example, a phosphatase or a kinase, e.g., aprotein tyrosine, serine, or threonine kinase), an adaptor protein gene,a gene encoding a G protein superfamily molecule, or a gene encoding atranscription factor.

Further examples of suitable gene targets useful in the methods oftreating a disease associated with defective gene expression and/oractivity as described herein include the following genes or genesencoding the following proteins: MEX3, MMP2, ApoB, ERBB2, VascularEndothelial Growth Factor (VEGF), Vascular Endothelial Growth FactorReceptor (VEGFR), Platelet Derived Growth Factor Receptor (PDGF), ABL,KITT, FMS-like tyrosine kinase 3 (FLT3), Cav-1, Epidermal Growth FactorReceptor (EGFR), H-Ras, K-Ras, N-Ras, Bcl-2, Survivin, FAK, STAT-3,HER-3, Beta-Catenin, ornithine transcarbamylase, alpha-1-antitrypsin,and Src.

Other examples of suitable gene targets useful in the methods oftreating a disease associated with defective gene expression and/oractivity as described herein include tumor suppressors, where loss offunction of the mutated gene can be corrected by delivery of mRNAencoding the functional protein to treat cancer. Suitable tumorsuppressor targets include Retinoblastoma protein (pRb), p53tumor-suppressor protein, Phosphatase and tensin homolog (PTEN), VonHippel-Lindau tumor suppressor (pVHL), Adenomatous polyposis coli (APC),FAS receptor (FasR), Suppression of tumorigenicity 5 (ST5), YPEL3,Suppressor of tumorigenicity protein 7 (ST7), and Suppressor oftumorigenicity 14 protein (ST14).

In certain embodiments, a membrane-destabilizing polymer and a lipidnanoparticle comprising a therapeutic agent as described herein is usedin the preparation of a medicament or combination of medicaments for thetreatment of a disease amenable to treatment with the therapeutic agent.In some such embodiments, the disease is a disease associated withdefective gene expression and/or activity in a subject.

In some embodiments, a membrane-destabilizing polymer and a lipidnanoparticle comprising an mRNA encoding a functional protein asdescribed herein is used in the preparation of a medicament orcombination of medicaments for the treatment of a disease associatedwith deficiency in a functional protein.

The invention is further illustrated by the following non-limitingexamples.

EXAMPLES

Throughout this description, various known acronyms and abbreviationsare used to describe monomers or monomeric residues derived frompolymerization of such monomers. Without limitation, unless otherwisenoted: “BMA” (or the letter “B” as equivalent shorthand notation)represents butyl methacrylate or monomeric residue derived therefrom;“DMAEMA” (or the letter “D” as equivalent shorthand notation) representsN,N-dimethylaminoethyl methacrylate or monomeric residue derivedtherefrom; “PAA” (or the letter “P” as equivalent shorthand notation)represents 2-propylacrylic acid or monomeric residue derived therefrom;“PEGMA_(n)”, wherein n=8-9 or 4-5, refers to the pegylated methacrylicmonomer, CH₃O(CH₂CH₂O)_(n)C(O)C(CH₃)CH₂ or monomeric residue derivedtherefrom; “PDSMA” represents 2-(pyridin-2-yldisulfanyl)ethylmethacrylate or monomeric residue derived therefrom; “TFPMA” represents2,3,5,6-tetrafluorphenyl methacrylate or monomeric residue derivedtherefrom; “PFPMA” represents pentafluorophenyl methacrylate ormonomeric residue derived therefrom. In each case, any such designationindicates the monomer (including all salts, or ionic analogs thereof),or a monomeric residue derived from polymerization of the monomer(including all salts or ionic analogs thereof), and the specificindicated form is evident by context to a person of skill in the art.Figures of polymers or macro CTAs in the following examples are notmeant to describe any particular arrangement of the constitutional unitswithin a particular block. “KDa” and “k” as used herein refer tomolecular weight in kilodaltons.

The following figure is illustrative of the structures of the monomersused in the preparation of the polymers:

¹H NMR spectra of the monomers and polymers were recorded on a Varian400 MHz in deuterated solvents at 25° C.

Mass spectra was acquired on Bruker Esquire Ion Trap instrument usingthe following settings: electro-spray ionization, capillary exit voltageof 100.0 V, scanning from 80.00 m/z to 2200.00 m/z, dry gas flow of 6.0L/min. Mass spectroscopy was also conducted on a 6520 Accurate MassQ-TOF LC/MS equipped with an Agilent 1290 Infinity UHPLC system with UVdetector.

Gel permeation chromatography (GPC) was used to determine molecularweights and polydispersities (PDI, M_(w)/M_(n)) of the copolymer samplesin DMF using a Viscotek GPCmax VE2001 and refractometer VE3580(Viscotek, Houston, Tex.). Analysis was conducted using two PolarGel-Mcolumns (300 mm×7.5 mm, Agilent Technologies) with matching guard columnin series at 57° C., or two PolarGel-L columns (300 mm×7.5 mm, AgilentTechnologies) with matching guard column in series at 57° C., or twoTSKgel G3000SW columns (300 mm×7.5 mm, 10 μm, Tosoh Biosciences LLC) inseries at 57° C. HPLC-grade dimethylformamide (DMF) containing 1.0 wt %LiBr was used as the mobile phase.

UV/Vis spectroscopy was performed using a NanoDrop UV/Vis spectrometer(path length 0.1 cm).

Particle sizes of the polymers were measured by dynamic light scatteringusing a Malvern Zetasizer Nano ZS.

HPLC analysis was performed on Shimadzu LD-20AB with thevariable-wavelength UV detector with a C18 analytical reverse phasecolumn (ES Industries Chromega Columns, Sonoma C18 catalog number155B21-SMA-C18(2), 100 Å, 25.0 cm×4.6 mm, column heated to 30° C., or aC18 Phenomenex 5μ 100 Å 250×4.6 mm×5 micron (Part#00G-4252-E0) Lunacolumn with guard column heated to 30° C.).

All reagents were from commercial sources, unless indicated otherwise,and the monomers were purified from traces of stabilizing agents priorto use in the polymerization reactions.Cyano-4-(ethylsulfanylthiocarbonyl) sulfanylpentanoic acid (ECT) wasobtained from Omm Scientific. Azobisisobutyronitrile (AIBN) (Wakochemicals) was used as the radical initiator in all polymerizationreactions, unless stated otherwise.

Example 1 Lipid mRNA Nanoparticle Formulation with Sequential Injectionof a Polymer

DOTAP (Corden Pharma, Boulder, Colo., USA; catalog number LP-R4-117) orDOTMA (Avanti Polar Lipid Alabaster, Ala., USA; catalog number 890898P)was solubilized at 200 mg/mL in 200 proof ethanol at room temperaturefor 15 minutes. The DMPE-PEG_(2K) (Corden Pharma, Boulder, Colo., USA;catalog number LP-R4-123) was solubilized at 25 mg/mL in 200 proofethanol at room temperature for 15 minutes. The cholesterylhemisuccinate (CHEMS) (Avanti Polar Lipid Alabaster, Ala., USA; catalognumber 850524P) and the Cholesterol (CHOL) (Corden Pharma, Boulder,Colo., USA; catalog number CH-0355) were individually solubilized at 25mg/mL in 200 proof at 75° C. for 5 minutes. Typically, for a 2 mLpreparation of a DOTAP:CHEMS:CHOL:DMPE-PEG_(2K) (50:32:16:2 mol %) LNPat N:P ratio of 7, a lipid ethanolic mixture containing 22 μl of DOTAPat 200 mg/mL in 200 proof ethanol, 79 μL of CHEMS at 25 mg/mL in 200proof ethanol, 31.4 μL of CHOL at 25 mg/mL in 200 proof ethanol, 27.4 μLof DMPE-PEG_(2K) at 25 mg/mL in 200 proof ethanol and 506 μL of 200proof ethanol was prepared for a final volume of 0.666 mL and a finallipid concentration of 11.83 mg/mL. The lipid nanoparticle (LNP)formulations were prepared at N:P (nitrogen to phosphate) ratios from3.5 to 28 based on the DOTAP or DOTMA concentration. The DOTAP:CHEMS orDOTMA:CHEMS ratio was fixed at 1.6 at 50:32 mol % respectively at thevarious N:P ratios. DMPE-PEG_(2K) was varied from 2 to 5 mol %. The CHOLmol % was adjusted to result in 100 mol % final lipid concentration.

The Fluc (firefly luciferase) mRNA stock solution at 1 mg/mL in 10 mMTris-HCl (pH 7.5) (TriLink Biotechnologies, San Diego, Calif., USA;catalog number L-6107) was diluted to 0.225 mg/mL in 20 mM HEPES/5%glucose, pH 7.4 buffer (HEPES buffer). The mRNA/LNPs were assembled atN:P ratios from 3.5 to 28 by mixing the ethanolic lipid solution with0.225 mg/mL mRNA in HEPES buffer at a 1:3 ratio (lipid mixture inethanol, mRNA in HEPES buffer) using the microfluidic device fromPrecision NanoSystems Inc (Vancouver BC, Canada) at a 12 mL/minute flowrate. The mRNA/LNPs in 33% ethanol were then incubated at roomtemperature for 60 minutes prior to dialysis for 18 hours against 100volumes (200 mL) of HEPES buffer.

The polymer used for the sequential injection, polymer P1435(NAG-C₅N-PEG_(0.6 k)-[PEGMA300_(87.9%)-PDSMA_(12.1%)]_(3.9 kDa)-b-[DMAEMA_(34.7%)-BMA_(53.5%)-PAA_(11.8%)-]_(6.1 kDa)),was solubilized at 20 mg/mL in HEPES buffer with agitation at 400 rpmfor 1 hour and then stored overnight at 4° C. The polymer was diluted to7.5 mg/mL in HEPES buffer prior injection.

If mRNA/LNP and polymer were co-injected, a 2× solution of each wasprepared. Just prior to dosing, the solutions were mixed and injectedimmediately.

The formulation particle size was measured by adding 10 μL offormulation to 90 μL of HEPES buffer into a disposable micro-cuvette andanalyzed using the Malvern Instrument ZETASIZER NANO-ZS. The LNPs showeda particle size of 52 nm (z-average). The formulation zeta-potential atpH 7.4 was measured by adding 10 μL of formulation to 740 μL of HEPESbuffer into a disposable 1 mL cuvette. The formulation zeta-potential atpH 4 was measured by adding 10 μL of formulation to 740 μL of sucroseacetate buffer (pH 4) into a disposable 1 mL cuvette. The zeta dip cellwas inserted into the 1 mL cuvette and the formulation was analyzedusing the ZETASIZER NANO-ZS. Typically, the DOTMA LNPs had a zetapotential of +12 mV at pH 7 and +16 mV at pH 4.0. The ability of the LNPto compact the mRNA was measured in a 96 well plate using a SYBR Golddye accessibility assay. Typically, 50 μL of the lipid formulation at0.01 mg/mL mRNA was added to 150 μL of diluted SYBR Gold stock solution(1 μL of Stock SYBR Gold in 3 mL of HEPES buffer) and incubated for 15minutes at room temperature with agitation (100 RPM). The fluorescencewas read at an excitation wavelength of 495 nm and emission wavelengthof 538 nm. The percent dye accessibility was calculated by dividing thefluorescence intensity of the formulated mRNA by the fluorescenceintensity of the free mRNA×100. The DOTMA LNPs showed 2% dyeaccessibility when prepared in HEPES buffer. Table 2 below shows acharacterization of an exemplary LNP formulation.

TABLE 2 Sample # RP450-2 Polymer or Lipid DOTMA:CHEMS:CHOL:DMPE- PEG2K(50:32:13:5) N/P 27 Polymer or Lipid 10.0 Concentration (mg/mL) VisualAppearance Opalescent (+) % Dye Access HEPES pH 7.4 2% Z-Ave (nm) 52 PDI0.200 Number (nm) 30 Pk 1 Mean Int (nm) 57 Pk 2 Mean Int (nm) 4191 Pk 1Area Int (%) 97 Pk 2 Area Int (%) 4 ZP pH 7.4 (mV) 12 ZP pH 4 (mV) 16Sizing data quality Good

Example 2 In Vivo Expression of mRNA with Lipid-mRNA Formulations andCo-Injection or Sequential Injection of Polymer

Female CD-1 mice (7-10 weeks old) were used for evaluating the FlucmRNA/LNP+polymer formulations. The formulations were dosed intravenouslyat 1 mg/kg of mRNA and 13 to 103 mg/kg of lipid, with 5 mice injectedper group. Polymer P1435 alone at 75 mg/kg was injected intravenouslyeither as a co-injection or sequentially at 1, 5, 10, 30, 60 or 120minutes post the Fluc mRNA/LNP injection. Mice injected with HEPESbuffer was used as control. For each injection mice were given a finaldose volume of approximately 0.25 mL or 10 mL/kg based on individualbody weights.

The in vivo expression of luciferase was evaluated by detectingluminescence in mice using the Xenogen IVIS Lumina II Imaging System(Caliper Life Sciences, now Perkin Elmer). The imaging was performed at6 hours following dosing. 15 minutes prior to imaging, each mousereceived 0.25 mL, of D-luciferin (Perkin Elmer), a luciferase substrate,at 15 mg/mL (dissolved in PBS) by intra-peritoneal injection. A fewminutes before imaging, mice were place in an isoflurane chamber toinduce anesthesia (isoflurane concentration at ˜3%). Subsequently, micewere moved into the IVIS imaging chamber, with the snout connected to anisoflurane-filled nose cone with the mouse's ventral side up. Theluminescence images were acquired using Living Image software (CaliperLife Sciences) with the exposure time, binning and F/Stop remaining thesame throughout the study. Mice were put back to the cage as soon as theimaging was finished and they recovered within 1-3 minutes.

After the image acquisition was finished for all mice, the luminescenceresults were analyzed using Living Image software. Briefly, the colorscale of each image was first adjusted to display specific luminescencesignal and eliminate background signal. Then a region of interest (ROI)for the liver was defined using the ROI tools, and ROI measure buttonwas clicked to show the photon flux data. Total flux (photons/sec) ofthe ROI on each animal was used to represent the intensity ofluminescence. Total flux was averaged from all 5 mice for eachformulation group for comparison.

Table 3 displays luminescence values in the liver for animals treatedwith DOTMA:CHEMS:CHOL:DMPE-PEG2 k+Fluc mRNA nanoparticle with or withoutsequential injection of polymer P1435 at 10 minutes following the firstinjection. Data was acquired at 6 hours post dose. Fluc mRNA/LNP aloneshowed little luminescence (only 3-fold above buffer) but with polymerP1435 sequential injection, a 100-fold improvement in luminescencesignal was detected.

TABLE 3 Lipid mRNA Polymer Timing Total Flux Lipid-mRNA Dose Dose DoseBetween (photons/sec) Nanoparticle (mg/kg) (mg/kg) Polymer (mg/kg)Injections Geomean STDEV Buffer 0 0 None 0 NA 3.38E+05 1.00E+00DOTMA:CHEMS: 100 1 None 0 NA 6.24E+05 2.66E+05 CHOL:DMPE- 100 1 P1435 7510 min 6.97E+07 4.86E+07 PEG2K (50:32:13:5) N:P 27 + Fluc mRNA

Table 4 displays luminescence values in the liver for animals treatedwith DOTAP:CHEMS:CHOL:DMPE-PEG2 k+Fluc mRNA nanoparticle with or withoutsequential injection of polymer P1435 or polymer P1299 at 10 minutesfollowing the first injection. N:P ratios from 14 to 27 and 2-5 mol %DMPE-PEG2 k variations were evaluated. Data was acquired at 6 hours postdose. Again the mRNA/LNP alone showed little luminescence but withpolymer P1435 sequential injection, a 100-fold improvement inluminescence signal was detected. Reducing the N:P ratio from 27 to 14,and reducing the DMPE-PEG2 k from 5 to 3.5 mol % further improved theluminescence signal by another 3-fold. Sequential injection of polymerP1299(NAG-C₅N-PEG_(0.6 k)-[PEGMA300_(80%)-PDSMA_(10%)-BPAM_(10%)-]_(3.5 kDa)-b-[DMAEMA_(34%)-BPAM_(56%)-PAA_(10%)]_(6.3 kDa))showed 5-fold improvement in luminescent signal compared to mRNA/LNPalone.

TABLE 4 DMPE- Lipid mRNA Timing Total Flux Lipid-mRNA PEG2k Dose DoseBetween (photons/sec) Nanoparticle N:P mol % (mg/kg) (mg/kg) PolymerInjections Geomean STDEV Buffer NA NA 0 0 None NA 2.58E+05 NADOTAP:CHEMS: 27 5 113 1 None NA 1.70E+06 8.94E+05 CHOL:DMPE- 27 5 113 1P1435 10 min 1.38E+08 1.88E+08 PEG2K 21 5 88 1 75 mg/kg 1.61E+089.48E+07 (2-5%) 14 5 59 1 2.51E+08 2.07E+08 (50:32:13: X 27 3.5 107 13.43E+08 9.68E+07 mol %) + 14 3.5 56 1 3.80E+08 1.26E+08 Fluc mRNA 27 2102 1 2.26E+08 2.24E+08 27 5 113 1 P1299 8.34E+06 1.22E+07 75 mg/kg

Table 5 displays luminescence values in the liver for animals treatedwith DOTAP:CHEMS:CHOL:DMPE-PEG2 k+Fluc mRNA nanoparticle with or withoutsequential injection of polymer P1435 at 10 minutes following the firstinjection or co-injection. N:P ratios from 3.5 to 14 and were evaluated.Data was acquired at 6 hours post dose. Again the mRNA/LNP alone showedlittle luminescence but with polymer P1435 sequential injection, a300-fold improvement in luminescence signal was detected. Reducing theN:P ratio from 14 to 7, and reducing the DMPE-PEG2 k to 2 mol % resultedin nearly a 500-fold improvement in luminescence signal compared tomRNA/LNP alone. Further reducing the N:P ratio to 3.5 resulted in lowerluminescence. Sequential injection of mRNA/LNP and polymer P1435 showedslightly better luminescence signal compared to co-injection.

TABLE 5 Lipid mRNA Timing Total Flux Lipid-mRNA Dose Dose Between(photons/sec) Nanoparticle N:P (mg/kg) (mg/kg) Polymer InjectionsGeomean STDEV Buffer NA 0 0 None NA 3.19E+05 NA DOTAP:CHEMS: 14 53 1None NA 1.07E+06 1.31E+05 CHOL:DMPE- 3.5 13 1 P1435 10 min 5.82E+075.61E+07 PEG2K 7 26 1 75 mg/kg 5.07E+08 6.21E+08 (50:32:14.5:2 14 53 13.58E+08 3.93E+08 mol %) + 14 53 1 co-injection 2.48E+08 3.69E+08 FlucmRNA

Table 6 displays luminescence values in the liver for animals treatedwith DOTAP:CHEMS:CHOL:DMPE-PEG2 k+Fluc mRNA nanoparticle with sequentialinjection of polymer P1435 from 1 to 120 minutes following the firstinjection or co-injection. Data was acquired at 6 hours post dose. Theluminescence signal was similar between 1 and 10 minutes and droppedfrom 30 to 120 minutes. Sequential injection of mRNA/LNP and polymerP1435 showed four-fold higher luminescence signal compared toco-injection.

TABLE 6 Total Flux (photons/sec) Timing mRNA Lipid-mRNA Between DoseNanoparticle Polymer Injections (mg/kg) Geomean STDEV Buffer None None 02.52E+05 NA DOTAP:CHEMS: P1435 co-injection 1 1.57E+08 1.38E+08CHOL:DMPE- 75 mg/kg  1 min 1 6.09E+08 3.40E+08 PEG2K  5 min 1 8.24E+072.28E+08 (50:32:16:2) N:P 7  10 min 1 3.22E+08 2.43E+08 26 mg/kg +  30min 1 7.69E+07 5.23E+07 Fluc mRNA  60 min 1 1.57E+07 1.24E+07 120 min 16.03E+06 1.30E+07

Table 7 displays luminescence values in the liver for animals treatedwith DOTAP:CHEMS:CHOL:DMPE-PEG2 k+Fluc mRNA nanoparticles withsequential injection of polymer P1435 at 1 minute following the firstinjection. Data was acquired at 6 hours post dose. In this study, twodifferent Fluc mRNAs were tested. Fluc 2 mRNA showed a 15-foldimprovement in luminescence signal compared to Fluc 1 mRNA. Fluc 2 mRNAcontains Pseudo U only, a Cap 1 structure obtained from enzymaticcapping and a longer poly A tail (approximately double that of Fluc1-˜220 bases) compared to Fluc 1 which has an ARCA cap structure, PseudoU/5-methyl-C modifications, and a poly A tail length of 120 bases.

TABLE 7 Timing mRNA Total Flux Lipid-mRNA Fluc Between Dose(photons/sec) Nanoparticle Polymer mRNA Injections (mg/kg) Geomean STDEVBuffer None None NA 0 1.82E+05 NA DOTAP:CHEMS: P1435 Fluc1 1 min 12.10E+08 1.57E+08 CHOL:DMPE- 75 mg/kg mRNA PEG2K (50:32:16:2) Fluc2 13.04E+09 2.12E+09 N:P 7 26 mg/kg mRNA

Example 3 Synthesis of PEG_(0.6 k)-CTA (Compound 6)

HOOC-PEG_(0.6K)-ECT (Compound 6). To a 100 mL one-neck round-bottomflask was added ECT (473 mg, 2.0 mmol, Omm Scientific) followed byanhydrous tetrahydrofuran (20 mL) and triethylamine (0.307 mL, 2.2mmol). This mixture was stirred at 0° C. for 5 min beforetrifluoroacetic acid pentafluorophenyl ester (0.368 mL, 2.14 mmol) wasadded drop wise to the stirred reaction. The mixture was stirred at 0°C. for 5 min then warmed to room temperature.

After allowing to react for 20 min at room temperature, the reaction wasdiluted into EtOAc (100 mL) and extracted with saturated aqueoussolution of NaHCO₃ (3×40 mL). The EtOAc layer was separated, dried overNa₂SO₄, filtered and then evaporated providing the crude PFP-ester 4 asyellow oil.

The crude ester 4 was dissolved in anhydrous CH₂Cl₂ (20 mL) and thencooled to 0° C. To the cooled stirred solution was added triethylamine(0.251 mL, 1.8 mmol) and Amino-dPEG12-acid (1.12 g, 1.8 mmol, QuantaBiodesign), and the mixture was warmed to room temperature. Afterstirring for 20 min at room temperature, the reaction mixture wasevaporated using a rotary evaporator providing yellow oil. The yellowoil was dissolved in CH₂Cl₂ (approximately 2 mL) and the product waspurified by flash chromatography (SiO₂, column size 5.0 cm ID×10.0 cmlength; isocratic elution with 100% CH₂Cl₂ for 500 mL; then CH₂Cl₂/MeOH,20:1 v/v for 500 mL; then CH₂Cl₂/MeOH, 10:1 v/v for 3.0 L). Theproduct-containing fractions, as determined by TLC, were combined, andthe solvent was removed by rotary evaporation providing 750 mg (48%) ofthe desired compound 6 as orange oil. ¹H NMR (CD3OD): δ 1.35 (t, 3H,J=7.5 Hz, CH₃), 1.89 (s, 3H, CH₃), 2.38-2.57(m, 6H), 3.32-3.41 (m, 4H),3.50-3.75 (m, 48H).

Example 4 Synthesis of Nag(OAc4)C5N-PEG_(0.6 K)-CTA (Compound 8) Step 1.Synthesis of Compound 3.

N-t-Boc-5-amino-1-pentanol. To a 1.0 L one-neck round-bottom flaskcontaining a solution of 5-amino-1-pentanol (15.0 g, 145.4 mmol) inwater (140 mL) and saturated aqueous NaHCO₃ (1.4 mL), a solution ofdi-tert-butyl dicarbonate (33.3 g, 152.7 mmol) in THF (280 mL) wasadded. The mixture was then stirred at room temperature overnight withthe flask open to the atmosphere. The reaction mixture was diluted withsaturated aqueous NaHCO₃ (90 mL) and extracted with EtOAc (400 mL). Theorganic layer was separated, dried over Na₂SO₄, filtered, and thesolvent was evaporated providing 28.9 g (98%) of the final product asclear colorless oil. ¹H NMR analysis showed the product was clean ofimpurities, and no further purification was attempted. Alternatively,N-t-Boc-5-amino-1-pentanol can be obtained from TCI America of Portland,Oreg.

Compound 2. Compound 2 was prepared by a procedure adopted from theliterature (Westerlind, U. et al. Glycoconj. J. 2004, 21, 227-241). To a500-mL one-neck round-bottom flask was added2-acetamido-1,3,4,6-tetra-O-acetyl-2-deoxy-D-galactopyranose 1 (12.8 g,32.8 mmol) followed by anhydrous CH₂Cl₂ (150 mL) and trimethylsilyltrifluoromethanesulfonate (14.3 mL, 79.2 mmol). This mixture was stirredat reflux overnight (ca. 18 h) under a flow of argon gas. The reactionmixture was cooled to 0° C. and treated with triethylamine (6.4 mL, 45.9mmol) for 30 min before being warmed to room temperature, then washedwith saturated aqueous NaHCO₃ (100 mL). The organic layer was separatedand dried over Na₂SO₄, filtered and evaporated providing crude oxazolineintermediate. To the crude oxazoline product was added anhydrous CH₂Cl₂(200 mL), N-t-Boc-5-amino-1-pentanol (10.0 g, 49.2 mmol) and 3 Åmolecular sieves (18.0 g, dried at 150° C. for >24 h). This mixture wasstirred at room temperature for 30 min under a blanket of argon gas.Trimethylsilyl trifluoromethanesulfonate (2.97 mL, 16.4 mmol) was addedto the reaction mixture, and the solution was stirred at roomtemperature overnight. The solution was cooled to 0° C. and treated withtriethylamine (3.2 mL, 23.07 mmol) for 30 min before being warmed toroom temperature. After the reaction reached room temperature themixture was filtered, and the mother liquor was evaporated providing thecrude product as brown oil which was dissolved in anhydrous pyridine(100 mL) and treated with acetic anhydride (36 mL, 38.2 mmol). Thismixture was stirred under an argon atmosphere at room temperatureovernight, then evaporated under vacuum yielding a brown liquid, whichwas dissolved in CH₂Cl₂ (200 mL). The solution was vigorously stirredwith a saturated aqueous NaHCO₃ solution (100 mL) and solid NaHCO₃ in anopen flask at room temperature to quench remaining Ac₂O and the organiclayer was separated. The aqueous layer was extracted with CH₂Cl₂ (1×200mL) and all organic layers were combined. The organic layers were washedwith saturated aqueous NaHCO₃ solution (1×100 mL), separated, dried overNa₂SO₄, filtered and evaporated providing the crude product as a brownoil which was then dissolved in CH₂Cl₂ (15 mL) and purified using columnchromatography (SiO₂, column size 7.5 cm ID×16.0 cm length, EtOAc:Hexanes 1:3 v/v for 500 mL, EtOAc:Hexanes 4:1 v/v for 500 mL, 100% EtOAcfor 1.0 L, 10% MeOH in EtOAc v/v for 3.0 L). Product-containingfractions were pooled and evaporated under vacuum to a white solid whichwas further purified by trituration with ether to yield the desiredproduct as a white solid (5 g, 29%). ESI MS [M+H]⁺ m/z 533.4.

Compound 3. To a 100 mL round bottom flask was added Compound 2 (3.14 g,5.9 mmol) followed by trifluoroacetic acid (10 mL, TFA). The mixture wasstirred until all of the carbohydrate was completely dissolved, then theTFA was evaporated under vacuum to yield light yellow oil. To the oilyresidue was added diethyl ether (10 mL), the mixture was sonicated for2-5 min, and the supernatant was decanted. The trituration process wasrepeated (3×10 mL Et₂O), and the crude product was dried under vacuum toyield a white foam (3.2 g), which was used as described below.

Step 2.

Compound 7. To a 250 mL one-neck round-bottom flask was added Compound 6(3.37 g, 3.9 mmol, HPLC purified) followed by anhydrous CH₂Cl₂ (40.0mL), and triethylamine (2.17 mL, 15.6 mmol). This solution was stirredat 0° C. under a low flow of argon gas for 5 min before trifluoroaceticacid pentafluorophenyl ester (737 μL, 4.29 mmol) as added dropwise tothe reaction mixture. Then the mixture was warmed to room temperatureand was stirred at room temperature for 30 min.

The reaction progress was followed by TLC (SiO₂, CH₂Cl₂ and MeOH, 9:1v/v) by looking for the disappearance of the starting material (R₄=0.30)and the appearance of the PFP activated product (R_(f)=0.64). Once thestarting material was consumed by TLC, the crude reaction was dilutedwith CH₂Cl₂ (300 mL) and the mixture was extracted using NaHCO₃ (3×50mL). The organic layer was separated, dried over Na₂SO₄, filtered andevaporated providing 3.9 g (97%) of the final product as orange oil. Allsolvents and volatile reagents were thoroughly removed using high vacuumovernight before the crude product is carried on to the next syntheticstep.

Compound 8. To a 100 mL one-neck round-bottom flask was added Compound 7(3.6 g, 3.5 mmol) followed by anhydrous acetonitrile (7.5 mL) andtriethylamine (1.46 mL, 10.5 mmol).

The mixture was stirred under a flow of argon gas until all of thematerial was dissolved, then cooled to 0° C. with an ice bath.Deprotected amine 3 (1.81 g, 3.32 mmol) was dissolved in anhydrousacetonitrile (7.5 mL), and the resulting solution was added to thereaction mixture at 0° C. dropwise over 5 min. The reaction was allowedto warm to room temperature and was stirred at room temperatureovernight. The solvents were evaporated using a rotary evaporator, andthe crude product was dried under high vacuum. The reaction progress wasfollowed by analytical HPLC by diluting the reaction mixture (5 μL) intoCH₃CN (695 μL) and 50 μL of the diluted mixture was analyzed by HPLC(10% CH₃CN for 2 min, then linear gradient from 10% to 60% CH₃CN over 20min, total flow rate of 1.0 mL/min). The desired product had a retentiontime of 21.0 min.

The crude product was dissolved in MeOH (approximately 40 mL) andpurified in 2-mL aliquots using preparative reverse phase HPLC(Phenomenex, Luna 5 C18(2), 100 Å, 25.0 cm×21.2 mm, equipped with aSecurityGuard PREP Cartridge, C18 15×21.2 mm ID, CH₃CN/H2O, 30% CH₃CNfor 5 min, then linear gradient from 30% to 53% CH₃CN over 20 min, totalflow rate of 20.0 mL/min,). The desired product eluted between 22.0 and23.0 min. All the fractions containing the desired product werecombined, and the solvent was completely removed using a rotaryevaporator to yield 2.54 g (60%) of compound 8 after overnight dryingunder vacuum.

ESI MS: m/z 1277.6 ([M+H]⁺¹), 650.6 ([M+Na+H]⁺²), 658.5 ([M+K+H]⁺²),661.7 ([M+2Na]⁺²), 669.7 ([M+Na+K]⁺²), 677.5 ([M+2K]⁺²).

1H NMR (CD3OD): δ 1.35 (t, 3H, J=7.5 Hz), 1.33-1.62 (m, 6H), 1.88 (s,3H), 1.93 (s, 3H), 1.95 (s, 3H), 2.03 (s, 3H), 2.15 (s, 3H), 2.32-2.56(m, 6H), 3.15-3.25 (m, 2H), 3.25-3.42 (m, 6H), 3.50-3.70 (m, 44H),3.97-4.20 (m, 4H), 4.55 (d, 1H, J=8.4 Hz), 5.05 (dd, 1H, J₁=11.4 Hz,J₂=3.4 Hz), 5.33 (dd, 1H, J₁=3.4 Hz, J₂=0.9 Hz).

Example 5 Preparation of Nag(OH)C5N-PEG_(0.6 K)-CTA (Compound 8a)

Nag(OH)C5N-PEG0.6K-CTA (Compound 8a) was prepared in a similar manner tothe Nag(OAc4)C5N-PEG_(0.6K)-CTA in Example 4 (Compound 8) except thatcompound 3 in Example 4 is replaced by the unprotected sugar compound ofcompound 3a and the coupling reaction between compound 6 of Example 3and compound 3 of Example 4 has been modified as shown below forcompounds 6a and 3a.

Compound 3a is prepared as follows from compound 3b.

To a 250 mL one-neck round-bottom flask was added compound 3b (1.86 g,3.5 mmol) followed by 4M HCl in dioxane (30 mL). This mixture wasstirred and sonicated until all of the sugar was completely dissolved.Then the mixture was evaporated on a rotary evaporator providing an oilyresidue. To completely remove all HCl gas the compound was dissolved indioxane (30 mL) and solvents removed by rotary evaporation. The solventexchange process was performed a total of 3 times to completely removeall HCl. Then the flask was put under high vacuum for >30 min providinga white foam solid. The crude compound was dissolved in anhydrous MeOH(25 mL) and treated with 0.5 M sodium methoxide solution in MeOH (5.80g, 7.175 mL, 3.59 mmol, 1.025 eq, measured by weight to ensure accuracyof addition). The first equivalent of NaOMe is used to de-protonate thequaternary amine salt liberating the free amine Only a slight excess ofNaOMe beyond one equivalent (i.e., 0.025 eq, 0.09 mmol) is needed tofacilitate the acetyl deprotection. Once NaOMe is added the mixture isthen stirred under a flow of argon overnight at room temperature.Reaction progress was monitored by LCMS using Agilent Q-TOF LiquidChromatography Mass Spectrometer by dissolving the product in MeOH atca. 1.0 μg/mL. The LC used a C18 UPLC column (Agilent Eclipse Plus C18,catalog number 959757-902, 1.8 μm, 2.1 mm×50 mm, column at roomtemperature, CH₃CN/H₂O containing 0.1% formic acid, isocratic gradientat 5% CH₃CN for 1 min, then linear gradient from 5% to 90% CH₃CN over 4min, total flow rate of 0.4 mL/min). The desired product elutes between0.4-0.5 min using the above HPLC conditions while the crude intermediateproduct (i.e., Boc removed with acetyls still present) elutes between2.0-2.2 min. Once the sugar was fully de-protected the catalytic NaOMe(0.09 mmol) is quenched by adding a slight excess of acetic acid (10 μL,0.175 mmol) to the reaction mixture. Then all solvents are removed byevaporating on a rotary evaporator. This process yielded 1.1 g (100%) ofthe final product as a white solid. The final product was characterizedusing a 400 MHz 1H NMR with CD₃OD as solvent and all spectra wereconsistent with the desired product compound 3a.

Nag(OH)C5N-PEG_(0.6)K-CTA (Nag(OH)C5N-PEG₁₂-CTA; Compound 8a) wasprepared as follows. Compound 6a was prepared as in Example 3 (Compound6).

To a 250 mL one-neck round-bottom flask was added compound 6a (3.17 g,3.68 mmol) followed by anhydrous acetonitrile (10 mL). In a separateflaks the compound 3a (1.07 g, 3.5 mmol) was dissolved in anhydrous DMF(10 mL). Once compound 3a was partially dissolved as a milky whitesuspension the solution was transferred to a 100 mL addition funnel. Inanother flask was added PyBOP (2.0 g, 3.85 mmol) and anhydrous DMF (10mL). The PyBOP/DMF solution was taken up into a 20 mL, syringe. Then all3 solutions (compound 6a/CH₃CN, compound 3a/DMF, and PyBOB/DMF) werecombined simultaneously and as fast as possible while the reactionsolution was vigorously stirred. Once the additions were complete thereaction was treated with N,N-diisopropylethylamine (1.22 mL, 7.0 mmol)and the solution was stirred at room temperature under a flow of argongas for 30 min. The reaction progress was determined using Agilent Q-TOFLiquid Chromatography Mass Spectrometer by dissolving the crude reaction(1.0 μL) into MeOH (1.0 mL) and injecting 1.0 μL (FIGS. 1-2 ). The LCused a C18 UPLC column (Agilent Eclipse Plus C18, catalog number959757-902, 1.8 μm, 2.1 mm×50 mm, column at room temperature, CH₃CN/H₂Ocontaining 0.1% formic acid, isocratic gradient at 5% CH₃CN for 1 min,then linear gradient from 5% to 90% CH₃CN over 4 min, total flow rate of0.4 mL/min) The desired product elutes between 3.0-3.1 min using theabove HPLC conditions. The sugar starting material (i.e., compound 3a)was not detected on the mass spec analysis after the reaction wasstirred at room temperature for 30 min. Mass spec analysis confirms thepresence of compound 8a [M+Na]⁺¹=1173.5207 m/z; [M+H]⁺¹=1151.5397 m/z).

After reacting for 30 min the crude reaction mixture of compound 8a wasdiluted by the addition of H₂O (25 mL) and purified using C18preparative reverse phase HPLC by Shimadzu (Phenomenex, Luna 5 C18(2),part number 00G-4252-P0-AX, 100 Å, 25.0 cm×21.2 mm, with a SecurityGuardPREP Cartridge, C18 15×21.2 mm TD, part number AJ0-7839, CH₃CN/H2O with0.01% TFA, isocratic gradient at 5% CH₃CN for 5 min, then lineargradient from 5% to 50% CH₃CN over 17 min, then 50% to 53% CH3CN over 3min, total flow rate of 20.0 mL/min, column at room temperature). 2.0 mLof the crude compound dissolved in DMF/H₂O (ca. 75 mg/mL) were injectedeach HPLC run. Using the HPLC purification conditions above the desiredproduct compound 8a eluted between 21.5 and 22.5 min. All the fractionscontaining the desired product were combined and the water/CH3CN solventwas completely removed using a rotary evaporator then high vacuumovernight. The combined yield of the final product after HPLCpurification and overnight high vacuum produced 3.05 g (76%) of thedesired product as a bright orange solid. ¹H NMR analysis was consistentwith the presence of the desired product compound 8a.

Example 6 General Procedure for Polymer Synthesis

First block synthesis general procedure: The first block polymer isprepared using the following approximate ratios:[Monomer/CTA/Initiator]=[15-20/1/0.5] at approximately 1.3 M in DMF.Following oxygen purge with Nitrogen or Argon, the polymerizationreaction is heated to 60-68° C. for a particular amount of time(generally 1 h 15 min-3 h) until the desired molecular weight isreached. The polymerization reaction is stopped by placing in an icebath and opening the reaction to air. The desired polymer is purified bydialysis against methanol (3-7 days) using 2 KDa MWCO dialysis tubing.The resulting polymer is isolated by removing solvent under reducedatmosphere.

Second block synthesis general procedure: The second block polymer isprepared using the following approximate ratios::[Monomer/CTA/Initiator]=[100-130/1/0.5] at approximately 2-3 M in DMF.Following oxygen purge with Nitrogen or Argon, the polymerizationreaction is heated to 60-68° C. for a particular amount of time(generally 3-6 h) until the desired molecular weight is reached. Thepolymerization reaction is stopped by placing in an ice bath and openingthe reaction to air. The desired polymer is purified by precipitationinto diethylether/hexanes and/or dialysis against methanol (3-5 days)using 2 KDa MWCO dialysis tubing. The resulting polymer can be isolatedby removing solvent under reduced atmosphere, or dialysis against waterusing 2 KDa MWCO dialysis tubing, followed by lyophilization.

Example 7 Determining Monomer Incorporation within Individual Blocks ofa Polymer During Polymer Synthesis

The amount of a given monomer within a given polymer block, typicallythe first or hydrophilic polymer block, of the polymers exemplified andclaimed herein has been determined by the following procedure. Samplestaken before and after the polymerization reaction (i.e., T₀ (time zero)and T_(f) (time final)) are analyzed by analytical HPLC to determine theextent of monomer consumption and/or monomer incorporation.

The initial monomer amounts in the polymerization reaction (time 0, T₀)are determined by sampling the polymerization reaction solution prior tonitrogen or argon purge. A (20 μL) sample of the reaction solution iswithdrawn from the reaction solution and diluted into 180 μL of Methanol(MeOH). A portion of the resulting solution (10 μL) is further dilutedinto 590 μL MeOH, to afford a test sample with an overall dilution of1:600 (from the polymerization reaction) for analysis by analyticalHPLC.

Upon completion of the polymerization reaction a time final (T_(f))sample is prepared analogous to the T₀ sample described above.

Analytical HPLC analysis of the T₀ and T_(f) samples are performed usinga C18 Phenomenex 5μ 100 Å 250×4.6 mm×5 micron (Part#00G-4252-E0) Lunacolumn with guard column heated to 30° C. Three independent dilutionsfor each time point (i.e., T₀, and T_(f)) are prepared and analyzed foreach time point. A 10 μl of sample is injected onto the column andeluted with the following gradient. Hold an isocratic eluent of 5%acetonitrile/water with 0.1% TFA for 2 minutes. Switch to a lineargradient from 5% to 95% acetonitrile over 25 minutes. Hold an isocraticeluent of 95% acetonitrile for 5 minutes. Return to 5% acetonitrile over0.01 minutes. Hold the isocratic eluent of 5% acetonitrile/water with0.1% TFA for 5 minutes. At least three independent sample preparationsfor both T₀ and T_(f) were used for the calculation of monomerincorporation within the block.

The following methodology is used to calculate the % incorporation of agiven monomer:

-   -   a. Calculate the average T₀, and T_(f) monomer peak areas from        the three independent sample preparations    -   b. Calculate the consumption of individual monomers in the        reaction (monomer % consumption):

=(1-(T_(f·avg) monomer peak area/T_(0_avg) monomer peak area)×100.

-   -   c. Calculate the molar fraction consumed of the individual        monomers based on monomer input percent

=(Monomer % conversion (calculated in step (b) above)×0.01)×monomer feed%.

-   -   d. Total monomer consumption in the polymerization reaction and        overall percent conversion:        -   i. Total monomer consumption=sum of molar fraction consumed            for the individual monomers calculated in step (c) above.        -   ii. Overall % conversion=Total monomer consumption            (calculated in step (d)(i) above)×100.    -   e. Calculate the percent monomer incorporation for each monomer        in the polymer        -   i. =(Monomer molar fraction consumed (step (c) above)/total            monomer consumed (step (d)(i) above)×100.

Example 8 Determining Monomer Incorporation within Individual Blocks ofa Polymer During Polymer Synthesis

The amount of a given monomer within a given polymer block, typicallythe second polymer block or the polymer block containing PAA, BMA andDMAEAMA, of the polymers exemplified and claimed herein has beendetermined by the following procedure. Samples taken before and afterthe polymerization reaction (i.e., T₀ (time zero) and T_(f)(time final))are analyzed by analytical HPLC to determine the extent of monomerconsumption and/or monomer incorporation.

The initial monomer amounts in the polymerization reaction (time 0, T₀)are determined by sampling the polymerization reaction solution prior tonitrogen purge. A (20 μL) sample of the reaction solution is withdrawnand diluted into 180 μL of 1,1,1,3,3,3-hexafluoro-2-propanol(HFIP)/Methanol (MeOH)/Nano-pure water (H₂O) (2:1:1, v/v) containing0.1% TFA. A portion of the resulting solution (10 μL) is further dilutedinto 590 μL of HFIP/MeOH/H₂O (2:1:1, v/v) containing 0.1% TFA, to afforda test sample with an overall dilution of 1:600 (from the polymerizationreaction) for analysis by analytical HPLC.

Upon completion of the polymerization reaction a time final (T_(f))sample is prepared analogous to the T₀ sample described above. A (20 μL)sample of the reaction solution is withdrawn and diluted into 180 μL of1,1,1,3,3,3-hexafluoro-2-propanol (HFIP)/Methanol (MeOH)/Nano-pure water(H₂O) (2:1:1, v/v) containing 0.1% TFA. A portion of the resultingsolution (10 μL) is further diluted into 590 μL of HFIP/MeOH/H₂O (2:1:1,v/v) containing 0.1% TFA, to afford a test sample with an overalldilution of 1:600 (from the polymerization reaction) for analysis byanalytical HPLC.

Analytical HPLC analysis of the T₀, and T_(f) samples are performedusing a C18 Phenomenex 5μ 100 Å 250×4.6 mm×5 micron (Part#00G-4252-E0)Luna column with guard column heated to 30° C. Three independentdilutions for each time point (i.e., T₀, and T_(f)) are to be preparedand analyzed. A 10 μL of sample is injected onto the column and elutedwith the following gradient. Hold an isocratic eluent of 5%acetonitrile/water with 0.1% TFA for 10 minutes. Switch to a lineargradient from 5% to 15% acetonitrile over 10 minutes. Switch to a lineargradient from 15% to 95% acetonitrile over 20 minutes. Hold an isocraticeluent of 95% eluent acetonitrile for 5 minutes. Return to 5%acetonitrile over 0.01 minutes. Hold the isocratic eluent of 5%acetonitrile/water with 0.1% TFA for 5 minutes. At least threeindependent sample preparations for both T₀, and T_(f) were used for thecalculation of monomer incorporation within the block.

The following methodology is used to calculate the % incorporation of agiven monomer:

-   -   a. Calculate the average T₀, and T_(f) monomer peak areas from        the three independent sample preparations    -   b. Calculate the consumption of individual monomers in the        reaction (monomer % consumption):

=(1-(T_(f-avg) monomer peak area/T_(0-avg) monomer peak area)×100

-   -   c. Calculate the molar fraction consumed of the individual        monomers based on monomer input percent

=(Monomer % conversion (calculated in step b)×0.01)×monomer feed % (forexample, DMAEMA=0.25, PAA=0.25, BMA=0.50)

-   -   d. Total monomer consumption in the polymerization reaction and        overall percent conversion:        -   i. Total monomer consumption=sum of molar fraction consumed            for the individual monomers calculated in (c).        -   ii. Overall % conversion=Total monomer consumption            (calculated in (d)(i)×100    -   e. Calculate the percent monomer incorporation for each monomer        in the polymer        -   i. =(Monomer molar fraction consumed (calculated in (c)            above)/total monomer consumed (calculated in (d)(i)))×100

Example 9 Synthesis of PolymerNagC5N-PEG_(0.6)-[PEGMA4-5₈₀-PDSMA₁₀-BPAM₁₀]₆₋₄-b-[D₂₅-B₅₀-P₂₅]_(6.3)(P1) Example 9.1 Synthesis of Macro-CTA CI

PEGMA4-5 (0.675 g, 2.25 mmol), PDSMA (0.072 g, 0.282 mmol), BPAM (0.077g, 0.282 mmol), Nag(OAc4)C5N-PEG_(0.6K)-CTA (Compound 8) (0.090 g,0.0704 mmol; 1:40 CTA:Monomers), AIBN (0.578 mg, 0.00252 mmol; CTA: AIBN20:1) and DMF (1.65 g) were introduced under nitrogen in a sealed vial.The mixture was degassed by bubbling nitrogen for 30 minutes, and thereaction was allowed to proceed at 68° C. with rapid stirring for 2hours. The reaction was stopped by placing the vial in ice and exposingthe mixture to air. The polymer was purified by dialysis againstmethanol for 24 hours (Spectrum Labs, Spectra/Por Dialysis MembraneMWCO: 2000), followed by removal of solvents under vacuum. The resultingMacro-CTA was dried under vacuum for 6 hours. The structure andcomposition of the purified polymer were verified by NMR, which alsoconfirmed the absence of signals corresponding to vinyl groups ofun-incorporated monomers. Purity of the polymer was confirmed by GPCanalysis. M_(n,GPC)=7.7 kDa, dn/dc=0.05700, PDI=1.28.

Example 9.2 Synthesis of Polymer P1

BMA (0.246 g, 1.73 mmol), PAA (0.099 g, 0.87 mmol), DMAEMA (0.136 g,0.87 mmol), MacroCTA C1 (0.113 g, 0.0147 mmol; 1:236 CTA:Monomers), AIBN(0.241 mg, 0.00147 mmol; CTA:AIBN 10:1) and DMF (0.615 g) wereintroduced in a vial. The mixture was degassed by bubbling nitrogen intothe mixture for 30 minutes, and then allowed to react for 10 hr at67-68° C. The reaction was stopped by placing the vial in ice andexposing the mixture to air. The polymer was purified by dialysis fromacetone/DMF 1:1 into hexane/ether 75/25 (three times). The resultingpolymer was dried under vacuum for at least 8 hours. The structure andcomposition of the purified polymer were verified by ¹H NMR, which alsoconfirmed the absence of signals corresponding to vinyl groups fromun-incorporated monomers. GPC analysis: M_(n,)=13.996 kDa,dn/dc=0.056505, PDI=1.26.

The acetyl groups were removed by treatment of the polymer with sodiummethoxide (6 equivalents) in anhydrous methanol/chloroform under anatmosphere of argon at room temperature for 1.0 hour. The polymer wascapped with 2,2′-dipyridyl disulfide (2 equivalents relative to pyridyldisulfide residues in the polymer) at room temperature for 1.0 hourunder a flow of argon gas. After the capping the reaction was dilutedwith MeOH and filtered. The filtrate was transferred to a dialysismembrane with a 2000 g/mol molecular weight cut off (Spectrum Labs,Spectra/Por Dialysis Membrane MWCO: 2000) and dialyzed against MeOH over24 hours followed by dialysis against water. The solvent was evaporated,and the polymer was dried under vacuum.

Example 10 Synthesis of PolymerNagC5N-PEG_(0.6)-[PEGMA4-5₈₀-PDSMA₁₀-BPAM₁₀]₇₂-b-[D₂₅-B₅₀-P₂₅]_(6.1)(P2) Example 10.1 Preparation of MacroCTA C2

MacroCTA C2 was prepared as described in Example 9.1 starting fromPEGMA4-5 (8.083 g, 27.0 mmol), PDSMA (0.860 g, 3.37 mmol), BPAM (0.921g, 3.37 mmol), Nag(OAc4)C5N-PEG_(0.6K)-CTA (Compound 8) (1.076 g, 0.842mmol; 1:40 CTA:Monomers), AIBN (6.914 mg, 0.0421 mmol; CTA: AIBN 20:1)and DMF (19.73 g). Polymerization time was 2 hr 55 min. GPC: M_(n)=8.500kDa; PDT˜1.23; dn/dc=0.5780.

Example 10.2 Preparation of Polymer P2

Extension of MacroCTA C2 by RAFT polymerization was carried out asdescribed in Example 10.1 using BMA (0.553 g, 3.89 mmol), PAA (0.226 g,1.98 mmol), DMAEMA (0.311 g, 1.98 mmol), MacroCTA C2 (0.560 g, 0.0659mmol; 1.98 CTA:Monomers), AIBN (1.082 mg, 0.00659 mmol; CTA:ATBN 10:1)and DMF (1.37 g+0.69 g). Polymerization was stopped after 5 hours, andthe product was purified by dialysis from Acetone/DMF 1:1 intohexane/ether 75/25 (three times). GPC: dn/dc=0.053188; M_(n)=14.7 kDa;PDI=1.31. The acetyl groups were removed with NaOMe as described inExample 9.2.

Example 11 Synthesis of PolymerNagC5N-PEG_(0.6)-[PEGMA4-5₈₀-PDSMA₁₀-BPAM₁₀]_(7.2)-b-[D₂₅-B₅₀-P₂₅]_(10.8)(P3)

MacroCTA C2 (Example 10) was extended by RAFT polymerization asdescribed in Example 10.2 using BMA (0.197 g, 1.39 mmol), PAA (0.079 g,0.69 mmol), DMAEMA (0.109 g, 0.69 mmol), Macro-CTA (0.100 g, 0.0118mmol; 1:236 CTA:Monomers), AIBN (0.193 mg, 0.00118 mmol; CTA : AIBN10:1) and DMF (0.492 g) for 4.5 hours, and the product was purified bydialysis from Acetone/DMF 1:1 into hexane/ether 75/25 (three times).GPC: dn/dc=0.053160; Mn=19.3 kDa; PDI=1.39. The acetyl groups wereremoved with NaOMe as described in Example 10.2.

Example 12 Synthesis of PolymerPEG_(0.6)-[PEGMA4-5₈₀-PDSMA₁₀-BPAM₁₀]_(6.7)-b-[D₂₅-B₅₀-P₂₅]_(6.2) (P4)Example 12.1 Preparation of MacroCTA C4

Macro-CTA C4 was prepared as described in Example 9 starting withPEGMA4-5 (5.128 g, 17.1 mmol), PDSMA (0.546 g, 2.14 mmol), BPAM (0.584g, 2.14 mmol), PEG_(0.6K)-CTA (Compound 6) (0.461 g, 0.534 mmol; 1:40CTA:Monomers), AIBN (4.385 mg, 0.0267 mmol; CTA: AIBN 20:1) and DMF(12.52 g); reaction time was 1 hr 40 min. GPC: Mn=7.50 kDa; PDI˜1.20;dn/dc=0.053910.

Example 12.2 Preparation of Polymer P4

Synthesis and purification of Polymer P4 was carried out as described inExample 8.2 using BMA (1.656 g, 11.6 mmol), PAA (0.676 g, 5.92 mmol),DMAEMA (0.931 g, 5.92 mmol), MacroCTA C4(1.5 g, 0.197 mmol; 1:118CTA:Monomers), AIBN (3.241 mg, 0.0197 mmol; CTA:AIBN 10:1) and DMF (4.16g+2.08 g). GPC: dn/dc=0.050; M_(n)=13.8 kDa; PDI=1.1.

Example 13 Synthesis of PolymerNagC5N-PEG_(0.6)-[PEGMA4-5₈₀-PDSMA₁₀-BPAM₁₀]_(6.6)-b-[D₂₅-B₅₀-P₂₅]_(4.7)(P5) Example 13.1 Preparation of MacroCTA C5

MacroCTA C5 was synthesized as described in Example 9.1 starting fromPEGMA4-5 (0.5 g, 1.67 mmol), PDSMA (0.053 g, 0.208 mmol), BPAM (0.057 g,0.208 mmol), Nag(OAc4)C5N-PEG_(0.6K)-CTA (Compound 8) (0.0665 g, 0.0521mmol; 1:40 CTA: Monomers), AIBN (0.428 mg, 0.0026 mmol; CTA:AIBN 20:1)and DMF (1.22 g). Polymerization time was 2 hr 30 min. GPC: Mn=7.85 kDa;PDI=1.18; dn/dc=0.066.

Example 13.2 Preparation of Polymer P5

Synthesis and purification of Polymer P5 was carried out as described inExample 9.2 using BMA (0.62 g, 4.36 mmol), PAA (0.249 g, 2.18 mmol),DMAEMA (0.342 g, 2.18 mmol), MacroCTA CS 89 g, 0.0242 mmol; 1:360CTA:Monomers), AIBN (0.398 mg, 0.00242 mmol; CTA:AIBN 10:1) and DMF(1.55 g). Polymerization was allowed to proceed for 10 hrs. GPC:dn/dc=0.063851; M_(n)=22.5 kDa; PDI=1.41. Deprotection was carried outas described in Example 9.2.

Example 14 Synthesis of PolymerNagC5N-PEG_(0.6)-[PEGMA4-5₈₀-PDSMA₁₀-BPAM₁₀]_(3.5)-b-[D₂₅-B₅₀-P₂₅]_(6.3)(P6) Example 14.1 Preparation of MacroCTA C6

Macro-CTA C6 was synthesized as described in Example 9.1 starting fromPEGMA4-5 (1.503 g, 5.00 mmol), PDSMA (0.160 g, 0.626 mmol), BPAM (0.171g, 0.626 mmol), Nag(OAc4)C5N-PEG_(0.6K)-CTA (Compound 8) (0.500 g, 0.391mmol; 1:40 CTA:Monomers), AIBN (3.213 mg, 0.0196 mmol; CTA:AIBN 20:1)and DMF (3.668 g); reaction time was 1 hr 45 min. GPC: M_(n)=4.8 kDa;PDI=1.19; dn/dc=0.061481.

Example 14.2 Preparation of Polymer P6

Synthesis and purification of Polymer P6 was carried out as described inExample 9.2 using BMA (0.218 g, 1.54 mmol), PAA (0.089 g, 0.781 mmol),DMAEMA (0.123 g, 0.781 mmol), MacroCTA C6 (0.125 g, 0.0260 mmol; 1:118CTA:Monomers), AIBN (0.428 mg, 0.00260 mmol; CTA:AIBN 10:1) and DMF(0.830 g). Polymerization was allowed to proceed for 4 hrs and 50 min.GPC:dn/dc=0.05812; M_(n)=11.1 kDa; PDI=1.38. Deprotection was carriedout as described in Example 9.2.

Example 15 Synthesis of PolymerNagC5N-PEG_(0.6)-[PEGMA4-5₈₆-PDSMA₁₄]_(3.82 kDa)-[BMA₄₅-PAA₁₅-DMAEMA₄₀]_(5.98 KDa)(P7) Example 15.1 Preparation of MacroCTA C7:

AIBN/DMF (21.93 g of 1.05603 mg/g ABIN in DMF) was added toNag(OH)C5N-PEG_(0.6K)-CTA (synthesized as described in Example 5compound 8a) (3.075 g; 2.6705 mmol) in a 40 ml reaction vessel and mixedto dissolve the CTA. DMF was then added until the total weight of DMFwas 24.9627 g. To the resulting solution was added PEGMA (11.18 g,37.2621 mmol, filtered through aluminum oxide (activated, basic,Brockmann I) and PDSMA (1.1211 g, 4.1393 mmol). The resulting solutionwas mixed and then transferred to a sealed 50 mL round bottom flaskequipped with a magnetic stir bar. The resulting solution wasde-oxygenated by bubbling nitrogen into the solution for 50 min on ice.The flask was moved to room temperature for 4 min and then placed in anoil bath pre-heated to 68° C. for 1 hour 42 minutes (stir speed was setat 350 rpm). The reaction was stopped by placing the vial in ice andexposing the mixture to air. The reaction solution was diluted withMeOH, transferred to dialysis membranes (Spectrum Labs, SpectrumSpectra/Por 6 Dialysis Membrane Tubing MWCO: 2000) and dialyzed againstMeOH (6×4000 mL) for 6 days. Samples were taken for LC-MS, GPC and ¹HNMR analyses. After dialysis, the solvent was removed under reducedatmosphere followed by high vacuum to afford 2.45 g of polymer. LC-MSanalysis indicated no residual CTA peak. ¹H NMR, which also confirmedthe absence of signals corresponding to vinyl groups of un-incorporatedmonomers. Purity of the polymer was confirmed by GPC analysis.M_(n,GPC)=4.97 KDa, PDI=1.12, dn/dc=0.06469, PDI=1.12.

Example 15.2 Synthesis of Polymer P7

AIBN/DMF solution (7.0225 g; L10468 mg/g AIBN in DMF) was added tomacro-CTA C7 (2.350 g) in a 40 mL reaction vessel; the sample was mixedto dissolve the macro-CTA. DMF was then added until the total weight ofDMF was 15.05 g. BMA (3.967 g, filtered through aluminum oxide(activated, basic, Brockmann I), PAA (1.6217 g) and DMAEMA (2.237 g,filtered through aluminum oxide [activated, basic, Brockmann I]) wereadded to the resulting solution and the solution was mixed. The mixturewas vortexed for several minutes to give a homogeneous stock solutionand transferred to a sealed 50 mL, round bottom flask equipped with amagnetic stir bar. The mixture was then cooled to 0° C. using an icebath and maintained at 0° C. while degassed by vigorously bubblingnitrogen inside the solution for 55 minutes. The flask septa was placedinto an oil bath pre-heated to 61° C. (stirring speed was 350) andallowed to stir for 4 hours 30 minutes. The reaction was stopped byplacing the vial in ice and exposing the mixture to air. The reactionwas then diluted with acetone (roughly the same volume of acetone as theDMF used in the reaction vial) and precipitated into a stirred mixtureof ether/hexanes (1:3 v/v) in a 50 mL centrifuge tube once and then intoa large beaker with 600 mL ether/hexanes (1:3 v/v). The polymerprecipitate was isolated and dissolved with MeOH, transferred to threeindividual dialysis membranes (Spectrum Labs, Spectrum Spectra/Por 6Dialysis Membrane Tubing MWCO: 2,000) and dialyzed against methanol(5×4000 mL) for 4 days. After the dialysis against methanol, it wasdialyzed against nanopure water using the same membrane (×6, waterchanged every hour). When the dialysis was complete, the solution wastransferred to tared vials and treated with liquid nitrogen before beinglyophilized for 5 days to afford 3.46 g of the final product. The finalproduct was analyzed by NMR, GPC and HPLC equipped with RI detector (forbatch do/dc). Analysis of the polymer by ¹H-NMR indicated a polymer withno vinyl groups remaining and the presence of PDSMA. The NMR isconsistent for proposed structure. GPC results: Mn=10.936 KDa, PDI=L30,dn/dc=0.057867.

Example 16 Synthesis of PolymerNAG-PEG-_(0.6)-[PEGMA₁₀₀]_(3.5 k)-[BMA₄₉-PAA₁₀-DMAEMA₃₃-PDSMA₈]_(7.1 k)(P8) Example 16.1 Preparation of MacroCTA C8

To a 20 mL reaction vial was added to Nag(OH)C5N-PEG_(0.6K)-CTA(synthesized as described in Example 5, compound 8a) (794.6 mg, 0.6922mmol, CTA) followed by a solution of AIBN (5.0438 g solution dissolvedin DMF at a concentration of 1.1268 mg/g, 5.68 mg AIBN, 0.03461 mmol,2,2′-azobis(2-methylpropionitrile), compound recrystallized from MeOH)then an additional amount of DMF (432.2 mg) was added bringing the totalamount of DMF used in this reaction to 5.4760 g. This solution was mixedand vortexed for several minutes until all of the CTA was completelydissolved. Once all the CTA was completely dissolved PEGMA (3219.3 mg,10.730 mmol, poly(ethylene glycol) methyl ether methacrylate withaverage M_(n)=300 g/mol, inhibited with 100 ppm MEHQ and 300 ppm of BHTinhibitors, Aldrich part number 447935-500 mL, inhibitors removed bypassing the neat monomer through a plug of Al₂O₃, was added to thereaction vial. This mixture was stirred for several minutes. Thereaction vial was partially sealed and cooled to 0° C. using an ice bathwhile the mixture was degassed by vigorously bubbling nitrogen for 30minutes with magnetic stirring of the reaction solution. Then the vialwas completely sealed and placed into a heater block. The stirring speedwas set at 300 rpm, the thermometer was set at 68° C. and was maintainedat this temperature during the entire process. The reaction was left tostir at 68° C. for 1 hours and 47 minutes. After the reaction iscomplete it was quenched by opening the vial and then placing thereaction vial in ice exposing the mixture to air. The reaction vial wasdiluted with MeOH (10 mL) and transferred to a dialysis membrane with a2000 g/mol molecular weight cut off (Spectrum Labs, Spectrum Spectra/Por6 Dialysis Membrane Tubing MWCO: 2000) and dialyzed against MeOH (3×4000mL) for 4 days. The dialysis solution was changed every day for 3iterations total. The polymer in the dialysis bag was analyzed accordingto the following procedure: A small aliquot of the dialysis solution(ca. 500-1000 μL) was withdrawn from the dialysis tubing and placed intoa tared vial. The solution was then evaporated using a rotaryevaporator. Once the solvents are removed the vial was transferred to ahigh vacuum line and placed under high vacuum. The compound is dried for<15 min. Once the vial weight is constant then the compound wasdissolved immediately in DMF with 1% weight LiBr solution. The finalconcentration of the polymer was approximately 8 mg/mL in DMF with 1% wtLiBr (DMF measured by weight then converted to volume). A 20 kDapolystyrene standard (Fluka, part number 81407-1G) dissolved in DMF with1% wt LiBr at a concentration of roughly 3 mg/mL (DMF measured by weightthen converted to volume) is then injected (100 μL) on the GPC followedby the polymer sample of interest (60, 80, 100, and 120 μL). Once thefinal GPC analysis is determined then the dialysis solution wastransferred to a 40 mL reaction vial then the solvents were removedusing a rotary evaporator. Then the material was place on a high vacuumline (pressure<0.5 toff) for >24 hours. This process provided 682.9 mgof the final product. The final product is then analyzed by NMR and GPC.The final product was stored at room temperature under high vacuum. TheNMR is consistent for proposed structure. GPC results: Mn=4.600,dn/dc=0.053354.

Example 16.2 Synthesis of Polymer P8

To a 40 mL reaction vial was added macro-CTA C8 (682.1 mg, 0.148 mmol)followed by a solution of AIBN (2.2338 g solution dissolved in DMF at aconcentration of 1.0927 mg/g, (2.44 mg AIBN, 0.0148 mmol,2,2′-azobis(2-methylpropionitrile), compound recrystallized from MeOH)then an additional amount of DMF (2.6163 g) was added bringing the totalamount of DMF used in this reaction to 4.8501 g. This solution was mixedand vortexed for several minutes until all of the CTA was completelydissolved. Once all the CTA was completely dissolved then BMA (1.1849 g,8.314 mmol, purified by passing the neat monomer through a plug ofAl₂O₃, butyl methacrylate, d−0.894 g/mL), PAA (488.0 mg, 4.231 mmol,unpurified 2-propylacrylic acid, d−0.951 g/mL), DMAEMA (661.8 mg, 4.231mmol, purified by passing the neat monomer through a plug of Al₂O₃,2-(dimethylamino)ethyl methacrylate, d−0.933 g/mL), and PDSMA (227.0 mg,0891 mmol). This mixture was mixed for several minutes. The reactionmixture was then transferred to a brand new 20 mL reaction vialcontaining a magnetic stir bar. The reaction vial was partially sealedand cooled to 0° C. using an ice bath while the mixture was degassed byvigorously bubbling nitrogen for 30 minutes with magnetic stirring ofthe reaction solution. The vial was then completely sealed and placedinto a heater block. The stirring speed was set at 300, the thermometerwas set at 62° C. The reaction was left to stir at 62° C. for 5 hoursand 50 minutes. After the reaction is complete it was quenched byopening the vial and then placing the reaction vial in ice exposing themixture to air. The reaction solution was then diluted with acetone (˜5mL, roughly the same volume of acetone as the DMF used in the reactionvial) and precipitated into a stirred mixture of Et₂O/hexanes (1000 mL,1:4 v/v) in a glass beaker. After the polymer had settled to the bottom(ca. 15 min) the solvents were decanted off. The precipitated polymerdissolved in MeOH was transferred into dialysis membranes with a 2000g/mol molecular weight cut off (Spectrum Labs, Spectrum Spectra/Por 6Dialysis Membrane Tubing MWCO: 2000) and dialyzed against MeOH (3×4000mL) for 3 days (72 h). The dialysis solution was changed every day for 3iterations total. After 3 days (72 h) dialysis against MeOH the dialysissolution is changed to nanopure H₂O and dialyzed against H₂O (5×4000 mL)for 5 hr. The dialysis solution was changed roughly every hour for 5iterations total. Upon completion of dialysis the solutions weretransferred to tared vials and frozen solid using a bucket of dry ice.Then the material was placed into the lyophilizer for >4 days totaldrying time. This process provided 1.0325 g of the final product. Thefinal product was then analyzed by NMR and GPC. Analysis of the polymerby ¹H-NMR indicated a polymer with no vinyl groups remaining and thepresence of PDSMA. The NMR is consistent for proposed structure. GPCresults: Mn=11.7 kDa, dn/dc=0.058046. The final product was stored inglass vials with rubber septum that were purged with argon and sealedwith parafilm. The vials were stored at −20° C.

Example 17 Polymer Synthesis

By similar methods, the following polymers were synthesized according tothe following conditions shown in Tables 8-67, below.

-   A. P67: NAG-PEG12-[PEGMA(300, 79.1%)-BPAM(10.0%)-PDSMA(10.9%)] 3.56    KDa-b-[DMAEMA(34.7%)-BMA(54.7%)-PAA(10.5%)]4.71 KDa

TABLE 8 P67 Block 1 Block 2 [M/CTA/I] [12.8:1.6:1.6/1/0.05][30:59:30/1/0.1] [concentration] 1.17M 2.61M Time l h 45 m 5 h 35 mTemperature 67° C. 61° C. CTA = Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   B. P68: NAG-PEG12-[PEGMA(300; 89.8%)-PhEMA(10.2%)]3.23    KDa-b4DMAEMA(33%)-BMA(57%)-PAA(10%)16.0 KDa

TABLE 9 P68 Block 1 Block 2 [M/CTA/I] [13.95:1.55/1/0.05][30:59:30/1/0.1] [concentration] 1.2M 2.3M Time 1 h 30 m 4 h 30 mTemperature 67° C. 65° C. CTA = Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   C. P69: NAG-PEG12-[PEGMA(300;78.7%)-PhEMA(21.3%)]3.25    KDa-b-[DMAEMA(32.9%)-BMA(54.8%)-PAA(12.3%)]5.4 KDa

TABLE 10 P69 Block 1 Block 2 [M/CTA/I] [12.4:3.1/1/0.05][30:59:30/1/0.1] [concentration] 1.2M 2.3M Time 1 h 30 m 4 h 30 mTemperature 67° C. 65° C. CTA = Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   D. P70: NAG-PEG12-[PEGMA(300,88.6)-PhEMA(11.4%)]3.02    KDa-b-[DMAEMA(36.8%)-BMA(56.3%)-PAA(6.9%]4.39 KDa

TABLE 11 P70 Block 1 Block 2 [M/CTA/I] [12.4:3.1/1/0.05][30:59:30/1/0.1] [concentration] 1.2M 2.3M Time 1 h 30 m 4 h 30 mTemperature 67° C. 65° C. CTA = Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   E. P71: NAG-PEG12-[PEGMA(300, 69.5%)-BPAM (19.2%)-PDSMA (11.3%)]    3.59 KDa-b-[DMAEMA (35.2%)-BMA (53.9%)-PAA (10.9%)]5.27 Kda

TABLE 12 P71 Block 1 Block 2 [M/CTA/I] [12.8:3.2:1.65/1/0.05][30:59:30/1/0.1] [concentration] 1.22M 2.62M Time l h 45 m 5 h 35 mTemperature 67° C. 61° C. CTA = Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   F. P72: NAG-PEG12-[PEGMA(300, 80.3%)-ImMA(19.7)]3.7    KDa-b-[DMAEMA(35.9%)-BMA(53.9%)-PAA(10.2%)]4.7 KDa

TABLE 13 P72 Block 1 Block 2 [M/CTA/I] [13:4.1/1/0.05] [30:59:30/1/0.1][concentration] 1.2M 2.3M Time 1 h 30 m 5 h Temperature 67° C. 65° C.CTA = Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   G. P73: NAG-PEG12-[PEGMA(300, 73.1%)-BMA(14.4%)-PhEMA(12.5%)]3.8    KDa-b-[DMAEMA(37.6%)-BMA(52.3%)-PAA(10.1%)]4.2 KDa

TABLE 14 P73 Block 1 Block 2 [M/CTA/I] [12.8:1.6:1.6/1/0.05][30:59:30/1/0.1] [concentration] 1.2M 2.3M Time 1 h 30 m 5 h Temperature67° C. 61° C. CTA = Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   H. P74: NAG-PEG12-[PEGMA(300, 80.3%)-BMA(23.3%)]3.8    KDa-b-[DMAEMA(38.2%)-BMA(51.5%)-PAA(10.3%)]3.5 KDa

TABLE 15 P74 Block 1 Block 2 [M/CTA/I] [12.8:3.2/1/0.05][30:59:30/1/0.1] [concentration] 1.2M 2.3M Time 1 h 30 m 5 h Temperature67° C. 61° C. CTA = Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   I. P75: NAG-PEG12-[PEGMA(300, 75.8%)-isoA-MA(11.8%)-PhEMA(12.4%)]3.3    KDa-b-[DMAEMA(39.1%)-BMA(51.6%)-PAA(9%)]4.95 KDa

TABLE 16 P75 Block 1 Block 2 [M/CTA/I] [12.8:1.6:1.6/1/0.05][30:59:30/1/0.1] [concentration] 1.2M 2.3M Time 1 h 40 m 5 h Temperature67° C. 61° C. CTA = Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   J. P76: NAG-PEG12-[PEGMA(300, 74.9%)-isoA-MA(25.1%)]2.9    KDa-b-[DMAEMA(38%)-BMA(53%)-PAA(9.1%)]5.2 KDa

TABLE 17 P76 Block 1 Block 2 [M/CTA/I] [12.8:3.2/1/0.05][30:59:30/1/0.1] [concentration] 1.2M 2.3M Time 1 h 40 m 5 h Temperature67° C. 61° C. CTA = Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   K. P77: NAG-PEG12-[PEGMA (300, 86%)-CyHexMA (14%)]2.98 KDa-b-[DMAEMA    (36.2%)-BMA (51.7%)-PAA (12.2%)]4.66 KDa

TABLE 18 P77 Block 1 Block 2 [M/CTA/I] [12.8:2.2/1/0.05][30:59:30/1/0.1] [concentration] 1.21M 2.6M Time 2 h 35 m 5 hTemperature 67° C. 61° C. CTA = Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   L. P78: NAG-PEG12-[PEGMA(300, 72.5%)-BPAM(27.5%)]3.8    KDa-b-[DMAEMA(25.6%)-BMA(64.8%)-PAA(9.6%)]5.5 KDa

TABLE 19 P78 Block 1 Block 2 [M/CTA/I] [12.8:5/1/0.05] [30:59:30/1/0.1][concentration] 1.2M 2.3M Time 1 h 45 m 5 h 15 m Temperature 67° C. 61°C. CTA = Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   M. P79: NAG-PEG12-[PEGMA (300, 69.9%)-HMA(30.1%)] 2.93 KDa-b-[DMAEMA    (34.4%)-BMA (53.6%)-PAA (12%)]4.43 Kda

TABLE 20 P79 Block 1 Block 2 [M/CTA/I] [10.8:5.2/1/0.05][30:59:30/1/0.1] [concentration] 1.21M 2.96M Time 1 h 50 m 4 h 40 mTemperature 68° C. 61° C. CTA = Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   N. P80: NAG-PEG12-[PEGMA (300, 85.4%)-EHMA(14.6%)] 3.36    KDa-b-[DMAEMA (36.5%)-BMA (53.7%)-PAA (9.7%)]4.18 KDa

TABLE 21 P80 Block 1 Block 2 [M/CTA/I] [16/1/0.05] [30:59:30/1/0.1][concentration] 1.21M 2.62M Time 2 h 5 h Temperature 68° C. 61° C. CTA =Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   O. P81: NAG-PEG12-[PEGMA(300, 72%)-F1-BMA(28%)]3.75    KDa-b-[DMAEMA(30.7%)-BMA(56.7%)-PAA(12.6%)]5.7 KDa

TABLE 22 P81 Block 1 Block 2 [M/CTA/I] [12.8:3.5/1/0.05][26:51:26/1/0.1] [concentration] 1.2M 2.3M Time 1 h 35 m 5 h 15 mTemperature 67° C. 61° C. CTA = Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   P. P82: NAG-PEG12-[PEGMA(300, 71.9%)-F1-BMA(28.1%)]3.55    KDa-b-[DMAEMA(29.9%)-BMA(57.6%)-PAA(12.4%)]5.3 KDa

TABLE 23 P82 Block 1 Block 2 [M/CTA/I] [12.8:3.5/1/0.05][26:51:26/1/0.1] [concentration] 1.2M 2.3M Time 1 h 35 m 5 h 15 mTemperature 67° C. 61° C. CTA = Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   Q. P83: NAG-PEG12-[PEGMA(300, 78.9%)-F-CyHexMA(21.1%)]4.56    KDa-b-[DMAEMA(33.2%)-BMA(55.4%)-PAA(11.4%)]5.3 KDa

TABLE 24 P83 Block 1 Block 2 [M/CTA/I] [12.8:3.5/1/0.05][30:59:30/1/0.1] [concentration] 1.2M 2.3M Time 1 h 35 m 5 h 15 mTemperature 67° C. 61° C. CTA = Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   R. P84: NAG-PEG12-[PEGMA(300, 77.9%)-F-HPenMA(22.1%)]3.26    KDa-b-[DMAEMA(30.9%)-BMA(57.4%)-PAA(11.6%)]6.5 KDa

TABLE 25 P84 Block 1 Block 2 [M/CTA/I] [12.8:4/1/0.05] [30:59:30/1/0.1][concentration] 1.2M 2.3M Time 1 h 35 m 5 h 15 m Temperature 67° C. 61°C. CTA = Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   S. P85: NAG-PEG12-[PEGMA(300, 79%)-BMA(21%)]2.9    KDa-b-[DMAEMA(29.3%)-BMA(26.6%)-F1-BMA(34.6%)-PAA(9.5%)]5.8 KDa

TABLE 26 P85 Block 1 Block 2 [M/CTA/I] [12.8:3.2/1/0.05][30:59:30/1/0.1] [concentration] 1.2M 2.3M Time 1 h 40 m 5 h 15 mTemperature 67° C. 61° C. CTA = Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   T. P86: NAG-PEG12-[PEGMA (300, 78.1%)-C12MA(21.9%)]3.67    KDa-b-[DMAEMA (32.1%)-BMA (53.7%)-PAA (14.2%)]4.7 KDa

TABLE 27 P86 Block 1 Block 2 [M/CTA/I] [12.8:3.2/1/0.05][30:59:30/1/0.1] [concentration] 1.21M 2.38M Time 2 h 35 m 5 h 30 mTemperature 68° C. 61° C. CTA = Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   U. P87: NAG-PEG12-[PEGMA (300, 69.7%)-EHMA (30.3%)]3.9 KDa-b-[DMAEMA    (31.1%)-BMA(56.7%)-PAA (12.1%)]5.1 KDa

TABLE 28 P87 Block 1 Block 2 [M/CTA/I] [15.1:6.3/1/0.05][30:59:30/1/0.1] [concentration] 1.24M 2.96M Time 2 h 15 m 6 hTemperature 68° C. 62° C. CTA = Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   V. P88: NAG-PEG12-[PEGMA (300, 76%)-5-NMA (24%)] 3.0 KDa-b-[DMAEMA    (34.4%)-BMA (54%)-PAA (11.6%)]5.6 KDa

TABLE 29 P88 Block 1 Block 2 [M/CTA/I] [13.5:4.5/1/0.05][30:59:30/1/0.1] [concentration] 1.21M 2.6M Time 2 h 6 h Temperature 67°C. 61.5° C. CTA = Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   W. P89: NAG-PEG12-[PEGMA (300,73.8%)-BMA (26.2%)]3.5 KDa-b-[DMAEMA    (30.7%)-BMA(58.9%)-PAA (10.4%)]4.9 KDa

TABLE 30 P89 Block 1 Block 2 [M/CTA/I] [13.5:4.5/1/0.05][30:59:30/1/0.1] [concentration] 1.29M 2.61M Time 2 h 5 m 5 h 45 mTemperature 69° C. 61° C. CTA = Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   X. P90: NAG-PEG12-[PEGMA (300, 72.6%)-HMA (27.4%)]3.58 KDa-b-[DMAEMA    (30.6%)-BMA(56.2%)-PAA (13.3%)]5.6 KDa

TABLE 31 P90 Block 1 Block 2 [M/CTA/I] [13:4.5/1/0.05] [30:59:30/1/0.1][concentration] 1.3M 2.72M Time 2 h 30 m 5 h 48 m Temperature 69° C. 61°C. CTA Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   Y. P91: CH3O-PEG12-[PEGMA (300, 92.8%)-PDSMA (7.2%)]3.6    KDa-b-[DMAEMA (34.2%)-BMA(54.7%)-PAA (11%)]6.5 KDa

TABLE 32 P91 Block 1 Block 2 [M/CTA/I] [14:1.55/1/0.05] [30:59:30/1/0.1][concentration] 1.21M 2.35M Time 1 h 45 m 5 h Temperature 67° C. 65.5°C. CTA CH3O-PEG₁₂-CTA; I = AIBN

-   Z. P92: NAG-PEG12-[PEGMA (300, 83.2%)-AEOMA (16.8%)]3.0    KDa-b-[DMAEMA (36.2%)-BMA(52.2%)-PAA (11.6%)]5.6 KDa

TABLE 33 P92 Block 1 Block 2 [M/CTA/I] [12.8:2.2/1/0.05][30:59:30/1/0.1] [concentration] 1.21M 2.5M Time 1 h 50 m 5 h 20 mTemperature 67° C. 61° C. CTA Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   AA. P93: NAG-PEG12-[PEGMA (300, 77.6%)-CyHexMA (22.4%)]2.64    KDa-b-[DMAEMA (32.1%)-BMA(43.1%)-PAA (12.6%)-CyHexMA(12.3%)]4.67 KDa

TABLE 34 P93 Block 1 Block 2 [M/CTA/I] [8.4:2.3/1/0.05] [30:45:30/1/0.1][concentration] 1.21M 2.3M Time 1 h 55 m 4 h Temperature 68° C. 61° C.CTA Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   BB. P94: NAG-PEG12-[PEGMA (300, 72.2%)-B-F1-HMA (27.8%)]4.2    KDa-b-[DMAEMA (35.7%)-BMA(54.4%)-PAA (9.9%)]4.7 KDa

TABLE 35 P94 Block 1 Block 2 [M/CTA/I] [13:4.5/1/0.05] [30:59:30/1/0.1][concentration] 1.2M 2.3M Time 1 h 35 m 5 h 15 m Temperature 67° C. 61°C. CTA Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   CC. P95: NAG-PEG12-[PEGMA(300, 71.2%)-F1-BMA(28.8%)]3.55    KDa-b-[DMAEMA(34.2%)-BMA(57.9%)-PAA(7.9%)]4.9 KDa

TABLE 36 P95 Block 1 Block 2 [M/CTA/I] [12.8:3.5/1/0.05][26:51:26/1/0.1] [concentration] 1.2M 2.3M Time 1 h 35 m 5 h 15 mTemperature 67° C. 61° C. CTA Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   DD. P96: NAG-PEG12-[PEGMA(300, 72.6%)-F1-BMA(27.4%)]3.55    KDa-b-[DMAEMA(30.7%)-BMA(56.1%)-PAA(13.2%)]4.9 KDa

TABLE 37 P96 Block 1 Block 2 [M/CTA/I] [12.8:3.5/1/0.05][26:51:26/1/0.1] [concentration] 1.2M 2.3M Time 1 h 35 m 5 h 15 mTemperature 67° C. 61° C. CTA Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   EE. P97: NAG-PEG12-[PEGMA(300, 70.0%)-F1-BMA(30.0%)]3.55    KDa-b-[DMAEMA(31.3%)-BMA(60.7%)-PAA(8.0%)]5.1 KDa

TABLE 38 P97 Block 1 Block 2 [M/CTA/I] [12.8:3.5/1/0.05][26:51:26/1/0.1] [concentration] 1.2M 2.3M Time 1 h 35 m 5 h 15 mTemperature 67° C. 61° C. CTA Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   FF. P98: NAG-PEG12-[PEGMA(300, 75%)-2-Bu1-OMA(25%]4.26    KDa-b-[DMAEMA(32.1%)-BMA(55.7%)-PAA(12.2%)]5.69 KDa

TABLE 39 P98 Block 1 Block 2 [M/CTA/I] [15:6.1/1/0.05][30:59.5:30/1/0.1] [concentration] 1.3M 2.97M Time 2 h 30 m 5 h 45 mTemperature 70° C. 62° C. CTA Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   GG. P99: NAG-PEG12-[PEGMA(300, 73.3%)-5-NMA(26.7%)]4.05    KDa-b-[DMAEMA(31.5%)-BMA(55.2%)-PAA(13.3%)]5.20 KDa

TABLE 40 P99 Block 1 Block 2 [M/CTA/I] [15:6.1/1/0.05] [30:59:30/1/0.1][concentration] 1.3M 2.76M Time 2 h 30 m 5 h 40 m Temperature 70° C. 62°C. CTA Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

HH. P100: NAG-PEG12-[PEGMA(300, 74.1%)-F1-BMA(25.9%)]13.79KDa-b-[DMAEMA(29.9%)-BMA(56.2%)-PAA(13.9%)]5.44 KDa

TABLE 41 P100 Block 1 Block 2 [M/CTA/I] [13:3.5/1/0.05] [30:59:30/1/0.1][concentration] 1.22M 2.52M Time 2 h 5 m 5 h 35 m Temperature 68° C. 62°C. CTA Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   II. P101: NAG-PEG12-[PEGMA(300, 72.2%)-B-F1-OMA(27.8%)]4.2    KDa-b-[DMAEMA(35.7%)-RMA(54.4%)-PAA(9.9%)]5.6 KDa

TABLE 42 P101 Block 1 Block 2 [M/CTA/I] [13:5/1/0.05] [30:59:30/1/0.1][concentration] 1.2M 2.3M Time 1 h 35 m 5 h 15 m Temperature 67° C. 61°C. CTA Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   JJ. P102: NAG-PEG12-[PEGMA(300, 71.9%)-F1-BMA(28.1%)]3.55    KDa-b-[DMAEMA(27.3%)-BMA(60.9%)-PAA(11.9%)]4.55 KDa

TABLE 43 P102 Block 1 Block 2 [M/CTA/I] [12.8:3.5/1/0.05][26:51:26/1/0.1] [concentration] 1.2M 2.3M Time 1 h 35 m 5 h 15 mTemperature 67° C. 61° C. CTA Nag(OH)C5N-PEG₁₂-CTA; I = AIBN

-   KK. P106: NAG-PEG12-[PEGMA(300, 74%)-HMA(26%)]4.1    KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]*6.5 KDa

TABLE 44 P# Block 1 Block 2 [M/CTA/I] [15.5:4.5/1/0.05] [30:59:30/1/0.1][concentration] 1.35M 2.3M Time 3 h 15 m 5 h 30 m Temperature 69° C. 61°C. CTA Nag(OH)C5N-PEG₁₂-CTA; I = AIBN *Monomer incorporation for blockis estimated based on historical incorporation levels

-   LL. P107: NAG-PEG12-[PEGMA(300, 74%)-HMA(26%)]*4.1    KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]*4.2 KDa

TABLE 45 P# Block 1 Block 2 [M/CTA/I] [15.5:4.5/1/0.05][27:51:36.5/1/0.1] [concentration] 1.35M 2.3M Time 3 h 15 m 5 h 30 mTemperature 69° C. 61° C. CTA Nag(OH)C5N-PEG₁₂-CTA; I = AIBN *Monomerincorporation for block is estimated based on historical incorporationlevels

-   MM. P108: NAG-PEG12-[PEGMA(300, 80%)-HMA(20%)]*4.96    KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]*5.5 KDa

TABLE 46 P# Block 1 Block 2 [M/CTA/I] [19.5:4.5/1/0.05] [30:59:30/1/0.1][concentration] 1.5M 2.3M Time 3 h 10 m 6 h 10 m Temperature 69° C. 61°C. CTA Nag(OH)C5N—PEG₁₂—CTA; I = AIBN *Monomer incorporation for blockis estimated based on historical incorporation levels

-   NN. P109: NAG-PEG12-[PEGMA(300, 80%)-HMA(20%)]*4.96    KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]*6.5 KDa

TABLE 47 P# Block 1 Block 2 [M/CTA/I] [19.5:4.5/1/0.05] [30:59:30/1/0.1][concentration] 1.5M 2.9M Time 3 h 10 m 7 h Temperature 69° C. 62° C.CTA Nag(OH)C5N—PEG₁₂—CTA; I = AIBN *Monomer incorporation for block isestimated based on historical incorporation levels

-   OO. P110: NAG-PEG12-[PEGMA(300, 77.7%)-EHMA(22.3%)]4.37    KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]*6 KDa

TABLE 48 P# Block 1 Block 2 [M/CTA/I] [16.5/1/0.05] [30:59:30/1/0.1][concentration] 1.3M 3M Time 3 h 6 h 30 m Temperature 68° C. 62° C. CTANag(OH)C5N—PEG₁₂—CTA; I = AIBN *Monomer incorporation for block isestimated based on historical incorporation levels

-   PP. P111: NAG-PEG12-[PEGMA(300, 77%)-F1-BMA(23%)]5.80    KDa-b-[DMAEMA(27.3%)-BMA(60.9%)-PAA(11.9%)]*5.74 KDa

TABLE 49 P# Block 1 Block 2 [M/CTA/I] [20:4.3/1/0.05] [30:59:30/1/0.1][concentration] 1.5M 2.3M Time 3 h 6 h 20 m Temperature 68° C. 61° C.CTA Nag(OH)C5N—PEG₁₂—CTA; I = AIBN *Monomer incorporation for block isestimated based on historical incorporation levels

-   QQ. P112: NAG-PEG12-[PEGMA(300, 77%)-F1-BMA(23%)]5.80    KDa-b[DMAEMA(27.3%)-RMA(60.9%)-PAA(11.9%)]*6.10 KDa

TABLE 50 P# Block 1 Block 2 [M/CTA/I] [20:4.3/1/0.05] [30:59:30/1/0.1][concentration] 1.5M 2.3M Time 3 h 7 h 20 m Temperature 68° C. 61° C.CTA Nag(OH)C5N—PEG₁₂—CTA; I = AIBN *Monomer incorporation for block isestimated based on historical incorporation levels

-   RR. P113: NAG-PEG12-[PEGMA(300, 84.9%)-Chol-MA(15.1%)]*3.5    KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]*4.67 KDa

TABLE 51 P# Block 1 Block 2 [M/CTA/I] [12.8:2.2/1/0.05] [26:51:26/1/0.1][concentration] 0.97M 2.3M Time 2 h 15 m 5 h Temperature 67° C. 63° C.CTA Nag(OH)C5N—PEG₁₂—CTA; I = AIBN *Monomer incorporation for block isestimated based on historical incorporation levels

-   SS. P114: NAG-PEG12-[PEGMA(300, 67%)-HMA(33%)]*5.7    KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]*6.15 KDa

TABLE 52 P# Block 1 Block 2 [M/CTA/I] [20:7.5/1/0.05] [30:59:30/1/0.1][concentration] 1.55M 2.89M Time 4 h 5 h 45 m Temperature 68° C. 62° C.CTA Nag(OH)C5N—PEG₁₂—CTA; I = AIBN *Monomer incorporation for block isestimated based on historical incorporation levels

-   TT. P115: NAG-PEG12-[PEGMA(300, 67%)-HMA(33%)]*5.7    KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]*6 KDa

TABLE 53 P# Block 1 Block 2 [M/CTA/I] [20:7.5/1/0.05] [30:59:30/1/0.1][concentration] 1.55M 2.89M Time 4 h 7 h Temperature 68° C. 62° C. CTANag(OH)C5N—PEG₁₂—CTA; I = AIBN *Monomer incorporation for block isestimated based on historical incorporation levels

-   UU. P116: NAG-PEG12-[PEGMA(300, 73%)-F1-BMA(27%)]*⁺6.3    KDa-b-[DMAEMA(27.3%)-BMA(60.9%)-PAA(11.9%)]*⁺5.9 KDa

TABLE 54 P# Block 1 Block 2 [M/CTA/I] [20:6.5/1/0.05] [30:59:30/1/0.1][concentration] 1.5M 2.3M Time 3 h 7 h Temperature 68° C. 61° C. CTANag(OH)C5N—PEG₁₂—CTA; I = AIBN *Monomer incorporation for block isestimated based on historical incorporation levels +Molecular weight ofblock is estimated based on trace overlays with polymers of knownmolecular weight

-   VV. P117:

NAG-PEG12-[PEGMA(300, 72%)-PF-BMA(28%)]*⁺3.7KDa-b-[DMAEMA(27.3%)-BMA(60.9%)-PAA(11.9%)]*5.0 KDa

TABLE 55 P# Block 1 Block 2 [M/CTA/I] [12.8:3.5/1/0.05] [26:51:26/1/0.1][concentration] 1.5M 2.3M Time 1 h 45 min 5 h 20 min Temperature 68° C.61° C. CTA Nag(OH)C5N—PEG₁₂—CTA; I = AIBN *Monomer incorporation forblock is estimated based on historical incorporation levels +Molecularweight of block is estimated based on trace overlays with polymers ofknown molecular weight

-   WW. P118: NAG-PEG12-[PEGMA(300, 70%)-HMA(30%)]*5.2    KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]*5.7 KDa

TABLE 56 P# Block 1 Block 2 [M/CTA/I] [20:7/1/0.05] [30.7:60:30.7/1/0.1][concentration] 1.5M 2.3M Time 3 h 15 min 5 h 45 min Temperature 69° C.61° C. CTA Nag(OH)C5N—PEG₁₂—CTA; I = AIBN *Monomer incorporation forblock is estimated based on historical incorporation levels

-   XX. P119: NAG-PEG12-[PEGMA(300, 70%)-HMA(30%)]*5.2    KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]*5 KDa

TABLE 57 P# Block 1 Block 2 [M/CTA/I] [20:7/1/0.05] [26:52:26/1/0.1][concentration] 1.5M 2.3M Time 3 h 15 min 5 h 25 min Temperature 69° C.61° C. CTA Nag(OH)C5N—PEG₁₂—CTA; I = AIBN *Monomer incorporation forblock is estimated based on historical incorporation levels

-   YY. P120: NAG-PEG12-[PEGMA(300, 75%)-CyHexMA(25%)]*4    KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]*5.2 KDa

TABLE 58 P# Block 1 Block 2 [M/CTA/I] [15.5:4.5/1/0.05][30.7:60:30.7/1/0.1] [concentration] 1.3M 2.3M Time 3 h 5 h 40 minTemperature 69° C. 61° C. CTA Nag(OH)C5N—PEG₁₂—CTA; I = AIBN *Monomerincorporation for block is estimated based on historical incorporationlevels

-   ZZ. P121: NAG-PEG12-[PEGMA(300, 75%)-Me-CyHexMA(25%)]*4.3    KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]*5.1 KDa

TABLE 59 P# Block 1 Block 2 [M/CTA/I] [16:4/1/0.05] [30.7:60:30.7/1/0.1][concentration] 1.3M 2.3M Time 3 h 5 h 35 min Temperature 69° C. 61° C.CTA Nag(OH)C5N—PEG₁₂—CTA; I = AIBN *Monomer incorporation for block isestimated based on historical incorporation levels

-   AAA. P122: NAG-PEG12-[PEGMA(300, 73%)-F1-BMA(27%)]*⁺6.3    KDa-b-[DMAEMA(27.3%)-BMA(60.9%)-PAA(11.9%)]*⁺6.9 KDa

TABLE 60 P# Block 1 Block 2 [M/CTA/I] [20:6.5/1/0.05] [30:59:30/1/0.1][concentration] 1.5M 2.6M Time 3 h 9 h Temperature 68° C. 61° C. CTANag(OH)C5N—PEG₁₂—CTA; I = AIBN *Monomer incorporation for block isestimated based on historical incorporation levels +Molecular weight ofblock is estimated based on trace overlays with polymers of knownmolecular weight

-   BBB. P123: NAG-PEG12-[PEGMA(300, 79%)-Bu1-O-MA(21%)]*4.88    KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]*4.6 KDa

TABLE 61 P# Block 1 Block 2 [M/CTA/I] [16:4/1/0.05] [30.7:60:30.7/1/0.1][concentration] 1.3 M 2.3 M Time 3 h 30 m 5 h 20 m Temperature 69° C.61° C. CTA Nag(OH)C5N—PEG12—CTA; I = AIBN *Monomer incorporation forblock is estimated based on historical incorporation levels

-   CCC. P124: NAG-PEG12-[PEGMA(300, 74%)-HMA(26%)]*4.15    KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]*5 KDa

TABLE 62 P# Block 1 Block 2 [M/CTA/I] [15.5:4.5/1/0.05] [30:59:30/1/0.1][concentration] 1.35 M 2.3 M Time 3 h 15 m 5 h 30 m Temperature 69° C.61° C. CTA Nag(OH)C5N—PEG₁₂—CTA; I = AIBN *Monomer incorporation forblock is estimated based on historical incorporation levels

-   DDD. P125: NAG-PEG12-[PEGMA(300, 74%)-HMA(26%)]*4.15    KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]*5 KDa

TABLE 63 P# Block 1 Block 2 [M/CTA/I] [15.5:4.5/1/0.05] [30:59:30/1/0.1][concentration] 1.35 M 2.3 M Time 3 h 15 m 5 h 30 m Temperature 69° C.61° C. CTA Nag(OH)C5N—PEG₁₂—CTA; I = AIBN *Monomer incorporation forblock is estimated based on historical incorporation levels

-   EEE. P103: NAG-PEG12-[PEGMA(300, 70.3%)-R-BMA(29.7%)]3.6    KDa-b-[DMAEMA(32.2%)-BMA(57.6%)-PAA(10.9%)]5 KDa

TABLE 64 P# Block 1 Block 2 [M/CTA/I] [12.8:3.5/1/0.05] [26:52:26/1/0.1][concentration] 1.2 M 2.3 M Time 1 h 42 m 5 h 30 m Temperature 68° C.61° C. CTA Nag(OH)C5N—PEG₁₂—CTA; I = AIBN

-   FFF. P104: NAG-PEG12-[PEGMA(300, 68%)-F1-BMA(32%)]*3.7    KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]*5.3 KDa

TABLE 65 P# Block 1 Block 2 [M/CTA/I] [12.8:3.5/1/0.05] [26:51:26/1/0.1][concentration] 1.2 M 2.3 M Time 1 h 40 m 5 h 30 m Temperature 67° C.61° C. CTA Nag(OH)C5N—PEG₁₂—CTA; I = AIBN *Monomer incorporation forblock is estimated based on historical incorporation levels

-   GGG. P105: NAG-PEG12-[PEGMA(300, 73%)-F1-BMA(27%)]*⁺4.3    KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]*⁺5.3 KDa

TABLE 66 P# Block 1 Block 2 [M/CTA/I] [12.8:3.5/1/0.05] [26:51:26/1/0.1][concentration] 1.2 M 2.3 M Time 1 h 40 m 5 h 30 m Temperature 67° C.61° C. CTA Nag(OH)C5N—PEG₁₂—CTA; I = AIBN *Monomer incorporation forblock is estimated based on historical incorporation levels +Molecularweight of block is estimated based on trace overlays with polymers ofknown molecular weight?

-   HHH. P106: NAG-PEG12-[PEGMA(300, 73%)-F1-BMA(27%)]*⁺4.3    KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]*⁺5.3 KDa

TABLE 67 P# Block 1 Block 2 [M/CTA/I] [12.8:3.5/1/0.05] [26:51:26/1/0.1][concentration] 1.2 M 2.3 M Time 1 h 40 m 5 h 30 m Temperature 67° C.61° C. CTA Nag(OH)C5N—PEG₁₂—CTA; I = AIBN *Monomer incorporation forblock is estimated based on historical incorporation levels +Molecularweight of block is estimated based on trace overlays with polymers ofknown molecular weight?

Example 18 In Vivo Expression of mRNA with Lipid-mRNA Formulations andCo-Injection or Sequential Injection of Additional Polymers

Additional polymers were tested with sequential or co-injection withmRNA/LNP using the same methods as described in Example 2.

Table 68 displays luminescence values in the liver for animals treatedwith DOTAP:CHEMS:CHOL:DMPE-PEG2 k+Fluc mRNA nanoparticles withsequential injection of polymer P1435, P1299, or P67 at 1 minutefollowing the first injection. Data was acquired at 6 hours post dose.mRNA/LNP+polymer P67 showed 5-fold and 8-fold improvement in luminescentsignal compared to polymers P1435 or P1299, respectively.

TABLE 68 Timing mRNA Total Flux Lipid-mRNA Fluc Between Dose(photons/sec) Nanoparticle Polymer mRNA Injections (mg/kg) Geomean STDEVBuffer None None NA 0 1.83E+05 NA DOTAP:CHEMS: P1435 Fluc 3 1 min 11.23E+09 1.15E+09 CHOL:DMPE- 75 mg/kg mRNA PEG2K P1299 Fluc 3 1 7.80E+092.19E+09 (50:32:16:2) 75 mg/kg mRNA N:P 7 26 mg/kg P67 Fluc 3 1 6.23E+097.28E+09 75 mg/kg mRNA

Table 69 displays luminescence values in the liver for animals treatedwith DOTAP:CHEMS:CHOL:DMPE-PEG2 k+Fluc mRNA nanoparticles withsequential injection of polymer P67 at 1 minute following the firstinjection. Data was acquired at 6 hours post dose. In this study, twodifferent Fluc mRNAs were tested. Fluc 2 mRNA showed a 21-foldimprovement in luminescence signal compared to Fluc 1 mRNA.Modifications of Fluc 1 and Fluc 2 mRNAs are described above in Example2.

TABLE 69 Timing mRNA Total Flux Lipid-mRNA Fluc Between Dose(photons/sec) Nanoparticle Polymer mRNA Injections (mg/kg) Geomean STDEVBuffer None None NA 0 2.81E+05 NA DOTAP:CHEMS: P67 Fluc 1 1 min 14.20E+08 1.82E+08 CHOL:DMPE- 75 mg/kg mRNA PEG2K (50:32:16:2) Fluc 2 18.85E+09 3.90E+09 N:P 7 26 mg/kg mRNA

Table 70 displays luminescence values in the liver for animals treatedwith DOTAP:CHEMS:CHOL:DMPE-PEG2 k+Fluc mRNA nanoparticles withco-injection of NAG targeted polymer P67 compared to non-targetedpolymer P91. mRNA/LNP+polymer were mixed at a 1:1 ratio and injectedimmediately into mice. Data was acquired at 6 hours post dose.mRNA/LNP+NAG targeted polymer P67 showed 130-fold improvement inluminescent signal compared to non-targeted polymer P91.

TABLE 70 Timing mRNA Total Flux Lipid-mRNA Fluc Between Dose(photons/sec) Nanoparticle Polymer mRNA Injections (mg/kg) Geomean STDEVBuffer None None NA 0 2.03E+05 DOTAP:CHEMS: P67 Fluc 2 co-injection 14.03E+09 7.04E+09 CHOL:DMPE- 75 mg/kg mRNA PEG2K (50:32:16:2) P91 Fluc 21 3.07E+07 9.45E+06 N:P 7 26 mg/kg 75 mg/kg mRNA

Example 19 DOTAP:CHEMS:Cholesterol:DSPE-PEG_(2 k) andDOTAP:CHEMS:Cholesterol:DSPE-PEG_(2 k)-NAG mRNA Nanoparticle Formulationwith Sequential pr Co-injection of a Polymer: FormulationCharacteristics

DOTAP (Corden Pharma, Boulder, Colo., USA; catalog number LP-R4-117) wassolubilized at 50 mg/mL in 200 proof ethanol at room temperature for 15minutes. The DSPE-PEG_(2K) (Corden Pharma, Boulder, Colo., USA; catalognumber LP-R4-039) or the DSPE-PEG-NAG (PhaseRx Inc.) was solubilized at50 mg/mL in 200 proof ethanol at room temperature for 15 minutes. Thecholesteryl hemisuccinate (CHEMS) (Avanti Polar Lipid Alabaster, Ala.,USA; catalog number 850524P) and the Cholesterol (CHOL) (Corden Pharma,Boulder, Colo., USA; catalog number CH-0355) were individuallysolubilized at 25 mg/mL in 200 proof at 75° C. for 5 minutes. Typically,for a 2 mL preparation of DOTAP:CHEMS:CHOL:DSPE-PEG_(2K) (50:32:8:10 mol%) LNP at a N:P ratio of 7, a lipid ethanolic mixture containing 178 μLof DOTAP at 50 mg/mL in 200 proof ethanol, 158 μL of CHEMS at 25 mg/mLin 200 proof ethanol, 31 μL of CHOL at 25 mg/mL in 200 proof ethanol,143 μL of DSPE-PEG_(2K) at 50 mg/mL in 200 proof ethanol and 156 μL of200 proof ethanol was prepared for a final volume of 0.666 mL and atotal lipid concentration of 31 mg/mL. For 2 mL preparation ofDOTAP:CHEMS:CHOL:DSPE-PEG_(2K)-NAG (50:32:8:10 mol %) LNP at a N:P ratioof 7, the lipid ethanolic mixture containing 178 μL of DOTAP at 50 mg/mLin 200 proof ethanol, 158 μL of CHEMS at 25 mg/mL in 200 proof ethanol,31 μL of CHOL at 25 mg/mL in 200 proof ethanol, 160 μL ofDSPE-PEG_(2K)-NAG at 50 mg/mL in 200 proof ethanol and 161 μL of 200proof ethanol was prepared for a final volume of 0.666 mL and a totallipid concentration of 32.5 mg/mL.

The lipid nanoparticle (LNP) formulations were prepared at N:P (nitrogento phosphate) ratios from 1.75 to 14 based on the DOTAP concentration.The DOTAP:CHEMS ratio was fixed at 1.6 at 50:32 mol % respectively atthe various N:P ratios. DSPE-PEG_(2K) or DSPE-PEG_(2K)-NAG were variedfrom 1 to 15 mol %. The CHOL mol % was adjusted to result in 100 mol %final lipid concentration.

The Fluc (firefly luciferase) mRNA stock solution at 1 mg/mL in 10 mMTris-HC1 (pH 7.5) was diluted to 0.45 mg/mL in 300 mM sucrose 20 mMphosphate, pH 7.4 buffer (SUP buffer). The mRNA/LNPs were assembled atN:P ratios from 1.75 to 14 by mixing the ethanolic lipid solution with0.45 mg/mL mRNA in SUP buffer at a 1:2 ratio (lipid ethanolicmixture:mRNA in SUP buffer) using the microfluidic device from PrecisionNanoSystems Inc (Vancouver BC, Canada) at a 12 mL/minute flow rate. ThemRNA/LNPs in 33% ethanol were then incubated at room temperature for 60minutes prior to dialysis for 18 hours against 100 volumes (200 mL) ofSUP buffer.

The polymers used for sequential injection or co-injection weresolubilized at 20 mg/mL in SUP buffer with agitation at 400 rpm for 1hour and then stored overnight at 4° C. The polymers were diluted to5-10 mg/mL in SUP buffer prior to injection.

If mRNA/LNP and polymer were co-injected, a 2× solution of each wasprepared. Just prior to dosing, the solutions were mixed and injectedimmediately.

The formulation particle size was measured by adding 10 μL offormulation to 90 μL of SUP buffer into a disposable micro-cuvette andanalyzed using the Malvern Instrument ZETASIZER NANO-ZS. The LNPs showeda particle size of 85 nm (Z-average). The formulation zeta-potential atpH 7.4 was measured by adding 10 μL of formulation to 740 μL of SUPbuffer into a disposable 1 mL cuvette. The formulation zeta-potential atpH 4 was measured by adding 10 μL of formulation to 740 μL of sucroseacetate buffer (pH 4) into a disposable 1 mL cuvette. The zeta dip cellwas inserted into the 1 mL cuvette and the formulation was analyzedusing the ZETASIZER NANO-ZS. Typically, the DOTAP LNPs had a zetapotential of +1.6 mV at pH 7 and +10 mV at pH 4.0. The ability of theLNP to compact the mRNA was measured in a 96 well plate using a SYBRGold dye accessibility assay. Typically, 50 μL of the lipid formulationat 0.01 mg/mL mRNA was added to 150 μL of diluted SYBR Gold stocksolution (1 μL of Stock SYBR Gold in 3 mL of SUP buffer) and incubatedfor 15 minutes at room temperature with agitation (100 RPM). Thefluorescence was read at an excitation wavelength of 495 nm and emissionwavelength of 538 nm. The percent dye accessibility was calculated bydividing the fluorescence intensity of the formulated mRNA by thefluorescence intensity of the free mRNA×100. The DOTAP LNPs showed 8%dye accessibility when prepared in SUP buffer. Table 71 below showscharacterization of exemplary LNP formulations.

TABLE 71 LNPs Characteristics RP600-1 RP495-13 Sample #DOTAP:CHEMS:CHOL:DSPE- DOTAP:CHEMS:CHOL:DSPE- Lipid PEG2K (50:32:8:10)PEG2K-NAG (50:32:8:10) N/P 7 7 Lipid Concentration (mg/mL)) 9.5 10.8Visual Appearance Opalescent (+) Opalescent (+) % Dye access SUP pH 7.48% 8% Z-Ave (nm) 85 98 PDI 0.242 0.312 Number (m,) 38 37 PDI 0.242 0.312Pk 1 Mean Int (nm) 105 232 Pk 2 Mean Int (nm) 4536 63 Pk 1 Area Int (%)97 57 Pk 2 Area Int (%) 3 43 ZP pH 7.4 (mV) 1.6 −5 ZP pH 4 (mV) 10 8Sizing data quality Good Good

Example 20 In Vivo Expression of mRNA withDOTAP:CHEMS:Cholesterol:DSPE-PEG_(2 k) and DOTAP:CHEMS:Cholesterol:DSPE-PEG_(2 k)-NAG mRNA Formulations and Co-Injection or SequentialInjection of Polymer

Additional LNPs described in Example 19 were tested with variouspolymers using sequential or co-injection and the same methods asdescribed in Example 2.

Table 72 displays luminescence values in the liver for animals treatedwith DOTAP:CHEMS:CHOL:DMPE-PEG_(2 k), DOTAP:CHEMS:CHOL:DSPE-PEG2 k, orDOTAP:CHEMS:CHOL:DSPE-PEG2 k-NAG+Fluc mRNA nanoparticles withco-injection of polymer P67. mRNA/LNP+polymer were mixed at a 1:1 ratioand injected immediately into mice. Data was acquired at 6, 24, and 48hours post dose. Both DOTAP:CHEMS:CHOL:DSPE-PEG2 k-NAG andDOTAP:CHEMS:CHOL:DSPE-PEG2 k LNP showed longer duration of expressionwith 8.7-fold and 2.6-fold greater luminescent signal in area under thecurve (AUC) values compared to DOTAP:CHEMS:CHOL:DMPE-PEG2 k LNPrespectively.

TABLE 72 Fold Change Fluc 2 to mRNA Imaging Total Flux DMPE- Lipid-mRNADose Time (photons/sec) PEG2K Nanoparticle Polymer (mg/kg) Point GeomeanSTDEV AUC LNP Buffer None 0  6 h 3.34E+05 DOTAP:CHEMS: P67 1  6 h3.61E+09 7.87E+08 CHOL:DMPE- 75 mg/kg 24 h 3.17E+08 1.23E+08 4.02E+101.0 PEG2K 48 h 1.11E+07 3.07E+06 (50:32:16:2) N:P 7 26 mg/kgDOTAP:CHEMS: P67 1  6 h 7.23E+09 3.87E+09 CHOL:DSPE- 75 mg/kg 24 h1.16E+09 1.08E+09 1.05E+11 2.6 PEG2K 48 h 2.15E+08 9.83E+07 (50:32:8:10)N:P 7 35 mg/kg DOTAP:CHEMS: P67 1  6 h 1.51E+10 2.15E+10 CHOL:DSPE- 75mg/kg 24 h 4.14E+09 6.19E+09 3.49E+11 8.7 PEG2K-NAG 48 h 1.19E+082.03E+08 (50:32:8:10) N:P 7 36 mg/kg

Table 73 displays luminescence values in the liver for animals treatedwith DOTAP:CHEMS:CHOL:DSPE-PEG2 k or DOTAP:CHEMS:CHOL:DSPE-PEG2k-NAG+Fluc mRNA nanoparticles with co-injection of polymer P71 or P81.mRNA/LNP+polymer were mixed at a 1:1 ratio and injected immediately intomice. Data was acquired at 6, 24, 48, 72, and 96 hours post dose.DOTAP:CHEMS:CHOL:DSPE-PEG2 k and DOTAP:CHEMS:CHOL:DSPE-PEG2 k-NAGLNPs+P81 showed 7-fold and 2.8-fold greater luminescent signal in areaunder the curve (AUC) values compared to either LNP+P71 respectively.

TABLE 73 Fluc 2 mRNA Imaging Total Flux Lipid-mRNA Dose Time(photons/sec) Nanoparticle Polymer (mg/kg) Point Geomean STDEV AUCBuffer None 0  6 h 1.35E+05 DOTAP:CHEMS:CHOL: P71 1  6 h 1.19E+109.52E+09 2.88E+11 DSPE-PEG2K 50 mg/kg 24 h 5.45E+09 3.96E+09(50:32:8:10) 48 h 9.81E+07 8.21E+07 N:P 7 35 mg/kg 72 h 6.66E+064.99E+06 96 h 1.86E+06 1.17E+06 DOTAP:CHEMS:CHOL: P81 1  6 h 9.40E+105.40E+10 2.01E+12 DSPE-PEG2K 45 mg/kg 24 h 3.26E+10 3.23E+10(50:32:8:10) 48 h 6.91E+08 7.29E+08 N:P 7 35 mg/kg 72 h 4.28E+074.38E+07 96 h 1.05E+07 9.19E+06 DOTAP:CHEMS:CHOL: P71 0.5  6 h 2.17E+101.88E+10 3.95E+11 DSPE-PEG2K-NAG 50 mg/kg 24 h 5.84E+09 4.45E+09(50:32:8:10) 48 h 8.88E+07 9.94E+07 N:P 7 36 mg/kg 72 h 7.06E+066.69E+06 96 h 2.10E+06 2.09E+06 DOTAP:CHEMS:CHOL: P81 0.5  6 h 6.06E+101.16E+10 7.95E+11 DSPE-PEG2K-NAG 35 mg/kg 24 h 9.87E+09 6.23E+09(50:32:8:10) 48 h 1.60E+08 1.33E+08 72 h 1.21E+07 7.43E+06 N:P 7 36mg/kg 96 h 3.91E+06 2.24E+06

Table 74 displays luminescence values in the liver for animals treatedwith DOTAP:CHEMS:CHOL:DSPE-PEG2 k+Fluc 2 mRNA nanoparticles withco-injection of polymer P71 or P92. mRNA/LNP+polymer were mixed at a 1:1ratio and injected immediately into mice. Data was acquired at 6 hourspost dose. Fluc mRNA/DOTAP:CHEMS:CHOL:DSPE-PEG2 k LNP+P71 showed 4 to13-fold greater luminescent signal compared to P92.

TABLE 74 Total Flux Fluc mRNA Polymer (photons/sec) Lipid-mRNANanoparticle Dose (mg/kg) Polymer Dose (mg/kg) Geomean STDEVDOTAP:CHEMS:CHOL: 1 P71 50 5.97E+09 8.09E+09 DSPE-PEG2K 1 P92 254.71E+08 7.35E+08 (50:32:8:10) 1 P92 50 1.37E+09 1.62E+09 N:P 7 35 mg/kg

Table 75 displays luminescence values in the liver for animals treatedwith DOTAP:CHEMS:CHOL:DSPE-PEG2 k+Fluc 2 mRNA nanoparticles withco-injection of polymer P71, P93, P79, or P80. mRNA/LNP+polymer weremixed at a 1:1 ratio and injected immediately into mice. Data wasacquired at 6 hours post dose. Fluc mRNA DOTAP:CHEMS:CHOL:DSPE-PEG2 kLNP+P80 or P79 showed 5-fold or 2-fold greater luminescent signalcompared to P71 respectively. P93 showed similar activity to P71.

TABLE 75 Total Flux Fluc mRNA Polymer (photons/sec) Lipid-mRNANanoparticle Dose (mg/kg) Polymer Dose (mg/kg) Geomean STDEVDOTAP:CHEMS:CHOL: 0.1 P71 50 4.74E+08 3.69E+08 DSPE-PEG2K 0.1 P93 252.04E+08 2.05E+08 (50:32:8:10) 0.1 P93 50 3.41E+08 3.65E+08 N:P 7 3.5mg/kg 0.1 P79 25 1.12E+09 4.36E+08 0.1 P80 25 2.37E+09 1.93E+09

Table 76 displays luminescence values in the liver for animals treatedwith DOTAP:CHEMS:CHOL:DSPE-PEG2 k+Fluc 2 mRNA nanoparticles withco-injection of polymer P71, P82, P94, or P86. mRNA/LNP+polymer weremixed at a 1:1 ratio and injected immediately into mice. Data wasacquired at 6 hours post dose. Fluc mRNA/DOTAP:CHEMS:CHOL:DSPE-PEG2 kLNP+P82, P94, or P86 showed 6 to 13-fold greater luminescent signalcompared to P71.

TABLE 76 Total Flux Fluc mRNA Polymer (photons/sec) Lipid-mRNANanoparticle Dose (mg/kg) Polymer Dose (mg/kg) Geomean STDEVDOTAP:CHEMS:CHOL: 0.5 P71 50 1.61E+09 1.75E+09 DSPE-PEG2K 1 P82 301.62E+10 6.45E+09 (50:32:8:10) 1 P82 40 1.53E+10 1.80E+10 N:P 7 35 mg/kg1 P94 40 2.01E+10 7.91E+09 1 P86 40 1.00E+10 1.21E+10

Table 77 displays luminescence values in the liver for animals treatedwith DOTAP:CHEMS:CHOL:DSPE-PEG2 k+Fluc 2 mRNA nanoparticles withco-injection of polymer P71, P87, P88, or P89. mRNA/LNP+polymer weremixed at a 1:1 ratio and injected immediately into mice. Data wasacquired at 6 hours post dose. Fluc mRNA/DOTAP:CHEMS:CHOL:DSPE-PEG2 kLNP+P87, P88, or P89 showed 3 to 18-fold greater luminescent signalcompared to P71.

TABLE 77 Total Flux Fluc mRNA Polymer (photons/sec) Lipid-mRNANanoparticle Dose (mg/kg) Polymer Dose (mg/kg) Geomean STDEVDOTAP:CHEMS:CHOL: 0.1 P71 50 1.54E+08 1.23E+08 DSPE-PEG2K 0.1 P87 254.05E+08 7.71E+08 (50:32:8:10) 0.1 P87 35 2.85E+09 3.22E+09 N:P 7 3.5mg/kg 0.1 P88 25 1.26E+09 1.87E+09 0.1 P89 25 3.89E+08 2.19E+08 0.1 P8935 6.06E+08 6.54E+08 0.1 P89 50 1.11E+09 9.00E+08

Table 78 displays luminescence values in the liver for animals treatedwith DOTAP:CHEMS:CHOL:DSPE-PEG2 k+Fluc 2 mRNA nanoparticles withco-injection of polymer P95, P90, P96, or P87. mRNA/LNP+polymer weremixed at a 1:1 ratio and injected immediately into mice. Data wasacquired at 6 hours post dose. Fluc mRNA/DOTAP:CHEMS:CHOL:DSPE-PEG2 kLNP+P90, P96, or P87 showed similar luminescent signal as P95.

TABLE 78 Total Flux Fluc mRNA Polymer (photons/sec) Lipid-mRNANanoparticle Dose (mg/kg) Polymer Dose (mg/kg) Geomean STDEVDOTAP:CHEMS:CHOL: 1 P95 30 1.17E+10 1.34E+10 DSPE-PEG2K 1 P95 404.18E+10 2.54E+10 (50:32:8:10) 1 P96 35 2.09E+10 2.35E+10 N:P 7 35 mg/kg1 P90 30 1.59E+10 1.78E+10 1 P87 35 3.72E+10 1.39E+10

Table 79 displays luminescence values in the liver for animals treatedwith DOTAP:CHEMS:CHOL:DSPE-PEG2 k+FLuc 2 mRNA nanoparticles withco-injection of polymer P71, P77, or P78. mRNA/LNP+polymer were mixed ata 1:1 ratio and injected immediately into mice. Data was acquired at 6hours post dose. Fluc mRNA/DOTAP:CHEMS:CHOL:DSPE-PEG2 k LNP+P77 or P78showed 3 to 8-fold greater luminescent signal compared to P71.

TABLE 78 Total Flux Fluc mRNA Polymer (photons/sec) Lipid-mRNANanoparticle Dose (mg/kg) Polymer Dose (mg/kg) Geomean STDEVDOTAP:CHEMS:CHOL: 0.5 P71 50 1.10E+09 1.02E+09 DSPE-PEG2K 0.5 P77 251.90E+09 1.01E+09 (50:32:8:10) 0.5 P77 50 1.12E+09 2.37E+09 N:P 7 17mg/kg 0.5 P77 75 9.02E+09 1.00E+10 0.5 P78 25 3.46E+08 3.56E+08 0.5 P7850 3.78E+09 1.85E+09

Table 80 displays luminescence values in the liver for animals treatedwith DOTAP:CHEMS:CHOL:DSPE-PEG2 k+FLuc 2 mRNA nanoparticles withco-injection of polymer P96, P98, P99, or P100. mRNA/LNP+polymer weremixed at a 1:1 ratio and injected immediately into mice. Data wasacquired at 6 hours post dose. Fluc mRNA/DOTAP:CHEMS:CHOL:DSPE-PEG2 kLNP+P98, P99, or P100 showed 3 to 5-fold greater luminescent signalcompared to P96.

TABLE 80 Total Flux Fluc mRNA Polymer (photons/sec) Lipid-mRNANanoparticle Dose (mg/kg) Polymer Dose (mg/kg) Geomean STDEVDOTAP:CHEMS:CHOL: 0.1 P96 35 1.30E+09 1.17E+09 DSPE-PEG2K 0.1 P98 251.23E+09 2.46E+09 (50:32:8:10) 0.1 P98 35 4.62E+09 2.14E+09 N:P 7 3.5mg/kg 0.1 P99 25 5.80E+09 1.54E+09 0.1 P100 25 1.22E+09 2.18E+09 0.1P100 35 3.24E+09 5.98E+09

Table 81 displays luminescence values in the liver for animals treatedwith DOTAP:CHEMS:CHOL:DSPE-PEG2 k+FLuc 2 mRNA nanoparticles withco-injection of polymer P82, P90, P106, or P107. mRNA/LNP+polymer weremixed at a 1:1 ratio and injected immediately into mice. Data wasacquired at 6 hours post dose. Fluc mRNA/DOTAP:CHEMS:CHOL:DSPE-PEG2 kLNP+P90, P106, or P107 showed 3 to 10-fold greater luminescent signalcompared to P82.

TABLE 81 Total Flux Lipid-mRNA Fluc 2 mRNA Polymer (photons/sec)Nanoparticle Dose (mg/kg) Polymer Dose (mg/kg) Geomean STDEVDOTAP:CHEMS:CHOL: 0.5 P82 30 3.78E+09 9.23E+09 DSPE-PEG2K 0.5 P90 257.12E+09 3.69E+09 (50:32:8:10) 0.5 P90 35 2.74E+10 8.39E+09 N:P 7 17.5mg/kg 0.5 P106 25 1.85E+10 1.43E+10 0.5 P106 35 4.12E+10 1.26E+10 0.5P106 45 1.65E+10 3.47E+10 0.5 P107 25 7.93E+09 4.97E+09 0.5 P107 351.47E+10 9.46E+09 0.5 P107 45 1.35E+10 1.34E+10

Table 82 displays luminescence values in the liver for animals treatedwith DOTAP:CHEMS:CHOL:DSPE-PEG2 k+FLuc 2 mRNA nanoparticles withco-injection of polymer P97, P104, P108, or P109. mRNA/LNP+polymer weremixed at a 1:1 ratio and injected immediately into mice. Data wasacquired at 6 hours post dose. Fluc mRNA/DOTAP:CHEMS:CHOL:DSPE-PEG2 kLNP+P104, P108, or P109 showed up to 2-fold greater luminescent signalcompared to P97.

TABLE 82 Total Flux Lipid-mRNA Fluc 2 mRNA Polymer (photons/sec)Nanoparticle Dose (mg/kg) Polymer Dose (mg/kg) Geomean STDEVDOTAP:CHEMS:CHOL: 0.5 P97 30 1.08E+10 5.89E+09 DSPE-PEG2K 0.5 P104 254.49E+09 9.32E+08 (50:32:8:10) 0.5 P104 30 6.82E+09 2.69E+10 N:P 7 17.5mg/kg 0.5 P104 35 2.58E+10 3.59E+09 0.5 P108 25 1.37E+10 1.40E+10 0.5P108 35 1.36E+10 1.58E+10 0.5 P108 45 2.37E+10 2.28E+10 0.5 P109 258.33E+09 1.25E+10 0.5 P109 35 2.07E+10 2.31E+10

Table 83 displays luminescence values in the liver for animals treatedwith DOTAP:CHEMS:CHOL:DSPE-PEG2 k+FLuc 2 mRNA nanoparticles withco-injection of polymer P103, P90, P106, or P108. mRNA/LNP+polymer weremixed at a 1:1 ratio and injected immediately into mice. Data wasacquired at 6 hours post dose. Fluc mRNA/DOTAP:CHEMS:CHOL:DSPE-PEG2 kLNP+P90, P106, or P108 showed up to 2-fold greater luminescent signalcompared to P103.

TABLE 83 Total Flux Lipid-mRNA Fluc 2 mRNA Polymer (photons/sec)Nanoparticle Dose (mg/kg) Polymer Dose (mg/kg) Geomean STDEVDOTAP:CHEMS:CHOL: 0.5 P103 30 5.94E+10 3.36E+10 DSPE-PEG2K 0.5 P103 357.11E+10 4.71E+10 (50:32:8:10) 0.5 P90 30 1.52E+10 2.78E+10 N:P 7 17.5mg/kg 0.5 P90 35 7.65E+09 2.03E+10 0.5 P106 30 1.18E+11 2.23E+10 0.5P106 35 4.94E+10 4.68E+10 0.5 P108 30 9.45E+10 2.12E+10 0.5 P108 354.99E+10 5.03E+10

Table 84 displays luminescence values in the liver for animals treatedwith DOTAP:CHEMS:CHOL:DSPE-PEG2 k+FLuc 2 mRNA nanoparticles withco-injection of polymer P95, P111, or P112. mRNA/LNP +polymer were mixedat a 1:1 ratio and injected immediately into mice. Data was acquired at6 hours post dose. Fluc mRNA/DOTAP:CHEMS:CHOL:DSPE-PEG2 k LNP+P111 orP112 showed up to 4-fold greater luminescent signal compared to P95.

TABLE 84 Total Flux Lipid-mRNA Fluc 2 mRNA Polymer (photons/sec)Nanoparticle Dose (mg/kg) Polymer Dose (mg/kg) Geomean STDEVDOTAP:CHEMS:CHOL: 0.5 P95 30 6.19E+09 1.71E+10 DSPE-PEG2K 0.5 P111 254.12E+09 6.41E+09 (50:32:8:10) 0.5 P111 35 1.90E+10 3.63E+09 N:P 7 17.5mg/kg 0.5 P112 25 7.28E+09 1.15E+10 0.5 P112 35 1.98E+10 1.49E+10 0.5P112 45 2.66E+10 1.46E+10

Table 85 displays luminescence values in the liver for animals treatedwith DOTAP:CHEMS:CHOL:DSPE-PEG2 k+FLuc 2 mRNA nanoparticles withco-injection of polymer P103, P106, P114 or P115. mRNA/LNP+polymer weremixed at a 1:1 ratio and injected immediately into mice. Data wasacquired at 6 hours post dose. Fluc mRNA/DOTAP:CHEMS:CHOL:DSPE-PEG2 kLNP+P106, P114, or P115 showed up to 7-fold greater luminescent signalcompared to P103.

TABLE 85 Total Flux Lipid-mRNA Fluc 2 mRNA Polymer (photons/sec)Nanoparticle Dose (mg/kg) Polymer Dose (mg/kg) Geomean STDEVDOTAP:CHEMS:CHOL: 0.5 P103 30 3.54E+09 5.27E+09 DSPE-PEG2K 0.5 P106 206.96E+09 4.36E+09 (50:32:8:10) 0.5 P106 25 1.19E+10 1.10E+10 N:P 7 17.5mg/kg 0.5 P114 25 2.46E+10 1.16E+10 0.5 P115 25 8.28E+09 1.93E+10

Table 86 displays luminescence values in the liver for animals treatedwith DOTAP:CHEMS:CHOL:DSPE-PEG2 k+FLuc 2 mRNA nanoparticles withco-injection of polymer P103, P116 or P117. mRNA/LNP+polymer were mixedat a 1:1 ratio and injected immediately into mice. Data was acquired at6 hours post dose. Fluc mRNA/DOTAP:CHEMS:CHOL:DSPE-PEG2 k LNP+P116 orP117 showed lower luminescent signal compared to P103.

TABLE 86 Total Flux Lipid-mRNA Fluc 2 mRNA Polymer (photons/sec)Nanoparticle Dose (mg/kg) Polymer Dose (mg/kg) Geomean STDEVDOTAP:CHEMS:CHOL: 0.5 P103 30 2.72E+10 1.13E+10 DSPE-PEG2K 0.5 P116 255.31E+09 3.32E+09 (50:32:8:10) 0.5 P116 35 1.20E+10 9.23E+09 N:P 7 17.5mg/kg 0.5 P117 25 5.53E+08 5.10E+08 0.5 P117 35 1.35E+09 1.44E+09

Table 87 displays luminescence values in the liver for animals treatedwith DOTAP:CHEMS:CHOL:DSPE-PEG2 k+FLuc 2 mRNA nanoparticles withco-injection of polymer P105, P98 or P123. mRNA/LNP+polymer were mixedat a 1:1 ratio and injected immediately into mice. Data was acquired at6 hours post dose. Fluc mRNA/DOTAP:CHEMS:CHOL:DSPE-PEG2 k LNP+P98 orP123 showed similar luminescent signal compared to P105.

TABLE 87 Total Flux Lipid-mRNA Fluc 2 mRNA Polymer (photons/sec)Nanoparticle Dose (mg/kg) Polymer Dose (mg/kg) Geomean STDEVDOTAP:CHEMS:CHOL: 0.5 P105 30 2.11E+10 2.54E+10 DSPE-PEG2K 0.5 P98 201.85E+10 1.60E+10 (50:32:8:10) 0.5 P98 30 7.79E+09 1.93E+10 N:P 7 17.5mg/kg 0.5 P98 40 2.07E+10 3.92E+10 0.5 P123 20 3.21E+10 1.56E+10 0.5P123 30 2.77E+10 3.78E+10 0.5 P123 40 3.50E+10 3.16E+10

Table 88 displays luminescence values in the liver for animals treatedwith DOTAP:CHEMS:CHOL:DSPE-PEG2 k+FLuc 2 mRNA nanoparticles withco-injection of polymer P105, P106, P124 or P125. mRNA/LNP+polymer weremixed at a 1:1 ratio and injected immediately into mice. Data wasacquired at 6 hours post dose. Fluc mRNA/DOTAP:CHEMS:CHOL:DSPE-PEG2 kLNP+P106, P124 or P125 showed up to 2-fold greater luminescent signalcompared to P105.

TABLE 88 Total Flux Lipid-mRNA Fluc 2 mRNA Polymer (photons/sec)Nanoparticle Dose (mg/kg) Polymer Dose (mg/kg) Geomean STDEVDOTAP:CHEMS:CHOL: 0.5 P105 30 1.80E+10 1.00E+10 DSPE-PEG2K 0.5 P106 256.46E+09 1.85E+10 (50:32:8:10) 0.5 P124 15 1.34E+10 2.10E+09 N:P 7 17.5mg/kg 0.5 P124 25 4.16E+10 2.27E+10 0.5 P125 15 6.31E+09 9.98E+09 0.5P125 25 3.79E+10 2.02E+10

Table 89 displays luminescence values in the liver for animals treatedwith DOTAP:CHEMS:CHOL:DSPE-PEG2 k+FLuc 2 mRNA nanoparticles withco-injection of polymer P105, P118, P119 or P110. mRNA/LNP+polymer weremixed at a 1:1 ratio and injected immediately into mice. Data wasacquired at 6 hours post dose. Fluc mRNA/DOTAP:CHEMS:CHOL:DSPE-PEG2 kLNP+P118, P119 or P110 showed similar luminescent signal compared toP105.

TABLE 89 Total Flux Lipid-mRNA Fluc 2 mRNA Polymer (photons/sec)Nanoparticle Dose (mg/kg) Polymer Dose (mg/kg) Geomean STDEVDOTAP:CHEMS:CHOL: 0.5 P105 30 2.78E+10 1.32E+10 DSPE-PEG2K 0.5 P118 201.99E+10 6.98E+09 (50:32:8:10) 0.5 P118 30 2.86E+10 1.66E+10 N:P 7 17.5mg/kg 0.5 P119 20 2.36E+10 8.30E+09 0.5 P119 30 2.42E+10 1.07E+10 0.5P110 20 9.48E+09 1.10E+10 0.5 P110 30 2.22E+10 1.95E+10

Example 21 Therapeutic Efficacy of mRNA with Lipid-mRNA Formulations andCo-Injection of Polymer in Ornithine Transcarbamylase Deficient Mice

Hyperammonemia was induced in OTC-spf^(ash) mice that were treated withAAV2/8 vector/OTC shRNA to knockdown residual endogenous OTC expressionand activity (Cunningham et al., Mol Ther 19: 854-859, 2011). Plasmaammonia levels and orotic acid levels were elevated in these mice. Four(4) days after AAV dosing, 1 mg/kg of OTC mRNA formulated inDOTAP:CHEMS:CHOL:DMPE-PEG_(2 k) (50:32: 16:2) at N:P 7+co-injection of50 mg/kg P67 was dosed into these mice twice a week. Urine was collectedon day 6 (post single mRNA dose) and day 13 (post 3 repeat mRNA doses)following AAV treatment and analyzed for orotic acid levels that werenormalized to creatinine levels. Significant reduction of orotic acidwas seen following OTC mRNA treatment to near normal levels (see FIG.1A). Plasma was collected on day 13 (post 3 repeat mRNA doses) followingAAV treatment and analyzed for ammonia levels. Plasma ammonia in OTCmRNA treated mice were at normal levels similar to that in wild type anduntreated OTC-spf^(ash) mice compared to hyperammonemic buffer treatedmice (see FIG. 1B).

In a separate hyperammonemia study in OTC-spf^(ash) mice similar to thatabove, 1 mg/kg of OTC mRNA formulated in DOTAP:CHEMS:CHOL:DSPE-PEG_(2 k)(50:32:8:10) at N:P 7+co-injection of 35 mg/kg P82 was dosed into thesemice twice a week. Urine was collected on day 6 (post single mRNA dose)and day 13 (post 3 repeat mRNA doses) following AAV treatment andanalyzed for orotic acid levels that were normalized to creatininelevels. Significant reduction of orotic acid was seen following OTC mRNAtreatment to normal levels (see FIG. 2A). Plasma was collected on day 13(post 3 repeat mRNA doses) following AAV treatment and analyzed forammonia levels. Plasma ammonia in OTC mRNA treated mice were normalizedcompared to hyperammonemic buffer treated mice (see FIG. 2B).

Example 22 Preparation of DSPE-PEG_(2K)-NAG

To compound 3a (204 mg, 0.665 mmol, 2 eq) was added DMF (1.5 mL), andthe solution was stirred for 25 min. To the resulting solution was addedtrimethylamine (TEA, 185 μL, 1.33 mmol, 4 eq). After 5 min, DSPE-020GS(NOF, 1.00 g, 0.332 mmol, 1 eq) was added, followed by dichloromethane(DCM, 2.0 mL) and additional DMF (0.5 mL), and the resulting solutionwas stirred at ambient temperature. After 5 h, solvent was removed underreduced atmosphere, and the residue was taken up in DCM (100 mL). TheDCM layer was washed with saturated NaHCO₃ (30 mL). The resulting NaHCO₃layer was washed with DCM (50 mL). The combined organic layer was dried(Na₂SO₄), and concentrated under reduced atmosphere. The resultingresidue was purified by silica gel chromatography (2.5×7.5 cm,eluent=10% MeOH/DCM (300 mL), then 15% MeOH/DCM (400 mL), then 20%MeOH/DCM (600 mL), fraction size=18×150 mm test tubes, fractionscollected after 125 mL eluent eluded from column). Fractions 11-40 wereconcentrated under reduced atmosphere to afford DSPE-PEG_(2K)-NAG (439mg, 41% yield).

Example 23 In Vivo Expression of mRNA with Repeat Doses ofDOTAP:CHEMS:Cholesterol:DMPE-PEG_(2 k) andDOTAP:CHEMS:Cholesterol:DSPE-PEG_(2 k) mRNA Formulations andCo-Injection of Polymer

LNP formulations co-injected with polymer were tested for mRNAexpression using a repeat dosing regime. Co-injections ofmRNA/LNP+polymer and evaluation of in vivo luciferase expression wereperformed using the same methods as described in Example 2.

Table 90 displays luminescence values in the liver for animals treatedwith DOTAP:CHEMS:CHOL:DMPE-PEG2 k or DOTAP:CHEMS:CHOL:DSPE-PEG2 k+FlucmRNA nanoparticles with co-injection of polymer P103. mRNA/LNP+polymerwere mixed at a 1:1 ratio and injected immediately into mice. Data wasacquired at 6 hours post each dose. Formulations were repeat dosed by IVadministration once a week for 10 weeks in CD-1 mice. Repeatadministration with LNP containing an exchangeable PEG lipid,DMPE-PEG2K, resulted in similar luminescent signal at each weekly doseout to 10 weeks. In contrast, repeat administration with LNP containinga stable PEG lipid, DSPE-PEG2K, resulted in a significant 20-fold dropin activity starting at week 3. This decrease ranged from 4 to 30-folddrop in activity over the subsequent 8 repeat doses compared to week 1activity.

TABLE 90 Fold Fluc 2 Repeat Total Flux Reduction Lipid-mRNA mRNA Dosedosing (photons/sec) from Week 1 Nanoparticle (mg/kg) Polymer time pointGeomean STDEV Activity DOTAP:CHEMS: 0.5 30 mg/kg Week 1 3.07E+101.70E+10 1 CHOL:DMPE- P103 Week 2 3.02E+10 2.79E+10 1.0 PEG2K Week 34.35E+10 2.16E+10 0.7 (50:32:16:2) Week 4 1.95E+10 1.16E+10 1.6 N:P 7 13mg/kg Week 5 8.85E+09 5.78E+09 3.5 Week 6 3.05E+10 1.24E+10 1.0 Week 72.57E+10 1.21E+10 1.2 Week 8 1.55E+10 1.07E+10 2.0 Week 9 2.72E+101.49E+10 1.1 Week 10 1.41E+10 5.50E+09 2.2 DOTAP:CHEMS: 0.5 30 mg/kgWeek 1 1.45E+10 9.30E+09 1 CHOL:DSPE- P103 Week 2 8.83E+09 7.23E+09 1.6PEG2K Week 3 7.03E+08 1.15E+09 20.6 (50:32:8:10) Week 4 7.49E+087.48E+08 19.4 N:P 7 17 mg/kg Week 5 4.72E+08 3.54E+08 30.7 Week 63.39E+09 3.53E+09 4.3 Week 7 9.52E+08 9.55E+08 15.2 Week 8 1.39E+091.16E+09 10.4 Week 9 2.67E+09 2.32E+09 5.4 Week 10 1.75E+09 1.89E+09 8.3

Example 24 Treatment of Argininosuccinic Aciduria with mRNA Formulationsin a Hypomorphic Argininosuccinic Lyase (ASL) Mouse Model

Groups of 5-10 hypomorphic Asl^(Neo/Neo) mice are treated by intravenousroute of administration with mRNA encoding argininosuccinic lyase (ASL)formulated in a lipid nanoparticle, either co-injected or sequentiallyinjected with a membrane-destabilizing polymer that targets hepatocytesin the liver as described herein, thereby achieving expression andactivity of ASL. Mice are treated with vehicle control or Asl mRNA from0.1-5 mg kg. Either single or repeat dosing is performed with a varietyof dosing intervals (e.g., daily, every 2 days, biweekly, etc.). Bloodis collected to examine plasma amino acids (argininosuccinic acid,citrulline, arginine), plasma ammonia, and serum transaminases atdifferent time points ranging from 3 hours to 72 hours post final doseon the short term or up to 2 weeks post dose for duration of effect. Atthese time points, mice are sacrificed and livers collected and sampledto measure ASL enzyme activity, ASL protein expression by westernanalysis and immunofluorescence of liver tissue sections. Body weightsare measured if longer term studies are carried out to monitor growthand survival as the Asl^(Neo/Neo) mice have significant growthrestrictions and mice die within 6 to 14 weeks of life despite ongoingtreatment with triple therapy (sodium benzoate, sodium nitrite,L-arginine) (Erez et al., Nat Med 2011. 17: 1619-1626).

Results are compared to vehicle-treated mice as well as to wild-typelittermate mice that have normal levels of ASL protein expression,plasma amino acid levels, plasma ammonia, and serum transaminasesEfficacy is shown by detectable levels of ASL protein expressionevaluated by western and immunofluorescence that is above the leveldetected in vehicle treated mice. Plasma argininosuccine acid (ASA)levels are normally not detectable and plasma citrulline levels are ˜70μM in wild-type littermate mice whereas Asl^(Neo/Neo) mice have ˜100 μMASA and ˜200 μM citrulline levels. Plasma ammonia levels in wild-typelittermate mice are normal, ˜50 μM, whereas in Asl^(Neo/Neo) mice levelsare elevated in the range of 100-500 μM. Efficacy by plasma amino acidand plasma ammonia levels is a correction towards levels seen inwild-type littermate mice. In longer term studies efficacy is shown byincreased growth and survival in comparison to vehicle treated mice.

Example 25 Treatment of Citrullinemia Type 1 (CTLN1) with mRNAFormulations in a Argininosuccinic Synthetase (ASS1) Deficient MurineModel of CTLN1 (Fold/Fold)

Groups of 5-10 Ass1^(fold/fold) mice are treated by intravenous route ofadministration with mRNA encoding argininosuccinic synthetase (ASS1)formulated in a lipid nanoparticle, either co-injected or sequentiallyinjected with a membrane-destabilizing polymer that targets hepatocytesin the liver as described herein, thereby achieving expression andactivity of ASS1. Mice are treated with vehicle control or ass1 mRNAfrom 0.1-5 mg kg. Either single or repeat dosing is performed with avariety of dosing intervals (e.g., daily, every 2 days, biweekly, etc.).Blood is collected to examine plasma amino acids (citrulline, arginine)and plasma ammonia levels at different time points ranging from 3 hoursto 72 hours post final dose on the short term or up to 2 weeks post dosefor duration of effect. At these time points, mice are sacrificed andlivers collected and sampled to measure ASS1 enzyme activity, ASS1protein expression by western analysis and immunofluorescence of livertissue sections. Body weights are measured if longer term studies arecarried out to monitor growth and survival as the Ass1^(fold/fold) micehave growth restrictions and die within the first 3 weeks of life if nottreated with sodium benzoate and L-arginine (Perez et al., Am J Pathol.177:1958-1968, 2010).

Results are compared to vehicle-treated mice as well as to wild-typelittermate mice that have normal levels of ASS1 enzyme activity, plasmaamino acid and plasma ammonia levels. Efficacy is shown by correction ofASS1 enzyme activity that is above the level detected in vehicle treatedmice. Plasma citrulline levels are ˜70 μM in wild-type littermate micewhereas Ass1^(fold/fold) mice have significantly elevated citrullinelevels, ˜2000-3000 μM. Plasma ammonia levels in wild-type littermatemice are normal, ˜50 μM, whereas Ass1^(fold/fold) mice have elevationsin the range of 100-500 μM. Levels are high if mice are not treated withsodium benzoate and L-arginine. Efficacy by plasma amino acid and plasmaammonia levels is a correction towards levels seen in wild-typelittermate mice. In longer term studies efficacy is shown by increasedgrowth and survival in comparison to vehicle treated mice if mice aretaken off sodium benzoate and L-arginine treatment.

Example 26 DOTAPen:CHEMS:Cholesterol:DMPE-PEG_(2 k) mRNA NanoparticleFormulation with Sequential or Co-Injection of a Polymer: FormulationCharacteristics

(R)-N,N,N-trimethyl-4,5-bis(oleoyloxy)pentan-1-aminium chloride(DOTAPen) was synthesized as described in Example 34 and solubilized at50 mg/mL in 200 proof ethanol at room temperature for 15 minutes. TheDMPE-PEG_(2 k) (Corden Pharma, Boulder, Colo., USA; catalog numberLP-R4-123) was solubilized at 50 mg/mL in 200 proof ethanol at roomtemperature for 15 minutes. The cholesteryl hemisuccinate (CHEMS)(Avanti Polar Lipid Alabaster, Ala., USA; catalog number 850524P) andthe Cholesterol (CHOL) (Corden Pharma, Boulder, Colo., USA; catalognumber CH-0355) were individually solubilized at 25 mg/mL in 200 proofat 75° C. for 5 minutes. For a 2 mL preparation ofDOTAPen:CHEMS:CHOL:DMPE-PEG_(2 k) (50:32:16:2 mol %) LNP at a N:P ratioof 7, a lipid ethanolic mixture containing 92 μL of DOTAPen at 50 mg/mLin 200 proof ethanol, 79 μL of CHEMS at 25 mg/mL in 200 proof ethanol,32 μL of CHOL at 25 mg/mL in 200 proof ethanol, 14 μL of DMPE-PEG_(2K)at 50 mg/mL in 200 proof ethanol and 450 μL of 200 proof ethanol wasprepared for a final volume of 0.666 mL and a total lipid concentrationof 27 mg/mL.

The lipid nanoparticle (LNP) formulations were prepared at N:P (nitrogento phosphate) ratios from 7 to 10 based on the DOTAPen concentration.The DOTAPen:CHEMS ratio was fixed at 1.6 at 50:32 mol % respectively atthe various N:P ratios.

The Fluc (firefly luciferase) mRNA stock solution at 1 mg/mL in 10 mMTris-HCl (pH 7.5) was diluted to 0.225 mg/mL in 300 mM sucrose 20 mMphosphate, pH 7.4 buffer (SUP buffer). The mRNA/LNPs were assembled atN:P ratios from 7 or 10 by mixing the ethanolic lipid solution with0.225 mg/mL mRNA in SUP buffer at a 1:2 ratio (lipid ethanolicmixture:mRNA in SUP buffer) using the microfluidic device from PrecisionNanoSystems Inc (Vancouver BC, Canada) at a 12 mL/minute flow rate. ThemRNA/LNPs in 33% ethanol were then incubated at room temperature for 60minutes prior to dialysis for 18 hours against 100 volumes (200 mL) ofSUP buffer.

The polymers used for co-injection were solubilized at 20 mg/mL in SUPbuffer with agitation at 400 rpm for 1 hour and then stored overnight at4° C. The polymers were diluted to 6 mg/mL in SUP buffer prior toinjection.

Since the mRNA/LNP and polymer were co-injected, a 2× solution of eachwas prepared. Just prior to dosing, the solutions were mixed andinjected immediately.

The formulation particle size was measured by adding 10 μL offormulation to 90 μL of SUP buffer into a disposable micro-cuvette andanalyzed using the Malvern Instrument ZETASIZER NANO-ZS. The LNPs showeda particle size of 88 nm (Z-average). The formulation zeta-potential atpH 7.4 was measured by adding 10 μL of formulation to 740 μL of SUPbuffer into a disposable 1 mL cuvette. The formulation zeta-potential atpH 4 was measured by adding 10 μL of formulation to 740 μL of sucroseacetate buffer (pH 4) into a disposable 1 mL cuvette. The zeta dip cellwas inserted into the 1 mL cuvette and the formulation was analyzedusing the ZETASIZER NANO-ZS. The DOTAPen LNPs had a zeta potential of −4mV at pH 7 and +12 mV at pH 4. The ability of the LNP to compact themRNA was measured in a 96-well plate using a RiboGreen dye accessibilityassay. 100 μL of nanoparticles diluted 1:64 in SUP for the dyeaccessible mRNA measurement or 100 μL of nanoparticles diluted 1:200 inSUP for total mRNA measurement was loaded in a 96-well plate. To this,100 μL of a 1:200 dilution of RiboGreen reagent in SUP buffer for thedye accessible measurement or 100 μL of a 1:200 dilution of RiboGreenreagent in 0.2% Triton X-100/SUP buffer for the total mRNA measurement,was added to each well, respectively. The plate was incubated at roomtemperature in the dark for 5 minutes. The fluorescence was read using aMolecular Devices SpectraMax M5 with excitation at 480 nm and emissionat 520 nm. Finally, the percent dye accessibility was calculated bysubtracting the μM concentration of dye accessible mRNA from the μMconcentration of the total mRNA, dividing that value by the μMconcentration of total mRNA, and then multiplying by 100.

The DOTAPen LNPs showed 28% dye accessibility when prepared in SUPbuffer. Table 91 below shows characterization of exemplary LNPformulations.

TABLE 91 LNPs Characteristics Sample # RP659- 1 RP659-2 LipidDOTAP:CHEMS:CHOL:DMPE-PEG2K (50:32:16:2) N/P 10 7 Lipid concentration(mg/mL) 3.9 2.7 Visual Appearance Opalescent (+) Opalescent (+) % Dyeaccess SUP pH 7.4 50% 28% Z-Ave (nm) 83 88 PDI 0.051 0.070 Number (nm)64 63 Pk 1 Mean Int (nm) 88 95 Pk 2 Mean Int (nm) 0 0 Pk 1 Area Int (%)100 100 Pk 2 Area Int (%) 0 0 ZP pH 7.4 (mV) −6 −4 ZP pH 4 (mV) 10 12Sizing data quality GOOD GOOD

Example 27 In Vivo Expression of mRNA withDOTAPen:CHEMS:Cholesterol:DMPE-PEG_(2 k) mRNA Formulations andCo-Injection of Polymer

DOTAPen-containing LNPs described in Example 26 were tested with P105using co-injection and the same methods as described in Example 2.

Table 92 displays luminescence values in the liver for animals treatedwith DOTAPen:CHEMS:CHOL:DMPE-PEG2 k+Fluc mRNA nanoparticles at N:P ratioof 7 or 10 with co-injection of polymer P105. Activity ofDOTAPen-containing LNPs was compared to DOTAP:CHEMS:CHOL:DSPE-PEG2k+Fluc mRNA nanoparticles with co-injection of polymer. mRNA/LNP+polymerwere mixed at a 1:1 ratio and injected immediately into mice. Data wasacquired at 6 hours post dose. Fluc mRNA/DOTAPen:CHEMS:CHOL:DSPE-PEG2 kLNP+P105 showed 3 to 6-fold lower luminescent signal compared to FlucmRNA/DOTAP:CHEMS:CHOL:DSPE-PEG2 k LNP+P105.

TABLE 92 Polyme Total Flux Lipid-mRNA Fluc 2 mRNA rDose (photons/sec)Nanoparticle Dose (mg/kg) Polymer (mg/kg) Geomean STDEVDOTAP:CHEMS:CHOL: 0.5 P105 30  180E+10 1.00E+10 DSPE-PEG2K (50:32:8:10)N:P 7 17.5 mg/kg DOTAPen:CHEMS:CHO: 0.5 P105 30 5.16E+09 5.74E+09DMPE-PEG2K (50:32:16:2) N:P 10 17.5 mg/kg DOTAPen:CHEMS:CHOL: 0.5 P10530 2.93E+09 3.45E+09 DMPE-PEG2K (50:32:16:2) N:P 7 17.5 mg/kg

Example 28 In Vivo Expression of hEPO mRNA withDOTAP:CHEMS:Cholesterol:DSPE-PEG_(2K) mRNA Formulations and Co-Injectionof Polymer

Female CD-1 mice (7-10 weeks old) were used for evaluating hEPO mRNAformulated in DOTAP:CHEMS:Cholesterol:DSPE-PEG2 k LNP with co-injectionof P96 polymer. The formulation was dosed intravenously at 1 mg/kg ofmRNA, 35 mg/kg of lipid, and 35 mg/kg of polymer with 5 mice injectedper group. Mice injected with sucrose phosphate buffer were used ascontrol. For each injection mice were given a final dose volume ofapproximately 0.25 mL or 10 mL/kg based on individual body weights.

The in vivo expression of hEPO mRNA was evaluated in mouse serumcollected at 6 hours post dose. Blood was taken by retro-orbitalsampling and collected in serum separator tubes. Serum was isolated bycentrifugation and stored frozen at −20° C. until assayed. For ELISAassay the serum was diluted in PBS and then run using Human EpoQuantikine IVD ELISA (R&D Systems #DEP00) according to manufacturer'sprotocol. Briefly, 100 μL of diluted sample was mixed with 100 μL Epoassay diluent in an ELISA plate and shaken at 500 RPM for 1 hour. Thesolution was removed and replaced with 200 μL of antibody conjugate andshaken for an additional hour. The plate was then washed and developedusing a two component HRP/TMB system and read at 450 nm.

Table 93 displays hEPO serum levels for animals treated with buffer orwith hEPO mRNA/LNP with co-injection of polymer P96. No detectablelevels of hEPO were seen in buffer treated mice in comparison to2.98×10⁶ pg/mL of hEPO detected with 1 mg/kg of hEPO mRNA.

TABLE 93 hEPO serum levels Lipid-mRNA hEPO mRNA Polymer Dose (pg/mL)Nanoparticle Dose (mg/kg) Polymer (mg/kg) Average STDEV None 0 none none<2.5 DOTAP:CHEMS:CHOL: 1 P96 35 2.98E+06 1.24E+06 DSPE-PEG2K(50:32:8:10) N:P 7 35 mg/kg

Example 29 In Vivo Cytokine Analysis of HPLC-Purified and Non-PurifiedmRNAs with DOTAP:CHEMS:Cholesterol:DSPE-PEG_(2 k) mRNA Formulations andCo-Injection of Polymer

Female CD-1 mice (7-10 weeks old) were used for evaluating HPLC-purifiedor non-purified Fluc mRNA formulated inDOTAP:CHEMS:Cholesterol:DSPE-PEG2 k LNP with co-injection of P95polymer. The formulation was dosed intravenously at 1 mg/kg of mRNA, 35mg/kg of lipid, and 30 mg/kg of polymer with 5 mice injected per group.Mice injected with sucrose phosphate buffer were used as control. Foreach injection mice were given a final dose volume of approximately 0.25mL or 10 mL/kg based on individual body weights.

Mouse IP-10 cytokine levels were quantified using R&D systems MouseCXCL10/IP-10/CRG-2 Quantikine ELISA kit (#SMCX100). Blood was taken byretro-orbital sampling at 3 hours post dose and collected in serumseparator tubes. Serum was isolated by centrifugation and stored frozenat −20° C. until assayed. For ELISA the serum was diluted in PBS andthen run according to manufacturer's protocol. Briefly, 50 μL of dilutedsample was mixed with 50 μL assay diluent in an ELISA plate andincubated at RT for two hours. The solution was removed and replacedwith 200 μL of antibody conjugate and incubated at RT for two hours. Theplate was then washed and developed using a two component HRP/TMB systemand read at 450 nm.

Table 94 displays IP-10 serum levels for animals treated with buffer orwith HPLC-purified or non-purified Fluc mRNA formulated in LNP withco-injection of polymer P95. IP-10 cytokine levels at 3 hours post dosewere significantly reduced with HPLC-purified Fluc mRNA in comparison tohigh IP-10 cytokine levels induced with non-purified Fluc mRNA.

TABLE 94 Mouse IP-10 serum Lipid-mRNA Polymer Dose levels (pg/mL)Nanoparticle mRNA Polymer (mg/kg) Average STDEV None 0 none none <30DOTAP:CHEMS:CHOL: 0.5 mg/kg Non- P95 30 10293 4254 DSPE-PEG2K PurifiedFluc 2 (50:32:16:2) mRNA N:P 7 17 or 35 mg/kg 1 mg/kg Non- P95 30 148272824 Purified Fluc 2 mRNA 0.5 mg/kg HPLC- P95 30 644 639 Purified Fluc 2mRNA 1 mg/kg HPLC- P95 30 2377 3175 Purified Fluc 2 mRNA

Example 30 In Vivo Expression of HPLC-Purified or Non-Purified Fluc mRNAwith DOTAP:CHEMS:Cholesterol:DSPE-PEG_(2 k) and Co-Injection of PolymerFollowing Repeat Dosing

HPLC-purified Fluc 2 mRNA and non-purified Fluc 2 mRNA formulated inDOTAP:CHEMS:CHOL:DSPE-PEG2 k LNPs with P95 using co-injection wererepeat dosed in CD-1 mice using the same methods described in Example 2.

Table 95 displays luminescence values in the liver for animals treatedwith DOTAP:CHEMS:CHOL:DSPE-PEG2 k+HPLC-purified or non-purified Fluc 2mRNA nanoparticles with co-injection of polymer P95. mRNA/LNP+polymerwere mixed at a 1:1 ratio and injected immediately into mice. Data wasacquired at 6 hours post each dose. Formulations were repeat dosed by IVadministration once a week for 5 weeks in CD-1 mice. Repeatadministration with HPLC-purified Fluc mRNA resulted in little reductionin luminescent signal (up to 8-fold) at each weekly dose out to 5 weeks.In contrast, repeat administration with non-purified Fluc mRNA resultedin up to 76-fold reduction in luminescent signal at each weekly dose outto 5 weeks.

TABLE 95 Fold Repeat Total Flux Reduction Lipid-mRNA dosing(photons/sec) from Week 1 Nanoparticle mRNA Dose Polymer time pointGeomean STDEV Activity DOTAP:CHEMS: 0.5 mg/kg 30 mg/kg Week 1 8.02E+095.83E+09 1 CHOL:DMPE- Non-Purified P95 Week 2 1.50E+09 3.16E+09 5.3PEG2K Fluc 2 mRNA Week 3 1.79E+08 2.32E+08 44.9 (50:32:16:2) Week 41.05E+08 4.96E+07 76.6 N:P 7 17.5 mg/kg Week 5 3.10E+08 9.54E+08 25.90.5 mg/kg 30 mg/kg Week 1 1.09E+10 1.12E+10 1 HPLC- P95 Week 2 4.82E+092.03E+09 2.3 Purified Fluc 2 Week 3 1.30E+09 8.92E+09 8.4 mRNA Week 41.82E+09 4.61E+09 6.0 Week 5 5.29E+09 1.20E+10 2.1

Example 31 In Vivo Cytokine Analysis of HPLC-Purified and Non-PurifiedmRNAs with DOTAP:CHEMS:Cholesterol:DMPE-PEG_(2 k) mRNA Formulations andCo-Injection of Polymer

Male OTC-spf^(ash) mice (8-12 weeks old) were used for evaluating HPLCpurified or non-purified hOTC or untranslatable hOTC control mRNA (AUGstart codon was mutated to AAG) formulated inDOTAP:CHEMS:Cholesterol:DMPE-PEG2 k LNP with co-injection of P103polymer. The formulation was dosed intravenously at 1 mg/kg of mRNA, 27mg/kg of lipid, and 30 mg/kg of polymer with 5 mice injected per group.Mice injected with sucrose phosphate buffer were used as control. Foreach injection mice were given a final dose volume of approximately 0.25mL or 10 mL/kg based on individual body weights.

Mouse IP-10 cytokine levels were quantified using R&D systems MouseCXCL10/IP-10/CRG-2 Quantikine ELISA kit (#SMCX100). Blood was taken byretro-orbital sampling at 3 hours post dose and collected in serumseparator tubes. Serum was isolated by centrifugation and stored frozenat −20° C. until assayed. For ELISA the serum was diluted in PBS andthen run according to manufacturer's protocol. Briefly, 50 μL of dilutedsample was mixed with 50 μL assay diluent in an ELISA plate andincubated at RT for two hours. The solution was removed and replacedwith 200 μL of antibody conjugate and incubated at RT for two hours. Theplate was then washed and developed using a two component HRP/TMB systemand read at 450 nm.

Table 96 displays IP-10 serum levels for animals treated with buffer orwith HPLC-purified or non-purified hOTC mRNA or untranslatable hOTCcontrol mRNA formulated in LNP with co-injection of polymer P103. Noinduction of IP-10 cytokine levels at 3 hours post dose was observedwith HPLC-purified mRNA in comparison to high IP-10 cytokine levelsinduced with non-purified mRNA.

TABLE 96 Polymer Mouse IP-10 serum Lipid-mRNA Dose levels (pg/mL)Nanoparticle mRNA Polymer (mg/kg) Average STDEV None-Buffer 0 none none<30 DOTAP:CHEMS:CHOL: 1 mg/kg HPLC-Purified P103 30 <30 DMPE-PEG2K hOTC(50:32:16:2) 1 mg/kg Non-Purified P103 30 8337 506 N:P 7 27 mg/kg hOTC 1mg/kg HPLC-Purified P103 30 <30 untranslatable hOTC control 1 mg/kgNon-Purified P103 30 5622 1330 untranslatable hOTC control

Example 32 Therapeutic Efficacy of HPLC-Purified mRNA with Lipid-mRNAFormulations and Co-Injection of Polymer in Ornithine TranscarbamylaseDeficient Mice

Hyperammonemia was induced in OTC-spf^(ash) mice as described in Example21. Four (4) days after AAV dosing, 1 mg/kg of HPLC-purified OTC mRNA or1 mg/kg of HPLC-purified untranslatable OTC control mRNA formulated inDOTAP:CHEMS:CHOL:DMPE-PEG_(2 k) (50:32:16:2) at N:P 7+co-injection of 30mg/kg polymer P103 was administered every 3 to 4 days for a total of 3repeat doses. Urine was collected 48 h post the second mRNA dose (on day9 following AAV treatment) and analyzed for orotic acid levels that werenormalized to creatinine levels. Orotic acid (OA) levels were reducedfollowing OTC mRNA treatment (336±166 μmol OA/mmol creatinine) incomparison to buffer treatment (999±192 μmol OA/mmol creatinine) oruntranslatable control mRNA treatment (882±192 μmol OA/mmol creatinine).Plasma was collected on day 12 (24 h post 3^(rd) repeat mRNA dose)following AAV treatment and analyzed for ammonia levels. Plasma ammonialevels were reduced to normal levels (43±29 μM ammonia) followingtreatment with OTC mRNA in comparison to hyperammonemic mice treatedwith untranslatable control mRNA (217±119 μM ammonia) or buffertreatment (110±24 μM ammonia). To examine whether any cytokine inductionwas observed following administration of HPLC-purified OTC oruntranslatable control mRNA, serum was collected at 3 h post the firstmRNA dose and examined for IP-10 levels. IP-10 levels were below thelevel of quantitation (<30 pg/mL) in both HPLC-purified OTC mRNA anduntranslatable control mRNA treated mice, similar to buffer treatedmice. In contrast, unpurified Fluc 2 mRNA control showed high inductionof IP-10 serum levels (13,009±4932 pg/mL).

Example 33 Expression of OTC mRNA with Lipid-mRNA Formulations andCo-Injection of Polymer in Ornithine Transcarbamylase Deficient Mice

OTC-spf^(ash) mice were administered a single IV dose of 3 mg kg of OTCmRNA, 3 mg/kg of untranslatable OTC control mRNA, or buffer. Each mRNAwas formulated in DOTAP:CHEMS:CHOL:DSPE-PEG_(2 k) (50:32:18:10) at N:P7+co-injection of 30 mg/kg polymer P105. Mice were sacrificed at 6, 24,or 48 h post dose and liver tissue samples were collected for OTCwestern analysis. To prepare protein extracts from liver tissue, 400-600μl of freshly prepared Pierce T-PER tissue lysis buffer (1 Pierceprotease and phosphatase inhibitor cocktail tablet for 10 ml of lysisbuffer) was added into each sample tube containing approximately 200 mgof liver tissue. Tubes were then loaded onto MP Bio Fastprep-24Instrument (Cat#116004500) to homogenize tissue for 20 seconds at aspeed of 6 m/s. Each tissue homogenate was centrifuged at 4° C., 13,000rpm for 15 minutes, and the supernatant was transferred to a newEppendorf tube. This whole cell lysate was further analyzed for totalprotein concentration by BCA assay (Thermo Scientific, Cat#23225). 25 μgof each sample was loaded per lane on 4-12% SDS-PAGE gels (Bio-Rad,Cat#345-0124) after mixing protein extract with 4× sample buffer(Bio-Rad, Cat#161-0791) and 20× XT Reducing Reagent (Bio-Rad,Cat#161-0792) for a final protein concentration of 5 μg/μl. Samples werethen heated at 95° C. for 5 minutes prior to running on gel. Followingelectrophoresis, blotting was performed by transferring proteins fromgels to PVDF membranes (Bio-Rad, Cat#170-4157) under Bio-RadTransfer-Blot Turbo system (Cat#170-4155). Subsequently, the blots wereblocked in Odyssey Blocking Buffer (LI-COR, Cat#927-40000) at roomtemperature for 1 hour, followed by incubation with OTC (Sigma,Cat#HPA000243, 1:2000 dilution) or HSP90 (Origene, Cat#TA500494, 1:8000dilution) primary antibodies at 4° C. overnight. After several washes inTBST buffer, the blots were incubated with HRP-conjugated secondaryantibody (Cell Signaling, Cat#7076S, 1:2000) at room temperature for 1hour. To visualize protein bands, the washed blots were incubated withluminescence-based HRP substrate (Millipore, Cat#WBLUF0500) and thenimaged under Bio-Rad ChemiDoc XRS system (Cat#170-8265). Thequantification of westerns was performed using Bio-Rad Image LabSoftware (Cat#170-9690) linked to the ChemiDoc system. To quantitate OTCexpression levels in treated OTC-spf^(ash) samples relative to wild-typelittermate sample, the intensity of the OTC protein band was divided bythat of loading control HSP90 in the same sample. This ratio was thendivided by a similar ratio of a wild-type littermate sample. This wasviewed as % OTC expression relative to wild-type.

Table 97 displays % OTC expression relative to wild-type littermatemouse for OTC-spf^(ash) mice treated with 3 mg/kg of OTC mRNA, 3 mg/kguntranslatable control mRNA, or buffer. At 24 and 48 h post dose, OTCmRNA treatment in OTC-spf^(ash) mice showed approximately 40% ofwild-type OTC expression levels. No OTC expression was detectable fromuntranslatable control mRNA above the level seen with buffer treatment.

TABLE 97 % OTC Expression Lipid-mRNA Polymer Time Point Relative toWild-Type Nanoparticle Treatment Dose (mg/kg) (h) AVG STDEVDOTAP:CHEMS:CHOL: Buffer none 6 h 10.4%    2% DSPE-PEG2K 3 mg/kg OTC 30mg/kg 6 h 13.4%  4.2% (50:32:8:10) mRNA 24 h 41.1% 13.1% N:P 7 105 mg/kg48 h 41.6% 10.1% 3 mg/kg 30 mg/kg 6 h 10.1%    1% untranslatable 24 h 9.9%  1.2% control mRNA

Example 34 Synthesis of Cationic Lipids Part 1: Synthesis of(R)-5-(dimethylamino)pentane-1,2-diyl dioleate hydrochloride(DODAPen-Cl)

(R)-5-bromopentane-1,2-diyl dioleate (1.66 g, 2.33 mmol) was dissolvedin anhydrous acetonitrile (50.0 mL) in a 100 mL round bottom flaskequipped with a magnetic stirring bar. Dimethylamine hydrochloride(0.951 g, 11.7 mmol) and diisopropylethylamine (2.03 mL, 11.7 mmol) wereadded successively to the suspension and the mixture was heated to 60°C. in an oil bath for 16 h. The now-clear solution was cooled to RT(upon which it turned cloudy) and the solvent was removed under reducedpressure on the rotovap to afford a brown oily residue. The cruderesidue was purified by silica gel chromatography using a gradient ofdichloromethane: methanol (0 to 10%) to afford the clean product as alight brown semi-solid (1.20 g, 1.77 mmol. Yield: 76%). Thehydrochloride salt was obtained by adding concentrated hydrochloric acidto the oily product and concentrating the mixture to dryness on therotovap and subsequently under high vacuum. The final product wasobtained as a waxy off-white. The final product was characterized by NMR(400 MHz 1H NMR with CD₃OD as solvent) and all spectra were consistentwith the desired.

Part 2: Synthesis of (R)-5-guanidinopentane-1,2-diyl dioleatehydrochloride (DOPen-G)

Part 2A: Synthesis of (R)-5-((tert-butoxycarbonyl)amino)pentane-1,2-diyldioleate

(R)-tert-butyl-(4,5-dihydroxypentyl)carbamate (2.10 g, 9.58 mmol) wasdissolved in anhydrous dichloromethane (50.0 mL) in a 250 mL roundbottom flask equipped with a magnetic stirring bar. Oleic acid (5.70 g,20.2 mmol) was added to the mixture and the stirring solution was cooledto 0° C. in an ice bath. Dicyclohexylcarbodiimide (4.94 g, 23.9 mmol)and dimethylaminopyridine (1.17 g, 9.58 mmol) were added to the coldsolution and the reaction was warmed to RT over 16 h. The soliddicyclohexyl urea precipitate was filtered out on a Buchner funnel andwashed with dichloromethane (4×25 mL). The dichloromethane filtrate wasconcentrated under reduced pressure on a rotovap to obtain an oilyresidue. The resulting residue was purified by silica gel chromatographyusing a gradient of hexane:ethyl acetate (0 to 10%). The pure productwas obtained as a colorless oil (6.89 g, 9.21 mmol). Yield: 96%. Theproduct was characterized by NMR (400 MHz 1H NMR with CD₃OD as solvent)and all spectra were consistent with(R)-5-((tert-butoxycarbonyl)amino)pentane-1,2-diyl dioleate.

Part 2B: Synthesis of (R)-5-aminopentane-1,2-diyl dioleate hydrochloride

(R)-5-((tert-butoxycarbonyl)amino)pentane-1,2-diyl dioleate (6.87 g,9.18 mmol) was dissolved in anhydrous 1,4-dioxane (50.0 mL) in a 250 mLround bottom flask equipped with a magnetic stirring bar. 4Nhydrochloric acid in 1,4-dioxane was added (46.0 mL, 184 mmol) and thesolution was stirred at RT for 4 h. The solvent was removed underreduced pressure on a rotovap and the product was dried under highvacuum for 16 h. The pure product was obtained as a viscous colorlessoil (6.29 g, 9.18 mmol) in quantitative yield. The product wascharacterized by NMR (400 MHz 1H NMR with CD₃OD as solvent) and allspectra were consistent with (R)-5-aminopentane-1,2-diyl dioleatehydrochloride.

Part 2C: Synthesis of(R)-5-(2,3-bis(tert-butoxycarbonyl)guanidino)pentane-1,2-diyl dioleate

(R)-5-aminopentane-1,2-diyl dioleate hydrochloride (2.46 g, 3.59 mmol)was dissolved in anhydrous dichloromethane (50.0 mL) in a 250 mL roundbottom flask equipped with a magnetic stirring bar. Triethylamine (1.00mL, 7.17 mmol) and 1,3-Di-Boc-2-(trifluoromethylsulfonyl)guanidine (1.55g, 3.96 mmol) were added successively and the mixture was stirred atambient temperature for 22 h. The solution was concentrated underreduced pressure on a rotovap to afford an oily residue. The resultingresidue was purified by silica gel chromatography using a gradient ofhexane:ethyl acetate (0 to 10%). The pure product was obtained as acolorless oil (3.00 g, 3.37 mmol). Yield: 94%. The product wascharacterized by NMR (400 MHz 1H NMR with CDCl₃ as solvent) and allspectra were consistent with(R)-5-(2,3-bis(tert-butoxycarbonyl)guanidino)pentane-1,2-diyl dioleate.

Part D: Synthesis of (R)-5-guanidinopentane-1,2-diyl dioleatehydrochloride (DOPen-G)

(R)-5-(2,3-bis(tert-butoxycarbonyl)guanidino)pentane-1,2-diyl dioleate(1.81 g, 2.03 mmol) was dissolved in anhydrous 1,4-dioxane (20.0 mL) ina 250 mL round bottom flask equipped with a magnetic stirring bar. 4Nhydrochloric acid in 1,4-dioxane was added (30.2 mL, 121 mmol) and thesolution was stirred at RT for 48 h. The solvent was removed underreduced pressure on a rotovap to afford an oily residue. The resultingresidue was purified on silica gel chromatography using a gradient ofdichloromethane: methanol (0 to 100%). The pure product was dried underhigh vacuum for 20 h to yield an off-white semi-solid (1.00 g, 1.38mmol). Yield: 68%. The product was characterized by NMR (400 MHz 1H NMRwith CD₃OD as solvent) and all spectra were consistent with DOPen-G.

Part 3: Synthesis of(R)-N,N,N-trimethyl-4,5-bis(oleoyloxy)pentan-1-aminium chloride(DOTAPen)

(R)-5-(dimethylamino)pentane-1,2-diyl dioleate (DODAPen, 0.700 g, 1.04mmol) was dissolved in anhydrous acetonitrile (10.0 mL) in a 100 mLround bottom flask equipped with a magnetic stirring bar.Diispopropylethylamine (1.80 mL, 10.3 mmol) and iodomethane (1.93 mL,31.0 mmol) were added successively and the solution was refluxed at 85°C. for 20 h. The solution was cooled to RT and diluted with diethylether (300 mL) upon which a precipitate of diisopropylethylaminiumiodide salt formed. The solid precipitate was filtered out and thecombined organic phase was concentrated under reduced pressure on arotovap. The crude residue was passed through a short silica gel columnusing a mixture of dichloromethane and methanol (10%). The pure product(iodide salt) was obtained as a brown-red semi-solid (780 mg). Theproduct was then passed through an Amberlite IRA 400 chlorideion-exchange resin column and eluted with a mixture of dichloromethanemethanol (33%). The column procedure was repeated 10 times to obtain thedesired product as the chloride salt. After drying under high vacuum,the pure product was obtained as a light brown waxy solid (430 mg, 0.592mmol). Yield: 57%. The product was characterized by NMR (400 MHz 1H NMRwith CD₃OD as solvent) and all spectra were consistent with DOTAPen.

From the foregoing, it will be appreciated that, although specificembodiments of the invention have been described herein for purposes ofillustration, various modifications may be made without deviating fromthe spirit and scope of the invention. Accordingly, the invention is notlimited except as by the appended claims All publications, patents, andpatent applications cited herein are hereby incorporated by reference intheir entireties for all purposes.

1-272. (canceled)
 273. A pH-sensitive, membrane-destabilizing polymer offormula V:T1-L-[PEGMA_(m)-M2_(n)]_(v)-[DMAEMA₁-PAA_(r)-BMA_(s)]_(w)   V whereinPEGMA is polyethyleneglycol methacrylate residue with 2-20 ethyleneglycol units; M2 is a methacrylate residue selected from the groupconsisting of a (C4-C18)alkyl-methacrylate residue; a (C4-C18)branchedalkyl-methacrylate residue; a cholesteryl methacrylate residue; a(C4-C18)alkyl-methacrylate residue substituted with one or more fluorineatoms; and a (C4-C18)branched alkyl-methacrylate residue substitutedwith one or more fluorine atoms; BMA is butyl methacrylate residue; PAAis propyl acrylic acid residue; DMAEMA is dimethylaminoethylmethacrylate residue; m and n are each a mole fraction greater than 0,wherein m is greater than n and m+n=1; q is a mole fraction of 0.2 to0.75; r is a mole fraction of 0.05 to 0.6; s is a mole fraction of 0.2to 0.75; q+r+S=1; v is 1 to 25 kDa; w is 1 to 25 kDa; T1 is a firsttargeting ligand comprising an N-acetylgalactosamine (NAF) residue; andL is a linking moiety comprising polyethylene glycol (PEG) moiety. 274.The polymer of claim 273, wherein M2 is a methacrylate residue selectedfrom the group consisting of a (C4-C18)alkyl-methacrylate residue; a(C4-C18)branched alkyl-methacrylate residue; and a(C4-C18)alkyl-methacrylate residue substituted with one or more fluorineatoms.
 275. The polymer of claim 274, wherein M2 is a(C4-C18)alkyl-methacrylate residue.
 276. The polymer of claim 273,wherein M2 is a methacrylate residue selected from the group consistingof 2,2,3,3,4,4,4-heptafluorobutyl methacrylate residue;3,3,4,4,5,6,6,6-octafluoro-5(trifluoromethyl)hexyl methacrylate residue;2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctyl 2-methylacrylateresidue; 3,3,4,4,5,5,6,6,6-nonafluorohexyl methacrylate residue;3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl methacrylate residue;2-ethylhexyl methacrylate residue; octyl methacrylate residue; n-decylmethacrylate residue; lauryl methacrylate residue; myristyl methacrylateresidue; stearyl methacrylate residue; cholesteryl methacrylate residue;neopentyl methacrylate residue; 5-nonyl methacrylate residue;2-butyl-1-octyl methacrylate residue; and 2-hexyl-1-decyl methacrylateresidue.
 277. The polymer of claim 276, wherein M2 is a methacrylateresidue selected from the group consisting of 2-ethylhexyl methacrylateresidue; 5-nonyl methacrylate residue; octyl methacrylate residue;n-decyl methacrylate residue; lauryl methacrylate residue; myristylmethacrylate residue; and stearyl methacrylate residue.
 278. The polymerof claim 277, wherein M2 is 2-ethylhexyl methacrylate residue or 5-nonylmethacrylate residue.
 279. The polymer of claim 273, wherein PEGMA ispolyethyleneglycol methacrylate residue having 4-5 ethylene glycol unitsor 7-8 ethylene glycol units.
 280. The polymer of claim 273, wherein Lincludes a polyethylene glycol (PEG) moiety having 2-20 ethylene glycolunits.
 281. The polymer of claim 273, wherein T1-L- in formula Vcomprises the structure


282. The polymer of claim 273, wherein the polymer of formula V isselected from the group consisting ofNAG-PEG₁₂-[PEGMA300_(m)-(F1-BMA)_(n)]_(v)-[D_(q)-P_(r)-B_(s)]_(w)   Vb;NAG-PEG₁₂-[PEGMA300_(m)-(OF1-5TFM-HMA)_(n)]_(v)-[D_(q)-P_(r)-B_(s)]_(w)  Vc;NAG-PEG₁₂-[PEGMA300_(m)-(F115-OMA)_(n)]_(v)-[D_(q)-P_(r)-B_(s)]_(w)  Vd;NAG-PEG₁₂-[PEGMA300_(m)-(B-F1-HMA)_(n)]_(v)-[D_(q)-P_(r)-B_(s)]_(w)  Ve;NAG-PEG₁₂-[PEGMA300_(m)-(B-F1-OMA)_(n)]_(v)-[D_(q)-P_(r)-B_(s)]_(w)  Vf;NAG-PEG₁₂-[PEGMA300_(m)-EHMA_(n)]_(v)-[D_(q)-P_(r)-B_(s)]_(w)   Vg;NAG-PEG₁₂-[PEGMA300_(m)-B_(n)]_(v)-[D_(q)-P_(r)-B_(s)]_(w)   Vh;NAG-PEG₁₂-[PEGMA300_(m)-C8MA_(n)]_(v)-[D_(q)-P_(r)-B_(s)]_(w)   Vj;NAG-PEG₁₂-[PEGMA300_(m)-C12MA_(n)]_(v)-[D_(q)-P_(r)-B_(s)]_(w)   Vk;NAG-PEG₁₂-[PEGMA300_(m)-Bu1-OMA_(n)]_(v)-[D_(q)-P_(r)-B_(s)]_(w)   Vl;andNAG-PEG₁₂-[PEGMA300_(m)-NMA_(n)]_(v)-[D_(q)-P_(r)-B_(s)]_(w)   Vm;wherein D is DMAEMA; P is PAA; B is BMA; NAG is an N-acetylgalactosamineresidue; PEG₁₂ is a linking moiety comprising polyethylene glycol having12 ethylene glycol units; F1-BMA is 2,2,3,3,4,4,4-heptafluorobutylmethacrylate residue; OF1-5TFM-HMA is3,3,4,4,5,6,6,6-octafluoro-5(trifluoromethyl)hexyl methacrylate residue;F115-OMA is 2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-pentadecafluorooctyl2-methylacrylate residue; B-F1-HMA is 3,3,4,4,5,5,6,6,6-nonafluorohexylmethacrylate residue; B-F1-OMA is3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl methacrylate residue; EHMAis 2-ethylhexyl methacrylate residue; CSMA is octyl methacrylateresidue; C12MA is lauryl methacrylate residue; 2-Bu1-OMA is2-butyl-1-octyl methacrylate residue; 5-NMA is 5-nonyl methacrylateresidue; m and n are each a mole fraction greater than 0, wherein m isgreater than n and m+n=1; q is a mole fraction of 0.2 to 0.75; r is amole fraction of 0.05 to 0.6; s is a mole fraction of 0.2 to 0.75;q+r+s=1; v is 1 to 25 kDa; and w is 1 to 25 kDa.
 283. The polymer ofclaim 282, wherein m is 0.7 to 0.85.
 284. The polymer of claim 282,wherein n is 0.15 to 0.3.
 285. The polymer of claim 282, wherein s is0.5 to 0.65.
 286. The polymer of claim 282, wherein v is 2.5 to 7 kDa.287. The polymer of claim 282, wherein w is 4 to 7 kDa.
 288. The polymerof claim 282, wherein q is 0.25 to 0.4.
 289. The polymer of claim 282,wherein r is 0.07 to 0.15.
 290. The polymer of claim 273, wherein thepolymer of Formula V is selected from the group consisting of P79:NAG-C5N-PEG12-[PEGMA (300, 69.9%)-HMA(30.1%)] 2.93 KDa-b-[DMAEMA(34.4%)-BMA (53.6%)-PAA (12%)]4.43 Kda; P90: NAG-C5N-PEG12-[PEGMA (300,72.6%)-HMA (27.4%)]3.58 KDa-b-[DMAEMA (30.6%)-BMA(56.2%)-PAA (13.3%)]5.6KDa; P106: NAG-C5N-PEG12-[PEGMA(300, 74%)-HMA(26%)]4.1KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]5 KDa; P107:NAG-C5N-PEG12-[PEGMA(300, 74%)-HMA(26%)]4.1KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]4.2 KDa; P108:NAG-C5N-PEG12-[PEGMA(300, 80%)-HMA(20%)]4.96KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]5.5 KDa; P109:NAG-C5N-PEG12-[PEGMA(300, 80%)-HMA(20%)]4.96KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]6.5 KDa; P114:NAG-C5N-PEG12-[PEGMA(300, 67%)-HMA(33%)]5.7KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]6.15 KDa; P115:NAG-C5N-PEG12-[PEGMA(300, 67%)-HMA(33%)]5.7KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]6 KDa; P118:NAG-C5N-PEG12-[PEGMA(300, 70%)-HMA(30%)]5.2KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]5.7 KDa; P119:NAG-C5N-PEG12-[PEGMA(300, 70%)-HMA(30%)]5.2KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]5 KDa; P124:NAG-C5N-PEG12-[PEGMA(300, 74%)-HMA(26%)]4.15KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]5 KDa; and P125:NAG-C5N-PEG12-[PEGMA(300, 74%)-HMA(26%)]4.15KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]5 KDa.
 291. The polymer of claim273, wherein the polymer of Formula V is selected from the groupconsisting of P74: NAG-C5N-PEG 12-[PEGMA(300, 80.3%)-BMA(23.3%)]3.8KDa-b-[DMAEMA(38.2%)-BMA(51.5%)-PAA(10.3%)]3.5 KDa; P89:NAG-C5N-PEG12-[PEGMA (300, 73.8%)-BMA (26.2%)]3.5 KDa-b-[DMAEMA(30.7%)-BMA(58.9%)-PAA (10.4%)]4.9 KDa; P80: NAG-C5N-PEG12-[PEGMA (300,85.4%)-EHMA(14.6%)] 3.36 KDa-b-[DMAEMA (36.5%)-BMA (53.7%)-PAA(9.7%)]4.18 KDa; P87: NAG-C5N-PEG12-[PEGMA (300, 69.7%)-EHMA(30.3%)] 3.9KDa-b-[DMAEMA (31.1%)-BMA(56.7%)-PAA (12.1%)]5.1 KDa; P110:NAG-C5N-PEG12-[PEGMA(300, 77.7%)-EHMA(22.3%)]4.37 KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]6 KDa; P88: NAG-C5N-PEG12-[PEGMA (300,76%)-5-NMA (24%)] 3.0 KDa-b-[DMAEMA (34.4%)-BMA (54%)-PAA (11.6%)]5.6KDa; P99: NAG-C5N-PEG12-[PEGMA(300, 73.3%)-5-NMA(26.7%)]4.05KDa-b-[DMAEMA(31.5%)-BMA(55.2%)-PAA(13.3%)]5.20 KDa; P76:NAG-C5N-PEG12-[PEGMA(300, 74.9%)-isoA-MA(25.1%)]2.9KDa-b-[DMAEMA(38%)-BMA(53%)-PAA(9.1%)]5.2 KDa; P86: NAG-C5N-PEG12-[PEGMA(300, 78.1%)-C12MA(21.9%)]3.67 KDa-b-[DMAEMA (32.1%)-BMA (53.7%)-PAA(14.2%)]4.7 KDa; P98: NAG-C5N-PEG12-[PEGMA(300, 75%)-2-Bul-OMA(25%]4.26KDa-b-[DMAEMA(32.1%)-BMA(55.7%)-PAA(12.2%)]5.69 KDa; P123:NAG-C5N-PEG12-[PEGMA(300, 79%)-Bul-O-MA(21%)]4.88KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]4.6 KDa; P94:NAG-C5N-PEG12-[PEGMA(300, 72.2%)-B-F1-HMA (27.8%)]4.2KDa-b-[DMAEMA(35.7%)-BMA(54.4%)-PAA (9.9%)]4.7 KDa; P103:NAG-C5N-PEG12-[PEGMA(300, 70.3%)-F1-BMA(29.7%)]3.6KDa-b-[DMAEMA(32.2%)-BMA(57.6%)-PAA(10.2%)]5 KDa; and P104:NAG-C5N-PEG12-[PEGMA(300, 68%)-F1-BMA(32%)]3.7KDa-b-[DMAEMA(31%)-BMA(56%)-PAA(13%)]5.3 KDa.